0001493152-22-009623.txt : 20220411 0001493152-22-009623.hdr.sgml : 20220411 20220411173025 ACCESSION NUMBER: 0001493152-22-009623 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 75 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220411 DATE AS OF CHANGE: 20220411 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NUTRALIFE BIOSCIENCES, INC CENTRAL INDEX KEY: 0001563463 STANDARD INDUSTRIAL CLASSIFICATION: DAIRY PRODUCTS [2020] IRS NUMBER: 461482900 STATE OF INCORPORATION: FL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55144 FILM NUMBER: 22820563 BUSINESS ADDRESS: STREET 1: 6601 LYONS ROAD CITY: L 6 COCONUT CREEK STATE: FL ZIP: 33073 BUSINESS PHONE: 888 509 8901 MAIL ADDRESS: STREET 1: 6601 LYONS ROAD CITY: L 6 COCONUT CREEK STATE: FL ZIP: 33073 FORMER COMPANY: FORMER CONFORMED NAME: NUTRAFUELS INC DATE OF NAME CHANGE: 20121210 FORMER COMPANY: FORMER CONFORMED NAME: NUTRAFUELS DATE OF NAME CHANGE: 20121203 10-K 1 form10-k.htm
0001563463 false FY Mar. 31, 2023 0001563463 2021-01-01 2021-12-31 0001563463 2021-06-30 0001563463 2022-03-23 0001563463 2021-12-31 0001563463 2020-12-31 0001563463 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001563463 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001563463 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001563463 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001563463 2020-01-01 2020-12-31 0001563463 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001563463 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001563463 us-gaap:CommonStockMember 2019-12-31 0001563463 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001563463 us-gaap:RetainedEarningsMember 2019-12-31 0001563463 2019-12-31 0001563463 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001563463 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001563463 us-gaap:CommonStockMember 2020-12-31 0001563463 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001563463 us-gaap:RetainedEarningsMember 2020-12-31 0001563463 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001563463 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001563463 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001563463 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001563463 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001563463 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001563463 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001563463 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001563463 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001563463 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001563463 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001563463 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001563463 us-gaap:CommonStockMember 2021-12-31 0001563463 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001563463 us-gaap:RetainedEarningsMember 2021-12-31 0001563463 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001563463 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001563463 NLBS:ConvertibleSeriesBPreferredStockMember 2021-01-01 2021-12-31 0001563463 NLBS:ConvertibleSeriesBPreferredStockMember 2020-01-01 2020-12-31 0001563463 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-12-31 0001563463 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-12-31 0001563463 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001563463 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001563463 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001563463 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001563463 us-gaap:PatentsMember 2019-02-28 0001563463 us-gaap:PatentsMember 2019-02-01 2019-02-28 0001563463 us-gaap:PatentsMember us-gaap:CommonStockMember 2019-02-01 2019-02-28 0001563463 us-gaap:PatentsMember us-gaap:CommonStockMember 2019-02-28 0001563463 us-gaap:PatentsMember 2021-01-01 2021-12-31 0001563463 NLBS:DistributorMember 2020-11-01 2020-11-02 0001563463 NLBS:DistributorMember us-gaap:ConvertiblePreferredStockMember 2020-11-01 2020-11-02 0001563463 NLBS:DistributorMember us-gaap:CommonStockMember 2020-11-01 2020-11-02 0001563463 NLBS:DistributorMember us-gaap:CommonStockMember 2020-11-02 0001563463 NLBS:OneYearAnniversaryMember NLBS:DistributorMember us-gaap:CommonStockMember 2020-11-02 0001563463 NLBS:OneYearAnniversaryMember NLBS:DistributorMember us-gaap:CommonStockMember 2020-11-01 2020-11-02 0001563463 NLBS:DistributorMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001563463 us-gaap:ConvertiblePreferredStockMember 2020-11-02 0001563463 us-gaap:ConvertiblePreferredStockMember us-gaap:MeasurementInputExpectedTermMember 2020-11-01 2020-11-02 0001563463 us-gaap:ConvertiblePreferredStockMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-11-02 0001563463 NLBS:DistributionAgreementMember 2021-12-31 0001563463 NLBS:DistributionAgreementMember 2020-12-31 0001563463 NLBS:DistributionAgreementMember 2020-01-01 2020-12-31 0001563463 NLBS:LicenseAgreementMember 2021-11-01 2021-11-30 0001563463 NLBS:LicenseAgreementMember srt:MaximumMember 2021-12-31 0001563463 NLBS:LicenseAgreementMember 2021-12-31 0001563463 NLBS:LicenseAgreementMember 2021-01-01 2021-12-31 0001563463 NLBS:LicenseAgreementMember us-gaap:LicenseMember 2021-01-01 2021-12-31 0001563463 NLBS:LicenseAgreementMember us-gaap:EquityMember 2021-01-01 2021-12-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2020-01-01 2020-03-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember srt:MinimumMember 2020-03-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember srt:MaximumMember 2020-03-31 0001563463 NLBS:NoteholdersMember 2020-01-01 2020-03-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2020-07-01 2020-09-30 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2020-09-30 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2020-09-01 2020-12-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember srt:MinimumMember 2020-12-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember srt:MaximumMember 2020-12-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2020-12-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2020-01-01 2020-12-31 0001563463 NLBS:TwoThousandTwentyConvertiblesNotesMember 2020-01-01 2020-12-31 0001563463 NLBS:SubscriptionAgreementMember 2020-01-01 2020-12-31 0001563463 NLBS:TwoThousandTwentySubscriptionAgreementNotesMember 2020-01-01 2020-12-31 0001563463 NLBS:TwoThousandTwentySubscriptionAgreementNotesMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001563463 NLBS:TwoThousandTwentySubscriptionAgreementNotesMember us-gaap:MeasurementInputOptionVolatilityMember 2020-12-31 0001563463 NLBS:TwoThousandTwentySubscriptionAgreementNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2020-12-31 0001563463 NLBS:TwoThousandTwentySubscriptionAgreementNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2020-12-31 0001563463 us-gaap:WarrantMember 2021-01-31 0001563463 us-gaap:WarrantMember 2021-03-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2021-01-01 2021-12-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2021-12-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember srt:MinimumMember 2021-12-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember srt:MaximumMember 2021-12-31 0001563463 us-gaap:WarrantMember NLBS:NoteholdersMember 2021-12-31 0001563463 NLBS:NoteholdersMember 2021-01-01 2021-12-31 0001563463 NLBS:NoteholdersMember us-gaap:MeasurementInputExpectedTermMember 2021-12-31 0001563463 NLBS:NoteholdersMember us-gaap:MeasurementInputOptionVolatilityMember srt:MinimumMember 2021-12-31 0001563463 NLBS:NoteholdersMember us-gaap:MeasurementInputOptionVolatilityMember srt:MaximumMember 2021-12-31 0001563463 NLBS:NoteholdersMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-12-31 0001563463 NLBS:NoteholdersMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2020-12-31 0001563463 NLBS:DebtSettlementAgreementsMember 2021-01-01 2021-12-31 0001563463 NLBS:DebtSettlementAgreementsMember 2021-12-31 0001563463 NLBS:DebtSettlementAgreementsMember NLBS:PrincipalAmountMember 2021-01-01 2021-12-31 0001563463 NLBS:DebtSettlementAgreementsMember NLBS:AccruedInterestMember 2021-01-01 2021-12-31 0001563463 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001563463 us-gaap:WarrantMember 2021-12-31 0001563463 us-gaap:WarrantMember us-gaap:MeasurementInputOptionVolatilityMember srt:MinimumMember 2021-12-31 0001563463 us-gaap:WarrantMember us-gaap:MeasurementInputOptionVolatilityMember srt:MaximumMember 2021-12-31 0001563463 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2021-12-31 0001563463 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2021-12-31 0001563463 NLBS:SecuredConvertibleFivePointSevenFivePercentagePromissoryNotePayableMember NLBS:InvestmentAgreementMember 2019-06-30 0001563463 NLBS:SecuredConvertibleFivePointSevenFivePercentagePromissoryNotePayableMember NLBS:InvestmentAgreementMember 2019-06-28 2019-06-30 0001563463 NLBS:PaycheckProtectionProgramMember 2020-04-22 2020-04-23 0001563463 NLBS:PaycheckProtectionProgramMember 2021-03-11 2021-03-12 0001563463 NLBS:PaycheckProtectionProgramMember 2021-02-25 2021-02-26 0001563463 NLBS:PaycheckProtectionProgramMember 2021-11-25 2021-11-26 0001563463 NLBS:TwoRevenueShareAgreementMember NLBS:ThirdPartyInvestorsMember 2021-01-01 2021-12-31 0001563463 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001563463 us-gaap:WarrantMember 2020-07-31 0001563463 us-gaap:WarrantMember 2020-07-01 2020-07-31 0001563463 NLBS:StockPurchaseAgreementMember NLBS:LordGlobalCorporationMember NLBS:SeriesXPreferredStockMember 2020-11-01 2020-11-30 0001563463 NLBS:StockPurchaseAgreementMember NLBS:LordGlobalCorporationMember NLBS:SeriesXPreferredStockMember 2020-11-30 0001563463 NLBS:ChiefExecutiveOfficerPresidentAndDirectorMember 2021-01-31 0001563463 srt:VicePresidentMember 2021-01-31 0001563463 NLBS:ProductionManagerMember 2021-04-30 0001563463 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-04-01 2021-04-30 0001563463 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-04-30 0001563463 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-04-30 0001563463 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2021-04-30 0001563463 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-04-30 0001563463 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-04-30 0001563463 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001563463 us-gaap:WarrantMember 2021-09-30 0001563463 2021-07-01 2021-07-31 0001563463 2021-12-01 2021-12-31 0001563463 us-gaap:PreferredStockMember srt:MaximumMember 2021-09-30 0001563463 us-gaap:SeriesAPreferredStockMember 2012-11-29 2012-11-30 0001563463 NLBS:EdgarWardMember us-gaap:SeriesAPreferredStockMember 2012-11-29 2012-11-30 0001563463 NLBS:EdgarWardMember us-gaap:SeriesAPreferredStockMember 2012-11-30 0001563463 NLBS:SeriesBConvertiblePreferredStockMember 2020-09-30 0001563463 NLBS:ThreeConsultantsMember us-gaap:SeriesBPreferredStockMember 2021-03-29 2021-03-31 0001563463 us-gaap:SeriesBPreferredStockMember 2021-07-01 2021-09-30 0001563463 NLBS:CoconutCreekFloridaMember 2022-01-01 2022-01-31 0001563463 NLBS:DeerfieldBeachFloridaMember 2017-06-01 2017-06-30 0001563463 NLBS:DeerfieldBeachFloridaMember 2017-06-30 0001563463 NLBS:PhytochemMember 2019-07-01 2019-09-30 0001563463 NLBS:PhytochemMember 2019-09-30 0001563463 NLBS:CoconutCreekFloridaMember 2019-07-01 2019-09-30 0001563463 NLBS:SubLeaseAgreementMember 2021-01-01 2021-12-31 0001563463 NLBS:ExercisePriceOneMember 2021-12-31 0001563463 NLBS:ExercisePriceOneMember 2020-12-31 0001563463 NLBS:ExercisePriceTwoMember 2021-12-31 0001563463 NLBS:ExercisePriceTwoMember 2020-12-31 0001563463 NLBS:ExercisePriceThreeMember 2021-12-31 0001563463 NLBS:ExercisePriceThreeMember 2020-12-31 0001563463 NLBS:ExercisePriceFourMember 2021-12-31 0001563463 NLBS:ExercisePriceFourMember 2020-12-31 0001563463 NLBS:ExercisePriceFiveMember 2021-12-31 0001563463 NLBS:ExercisePriceFiveMember 2020-12-31 0001563463 NLBS:ExercisePriceSixMember 2021-12-31 0001563463 NLBS:ExercisePriceSixMember 2020-12-31 0001563463 us-gaap:WarrantMember 2019-12-31 0001563463 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001563463 us-gaap:WarrantMember 2020-12-31 0001563463 srt:MaximumMember 2021-01-01 2021-12-31 0001563463 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NLBS:TwoCustomersMember 2021-01-01 2021-12-31 0001563463 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember NLBS:TwoCustomersMember 2020-01-01 2020-12-31 0001563463 us-gaap:SubsequentEventMember us-gaap:CommonStockMember NLBS:TwoSubscriptionAgreementMember 2022-01-01 2022-01-31 0001563463 us-gaap:SubsequentEventMember us-gaap:WarrantMember NLBS:TwoSubscriptionAgreementMember 2022-01-01 2022-01-31 0001563463 us-gaap:SubsequentEventMember us-gaap:WarrantMember NLBS:TwoSubscriptionAgreementMember 2022-01-31 0001563463 us-gaap:SubsequentEventMember us-gaap:CommonStockMember 2022-01-01 2022-01-31 0001563463 NLBS:DebtSettlementAgreementMember us-gaap:SubsequentEventMember NLBS:PrincipalMember 2022-02-01 2022-02-28 0001563463 NLBS:DebtSettlementAgreementMember us-gaap:SubsequentEventMember NLBS:AccruedInterestMember 2022-02-01 2022-02-28 0001563463 us-gaap:SubsequentEventMember NLBS:DebtSettlementAgreementMember 2022-02-01 2022-02-28 0001563463 us-gaap:SubsequentEventMember NLBS:MultipleShortTermPromissoryNotePayableMember 2022-01-01 2022-03-31 0001563463 us-gaap:SubsequentEventMember NLBS:MultipleShortTermPromissoryNotePayableMember 2022-03-01 2022-03-31 0001563463 us-gaap:SubsequentEventMember NLBS:MultipleShortTermPromissoryNotePayableMember 2022-03-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended December 31, 2021

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ___________to ___________

 

Commission File No. 000-55144

 

NUTRALIFE BIOSCIENCES, INC.

(Name of registrant as specified in its charter)

 

Florida   46-1482900

(State or other jurisdiction

of incorporation or organization)

  

(IRS Employer

Identification No.)

 

6601 Lyons Road, Suite L-6

Coconut Creek, FL 33073

(Address, of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: 888-509-8901

 

Securities registered under Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of each exchange on which registered
N/A   N/A   N/A

 

Securities registered under Section 12(g) of the Act:

Common Stock, $.0001 par value

(Title of class)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer ☐ Accelerated filer ☐  
  Non-accelerated filer ☒ Smaller reporting company ☒  
      Emerging growth company ☐  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

 

The aggregate market value of the registrant’s voting and non-voting common equity held by non-affiliates June 30, 2021 (the last business day of the registrant’s most recently completed second fiscal quarter) was $14,359,742 computed by reference to the closing sales price of the shares of common stock on June 30, 2021, which was $0.138.

 

The number of shares outstanding of the registrant’s common stock as of March 23, 2022, was 174,968,516 shares.

 

DOCUMENTS INCORPORATED BY REFERENCE — NONE

 

 

 

 

 

 

 

TABLE OF CONTENTS    
     
SECTION   PAGE
PART I   4
Item 1. Business   4
Item 1A. Risk Factors   25
Item 1B. Unresolved Staff Comments   35
Item 2. Properties   35
Item 3. Legal Proceedings   36
Item 4. Mine Safety Disclosures   36
Part II   36
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities   36
Item 6. [RESERVED]   43
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations   43
Item 7A. Quantitative and Qualitative Disclosures About Market Risk   45
Item 8. Financial Statements and Supplementary Data   46
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure   47
Item 9A. Controls and Procedures   47
Item 9B. Other Information   48
Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS   48
Part III   48
Item 10. Directors, Executive Officers and Corporate Governance   48
Item 11. Executive Compensation   50
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters   51
Item 13. Certain Relationships and Related Transactions, and Director Independence   53
Item 14. Principal Accounting Fees and Services   53
PART IV   54
Item 15. Exhibits and Financial Statement Schedules   54
Item 16. Form 10-K Summary   58
SIGNATURES   59

 

2
 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Information contained in this annual report on Form 10-K contains “forward-looking statements.” These forward-looking statements are contained principally in the sections titled “Business,” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend” or “project” or the negative of these words or other variations on these words or comparable terminology. The forward-looking statements herein represent our expectations, beliefs, plans, intentions or strategies concerning future events, our future financial performance, the continuation of historical trends; the sufficiency of our resources in funding our operations; our intention to engage in mergers and acquisitions; and our liquidity and capital needs. Our forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. Moreover, our forward-looking statements are subject to various known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. These risks, uncertainties and other factors include but are not limited to: the risks of limited management, labor and financial resources; our ability to establish and maintain adequate internal controls; our ability to develop and maintain a market in our securities; and our ability obtain financing, if and when needed, on terms that are acceptable. Except as required by applicable laws, we undertake no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.

 

3
 

 

PART I

 

Item 1. Business

 

Overview

 

NutraLife BioSciences, Inc., a Florida corporation (“us,” “we,” “our” or the “Company”) was founded in 2010 by Edgar Ward, the Company’s Chief Executive Officer, President & sole Director to engage in the development, manufacturing and distribution of nutritional and dietary nutritional supplement products. Since then, the Company has evolved into a branded and private label developer, manufacturer and distributor of a wide range of nutraceutical, wellness, and CBD products.

 

Amid the COVID-19 global pandemic, in 2020, the Company made a strategic pivot from our then-current nutraceutical manufacturing business by adding the manufacture of consumer sanitizer products utilizing the Company’s existing manufacturing capabilities and the Company’s ability to retrofit its operations and accommodate production due to the shortage of supply and increased demand for sanitizer products.

 

The Company’s manufacturing facility has been registered with the Food and Drug Administration and its manufacturing facility has operated in accordance with the Good Manufacturing Processes Standard (GMP) for more than five years. Our products adhere to high manufacturing standards throughout every step of the manufacturing and extraction process. Our products are formulated, developed, manufactured and produced under the supervision of Edgar Ward, our Chief Executive Officer, President and sole Director. Once produced, our products are tested by our in-house and third party laboratory chemists. We believe that our nutraceutical and industrial CBD products are of the highest-quality and are laboratory tested for strength, purity and contaminants such as microbials, heavy metals, pesticides, and solvents.

 

We offer a number of different core formulations which we modify to meet the specifications of our private label customers. We provide many different variations of our core formulations. Our private label ingestible and skincare products include CBD-infused oral sprays, tinctures, pet drops, pain balms, and face creams.

 

Our products are available in various formulations and strengths and are available for purchase online directly from the Company through its website at www.nutralifebiosciences.com, as well as through numerous other private label distributors, online retailers and retail outlets. Information available on, or accessible through the foregoing website is not a part of this Annual Report on Form 10-K and is not incorporated herein by reference.

 

Our financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. We sustained a net loss of approximately $5.8 and $2.9 million for the years ended December 31, 2021 and 2020, respectively, negative cash flows from operations for both years and had an accumulated deficit of approximately $47.6 million at December 31, 2021. These conditions raise substantial doubt about our ability to continue as a going concern. The independent auditors’ report on our financial statements for the years ended December 31, 2021 and 2020 contain explanatory paragraphs expressing substantial doubt as to our ability to continue as a going concern.

 

In December 2019, a novel strain of coronavirus was reported to have surfaced in China and spread to the U.S. in early 2020. The spread of this virus caused various business disruptions including temporary closures to the Company’s offices and facilities.

 

The Company is currently in the process of raising capital to complete and finalize the build-out of its facility in Deerfield Beach for the purpose of consolidating its operations. The structure of the capital raise is currently in development. The Company is seeking to continue its path to profitability through increased business development, marketing and sales of the Company’s multiple lines of topical, ingestible and skincare health and wellness products. The Company is also focused on completing an efficacy clinical study on its patented mosquito bug patch with plans upon a successful conclusion to launch globally in the future, adding to the Company’s suite of wellness products. However, there can be no assurance that the foregoing can occur as planned, or at all.

 

Failure to successfully continue to grow operational revenues could harm our profitability and adversely affect our financial condition and results of operations. We face all of the risks inherent in a new business, including the need for significant additional capital, management’s potential underestimation of initial and ongoing costs, and potential delays and other problems in connection with establishing sales channels.

 

We are continuing our plan to further grow and expand operations and seek sources of capital to pay our contractual obligations as they come due. Management believes that its current operating strategy will provide the opportunity for us to continue as a going concern as long as we are able to obtain additional financing; however, there is no assurance this will occur. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

 

4
 

 

Corporate History

 

The Company was formed as a limited liability company in the state of Florida on April 1, 2010. On December 3, 2012, we converted from a limited liability company to a Florida corporation.

 

We have four wholly owned subsidiaries:

 

  ● Precision Analytic Testing, LLC, a Florida limited liability company (“PAT”) formed on May 11, 2019;
  ● NutraDerma Technologies, Inc., (“NutraDerma”) a Florida corporation formed on January 28, 2019;
  ● PhytoChem Technologies, Inc., a Florida corporation (“PhytoChem”) formed on February 4, 2019; and
  ● TransDermalRX, Inc., a Florida corporation (“TransDermal”) formed on February 8, 2019.

 

Smaller Reporting Company

 

The Company is a “smaller reporting company” as defined in Rule 12b-2 under the Exchange Act. There are certain exemptions available to us as a smaller reporting company, including: (1) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act; (2) scaled executive compensation disclosures; and (3) the requirement to provide only two years of audited financial statements, instead of three years. As long as we maintain our status as a “smaller reporting company,” these exemptions will continue to be available to us.

 

Bankruptcy, Receivership or Similar Proceedings

 

We have not been involved in a bankruptcy receivership or similar proceeding. Additionally, we have not been involved in a reclassification, merger, consolidation, or purchase or sale of a significant amount of assets not in the ordinary course of business.

 

Our Business

 

We are a manufacturer and distributor of nutraceutical, dietary, wellness and other products, such as skincare and sanitizer products. Our products are sold to private label distributors who sell the products we manufacture under their own brand names as well as under our own brand names. We generate revenues from the sales of our products.

 

For the years ending on December 31, 2021 and 2020, we generated revenues of $626,619 and $1,255,784, respectively, from the sale of our products.

 

In March 2017, we began selling CBD products. For the years ending on December 31, 2021 and 2020, we generated revenues of $516,747 and $66,807 respectively, from the sale of our CBD products, representing 98% and 5.65% of our revenues for such periods.

 

Our Products and Services

 

We manufacture and distribute private label and branded products. In both of the years ended December 31, 2021 and 2020, private label sales represented 82% of our revenue.

 

Our Products

 

Our CBD products are derived from the seeds and mature stalks of the Cannabis Sativa plant which includes all parts and varieties of the cannabis sativa plant also known as hemp, which contain a tetrahydrocannabinol concentration (“THC”) that does not exceed 0.3 percent on a dry-weight basis. In December of 2018, the U.S. Food and Drug Administration completed an evaluation of three generally recognized as safe (GRAS) notices for hemp seed-derived food ingredients. The FDA stated that hulled hemp seed (GRN765), hemp seed protein powder (GRN771), and hemp seed oil (GRN778) are GRAS under their intended conditions of use.

 

Our CBD products are made from seeds and mature stalks of hemp and contain only trace amounts of THC which are far below 0.3 percent, and we believe they qualify as GRAS products.

 

5
 

 

Our CBD products include:

 

  ● Cannabinoid-rich hemp oil derived from industrial hemp;
  ● Tinctures;
  ● Topical lotions and oils applied directly to the skin designed to treat pain or inflammation;
  ● Face creams;
  ● Massage oils;
  ● Nutraceutical Sprays with CBD as an added ingredient; and
  ● Pet products taken internally.

 

Our other products include:

 

  ● Eddie’s Clean Hands
  ● Eddie’s Immune Boost
  ● INVISIPatch Bug Patch
  ● PCR- Pure

 

Recent Developments

 

In November of 2018, PAT began providing bulk material analytical, identity, potency and purity testing of raw industrial hemp.

 

In January of 2019, NutraDerma acquired the patent for a natural dermal skin patch that is designed to prevent mosquito and other insect bites.

 

In February of 2019, Phytochem entered into an agreement with Owen Morgan, an individual, whereby Mr. Morgan agreed to provide certain know how and services to Phytochem for the commercialization of certain technologies to separate and/or process the components of hemp to remove and/or modify, purify, dilute and extract bioactive ingredients and/or remove unwanted substances to produce finished products for a variety of applications. This agreement is further described under the heading “Material Agreements” below.

 

In March of 2019, we licensed our technology for a unique system for pharmaceutical grade delivery of testosterone into the human body to licensed pharmacist, Orlando Pharmacy, as further described under the heading “Material Agreements” below.

 

In March of 2019, we entered into an agreement with NewLeaf Assets, LLC, a Delaware Limited Liability Company (“NewLeaf”) as amended, (the “Agreement”) whereby NewLeaf invested an aggregate of $1,380,000 (the “Investment”) in our securities. This Agreement is further described under the heading “Material Agreements” below.

 

On June 7, 2019, the Company granted a bonus to its Chief Executive Officer and President, Edgar Ward, of ten percent (10%) of the future gross revenue generated by PhytoChem for a period of seven (7) years from the date that PhytoChem receives its first revenue.

 

In June 2019, and as amended in November 2019, we entered into an investment agreement, note, Security Agreement, Purchase Royalty Agreement, Pledge Agreement, Pledgor Royalty Agreement with PhytoChem Technologies, Inc., Kahn Family Limited PT II., and Brenda Hamilton as the pledgor, which were subsequently amended in November of 2019. The foregoing agreements are further described under the heading “Material Agreements” below.

 

Amid the COVID-19 global pandemic, in 2020, the Company made a strategic pivot from our then-current nutraceutical manufacturing business by adding the manufacture of consumer sanitizer products utilizing the Company’s existing manufacturing capabilities and the Company’s ability to retrofit its operations and accommodate production due to the shortage of supply and demand for sanitizer products. To do so, consistent with Food and Drug Administration (FDA) requirements, the Company registered and obtained a labeler code as an over-the-counter (OTC) manufacturing facility and began manufacturing and distributing a line of liquid-based multi-use sanitizer spray products under the Company’s in-house brand, “Eddie’s Clean Hands,” packaged as a multi-use sanitizer spray, formulated per the CDC’s recommendation of containing at least 60-95% ethanol or isopropanol alcohol to be effective.

 

In May 2020, we secured a supplier agreement with Grainger, and began drop-shipping its sanitizer products that include a 10-pack of Eddie’s Clean Hands 2 oz. sanitizer spray along with a larger 8 oz. sanitizer spray directly to Grainger and its customers. Grainger is a broad line, business-to-business distributor of maintenance, repair, and operating (MRO) products and services with operations primarily in North America, Japan, and Europe.

 

6
 

 

On September 30, 2020, the Company filed Articles of Amendment (the “Amendment”) to its Articles of Incorporation with the Florida Department of State that contained a Certificate of Designations to designate one hundred and ten (110) shares of the preferred stock of the Company, par value $0.0001 as Series B Convertible Preferred Stock (the “Series B Preferred Stock”). The Amendment was effective on September 30, 2020.

 

On November 2, 2020, the Company entered into a Stock Purchase Agreement with Lord Global Corporation and its wholly owned subsidiary, 27 Health Inc., and also entered into a Manufacturing, Distribution and Sales Agreement (the “MDS”) with 27 Health Inc. The MDS is a multi-year production, fulfillment, and distribution agreement with 27 Health Inc. to launch its patent-pending Oral Sanitizer mouth spray which we hope will provide some protection from viruses by reducing viral transmission. The foregoing agreements are further described under the heading “Material Agreements” below.

 

On December 18, 2020, the Company received its product registration number from the Food and Drug Administration (FDA) and completed its first production run of Oral Shield antiseptic protection mouth spray. The Company along with its partners plans to market and distribute the product on a global scale and seeks to provide a convenient, travel-size, quality, multi-functioning antiseptic mouth spray for consumers to use throughout the day. We believe that mouthwash products can be effective at killing viruses, reducing the viral load within the mouth essentially supporting the reduction of virus transmissions.

 

In September 2021, the Company entered a strategic partnership with KOR Medical to produce an initial order for a line of cannabinoid-based wellness products. The initial products produced under this venture is a line of four ingestible items formulated to help improve overall health, including helping consumers sleep better, feel better, be calmer, and improve their quality of life.

 

In November 20, 2021 the Company executed a definitive agreement with Cookie Retail Products, LLC (“CRP”) for a strategic partnership with Cookies (branded) Retail Products. Under the terms of the agreement, CRP will provide the Company with branding and marketing guidance while the Company becomes a preferred research and development profit participant and partner of CRP. The Company will utilize its nutraceutical and research resources to design, create, and provide options for non-regulated, federally legal for sale, innovative product introductions to be used for the parent Cookies brand. Cookies is an iconic billion-dollar brand with retail, ecommerce, and direct-to-consumer verticals across multiple channels of trade.

 

Our Operating Strategy

 

The Company manufactures and distributes unique dietary supplements, sold directly to consumers, as well as through retail and wholesale outlets. We are dedicated to bringing the highest quality, most beneficial, effective nutrients and delivery systems to the market. With over 35 years’ experience in nutritional supplementation, we know the importance of products that are natural and highly effective in maintaining one’s healthy lifestyle.

 

The Company’s products are formulated to cater to the daily health needs of men and women, and feature revolutionary nutrient delivery systems, such as oral sprays, tincture droppers, blast caps and nutritional drinking straws. These methods are approved for pharmaceutical and nutraceutical use and have been hailed for their convenience and precision.

 

The Company entered into strategic partnership with Cookies (branded) Retail Products (CRP). Under the terms of the agreement, CRP will provide the Company with branding and marketing guidance while the Company becomes a preferred research and development profit participant and partner of CRP. The Company will utilize its nutraceutical and research resources to design, create, and provide options for non-regulated, federally legal for sale, innovative product introductions to be used for the parent Cookies brand. Cookies is an iconic billion-dollar brand with retail, ecommerce, and direct-to-consumer verticals across multiple channels of trade.

 

In conjunction with recent private-label agreements, the Company is in the process of expanding its manufacturing operations and capabilities to accommodate the production of several new products expected to be released in the near future. These products include an immune booster drink shot infused with CBDA. CBDA along with CGBA have been found to “bind to the SARS-CoV-2 spike protein, blocking a critical step in the process the virus uses to infect people.” Steve Lundeberg, Oregon State University.

 

The Company is also preparing an application for a planned uplisting to the OTCQB, with the objectives of increasing its visibility and exposure within the North American financial community, and creating additional value for shareholders.

 

7
 

 

We plan to continue the development, manufacturing and distribution of nutritional dietary and skincare products and we believe a number of current industry trends will increase demand for private label products particularly in the industrial hemp CBD market. Our operating strategy for such products consists of the following key elements:

 

  ● We purchase raw materials and produce goods only upon receipt of a firm commitment from our private label customers and we require payment in full prior to shipping. Once a product is shipped to a customer, we generally do not accept returns unless the product is defective or delivered late. These practices minimize our need to carry unsold inventories.
  ● We regularly update our product line to keep up with consumer trends and industry developments.
  ● We provide superior customer service by controlling the entire production process of our products. By controlling the production process, we have the ability to tailor products to a customer’s specific needs, offer customers rapid order turnaround time, maintain flexible scheduling and maintain higher standards of quality control.
  ● We seek to add value to customers’ overall merchandising effort. We work closely with our customers to develop distinctive product lines at their particular price points. We believe that this process allows our customers to achieve a degree of differentiation from their retail competitors. We believe our ability to develop, manufacture and offer high quality, all-natural products is a competitive advantage and will lead to increased orders.
  ● We emphasize the development of long-term relationships with our customers by providing a high level of customer service through our sales force. We seek to capitalize on our knowledgeable and experienced sales force by maintaining regular interaction with our customers which provides us with an understanding of which products will meet their particular needs.

 

Our Growth Strategy

 

We intend to grow our business by pursuing the following strategies:

 

  ● We plan to continue to expand our manufacture of consumer products.
  ● We also plan to continue to brand ourselves as a High Quality GMP Compliant manufacturer of industrial hemp CBD products. Many manufacturers of CBD based products do not operate in compliance with GMP standards. All of our CBD products are tested at multiple stages of the production process to ensure product quality and a THC content of less than 0.3%.
  ● We will seek to increase sales to our existing customers by expanding sales of additional products. Certain of our customers began their relationship with us by purchasing only one of our products. Since these initial purchases, we have been able to expand our sales to such customers to multiple products. This strategy has enabled us to expand our product sales to our existing customers over time. We aggressively pursue these cross-selling opportunities. Our range of products enables us to pursue many of these cross-selling opportunities.
  ● We seek to increase sales to customers by offering products in categories outside of our traditional product offerings.
  ● We plan to leverage our sales, reputation for quality all-natural products to expand our customer base to other private label customers within the industrial hemp CBD and Nutraceutical markets.

 

8
 

 

Our Customers

 

Our customers for our consumer sanitizer products include Grainger, Riverhead Chamber of Commerce and ecommerce direct to consumer consumers.

 

Our private label sales represent several different brands of products manufactured by us. Sales to private label customers represented approximately 82% and 99% of our revenues for the years ended December 31, 2021 and 2020, respectively. Our industrial hemp CBD products represented 98% and 100% of private label sales in the years ended December 31, 2021and 2020, respectively.

 

We do not enter into long term contracts with our private label distributors and all sales are made by purchase order. Our private label customers are not obligated to order a minimum amount of product from us and can discontinue purchasing our product at any time.

 

We believe our private label products offer numerous benefits to our customers:

 

  ● Our private label products are premium products.
  ● Our private label products offer the opportunity for higher profit margins than brand name products.
  ● Distributing private label products builds brand recognition for the retail as well as the wholesale customer.
  ● We are registered with the FDA and follow GMP in the manufacturing process ensuring high quality products and consistent standards for our private label customers.
  ● Businesses using our private label products avoid the additional expense of manufacturing and creating the finished product.
  ● Our private label customers are able to focus their attention and resources on their business and not on manufacturing a final product.
  ● We believe that we offer high quality unique products with enhanced delivery systems that are effective and appealing to consumers.
  ● We offer a wide range of private label products providing our customers with a variety of options.

 

Manufacturing

 

As noted above, the Company entered into strategic partnership with Cookies (branded) Retail Products (CRP). Under the terms of the agreement, CRP will provide the Company with branding and marketing guidance while the Company becomes a preferred research and development profit participant and partner of CRP. The Company will utilize its nutraceutical and research resources to design, create, and provide options for non-regulated, federally legal for sale, innovative product introductions to be used for the parent Cookies brand. Cookies is an iconic billion-dollar brand with retail, ecommerce, and direct-to-consumer verticals across multiple channels of trade.

 

Also noted above, in 2020, the Company made a strategic pivot from our then-current nutraceutical manufacturing business by adding the manufacture of consumer sanitizer products utilizing the Company’s existing manufacturing capabilities and the Company’s ability to retrofit its operations and accommodate production due to the shortage of supply and demand for sanitizer products. To do so, consistent with FDA requirements, the Company registered and obtained a labeler code as an OTC manufacturing facility and began manufacturing and distributing a line of liquid-based multi-use sanitizer spray products under the Company’s in-house brand, “Eddie’s Clean Hands,” packaged as a multi-use sanitizer spray, formulated per the CDC’s recommendation of containing at least 60-95% ethanol or isopropanol alcohol to be effective. We plan to continue manufacturing and distributing liquid-based multi-use sanitizer spray products under the Company’s in-house brand, “Eddie’s Clean Hands”.

 

Also, as discussed above, on December 18, 2020, the Company received its product registration number from the FDA and completed its first production run of Oral Shield antiseptic protection mouth spray. The Company along with its partners plans to market and distribute the product on a global scale and seeks to provide a convenient, travel-size, quality, multi-functioning antiseptic mouth spray for consumers to use throughout the day. We believe that mouthwash products can be effective at killing viruses, reducing the viral load within the mouth essentially supporting the reduction of virus transmissions.

 

9
 

 

Once developed, our products are manufactured at our facility in Coconut Creek, Florida. We obtain all raw materials and ingredients for our products from third party suppliers. For all orders we receive, we manufacture, package, label and ship the product to the customer. We lease an aggregate of six thousand four hundred (6,400) square feet of office and warehouse space at 6601 Lyons Rd, Suites L-6&7, Coconut Creek, Florida 33073. Approximately five thousand eight hundred (5,800) square feet at this location is used for manufacturing, storage and distribution of our products.

 

On June 6, 2017, we entered into an agreement to lease nineteen thousand eight hundred and thirty-one (19,831) square feet in Deerfield Beach, FL 33441. We plan to use seventeen thousand eight hundred (17,800) square feet of the new Deerfield Beach location for manufacturing, storage and distribution of our products. We expect to begin manufacturing at this location in July of 2022.

 

By manufacturing our own products, we believe that we maintain better control over product quality and availability while also reducing production costs. Our manufacturing process generally consists of the following operations: (a) sourcing ingredients for products, (b) warehousing raw ingredients, (c) efficacy testing and measuring ingredients for inclusion in products, and (d) blending using automatic equipment. The next step, bottling and packaging, involves filling, capping, coding, labeling and placing the product in packaging with appropriate tamper-evident features then sending the packaged product to our customers.

 

The FDA requires companies manufacturing homeopathic medicines to have their facilities certified as Good Manufacturing Practices (“GMPs”). Our manufacturing facility is registered with the FDA and is compliant with its GMP certification. Our quality control program seeks to ensure the superior quality of our products and that they are manufactured in accordance with current GMP. Our processing methods are monitored closely to ensure that only quality ingredients are used and to ensure product purity. Periodically, we retain the services of outside GMP audit firms to assist us in our efforts to comply with GMPs.

 

Sources and Availability of Raw Materials

 

The raw materials for our industrial hemp CBD products consist of Cannabidiol rich oil and isolate. We obtain the raw materials for our industrial hemp CBD products from state licensed suppliers. We obtain the raw materials for our other non-CBD based products from several ingredient suppliers located in the U.S. These raw materials consist of naturally derived vitamins and nutrients. The raw materials used by us are available from a variety of suppliers. We maintain a good relationship with our suppliers and do not anticipate that any of our suppliers will terminate their relationship with us in the near term. We have ongoing relationships with secondary and tertiary suppliers. In the event we are unable to obtain any of our raw materials from our suppliers; we believe that we could obtain alternative sources of any raw materials from other suppliers. We do not have contracts with our suppliers and we order our raw materials on an as needed basis. We have not experienced any material adverse effects on our business as a result of shortages of raw materials or packaging materials used in the manufacturing of our products. An unexpected interruption or a shortage in supply of raw materials could adversely affect our business derived from these products.

 

Shipping and Delivery of Finished Products

 

Upon completion of the manufacturing process, our products are shipped directly to customers. Private label products are packaged by us in the packaging provided by each customer. All shipping, bills of lading and invoices are generated by us from our Coconut Creek, Florida facility.

 

We ship the product ordered within forty-five (45) days to our private label distributors, thirty (30) days to retail customers and within thirty (30) days to wholesale and third party (non-private label) distributors. All orders are shipped by freight delivery at the cost of the customer. We require a deposit of fifty percent (50%) upon an order being placed from our private label customers and the balance prior to shipping. Our retail customers must pay for their order at the time that the order is placed.

 

Product Development & Quality

 

We have in place comprehensive quality control procedures seeking to ensure that raw materials and finished goods meet our exacting quality standards. Each product we offer is based upon the research of Mr. Ward, with the assistance of our team and in-house chemists. Our products are and, in the future, will continue to be identified by Mr. Ward based upon suggestions from customers, and from industry and market research he conducts on an ongoing basis. We do not employ medical professionals and our management does not have experience in the healthcare industry or in the treatment of disease. Our products have not been confirmed in any respect by the FDA or any other governmental agency and may not produce the results intended. In developing products, we require:

 

  ● ingredients that are supported with a certificate of analysis, publicly available scientific research and references which our Chief Executive Officer reviews with our in-house chemists who assist in developing our final products;
  ● ingredients that are combined so that their effectiveness is not impaired;

 

10
 

 

  ● the THC contained in our products is less than 0.3% and all other ingredients are in dosage levels that fall within tolerable upper intake levels established for healthy people by the Institute of Medicine of the National Academies and products with hemp;
  ● our products do not contain adulterated ingredients such as ephedra, androstenedione, aspartame, steroids, or human growth hormones; and

 

Sales and Marketing

 

Mr. Ward actively participates in the planning of our marketing and selling efforts. We employ 1 in house sales representative and use the services independent sales representatives on a commission basis. We believe that this sales structure enables us to effectively control our costs and sales efforts.

 

We believe that our marketing mix of social media promotions and search engine optimization is an optimal strategy to increase sales for both our private label and branded products. We use web-based marketing to promote our brands and products including social media and promotion of our website at www.nutralifebiosciences.com. The information available on or accessible through our website is not a part of and is not incorporated by reference into this Annual Report. Our website provides useful information about our industry, new developments and our products and allows visitors to order our retail and wholesale wellness, nutraceutical and CBD products. We use Search Engine Optimization (SEO) on an ongoing basis to drive traffic to our website and social media pages and enhance our presence on major search engines such as Google, Bing and Yahoo.

 

We aim to emphasize the development of long-term relationships with our customers. We believe that we have established strong relationships with individual buyers at each of our private label customers, and more importantly we have also established relationships with senior management of our key private label customers.

 

A key component of our ability to achieve long-term relationships is the high level of services that we provide to our customers. Each salesperson is responsible for all aspects of a customer’s needs, including product samples, obtaining orders, coordinating product selection, monitoring production and delivering finished products. During the production process, such salesperson is responsible for informing the customer about the progress of an order, including any difficulties that might affect delivery time. In this way, we and our customer can make appropriate arrangements regarding any delay or other change in the order. Further, we seek to ensure that multiple salespersons are familiar with each customer account so that they can work cooperatively to assist one another on a reciprocal basis. We believe that this sales management technique provides an advantage over our competitors because it ensures that our customers always have a knowledgeable salesperson available to discuss product orders and related issues.

 

Our sales force is in constant contact with our customers to develop an understanding of the customers’ retail strategies and production requirements. We use this information to provide our customers with products that meet their particular requirements efficiently. We require that our sales force be knowledgeable about all aspects of our products. We believe our knowledgeable sales force enables it to provide our customers immediate feedback as to the various costs and availability of various raw materials, and production times.

 

Employees

 

As of the date hereof, we have approximately 12 full-time and part-time employees. 1 employee is a chemist engaged in product development and testing, 3 are engaged in executive or administrative capacities, 7 employees are engaged in manufacturing, packaging, or distribution and 1 is engaged in sales.

 

From time to time, we employ temporary employees which provides us with flexibility to adjust staffing levels in response to demand.

 

None of our employees are employed under a collective bargaining agreement. We believe we have an excellent relationship with our employees and independent contractors.

 

11
 

 

Return and Refund Policy

 

We will exchange any product found to be defective. A written exchange request must be submitted when a customer returns defective or damaged products. Purchasers can apply for a refund in the full amount of purchased products within ten (10) days of purchase. All shipping fees for product exchanges or returns must be paid by the purchaser. Historically, product returns as a percentage of our net sales have been nominal.

 

Patents and Trademarks

 

NutraDerma holds patent number 7,754,237 from the U.S. Patent and Trademark office, for an all-natural dermal patch designed to prevent mosquito and other insect bites. We plan to begin to test, manufacture and distribute this product in the near future.

 

Backlog of Orders

 

We have no backlog of orders.

 

Seasonal Aspect of our Business

 

None of our products are affected by seasonal factors.

 

Status of any Publicly Announced New Product or Service

 

As noted above, the Company entered into a strategic partnership with Cookies (branded) Retail Products (CRP). Under the terms of the agreement, CRP will provide the Company with branding and marketing guidance while the Company becomes a preferred research and development profit participant and partner of CRP. The Company will utilize its nutraceutical and research resources to design, create, and provide options for non-regulated, federally legal for sale, innovative product introductions to be used for the parent Cookies brand. Cookies is an iconic billion-dollar brand with retail, ecommerce, and direct-to-consumer verticals across multiple channels of trade.

 

In September 2021, the Company entered a strategic partnership with KOR Medical to produce an initial order for a line of cannabinoid-based wellness products. The initial products produced under this venture is a line of four ingestible items formulated to help improve overall health, including helping consumers sleep better, feel better, be calmer, and improve their quality of life.

 

As noted above, in 2020, the Company made a strategic pivot from our then-current nutraceutical manufacturing business by adding the manufacture of consumer sanitizer products utilizing the Company’s existing manufacturing capabilities and the Company’s ability to retrofit its operations and accommodate production due to the shortage of supply and demand for sanitizer products. To do so, consistent with FDA requirements, the Company registered and obtained a labeler code as an OTC manufacturing facility and began manufacturing and distributing a line of liquid-based multi-use sanitizer spray products under the Company’s in-house brand, “Eddie’s Clean Hands,” packaged as a multi-use sanitizer spray, formulated per the CDC’s recommendation of containing at least 60-95% ethanol or isopropanol alcohol to be effective. We plan to continue manufacturing and distributing liquid-based multi-use sanitizer spray products under the Company’s in-house brand, “Eddie’s Clean Hands”.

 

Also, as discussed above, on December 18, 2020, the Company received its product registration number from the FDA and completed its first production run of Oral Shield antiseptic protection mouth spray. The Company along with its partners plans to market and distribute the product on a global scale and seeks to provide a convenient, travel-size, quality, multi-functioning antiseptic mouth spray for consumers to use throughout the day. We believe that mouthwash products can be effective at killing viruses, reducing the viral load within the mouth essentially supporting the reduction of virus transmissions.

 

12
 

 

Material Agreements

 

Cookies Retail Products

 

As noted above, the Company entered into strategic partnership with Cookies (branded) Retail Products (CRP). Under the terms of the agreement, CRP will provide the Company with branding and marketing guidance while the Company becomes a preferred research and development profit participant and partner of CRP. The Company will utilize its nutraceutical and research resources to design, create, and provide options for non-regulated, federally legal for sale, innovative product introductions to be used for the parent Cookies brand. Cookies is an iconic billion-dollar brand with retail, ecommerce, and direct-to-consumer verticals across multiple channels of trade.

 

NewLeaf Assets LLC

 

On March 10, 2019, we entered into an agreement with NewLeaf as amended, (the “Agreement”) whereby NewLeaf invested an aggregate of $1,380,000 (the “Investment”) in our securities (the “Securities”) as follows:

 

(a) NewLeaf invested the sums of $250,000, $130,000 and $1,000,000 on July 31, 2018, August 31, 2018 and March 15, 2019, respectively;
(b) On July 31, 2018 NewLeaf was granted 2,000,0000 shares of our common stock and warrants to purchase 625,000 shares at the price of $.20 per share at any time for a period of three (3) years;
(c) On August 31, 2018 NewLeaf received warrants to purchase 325,000 shares of our common stock at the price of $.20 per share at any time for a period of three (3) years;
(d) On March 15, 2019, NewLeaf invested the sum of $1,000,000; and
(e) On March 15, 2019, we issued 13,764,705 common shares, warrants to purchase an additional 10 million common shares at the price of $.20 per share at any time until March 4, 2022 and an option to purchase an aggregate of 7,647,058 common shares at the aggregate price of $650,000 at any time prior to April 8, 2019. This option was not exercised prior to such date.

 

As of the date of the filing of this report, NewLeaf holds an aggregate of 15,764,705 of our common shares. The warrants to purchase an additional 10,950,000 common shares for an aggregate price of $2,190,000 at any time until March 4, 2022 and the option to purchase an additional 7,647,058 common shares for an aggregate price of $650,000 at any time prior to April 8, 2019, were not exercised prior to such dates.

 

The Company paid a finder’s fee of 10% in connection with the Investment to Mitchell Pasin. Under the terms of the Agreement, if NewLeaf sells, assigns, gifts or otherwise transfers any portion of the Securities to any other person or entity (the “Transferees”), the aggregate amount of the Securities that may be sold by all NewLeaf and the Transferees in the aggregate shall be 1% of the Company’s then outstanding common shares every ninety (90) days.

 

June 2019 Investment Agreement, Note, Security Agreement, Purchase Royalty Agreement, Pledge Agreement, Pledgor Royalty Agreement and November 2019 Amendments Thereto

 

June 2019 Investment Agreement

 

On June 6, 2019, the Company entered into that and Investment Agreement (the “June 2019 Investment Agreement” and collectively with the June 2019 Note, the June 2019 Purchaser Royalty Agreement, the June 2019 Security Agreement, the June 2019 Pledgor Royalty Agreement and the June 2019 Mortgage, each as hereinafter defined, the “Transaction Documents” by and among the Company, PhytoChem and Kahn Family Limited PT II (the “Purchaser”). Pursuant to the terms of the June 2019 Investment Agreement, the Company agreed to issue and sell, and the Purchaser agreed to purchase, a full recourse secured convertible promissory note bearing interest at the rate of 8.5% per annum in the principal amount (the “Principal Amount”) of $1,000,000 (the “June 2019 Note”). In addition to repayment of the June 2019 Note and the payment of interest as set forth in the June 2019 Note, the Company agreed to pay the following consideration to the Purchaser: (i) 500,000 shares of the Company’s common stock, and (ii) 8.5% of the revenue generated from the first four of the Ennea Processors monetized and/or commercialized by the Company pursuant to an agreement by and between Owen J. Morgan and the Company dated February 4, 2019 (the “Collateral Processors”) while the Principal Amount of the June 2019 Note is outstanding and 5.0% thereafter as set forth in that certain Royalty Participation Agreement dated June 6, 2019 by and among the Company, PhytoChem and the Purchaser (the “June 2019 Purchaser Royalty Agreement”).

 

13
 

 

Pursuant to the terms of the June 2019 Investment Agreement, the Principal Amount of the June 2019 Note is secured by the Collateral Processors in accordance with the terms of the June 2019 Note and that certain Security Agreement (the “June 2019 Security Agreement”) dated June 6, 2019 by and among the Company, PhytoChem and the Purchaser. The Principal Amount of the June 2019 Note is also secured by certain real property (the “Real Property”) owned by Brenda Hamilton (the “Pledgor”) pursuant to the terms of that certain Pledge Agreement (the “June 2019 Pledge Agreement”) dated June 6, 2019 by and among NutraLife, PhytoChem, the Pledgor and the Purchaser. Pursuant to the terms of the June 2019 Investment Agreement and the mortgage on the Real Property (the “June 2019 Mortgage”), the June 2019 Mortgage will be reduced by any and all consideration of any nature that is paid to the Purchaser by the Company under the Transaction Documents.

 

The June 2019 Investment Agreement provides that any controversy or claim arising out of or relating to the June 2019 Investment Agreement will be settled by binding arbitration and judgment on the award entered in any court having jurisdiction.

 

The Agreement contains customary representations, warranties and conditions.

 

June 2019 Note

 

On June 6, 2019, the Company issued the June 2019 Note in the Principal Amount of $1,000,000. Pursuant to the terms of the June 2019 Note, the entire outstanding principal balance of the June 2019 Note matures on December 7, 2020. The June 2019 Note provides that until such time as the Principal Amount of the June 2019 Note has been paid in full, interest will accrue at the fixed rate of 8.5% per annum. Beginning July 7, 2019 and through December 7, 2019, the Company agreed to make interest only payments at a fixed rate of 8.5% per annum on the Principal Amount of the June 2019 Note. Beginning on January 7, 2020 and continuing until the maturity date, the Company agreed to make equal monthly installment payments of principal and interest at the fixed rate of 8.5% per annum in an amount sufficient to fully amortize the Principal Amount of the June 2019 Note and all accrued interest over an amortization period of 12 months, until the amounts due under the June 2019 Note are paid in full.

 

Pursuant to the terms of the June 2019 Note, all payments made by the Company to the Purchaser under the Transaction Documents, including but not limited to the June 2019 Note, will be first applied to the Principal Amount then to accrued interest outstanding. Any and all consideration paid by the Company to the Purchaser under the Transaction Documents will reduce the amounts secured by the June 2019 Mortgage without affecting the amounts owed by the Company to the Purchaser under the Transaction Documents. The June 2019 Note is secured by the Collateral Processors pursuant to the terms of the June 2019 Investment Agreement and the June 2019 Security Agreement. The Company agreed to deliver a pledge of the Real Property to secure the Principal Amount pursuant to the terms of the June 2019 Pledge Agreement and June 2019 Mortgage, and the June 2019 Mortgage will be reduced from time to time by the consideration paid by the Company to the Purchaser. Simultaneously with the payment of consideration equal to the Principal Amount of the June 2019 Note, the Purchaser will record with the Palm Beach County Property Appraiser’s Officer a Satisfaction of the Mortgage releasing the Purchaser’s June 2019 Mortgage on the Real Property.

 

In the event of a default of the June 2019 Note, Purchaser has full recourse to all the assets of the Company and the Purchaser will be required to proceed against or exhaust all remedies against both the Company and PhytoChem’s assets prior to proceeding against the June 2019 Mortgage and/or commencing an action to foreclose the June 2019 Mortgage.

 

At any time while the June 2019 Note is outstanding, the Purchaser will have the option of converting the Principal Amount and accrued interest due on the June 2019 Note into common stock of the Company at a price of $1.00 per share. Upon conversion of the Principal Amount and/or interest, the Company will be forever released from all of its obligations and liabilities under the June 2019 Note. In the event Purchaser converts less than all principal and interest outstanding, the amount converted under the June 2019 Note will be first applied to reduce the principal until it is paid in full. Additionally, upon conversion of all outstanding principal at the time of conversion, the June 2019 Mortgage will be released as security for the obligations and liabilities under the June 2019 Note.

 

For purposes of the June 2019 Note, an event of default means that the Company has failed to make any payment required under the June 2019 Note within 15 days after the date the payment is due. If the Company is in default under the June 2019 Note, the unpaid principal and accrued interests and any other unpaid amounts and costs due will bear interest at the rate of 10% (the “Default Rate”) until the event of default is cured. From and after the Maturity Date any unpaid principal and interest and any other unpaid amounts and costs under the June 2019 Note will bear interest at the Default Rate. Additionally, and without limitation, all amounts owed under any judgment obtained by Purchaser against the Company with respect to the June 2019 Note will bear interest at the Default Rate. The June 2019 Note provides that any controversy or claim arising out of or relating to the June 2019 Note will be settled by binding arbitration and judgment on the award entered in any court having jurisdiction.

 

14
 

 

June 2019 Security Agreement

 

Pursuant to the terms of the June 2019 Security Agreement, the Company assigned and granted to the Purchaser a continuing lien on and security interest in the Collateral. The Company agreed that it would not sell or offer to sell or otherwise transfer or grant or allow the imposition of a lien or security interest upon the Collateral or use any portion thereof in any manner inconsistent with the June 2019 Security Agreement or with the terms and conditions of any policy of insurance thereon. The Company also irrevocably authorized Purchaser at any time and from time to time to file in any Uniform Commercial Code (“UCC”) jurisdiction any initial financing statements and amendments thereto relating to the Collateral as provided in the June 2019 Security Agreement.

 

The Company will, at the Purchaser’s option, be in default under the June 2019 Security Agreement upon the happening of any of the following events or conditions (each, a “June 2019 Security Agreement Event of Default”): (a) a failure to pay any amount due under the June 2019 Note or the June 2019 Security Agreement within 15 days after the due date; (b) failure by the Company to perform any of its other obligations under the June 2019 Security Agreement within 30 days of notice from Purchaser of the same; (c) falsity, inaccuracy or material breach by the Company or any written warranty, representation or statement made or furnished to the Purchaser by or on behalf of the Company; (d) an uninsured material loss, theft, damage, or destruction to any of the Collateral, or the entry of any judgment against the Company or any lien against or making of any levy, seizure or attachment of or on the Collateral; or (e) the failure of the Purchaser to have a perfected first priority security interest in the Collateral.

 

Upon the occurrence of any June 2019 Security Agreement Event of Default and at any time thereafter, the Purchaser may declare all obligations secured by the June 2019 Security Agreement immediately due and payable and will have, in addition to any remedies provided in the June 2019 Security Agreement or by any applicable law or in equity, all the remedies of a secured party under the UCC. The June 2019 Security Agreement provides that any controversy or claim arising out of or relating to the June 2019 Security Agreement will be settled by binding arbitration and judgment on the award entered in any court having jurisdiction.

 

If the Company is in default under the June 2019 Note, the unpaid principal and accrued interests and any other unpaid amounts and costs due will bear interest at the rate of 10% (the “Default Rate”) until the event of default is cured. From and after the Maturity Date any unpaid principal and interest and any other unpaid amounts and costs under the June 2019 Note will bear interest at the Default Rate. Additionally, and without limitation, all amounts owed under any judgment obtained by Purchaser against the Company with respect to the June 2019 Note will bear interest at the Default Rate.

 

June 2019 Purchaser Royalty Agreement

 

Pursuant to the terms of the June 2019 Purchaser Royalty Agreement, which has a 10-year term, commencing upon the fiscal quarter in which revenue is derived directly or indirectly from any of the Collateral Processors, the Company will pay to the Purchaser non-refundable royalty payments consisting of 8.5% of all Net Revenue (as defined in the June 2019 Purchaser Royalty Agreement) received by the Company as a result of the commercialization and/or monetization of the Collateral Processors until such time as the Principal Amount has been paid. At such time as the Principal Amount has been paid to the Purchaser, Purchaser will receive non-refundable royalty payments consisting of 5.0% of Net Revenue received by the Company as a result of the commercialization and/or monetization of the first two processors of the Collateral Processors. The royalty payments will be paid by the Company to the Purchaser within 15 days after the end of the quarter in which the Company receives payment for any Net Revenue from the Collateral Processors. The June 2019 Purchaser Royalty Agreement provides that any controversy or claim arising out of or relating to the June 2019 Purchaser Royalty Agreement will be settled by binding arbitration and judgment on the award entered in any court having jurisdiction.

 

15
 

 

June 2019 Pledge Agreement

 

Pursuant to the terms of the Pledge Agreement, to induce Brenda Hamilton (the “Pledgor”) to enter into the June 2019 Pledge Agreement and the Mortgage, the Company represented and warranted to the Pledgor and the Purchaser that the Company will timely pay all amounts owing to the Purchaser, and that it will deliver full and timely payment of all and any amounts due and/or which may become due to the Purchaser from the Company from time to time in connection with the Transaction Documents without limitation. Purchaser agreed that it understood that all consideration delivered to the Purchaser by the Company pursuant to the Transaction Documents will be applied to the Principal Amount and as a result, the Mortgage will be reduced by any and all payments of consideration of any type made by the Company to the Purchaser under the Transaction Documents.

 

In addition, under the terms of the June 2019 Pledge Agreement, based upon the representations of the Company and the Purchaser that they will perform and comply with their obligations and duties under the Transaction Documents, the Pledgor agreed to provide the Purchaser with the June 2019 Mortgage which will secure the Company’s payment of the Principal Amount pursuant to the Transaction Document. The June 2019 Mortgage will be reduced from time to time by any and all payments made by the Company to the Purchaser under the Transaction Documents. In exchange for providing the Real Property collateral, the Pledgor agreed to receive:

 

  (i) 500,000 shares of the Company’s common stock,
     
  (ii) Commencing on December 5, 2019, monthly payments equal to the interest paid by the Company to the borrower under the June 2019 Note accruing from time of the Purchaser’s delivery of the Principal Amount to the Company until the June 2019 Note is paid in full, and
     
  (iii) 8.5% of the Net Revenue while the Principal Amount is outstanding and 5.0% thereafter on the first two processors of the Collateral Processors as set forth in that certain Royalty Participation Agreement dated as of June 6, 2019 by and among the Company, PhytoChem and the Pledgor (the “June 2019 Pledgor Royalty Agreement”).

 

As set forth in the June 2019 Pledge Agreement, the terms including payment due dates and maturity dates of the June 2019 Note may not be extended by the Purchaser and the Company without the express written consent of the Pledgor. In the event that the June 2019 Note is amended or modified including to extend a payment due date or the maturity date of the June 2019 Note, without the Pledgor’s written consent, then Pledgor’s obligation to provide security under the June 2019 Pledge Agreement will automatically cease, and the June 2019 Mortgage will be deemed satisfied and released in full as security for the Principal Amount of the Amended Note, and (iii) the Purchaser will immediately record with the Palm Beach County Property Appraiser’s Officer a Satisfaction of Mortgage releasing the Purchaser’s lien on the Real Property.

 

Pursuant to the terms of the June 2019 Pledge Agreement, a default means that the Company has failed to make any payment required under the June 2019 Note, within 15 days after the date the payment is due. If after exhaustion of all other remedies, including enforcement of the lien against the Collateral and collection of all amounts due from the Company, there remains a default, then the Purchaser will provide written notice to the Pledgor of the default and the Pledgor will have the option but not the obligation to cure the default. In such event, the amounts paid by the Pledgor will bear interest at the highest rate allowed under Florida law. So long as the Company is in default of its obligations under the June 2019 Note, then the Company will pay the Pledgor interest on the amounts outstanding under the June 2019 Note at a rate of 10%.

 

If the Company defaults on its obligations under the June 2019 Note, the June 2019 Pledge Agreement or any of the other Transaction Agreements, the Company will reimburse the Pledgor on demand for (i) payments made by the Pledgor to Purchaser to cure a default by the Company under the June 2019 Investment Agreement and/or the June 2019 Note, and (ii) all costs and expenses, including attorneys’ fees and disbursements that the Pledgor incurs in exercising any right, power, or remedy provided by the June 2019 Note, the June 2019 Purchaser Royalty Agreement, the June 2019 Security Agreement, the June 2019 Pledgor Royalty Agreement, the June 2019 Mortgage or by law or defending any action arising out of the June 2019 Note, the June 2019 Purchaser Royalty Agreement, the June 2019 Security Agreement, the June 2019 Pledgor Royalty Agreement or the June 2019 Mortgage. Additionally, in the event of a default by the Company, all costs incurred and paid by the Pledgor will bear interest at the highest rate allowed under Florida law. The June 2019 Pledge Agreement provides that any controversy or claim arising out of or relating to the June 2019 Pledge Agreement will be settled by binding arbitration and judgment on the award entered in any court having jurisdiction.

 

16
 

 

June 2019 Pledgor Royalty Agreement

 

Pursuant to the terms of the June 2019 Pledgor Royalty Agreement, which has a 10-year term, commencing upon the fiscal quarter in which revenue is derived directly or indirectly from any of the Collateral Processors, the Company will pay to the Pledgor non-refundable royalty payments consisting of 8.5% of all Net Revenue received by the Company as a result of the commercialization and/or monetization of the Collateral Processors until such time as the Principal Amount has been paid. At such time as the Principal Amount has been paid to the Purchaser, the Pledgor will receive non-refundable royalty payments consisting of 5.0% of Net Revenue received by the Company as a result of the commercialization and/or monetization of the first two processors of the Collateral Processors. The royalty payments will be paid by the Company to the Pledgor within 15 days after the end of the quarter in which the Company receives payment for any Net Revenue from the Collateral Processors. The June 2019 Pledgor Royalty Agreement provides that any controversy or claim arising out of or relating to the June 2019 Pledgor Royalty Agreement will be settled by binding arbitration and judgment on the award entered in any court having jurisdiction.

 

Amended Investment Agreement

 

On November 13, 2019, the Company entered into an amended Investment Agreement (the “Amended Investment Agreement” and collectively with the Amended Note, the Amended Purchaser Royalty Agreement, the Amended Security Agreement, the Amended Pledgor Royalty Agreement and the Amended Mortgage, each as hereinafter defined, the “Amended Transaction Documents”) by and among the Company and the Purchaser. Pursuant to the terms of the Amended Investment Agreement, the Principal Amount of the Amended Note is secured by the current assets and future assets of the Company and its subsidiaries (the “Collateral”), including the Collateral Processors in accordance with the terms of provisions of the Amended Note and the Amended Security Agreement. Except as set forth herein, the terms of the Amended Investment Agreement are substantially similar to the terms of the June 2019 Investment Agreement.

 

Amended Note

 

Pursuant to the terms of the Amended Note dated November 13, 2019 from the Company to the Purchaser (the “Amended Note”), the entire outstanding principal balance of the Amended Note matured on December 7, 2020. The Amended Note provides that the Company make the first interest only payment on December 7, 2019 at the fixed rate of 5.75% per annum. Beginning January 7, 2020 and continuing until the maturity date, the Company agreed to make equal monthly instalment payments of principal and interest at the fixed rate of 5.75% per annum in an amount sufficient to fully amortize the Principal Amount of the Amended Note and all accrued interest over an amortization period of 18 months, until all amounts due under the Amended Note are paid in full. Interest will accrue from June 6, 2019 at the rate of 5.75% per annum until the maturity date of the Amended Note.

 

Pursuant to the terms of the Amended Note, all payments made by the Company to the Purchaser under the Transaction Documents, including but not limited to the Amended Note, will be first applied to the Principal Amount then to accrued interest outstanding. Any and all consideration paid by the Company to the Purchaser under the Transaction Documents will reduce the amounts secured by the Amended Mortgage without affecting the amounts owed by the Company to the Purchaser under the Transaction Documents.

 

The Amended Note is secured by the Collateral Processors, including the Collateral Processors. A pledge of the Real Property secures the Principal Amount pursuant to the terms of the Amended Pledge Agreement and Amended Mortgage, and the Amended Mortgage will be reduced from time to time by the consideration paid by the Company to the Purchaser. Simultaneously with the payment of consideration (whether interest, royalty and/or securities, as provided in the Amended Note and the Amended Investment Agreement) equal to the Principal Amount of the Amended Note, the Purchaser will record with the Palm Beach County Property Appraiser’s Officer a Satisfaction of the Mortgage releasing the Purchaser’s Amended Mortgage on the Real Property.

 

Pursuant to the terms of the Amended Note, Purchaser has full recourse to the Collateral and the Purchaser will be required to proceed against and exhaust all remedies against the Collateral prior to proceeding against the Amended Mortgage and/or commencing an action to foreclose the Amended Mortgage. Except as set forth herein, the terms of the Amended Note are substantially similar to the terms of the June 2019 Note.

 

Amended Security Agreement

 

Pursuant to the terms of an amended security agreement dated November 13, 2019 by and between the Company and the Purchaser (the “Amended Security Agreement”), the Company assigned and granted to the Purchaser a continuing lien on and security interest in the Collateral, including the Collateral Processors. Except as set forth herein, the terms of the Amended Security Agreement are substantially similar to the terms of the June 2019 Security Agreement.

 

17
 

 

Amended Purchaser Royalty Agreement

 

On November 13, 2019, the Company entered into that certain purchaser royalty agreement dated November 13, 2019 by and between the Company and the Purchaser (the “Amended Purchaser Royalty Agreement”). Aside from certain conforming changes, the terms of the Amended Purchaser Royalty Agreement are substantially similar to the terms of the June 2019 Purchaser Royalty Agreement.

 

Amended Pledge Agreement

 

On November 13, 2019, the Company entered into an amended pledge agreement by and among the Company, the Pledgor and the Purchaser (the “Amended Pledge Agreement”). Pursuant to the terms of the Amended Pledge Agreement, to induce Pledgor to enter into the Amended Pledge Agreement and the Mortgage, the Company and the Purchaser represented and warranted to the Pledgor that each of the Company and the Pledgor will timely comply with all requirements and obligations under the Transaction Documents and the Company will pay all amounts owing to the Purchaser, and that it will deliver full and timely payment of all and any amounts due and/or which may become due to the Purchaser from the Company from time to time in connection with the Transaction Documents without limitation. Purchaser agreed that it understood that all consideration delivered to the Purchaser by the Company pursuant to the Transaction Documents will be applied to reduce the Principal Amount secured by the Amended Mortgage and as a result, the Amended Mortgage will be reduced by any and all payments of consideration of any type (including cash or securities) made by the Company to the Purchaser under the Transaction Documents and the June 2019 Investment Agreement and June 2019 Note.

 

Pursuant to the terms of the Amended Pledge Agreement, based upon the representations of the Company and the Purchaser that they will perform and comply with their obligations and duties under the Transaction Documents, the Pledgor agreed to provide the Purchaser with the Amended Mortgage which will secure the Company’s payment of the Principal Amount pursuant to the Transaction Document. The Amended Mortgage will be reduced from time to time by any and all payments of any nature (including cash or securities) made by the Company to the Purchaser under the Transaction Documents. In exchange for providing the Real Property collateral, the Company agreed to pay to Pledgor:

 

  (i) 500,000 shares of the Company’s common stock, which were issued upon execution of the June 2019 Pledge Agreement,
     
  (ii) Commencing on December 7, 2019 and ending on the maturing date of the Amended Note, monthly payments equal to 5% interest on the Principal Amount accruing on the Principal Amount and accrued interest from June 6, 2019 until the maturity date of the Amended Note, and
     
  (iii) 8.5% of the Net Revenue so long as any portion of the Principal Amount is outstanding and 5.0% thereafter on the first two processors of the Collateral Processors as set forth in that certain Amended Royalty Participation Agreement dated as of November 13, 2019 by and among NutraLife, PhytoChem and the Pledgor (the “Amended Pledgor Royalty Agreement”).

 

As set forth in the Amended Pledge Agreement, the terms set forth in the Transaction Documents may not be extended by the Purchaser and the Company without the express written consent of the Pledgor so long as any portion of the Principal Amount is outstanding. In the event that any of the Transaction Documents is amended and/or modified in any respect without the Pledgor’s written consent while any portion of the Principal Amount is outstanding then (i) Pledgor’s obligation to provide security under the Amended Pledge Agreement will automatically cease, (ii) the Amended Mortgage will be deemed satisfied and released in full as security for the Principal Amount of the Amended Note, and (iii) the Purchaser will immediately record with the Palm Beach County Property Appraiser’s Officer a Satisfaction of Mortgage releasing the Purchaser’s lien on the Real Property at the cost of the Company.

 

Pursuant to the terms of the Amended Pledge Agreement, a default means that the Company has failed to make any payment required under the Amended Note, within 15 days after the date the payment is due. If after exhaustion of all other remedies, including enforcement of the lien against the Collateral and collection of all amounts due from the Company, there remains a default owed to the Purchaser, then the Purchaser will provide written notice to the Pledgor of the default and the Pledgor will have the option but not the obligation to cure the default. In such event, the amounts paid by the Pledgor to enforce its rights under the Amended Pledge Agreement will bear interest at the highest rate allowed under Florida law. So long as the Company is in default of its obligations under the Transaction Documents, then the Company will pay the Pledgor interest on the Principal and accrued interest outstanding under the Amended Note at the highest rate allowed under Florida law.

 

18
 

 

If the Company defaults on its obligations under the Amended Note, the Amended Pledge Agreement or any of the other Transaction Agreements, the Company will reimburse the Pledgor on demand for (i) payments made by the Pledgor to Purchaser to cure a default by the Company under the Amended Investment Agreement and/or the Amended Note, and (ii) all costs and expenses, including attorneys’ fees and disbursements that the Pledgor incurs in exercising any right, power, or remedy provided by the Amended Note, the Amended Purchaser Royalty Agreement, the Amended Security Agreement, the Amended Pledgor Royalty Agreement, the Amended Mortgage or by law or defending any action arising out of the Amended Note, the Amended Purchaser Royalty Agreement, the Amended Security Agreement, the Amended Pledgor Royalty Agreement or the Amended Mortgage. Additionally, in the event of a default by the Company, all costs incurred and paid by the Pledgor including but not limited to attorney fees and any amounts Pledgor pays to cure a default by the Company of the Amended Note will bear interest at the highest rate allowed under Florida law. Except as set forth herein, the terms of the Amended Pledge Agreement are substantially similar to the terms of the June 2019 Pledge Agreement.

 

Amended Pledgor Royalty Agreement

 

On November 13, 2019, the Company entered into the Amended Pledgor Royalty Agreement. Aside from certain conforming changes, the terms of the Amended Pledgor Royalty Agreement are substantially similar to the terms of the June 2019 Pledgor Royalty Agreement.

 

Company Default

 

The Company has not made the principal and interest payments on the Amended Note as of the date of this Annual Report. The Company now believes that it may have defences to the enforcement of the Transaction Documents as written, however this may not be the case. Additionally, the Purchaser has not indicated to the Company that it will seek to enforce its rights under the Transaction Documents or that it will proceed against the Collateral.

 

Stock Purchase Agreement

 

On November 2, 2020 (the “Closing Date”), the Company entered into a Stock Purchase Agreement (the “SPA”) by and between the Company, Lord Global Corporation, a Nevada corporation (the “Lord Global”) and 27 Health, Inc., a wholly-owned subsidiary of Lord Global (“27 Health”). Pursuant to the SPA, the Company acquired from Lord Global 250 shares of Series X Convertible Preferred Stock of Lord Global (the “Series X Stock”) in exchange for the issuance by the Company to 27 Health of 12,500,000 shares of common stock, par value $0.0001 per share, of the Company (the “NutraLife Common Stock”). The transactions pursuant to the SPA closed on the Closing Date.

 

Each share of Series X Stock is convertible into shares of common stock, par value $0.001 per share, of Lord Global (the “Lord Global Common Stock”) at the rate of 1,000 shares of Lord Global Common Stock per share of Series X Stock, subject to customary adjustments for stock splits, stock dividend, stock combinations, recapitalizations or other similar transactions. The conversion of the Series X Stock is subject to a customary beneficial limitation such that the Company may not convert the Series X Stock into Lord Global Common Stock if such conversion would result in the Company and its affiliates having beneficial ownership of in excess of 4.99% of the outstanding shares of Lord Global Common Stock, provided that the Company may elect to waive this limitation on 61 days’ notice to Lord Global.

 

In addition to the Series X Stock issued to the Company, in the event that, on the first business day following the 180-day anniversary of the Closing Date, the average volume weighted average price of the Lord Global Common Stock for the 10 trading day period prior to that date is less than $4.00 (subject to customary adjustments), then Lord Global will issue to the Company, for no additional consideration payable by the Company, a number of shares of Lord Global Common Stock equal to (i) $1,000,000, divided by (ii) the share price as of such date, minus 250,000 (the “First Adjustment Shares”). A second such adjustment shall be completed on the first business day following the one-year anniversary of the Closing Date, provided that at this adjustment the number of First Adjustment Shares will also be deducted from any additional shares to be issued to the Company.

 

19
 

 

Manufacturing, Distribution and Sales Agreement

 

In connection with the SPA and the transactions as set forth therein, on the Closing Date the Company also entered into a Manufacturing, Distribution and Sales Agreement (the “MDS Agreement”) by and between the Company and 27 Health. 27 Health, together with Lord Global (referred to in this section jointly as “27 Health”) has developed and currently manufactures and markets certain products related to the testing and treatment of COVID-19 (the “Coviguard Products”).

 

Pursuant to the MDS Agreement, 27 Health engaged the Company to manufacture the Coviguard Products and granted the Company the right, on a non-exclusive basis, to sell and distribute the Coviguard Products manufactured by the Company though all channels of distribution on a worldwide basis and to undertake advertising and marketing as determined to be necessary by the Company, with written notice, in connection therewith.

 

During the term of the Agreement, the Company has the exclusive right to manufacture the Coviguard Products, subject to the Company’s continued ability to meet in all material respects the production requirements of 27 Health for the Coviguard Products. In the event that the Company is unable, in the sole determination of 27 Health, to meet the production requirements, 27 Health may seek other sources for the manufacturing of the Coviguard Products or may terminate the MDS Agreement.

 

Pursuant to the MDS Agreement, the Company may elect to market the Coviguard Products directly, without any requirement of an order for the manufacturing of the products being supplied by 27 Health or accepted by the Company. All such direct sales will be made by the Company to the recipient of the products, and the Company will pay to 27 Health a set distributor price for the products, and retain the balance paid by the buyer.

 

In the event that the Company identifies a potential third-party customer for the Coviguard Products, but does not elect to sell the Coviguard Products directly to the customer as set forth above, the Company may refer such potential customer to 27 Health. If the customer is a not a current customer of 27 Health, then for any and all sales of Coviguard Products to such new customers, 27 Health will pay to the Company 15% commissions on these sales. No commissions would be paid for sales to customers who were already customers of 27 Health at the time.

 

The MDS Agreement has an initial term of 5 years, with automatic extensions of 1 year each, subject to earlier expiration or termination as set forth therein.

 

Competitive Business Conditions

 

The nutritional, dietary supplement and industrial hemp CBD industries, as well as the sanitizer products industry, are highly competitive. Numerous manufacturers and distributors compete with us for customers throughout the United States selling products to private label customers and retailers such as mass merchandisers, drug store chains, independent pharmacies and health food stores. We are also vulnerable to competition from companies that can manufacture similar products to our products and compete for private label customers. The markets for our products are highly competitive. We seek to compete on the basis of customer service, product quality, pricing and marketing support.

 

We compete with major private label and broadline brand manufacturers many of which are larger and have access to greater resources than us. Among other factors, competition among private label manufacturers is based upon price. If one or more private label or broadline brand manufacturers significantly reduce their prices in an effort to gain market share, our results of operations or market position could be adversely affected. We also compete with manufacturers of nationally advertised brand name products which are larger and have resources substantially greater than us. In the future, one or more of these companies could seek to compete more directly with us by manufacturing private label products or by significantly lowering the prices of their national brand products.

 

Many of our indirect competitors are substantially larger, have more experience than us, have longer operating histories, and have materially greater financial and other resources than us.

 

Costs and Effects of Compliance with Environmental Laws

 

We are in a business that involves the use of raw materials in a manufacturing process, however, we believe that it is unlikely that such materials are likely to result in the violation of any existing environmental rules and/or regulations. Further, we do not own any real property that could lead to liability as a landowner. Therefore, we do not anticipate that there will be any material costs associated with compliance with environmental laws and regulations.

 

20
 

 

Product Liability Insurance

 

We maintain commercial liability, including product liability coverage, and property insurance. Our policy provides for a general liability of five million dollars ($5,000,000) per occurrence, and five million dollars ($5,000,000) annual aggregate coverage which includes our main corporate facility. We carry property coverage on our main office facility to cover our legal liability, tenant’s improvements, business property, and inventory.

 

Regulation of our Hemp Finished Products

 

The sale of our Hemp Finished Products is potentially subject to a complex web of federal and state regulations that are evolving at a rapid rate. The formulation, manufacturing, packaging, labeling, advertising, and distribution of our products are subject to regulation by one or more federal agencies, principally the Food and Drug Administration (“FDA”), the Federal Trade Commission (“FTC”), and, to a lesser extent, the Consumer Product Safety Commission (“CPSC”), the United States Department of Agriculture (“USDA”), Drug Enforcement Agency (“DEA”) and the Environmental Protection Agency (“EPA”). Our activities are also regulated by various governmental agencies for the states and localities in which our products are sold, as well as by governmental agencies in certain countries outside the United States in which our products are sold. These agencies can change their rules at any time. Should we become subject to FDA, DEA or other enforcement proceedings we would have to cease operations.

 

The FDA under the Federal Food, Drug, and Cosmetic Act regulates the formulation, manufacturing, packaging, labeling, distribution and sale of drugs, food, including dietary supplements, and over-the-counter drugs.

 

Until 2014, when 7 U.S. Code §5940 became federal law as part of the Agricultural Act of 2014 (the “2014 Farm Act”), products containing oils derived from hemp, notwithstanding a minimal or non-existing THC content, were classified as Schedule I illegal drugs. The 2014 Farm Act expired on September 30, 2018, and was thereafter replaced by the Agricultural Improvement Act of 2018 on December 20, 2018 (the “2018 Farm Act”), which amended various sections of the U.S. Code, thereby removing hemp, defined as cannabis with less than 0.3% of THC, from Schedule 1 status under the Controlled Substances Act (“CSA”), and legalizing the cultivation and sale of hemp at the federal level, subject to compliance with certain federal requirements and state law, amongst other things. THC is the psychoactive component of plants in the cannabis family generally identified as marihuana or marijuana. We believe that our hemp products are and will continue to be federally legal in the United States in that they contain and will continue to contain less than 0.3% of THC in compliance with the 2018 Farm Bill guidelines and will have no psychoactive effects on our customers’ bodies. Notwithstanding, there is no assurance that the 2018 Farm Act will not be repealed or amended such that our products containing hemp-derived CBD would once again be deemed illegal under federal law.

 

The 2018 Farm Bill also shifted regulatory authority from the Drug Enforcement Administration to the Department of Agriculture. The 2018 Farm Bill did not change the FDA’s oversight authority over hemp products. The 2018 Farm Act delegated the authority to the states to regulate and limit the production of hemp and hemp derived products within their territories. Although many states have adopted laws and regulations that allow for the production and sale of hemp and hemp derived products under certain circumstances, no assurance can be given that such state laws may not be repealed or amended such that our hemp products would once again be deemed illegal under the laws of one or more states now permitting such products, which in turn would render such products illegal in those states under federal law even if the federal law is unchanged. In the event of either repeal of federal or of state laws and regulations, or of amendments thereto that are adverse to our hemp products, we may be restricted or limited with respect to those products that we may sell or distribute, which could adversely impact our operations with respect to such products.

 

Additionally, the FDA has indicated its view that certain types of hemp products may not be permissible under the United States Federal Food, Drug and Cosmetic Act (“FDCA”). The FDA’s position is related to its approval of Epidiolex, a marijuana-derived prescription medicine to be available in the United States. The active ingredient in Epidiolex is CBD. On December 20, 2018, after the passage of the 2018 Farm Bill, FDA Commissioner Scott Gottlieb issued a statement in which he reiterated the FDA’s position that, among other things, the FDA requires a cannabis product (hemp-derived or otherwise) that is marketed with a claim of therapeutic benefit, or with any other disease claim, to be approved by the FDA for its intended use before it may be introduced into interstate commerce and that the FDCA prohibits introducing into interstate commerce food products containing added hemp, and marketing products containing hemp as a dietary supplement, regardless of whether the substances are hemp-derived. Although we believe our hemp product offerings comply with applicable federal and state laws and regulations, legal proceedings alleging violations of such laws could have a material adverse effect on our business, financial condition and results of operations.

 

21
 

 

We do not intend to offer and do not compete with companies that offer cannabis products containing high levels of psychoactive THC in the United States. Although legal in some states in the United States, we are not in, and do not intend to enter into this market. We offer hemp-based products to customers in the United States but do not compete with any medical or recreational marijuana sellers of products for high THC content sales due to legal and regulatory restrictions and uncertainty in the United States.

 

The FDA under the Federal Food, Drug, and Cosmetic Act regulates the formulation, manufacturing, packaging, labeling, distribution and sale of drugs, food, including dietary supplements, and over-the-counter drugs and any inclusion of cannabis or cannabis-derived compounds, like CBD, in such products would be regulated by the FDA regardless of the source of the cannabis substance, be it hemp or marijuana.

 

Our CBD products are derived from the seeds and mature stalks of the Cannabis Sativa plant which includes all parts and varieties of the cannabis sativa plant also known as hemp, which contain a tetrahydrocannabinol concentration (“THC”) that does not exceed 0.3 percent on a dry-weight basis. In December of 2018, the U.S. Food and Drug Administration completed an evaluation of three generally recognized as safe (GRAS) notices for hemp seed-derived food ingredients. The FDA stated that hulled hemp seed (GRN765), hemp seed protein powder (GRN771), and hemp seed oil (GRN778) are GRAS under their intended conditions of use. Some of the intended uses for these ingredients include adding them as source of protein, carbohydrates, oil, and other nutrients to beverages (juices, smoothies, protein drinks, plant-based alternatives to dairy products), soups, dips, spreads, sauces, dressings, plant-based alternatives to meat products, desserts, baked goods, cereals, snacks and nutrition bars. Our CBD products are made from seeds and mature stalks of hemp and contain only trace amounts of THC, we believe they qualify as GRAS products.

 

We have not obtained and do not plan to obtain FDA approval of our CBD products. As a result, we could be subject to enforcement proceedings by the FDA. We do not believe that FDA enforcement proceedings are likely since our products only contain trace elements of THC and do not cause the “high” associated with the THC in marijuana. Additionally, Hemp Finished Products like those sold by us are sold by large retailers online including Whole Foods, Publix, Wal-Mart and others. Despite the foregoing, should we become subject to FDA or other enforcement proceedings we could have to cease operations.

 

Other Regulations Impacting our Hemp Finished - CBD Products

 

Some states are considering various taxation of marijuana-related products including hemp finished products. These considerations seem to range from routine sales taxes to taxes similar to those imposed on tobacco products. Though, for the reasons described above, we do not believe the Hemp Finished Products to be subject to any marijuana-related taxation schemes, it is unclear whether Hemp Finished Products would fall under these tax plans if and when they are imposed.

 

IRS section 280(E) prevents cannabis companies from deducting expenses from their income, except for those considered cost of goods sold. No deduction or credit is allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by federal law or the law of any State in which such trade or business is conducted. Though, for the reasons described above, we do not believe the Hemp Finished Products to be appropriately treated as a controlled substance, if IRC 280(E) is enforced against us relating to deductions concerning our Hemp Finished Products, such tax treatment could create operating and cash flow problems in the future.

 

Cannabis versus Hemp

 

While hemp and cannabis are both derived from the same species (Cannabis sativa), there are major differences in the characteristics of the respective plant strains that produce industrial hemp on the one hand, and cannabis products on the other. In short, hemp is a strain of the Cannabis sativa plant that has been grown primarily for use in industrial applications and has been specifically cultivated to produce a low tetrahydrocannabinol (“THC”) content and a high cannabidiol (“CBD”) content. THC is the psychoactive constituent of cannabis and is responsible for producing the psychoactive effects of the drug. CBD is another active ingredient present in Cannabis sativa plants, and it largely acts to neutralize the psychoactive effects of THC and is not associated with psychoactive effects. Since hemp strains have very little THC and a lot of CBD, they do not produce psychoactive effects when ingested.

 

22
 

 

Regulation of our Products not Containing CBD

 

The formulation, manufacturing, packaging, labeling, advertising, and distribution of our non-hemp based products are subject to regulation by one or more federal agencies, principally the FDA, the FTC, and, to a lesser extent, the CPSC, the USDA, and the Environmental Protection Agency “EPA”. Our activities are also regulated by various governmental agencies for the states and localities in which our products are sold, as well as by governmental agencies in certain countries outside the United States in which our products are sold. Among other matters, regulation by the FDA and FTC are concerned with product safety and claims made with respect to a product’s ability to provide health-related benefits. Specifically, the FDA, under the FDCA, regulates the formulation, manufacturing, packaging, labeling, distribution and sale of food, including dietary supplements, and over-the-counter drugs. The FTC regulates the advertising of these products. The National Advertising Division (“NAD”) of the Council of Better Business Bureaus oversees an industry sponsored, self-regulatory system that permits competitors to resolve disputes over advertising claims. The NAD has no enforcement authority of its own, but may refer matters that appear to violate the Federal Trade Commission Act or the FDCA to the FTC or the FDA for further action, as appropriate.

 

Federal agencies, primarily the FDA and the FTC, have a variety of procedures and enforcement remedies available to them including initiating investigations, issuing warning letters and cease and desist orders, requiring corrective labeling or advertising, requiring consumer redress (for example, requiring that a company offer to repurchase products previously sold to consumers), seeking injunctive relief or product seizures, imposing civil penalties, or commencing criminal prosecution. In addition, certain state agencies have similar authority. These federal and state agencies have in the past used these remedies in regulating participants in the food, dietary supplement and over-the-counter drug industries, including the imposition of civil penalties in the millions of dollars against a few industry participants.

 

The Dietary Supplement Health and Education Act (“DSHEA”) was enacted in 1994, amending the FDCA. We believe DSHEA is generally favorable to consumers and to the dietary supplement industry. DSHEA establishes a statutory class of “dietary supplements”, which includes vitamins, minerals, herbs, amino acids and other dietary ingredients for human use to supplement the diet. Dietary ingredients marketed in the United States before October 15, 1994 may be marketed without the submission of a “new dietary ingredient” (“NDI”) premarket notification to the FDA. Dietary ingredients not marketed in the United States before October 15, 1994 may require the submission, at least seventy-five (75) days before marketing of an NDI notification containing information establishing that the ingredient is reasonably expected to be safe for its intended use. Among other things, DSHEA prevents the FDA from regulating dietary ingredients in dietary supplements as “food additives” and allows the use of statements of nutritional support on product labels and in labeling. The FDA has issued final regulations under DSHEA and has issued draft guidance on NDI notification requirements. Further guidance and regulations are expected. Several bills to amend DSHEA in ways that would make this law less favorable to consumers and industry have been proposed in Congress.

 

The Nutrition Labeling and Education Act of 1990 (“NLEA”) amended the FDCA to establish additional requirements for ingredient and nutrition labeling and labeling claims for foods. If the NLEA labeling requirements change at a future time, we may need to revise our product labeling. Our non-CBD products are classified as dietary supplements. The FDA has concluded that THC and CBD products are excluded from the definition of a dietary supplement. The FDA issued a Final Rule on GMPs for dietary supplements on June 22, 2007. The GMPs cover manufacturers and holders of finished dietary supplement products, including dietary supplement products manufactured outside the United States that are imported for sale into the United States. Among other things, the new GMPs: (a) require identity testing on all incoming dietary ingredients, call for a “scientifically valid system” for ensuring finished products meet all specifications, (b) include requirements related to process controls, including statistical sampling of finished batches for testing and requirements for written procedures, and (c) require extensive recordkeeping.

 

We have reviewed the GMPs and have taken steps to ensure compliance. While we believe we are in compliance, there can be no assurance that our operations or those of our suppliers will be in compliance in all respects at all times. Additionally, there is a potential risk of increased audits as the FDA and other regulators seek to ensure compliance with the GMP’s.

 

23
 

 

On December 22, 2006, Congress passed the Dietary Supplement and Nonprescription Drug Consumer Protection Act, which went into effect on December 22, 2007. The law requires, among other things, that companies that manufacture or distribute nonprescription drugs or dietary supplements report serious adverse events allegedly associated with their products to the FDA and institute recordkeeping requirements for all adverse events (serious and non-serious). There is a risk that consumers, the press and government regulators could misinterpret reported serious adverse events as evidence of causation by the ingredient or product complained of, which could lead to additional regulations, banned ingredients or products, increased insurance costs and a potential increase in product liability litigation, among other things.

 

The Consumer Product Safety Improvement Act of 2008 (“CPSIA”) primarily addresses children’s product safety but also improves the administrative process of the CPSC. Among other things, the CPSIA requires testing and certification of certain products and enhances the CPSC’s authority to order recalls.

 

The FDA Food Safety Modernization Act (“FSMA”), enacted January 4, 2011, amended the FDCA to significantly enhance the FDA’s authority over various aspects of food regulation. The FSMA granted the FDA mandatory recall authority when the FDA determines if there is reasonable probability that a food is adulterated or misbranded and that the use of, or exposure to, the food will cause serious adverse health consequences or death to humans or animals. Other changes include the FDA’s expanded access to records; the authority to suspend food facility registrations and require high risk imported food to be accompanied by a certification; stronger authority to administratively detain food; the authority to refuse admission of an imported food if it is from a foreign establishment to which a U.S. inspector is refused entry for an inspection; and the requirement that importers verify that the foods they import meet domestic standards.

 

One of the FSMA’s more significant changes is the requirement of hazard analysis and risk-based preventive controls (“HARBPC”) for all food facilities required to register with the FDA, except dietary supplement facilities in compliance with both GMPs and the serious adverse event reporting requirements. Although dietary supplement facilities are exempt from the HARBPC requirements, dietary ingredient facilities might not qualify for the exemption. The HARBPC requirements, which the FDA has yet to propose, are expected to be onerous because facilities will have to develop and implement preventive controls to assure that identified hazards are significantly minimized or prevented, monitor the effectiveness of the preventive controls and maintain numerous records related to the HARBPC. The HARBPC requirements may increase the costs of dietary ingredients and/or affect our ability to obtain dietary ingredients.

 

As required by Section 113(b) of the FSMA, the FDA published in July 2011, a draft guidance document clarifying when the FDA believes a dietary ingredient is an NDI, when a manufacturer or distributor must submit an NDI premarket notification to the FDA, the evidence necessary to document the safety of an NDI and the methods for establishing the identity of an NDI. The draft guidance, if implemented as proposed, could have a material impact on our operations. Although our industry has strongly objected to several aspects of the draft guidance, it is unclear whether the FDA will make changes to the final guidance. In addition, it is possible that the FDA will begin taking enforcement actions consistent with the interpretations in the draft guidance before issuing a final version. The new FSMA requirements, as well as the FDA enforcement of the NDI guidance as written, could require us to incur additional expenses, which could be significant, and negatively impact our business in several ways, including, but not limited to, the detention and refusal of admission of imported products, the injunction of manufacturing of any dietary ingredients or dietary supplements until the FDA determines that such ingredients or products are in compliance and the potential imposition of fees for re-inspection of noncompliant facilities. Each of these events would increase our liability and could have a material adverse effect on our financial condition, results of operations or cash flows.

 

The FTC and the FDA have pursued a coordinated effort to challenge what they consider to be unsubstantiated and unsafe weight-loss products, and have also coordinated enforcement against dietary supplement claims in other areas, including children’s products. Their efforts to date have focused on manufacturers and marketers as well as media outlets, and have resulted in a significant number of investigations and enforcement actions, some resulting in civil penalties of several million dollars under the Federal Trade Commission Act. We expect that the FTC and the FDA will continue to focus on health-related claims for dietary supplements and foods which could cause our non-CBD products to be the subject of an FTC/FDA inquiry.

 

24
 

 

Item 1A. Risk Factors

 

YOU SHOULD CAREFULLY CONSIDER THE RISKS AND UNCERTAINTIES DESCRIBED BELOW AND THE OTHER INFORMATION CONTAINED OR INCORPORATED BY REFERENCE IN THIS ANNUAL REPORT ON FORM 10-K BEFORE DECIDING WHETHER TO INVEST IN THE COMPANY’S COMMON STOCK. ADDITIONAL RISKS AND UNCERTAINTIES NOT PRESENTLY KNOWN TO THE COMPANY OR THAT THE COMPANY CURRENTLY DEEMS IMMATERIAL MAY ALSO IMPAIR THE COMPANY’S BUSINESS OPERATIONS. IF ANY OF THE FOLLOWING RISKS ACTUALLY OCCUR, THE COMPANY’S BUSINESS, FINANCIAL CONDITION OR OPERATING RESULTS COULD BE MATERIALLY ADVERSELY AFFECTED. IN SUCH CASE, THE TRADING PRICE OR THE COMPANY’S COMMON STOCK COULD DECLINE AND YOU MAY LOSE PART OR ALL OF YOUR INVESTMENT. THIS ANNUAL REPORT ON FORM 10-K ALSO CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE RISKS AND UNCERTAINTIES. PLEASE SEE “CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS”.

 

Risks Related to our Financial Condition

 

We are dependent on the sale of our securities to fund our operations.

 

During the years ended December 31, 2021 and 2020, we received $348,000 and $125,000 from the sale of our securities. For the years ended December 31, 2021 and 2020, our revenues were approximately $600,000 and $1,300,000, respectively from the sale of our products. Our operating expenses are presently approximately $380,000 per month or $4,600,000 annually which consist of rent, advertising, salaries and other general and administrative expenses. Our cash on hand as of the date of this Annual Report on Form 10-K is $135,769 which is not sufficient to pay our operating expenses. We are in the process of obtaining future financing and are dependent on the sale of our securities to help fund our operations. There is no assurance we will be able to obtain future funding for our operations from the sale of our securities. The future issuance of our securities will result in substantial dilution in the percentage of our common stock held by our then existing stockholders, and would likely have an adverse effect on any trading market for our common stock. Obtaining financing would be subject to a number of factors, including investor acceptance. These factors may adversely affect the timing, amount, terms, or conditions of any financing that we may obtain or make any additional financing unavailable to us. If we do not obtain additional financing to fund our future operations, our business could fail and you could lose your investment.

 

There is substantial doubt about our ability to continue as a going concern as a result of our limited operating history and financial resources, and if we are unable to generate significant revenue or secure financing we may be required to cease or curtail our operations.

 

For the years ended December 31, 2021 and 2020, we incurred net losses of approximately $5,800,000 and $2,900,000. As a result, our auditor has rendered an opinion that we may be unable to continue as a going concern. Our limited operating history and financial resources raises substantial doubt about our ability to continue as a going concern and our financial statements contain a going concern qualification. Our financial statements do not include adjustments that might result from the outcome of this uncertainty and if we are unable to generate significant revenue or secure financing we may be required to cease or curtail or completely suspend our operations.

 

We will need additional capital to fund our operations, which, if obtained, could result in substantial dilution or significant debt service obligations. Our inability to procure additional financing, if required, may have a material adverse effect on us. We may not be able to obtain additional capital on commercially reasonable terms, which could adversely affect our liquidity and financial position.

 

We require additional equity and/or debt financing to continue our operations. There can be no assurance that we will be able to obtain funds on commercially acceptable terms, if at all. We expect to have ongoing needs for working capital in order to fund operations and to continue to expand our operations. To that end, we may be required to raise additional funds through equity or debt financing. In order to continue operating, we may need to obtain additional financing, either through borrowings, private offerings, public offerings, or some type of business combination, such as a merger, or buyout, and there can be no assurance that we will be successful in such pursuits. We may be unable to acquire the additional funding necessary to continue operating. However, there can be no assurance that we will be successful in securing additional capital. If we are unsuccessful, we may need to (a) initiate cost reductions; (b) forego business development opportunities; (c) seek extensions of time to fund liabilities, or (d) seek protection from creditors. Our inability to obtain any additional financing could have a material adverse effect upon us. We may not be able to secure any additional financing we may need on terms favorable to us, or at all. These conditions raise substantial doubt about our ability to continue as a going concern for at least one year from the date of this filing.

 

25
 

 

In addition, if we are unable to generate adequate cash from operations, and if we are unable to find sources of funding, it may be necessary for us to sell one or more lines of business or all or a portion of our assets, enter into a business combination, or reduce or eliminate operations. These possibilities, to the extent available, may be on terms that result in significant dilution to our investors or that result in our investors losing all of their investment in our Company.

 

If we are able to raise additional capital, we do not know what the terms of any such capital raising would be. In addition, any future sale of our equity securities could be at prices substantially below prices at which our shares are currently valued. To the extent we require additional financing and cannot raise it, we may have to limit our then-current operations, curtail all or certain portions of our business objectives and plans or terminate our operations. We may seek to increase our cash reserves through the sale of additional equity or debt securities. The sale of convertible debt securities or additional equity securities could result in additional and potentially substantial dilution to our investors. The incurrence of indebtedness would result in increased debt service obligations and could result in operating and financing covenants that would restrict our operations and liquidity. In addition, our ability to obtain additional capital on acceptable terms is subject to a variety of uncertainties. We cannot assure you that financing will be available in amounts or on terms acceptable to us, if at all. Any failure to raise additional funds on favourable terms could have a material adverse effect on our liquidity and financial condition.

 

If we are unable to generate sufficient revenues for our operating expenses we will need financing, which we may be unable to obtain; should we fail to obtain sufficient financing, our potential revenues will be negatively impacted.

 

For the years ended December 31, 2021 and 2020, our revenues were $626,619 and $1,255,784 respectively, from the sale of our products. For the years ended December 31, 2021 and 2020, we incurred net losses of $5,827,507 and $2,889,940.

 

Because we lack historical financial data, including revenue data, our future revenues are unpredictable.

 

Our operating expenses are presently approximately $380,000 per month or $4,600,000 annually which consist of rent, advertising, salaries and other general and administrative expenses. Our cash on hand as of the date of this Form 10-K is $135,769 which is not sufficient to pay our operating expenses. In the future, we may require additional debt or equity funding to continue our operations. We intend to raise additional funds from an offering of our stock in the future; however, this offering may never occur, or if it occurs, we may be unable to raise the required funding. Further new offerings of our common shares will dilute our existing shareholders and your investment in our common shares. We do not have any plans or specific agreements for new sources of funding and we have no agreements for financing in place.

 

Our liabilities could adversely affect our ability to raise additional capital to fund our operations, limit our ability to react to changes in the economy or our industry and prevent us from meeting our obligations under our indebtedness.

 

As of December 31, 2021, our total liabilities were $5,563,655. Our liabilities could have important consequences for our investors, including: making it more difficult for us to make payments on indebtedness; increasing our vulnerability to general economic and industry conditions; requiring a substantial portion of cash flow from operations to be dedicated to the payment of principal and interest on indebtedness when our indebtedness become due. This reduces our ability to use our cash flow to fund our operations, capital expenditures and future business opportunities; limiting our ability and the ability of our subsidiaries to obtain additional financing for working capital, capital expenditures, product development, debt service requirements, acquisitions and general corporate or other purposes; and limiting our ability to adjust to changing market conditions and placing us at a competitive disadvantage compared to our competitors which have fewer liabilities. We may incur substantial additional indebtedness in the future. If new indebtedness is added to our current debt levels, the related risks that we face could increase.

 

26
 

 

We are currently in default on certain secured debt obligations which could negatively affect our financial condition and may cause us to curtail or cease our operations.

 

As discussed above, the Company has not made the principal and interest payments on the Amended Note as of the date of this Annual Report. Accordingly, the Company is currently in default on these secured debt obligations.

 

We are subject to the periodic reporting requirements of the Exchange Act that require us to perform accounting and reporting obligations with limited resources.

 

We are subject to the reporting requirements of the Exchange Act and are required to file periodic reports with the Securities and Exchange Commission (the “SEC”) pursuant to the Exchange Act and the rules and regulations promulgated thereunder. The reporting obligations require additional staff or consulting expenses. In addition, we have limited resources to allocate to such compliance functions, which increase the possibility of non-compliance.

 

Risks Related to Our Business

 

We have been growing rapidly and expect to continue to invest in our growth for the foreseeable future. If we are unable to manage our growth effectively, our revenue and profits could be adversely affected.

 

We have experienced rapid growth in a relatively short period of time. Our revenues were approximately $600,000 and $1,300,000 for the years ended December 31, 2021 and 2020, respectively. We plan to continue to expand our operations, and we anticipate that further significant expansion will place additional demands on our resources and operations. We presently operate our manufacturing and distribution from a 6,400 square foot facility. We plan to begin manufacturing at a second facility consisting of 20,000 square feet in addition to our existing facility. Our future operating results depend to a large extent on our ability to manage this expansion and growth successfully. Sustaining our growth will place significant demands on our management as well as on our administrative, operational, and financial resources. To manage our growth, we must continue to improve our sales and manage our operational systems. If we are unable to manage our growth successfully, our revenue and profits could be harmed. Risks that we face in undertaking future expansion include but are not limited to:

 

  ● effectively recruiting, integrating, training, and motivating new employees, including our sales force, while retaining existing private label distributors and effectively executing our new business plan focusing on the processing, extraction and sale of CBD products;
  ● satisfying existing customers and attracting new customers of our products and services;
  ● introducing new products and services;
  ● increasing our private label customers;
  ● controlling expenses and investments in expanded operations including our new manufacturing facility;
  ● implementing and enhancing our administrative, operational, and financial infrastructure, systems, and processes; and
  ● addressing new products to meet consumer preferences.

 

A failure to manage our growth effectively could harm our business, operating results and/or financial condition. Further, due to our recent rapid growth, we have limited experience operating at our current scale and potentially at a larger scale, and as a result, it may be difficult for us to fully evaluate future prospects and risks. Our recent and historical growth should not be considered indicative of our future performance. We have encountered in the past, and will encounter in the future, risks and uncertainties frequently experienced by growing companies in rapidly changing industries. If our assumptions regarding these risks and uncertainties, which we use to plan and operate our business, are incorrect or change, or if we do not address these risks successfully, our financial condition and operating results could differ materially from our expectations, our growth rates may slow and our business would by adversely impacted.

 

Our revenues are highly dependent upon two private label distributors, which represented 58%, and 24%, of our revenues for the year December 31, 2021 and should these distributors reduce their orders from us or should we lose these distributors; our revenues and results of operations would be negatively affected which could cause you to lose your investment.

 

Our revenues are concentrated and highly dependent on two (2) private label customers which represented 58%, and 24%, of our revenues for the year ended December 31, 2021. All sales made under a private label relationship are made on a purchase order basis and there are no long-term contracts with respect to any private label relationships. There can be no assurance that existing private label relationships will continue in the future or that we will be able to obtain new private label relationships on an ongoing basis, if at all. Our private label customers can reduce the products they order from us or cease ordering products from us at any time without notice. There can be no assurance that these private label customers will continue to place orders with us, that orders by such customers will continue at their previous levels or that we can replace any such lost business. Should this occur, our revenues and results of operations will be negatively affected which could cause you to lose your investment in our common shares.

 

27
 

 

As a result of our evolving business model, we have a limited operating history in our lines of business and, therefore, we may not be able to correctly estimate our future operating expenses, which could lead to cash shortfalls.

 

Since our inception, our business model has evolved significantly. In 2017, we began selling CBD products and as a result our revenues increased from approximately $1,800,000 in 2017 to approximately $3,700,000 in 2018 and then decreased to $2,130,000 in 2019 and $1,300,000 in 2020, and 600,000 in 2021. CBD became our main source of income, and we focused on generating revenue through private label manufacturers. As a result of the change in our business model, our revenues have significantly increased from prior periods. We have a limited operating history for our CBD products from which to evaluate our business. Additionally, amid the COVID-19 global pandemic, in 2020, the Company made a strategic pivot from our then-current nutraceutical manufacturing business by adding the manufacture of consumer sanitizer products utilizing the Company’s existing manufacturing capabilities and the Company’s ability to retrofit its operations and accommodate production due to the shortage of supply and demand for sanitizer products. We also have a limited operating history for our sanitized products from which to evaluate our business. Our failure to successfully execute our business plan would have a material adverse effect on our ability to continue operating. Accordingly, our prospects must be considered in light of the risks, expenses, and difficulties frequently encountered by companies in an early stage of development. We may not be successful in addressing such risks, and the failure to do so could have a material adverse effect on our business, operating results and financial condition.

 

Our quarterly and annual expenses are likely to increase substantially over the next several years depending upon the level of capital spending required to grow our revenues. Our operating results in future quarters may fall below expectations. Any of these events could adversely impact our business prospects and make it more difficult to raise additional equity capital at an acceptable price per share.

 

We do not have many written contracts with our customers. This allows such customers to use other companies instead of us which may negatively impact on our sales.

 

Because we do not have many written contracts with our customers who are free to purchase products from other suppliers, our customers can choose to use other companies instead. If a significant number of our customers began to use competing companies instead of us, our sales would decrease significantly.

 

An unexpected interruption or shortage in the supply or significant increase in the cost of components could limit our ability to manufacture any products, which could reduce our sales and margins.

 

An unexpected interruption of supply or a significant increase in the cost of components, for any reason, such as regulatory requirements, import restrictions, loss of certifications, disruption of distribution channels as a result of weather, terrorism or acts of war, fire, earthquake, or other national disaster, a work stoppage or other labor-related disruption, failure in supply or other logistical channels, electrical outages, or other events, could result in significant cost increases and/or shortages of our products. Our inability to obtain a sufficient amount of products or to pass through higher cost of products we offer could have a material adverse effect on our business, financial condition or results of operations.

 

28
 

 

The COVID-19 pandemic has already begun to adversely affect the Company’s business and the ultimate effect of the COVID-19 pandemic on the Company’s operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted.

 

The effects of the COVID-19 pandemic, including actions taken by businesses and governments, have adversely affected the global economy, disrupted global supply chains and created significant volatility in the financial markets. As a result, the Company’s business operations have been limited due to government actions or other restrictions in connection with the COVID-19 pandemic and may also be effected if Company’s personnel is unable to work effectively due to illness, quarantines, or other restrictions in connection with the COVID-19 pandemic. The COVID-19 pandemic has also already hindered the Company’s ability to raise capital and stay current in its reporting obligations with the SEC. If the COVID-19 pandemic continues for a prolonged period, the Company’s business, financial condition, results of operation and liquidity may be materially and adversely affected. The extent of the ultimate impact of the pandemic on the Company’s operational and financial performance will depend on various developments, including the duration and spread of the outbreak, and its impact on potential customers, employees, and vendors, all of which cannot be reasonably predicted at this time. These future developments will also include, but are not limited to, the actions taken by governmental authorities and other third parties in response to the pandemic. Disruptions and/or uncertainties related to the COVID-19 pandemic for a sustained period of time could result in delays or modifications to the Company’s strategic plans and initiatives and hinder the Company’s ability to achieve its goals.

 

Possible yet unanticipated changes in federal and state law in the U.S. could cause our products containing hemp to be illegal, or could otherwise prohibit, limit or restrict any of our products containing hemp.

 

Until 2014, when 7 U.S. Code §5940 became federal law as part of the Agricultural Act of 2014 (the “2014 Farm Act”), products containing hemp, notwithstanding a minimal or non-existing THC content, were classified as Schedule I illegal drugs. The 2014 Farm Act expired on September 30, 2018, and was thereafter replaced by the Agricultural Improvement Act of 2018 on December 20, 2018 (the “2018 Farm Act”), which amended various sections of the U.S. Code, thereby removing hemp, defined as cannabis with less than 0.3% of THC, from Schedule 1 status under the Controlled Substances Act (“CSA”), and legalizing the cultivation and sale of hemp at the federal level, subject to compliance with certain federal requirements and state law, amongst other things. THC is the psychoactive component of plants in the cannabis family generally identified as marihuana or marijuana. We anticipate that our hemp-based products are and will continue to be federally legal in the United States in that they do, and will contain less than 0.3% of THC in compliance with the 2018 Farm Bill guidelines and will have no psychoactive effects on our customers’ bodies. Notwithstanding, there is no assurance that the 2018 Farm Act will not be repealed or amended such that our products containing hemp would once again be deemed illegal under federal law.

 

The 2018 Farm Bill also shifted regulatory authority from the Drug Enforcement Administration to the Department of Agriculture. The 2018 Farm Bill did not change the FDA oversight authority over hemp-based products. The 2018 Farm Act delegated the authority to the states to regulate and limit the production of hemp and hemp derived products within their territories. Although many states have adopted laws and regulations that allow for the production and sale of hemp and hemp derived products under certain circumstances, no assurance can be given that such state laws may not be repealed or amended such that our products containing hemp would once again be deemed illegal under the laws of one or more states now permitting such products, which in turn would render such products illegal in those states under federal law even if the federal law is unchanged. In the event of either repeal of federal or of state laws and regulations, or of amendments thereto that are adverse to our hemp-based products, we may be restricted or limited with respect to those products that we may sell or distribute, which could adversely impact our business operations with respect to such products.

 

Additionally, the FDA has indicated its view that certain types of products containing hemp may not be permissible under the FDCA. The FDA’s position is related to its approval of Epidiolex, a marijuana-derived prescription medicine to be available in the United States. The active ingredient in Epidiolex is hemp-derived CBD. On December 20, 2018, after the passage of the 2018 Farm Bill, FDA Commissioner Scott Gottlieb issued a statement in which he reiterated the FDA’s position that, among other things, the FDA requires a cannabis product (hemp-derived or otherwise) that is marketed with a claim of therapeutic benefit, or with any other disease claim, to be approved by the FDA for its intended use before it may be introduced into interstate commerce and that the FDCA prohibits introducing into interstate commerce food products containing added hemp, and marketing products containing hemp-derived ingredients, including, but not limited to CBD, as a dietary supplement, regardless of whether the substances are hemp-derived. Although we believe our planned hemp-based product offerings do and will continue to comply with applicable federal and state laws and regulations, legal proceedings alleging violations of such laws could have a material adverse effect on our business, financial condition and results of operations.

 

FDA regulation could negatively affect the hemp industry, which would directly affect our financial condition.

 

The FDA may seek expanded regulation of hemp under the FDCA. Additionally, the FDA may issue rules and regulations, including certified good manufacturing practices, or cGMPs, related to the growth, cultivation, harvesting and processing of hemp. Clinical trials may be needed to verify efficacy and safety. It is also possible that the FDA would require that facilities where hemp is grown register with the FDA and comply with certain federally prescribed regulations. In the event that some or all of these regulations are imposed, we do not know what the impact would be on the hemp industry, including what costs, requirements and possible prohibitions may be enforced. If we or our partners are unable to comply with the regulations or registration as prescribed by the FDA, we and or our partners may be unable to continue to operate our and their business in its current or planned form or at all.

 

29
 

 

Confusion between legal hemp and illegal cannabis.

 

There is risk that confusion or uncertainty surrounding our products with regulated cannabis could occur on the state or federal level and impact us. We may have difficulty with establishing banking relationships, working with investment banks and brokers who would be willing to offer and sell our securities or accept deposits from stockholders, and auditors willing to certify our financial statements if we are confused with businesses that are in the cannabis business. Any of these additional factors, should they occur, could also affect our business, prospects, assets or results of operation could have a material adverse effect on the business, prospects, results of operations or financial condition of the Company.

 

Because we are subject to numerous laws and regulations we could incur substantial costs.

 

The manufacture, labeling and distribution of our products is regulated by various federal, state and local agencies. These governmental authorities may commence regulatory or legal proceedings, which could restrict the permissible scope of our product claims or the ability to sell our products in the future. The FDA regulates our nutraceutical and wellness products to ensure that the products are not adulterated or misbranded.

 

We are subject to additional regulation as a result of our CBD products. The shifting compliance environment and the need to build and maintain robust systems to comply with different compliance in multiple jurisdictions increase the possibility that we may violate one or more of the requirements. If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.

 

Failure to comply with FDA requirements may result in, among other things, injunctions, product withdrawals, recalls, product seizures, fines and criminal prosecutions. Our advertising is subject to regulation by the FTC under the FTCA. In recent years, the FTC has initiated numerous investigations of dietary and nutrition supplement products and companies. Additionally, some states also permit advertising and labeling laws to be enforced by private attorney generals, who may seek relief for consumers, seek class action certifications, seek class wide damages and product recalls of products sold by us. Any actions against us by governmental authorities or private litigants could have a material adverse effect on our business, financial condition and results of operations.

 

Adverse publicity or consumer perception of our products and any similar products distributed by others could harm our reputation and adversely affect our sales and revenues.

 

We are highly dependent upon positive consumer perceptions of the safety and quality of our products as well as similar products distributed by other wellness, nutraceutical and CBD companies. Consumer perception of nutrition supplements and our products, in particular, can be substantially influenced by scientific research or findings, national media attention and other publicity about product use. Adverse publicity from these sources regarding the safety, quality or efficacy of nutritional supplements and our products could harm our reputation and results of operations. The mere publication of news articles or reports asserting that such products may be harmful or questioning their efficacy could have a material adverse effect on our business, financial condition and results of operations, regardless of whether such news articles or reports are scientifically supported or whether the claimed harmful effects would be present at the dosages recommended for such products.

 

If the products we sell do not have the healthful effects intended, our business may suffer.

 

In general, our products contain food, nutritional supplements which do not currently require approval from the FDA or other regulatory agencies prior to sale. Many of our products contain innovative ingredients or combinations of ingredients. There is little long term experience with human or other animal consumption of certain of these ingredients or combinations thereof in concentrated form. Our products could have certain side effects if not taken as directed or if taken by a consumer that has certain medical conditions. Furthermore, there can be no assurance that any of the products, even when used as directed, will have the effects intended or will not have harmful side effects. Should our products cause unwanted side effects or not have the results intended, it could have a material adverse effect on our business, financial condition and results of operations.

 

30
 

 

We could suffer reputational and financial damage in the event of injury from our products or product recalls.

 

As a manufacturer and distributor of products intended for human consumption, we are subject to product liability claims if the use of our products for others is alleged to have resulted in injury. Our products consist of vitamins, minerals, herbs, lotions and other ingredients that are not subject to pre-market regulatory approval in the United States or internationally. Previously unknown adverse reactions resulting from human consumption of these ingredients could occur which would likely result in product liability claims against us which would increase our costs and adversely affect our reputation and harm our business. We may be held liable if any illness or injury caused by any product we develop, manufacture or distribute, if any such product is found to be unsuitable for use. In addition to any reputational damage we would suffer, we cannot guarantee that our product liability insurance or that of any of our suppliers would fully cover potential liabilities. In the event of litigation, any adverse judgments against us would have a material adverse effect on our financial condition, including our cash balances, and results of operations.

 

Our insurance coverage may not be sufficient to cover our legal claims or other losses that we may incur in the future.

 

We maintain insurance, including property, general and product liability, and workers’ compensation to protect ourselves against potential loss exposures. There is no assurance that our insurance will be sufficient to cover any claims that are asserted against us. In the future, insurance coverage may not be available at adequate levels or on adequate terms to cover potential losses, including on terms that meet our customer’s requirements. If insurance coverage is inadequate or unavailable, we may face claims that exceed coverage limits or that are not covered, which could increase our costs and adversely affect our operating results.

 

Our intellectual property rights are valuable, and any inability to protect them could reduce the value of our products and brand.

 

We manufacture products primarily for third parties who sell the products under their own brand names. We also sell products under our own brand names. Our product formulations are not patented and there are numerous companies selling similar products. As such, third parties could copy our products or sell similar products to our distributors and/or customers.

 

Our competitors may have or develop equivalent or superior manufacturing and design skills, and may develop an enhancement to our formulations that will be patentable or otherwise protected from duplication by others. Further, we may be unable or unwilling to strictly enforce our intellectual property rights, including our trademarks, from infringement. Our inability to obtain and/or failure to enforce our intellectual property rights could diminish the value of our product offerings and have a material adverse effect on our business, prospects, results of operations, and financial condition.

 

If we are unable to obtain and maintain protection of our intellectual property, the value of our products may be adversely affected.

 

Our business is dependent in part upon our ability to use intellectual property rights to protect our products from competition. To protect our products, we rely on a combination of patent and other intellectual property laws, employment, confidentiality and invention assignment agreements with our employees and contractors, and confidentiality agreements and protective contractual provisions with our partners, licensors and other third parties. These methods, however, afford us only limited protection against competition from other products.

 

We attempt to protect our intellectual property position, in part, by filing patent applications related to our proprietary technology, inventions and improvements that are important to our business. However, our patent position is not likely by itself to prevent others from commercializing products that compete directly with our products. In addition, the patent owned by us or issued to us could be challenged, invalidated, or held to be unenforceable. We also note that any patent granted may not provide a competitive advantage to us. Our competitors may independently develop technologies that are substantially similar or superior to our technologies. Further, third parties may design around our patented or proprietary products and technologies.

 

31
 

 

We rely on certain trade secrets and we may not be able to adequately protect our trade secrets even with contracts with our personnel and third parties. Also, any third party could independently develop and have the right to use, our trade secret, know-how and other proprietary information. If we are unable to protect our intellectual property rights, our business, prospects, financial condition and results of operations could suffer materially.

 

We may be involved in lawsuits or proceedings to protect or enforce our intellectual property rights or to defend against infringement claims, which could be expensive and time consuming.

 

Our success depends in part on our products not infringing on the patents and proprietary rights of other parties. For instance, in the United States, patent applications filed in recent years are confidential for 18 months, while older applications are not published until the patent issues. As a result, there may be patents and patent applications of which we are unaware, and avoiding patent infringement may be difficult. Litigation may be necessary to enforce our intellectual property rights, protect our trade secrets or determine the validity and scope of the proprietary rights of others. Interference proceedings conducted by a patent and trademark office may be necessary to determine the priority of inventions with respect to our patent applications. Litigation or interference proceedings could result in substantial costs and diversion of resources and management attention. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology. An adverse determination of any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. In addition, we may be enjoined from marketing one or more of our products if a court finds that such products infringe the intellectual property rights of a third party. During litigation, we may not be able to prevent the confidentiality of certain of our proprietary rights because of the substantial amount of discovery required in connection with intellectual property litigation. In addition, during the course of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If investors or customers perceive these results to be negative, it could have a material adverse effect on our business, prospects, financial condition and results of operations.

 

Our business is highly competitive, and our failure to compete effectively could adversely affect our market share, financial condition and future growth.

 

The nutritional supplement, wellness and CBD industries are highly competitive with respect to price, brand and product recognition and new product introductions. Many of our competitors are larger, more established and possess greater financial, personnel, distribution and other resources. We face competition (a) in the health food channel from a limited number of large nationally known manufacturers, private label brands and many smaller manufacturers of dietary and nutrition supplements; and (b) in the mass-market distribution channel from manufacturers, major private label manufacturers and others. Private label brands at mass-market chains represent substantial sources of income for these merchants and the mass-market merchants often support their own labels at the expense of other brands. As such, the growth of our brands within food, drug, and general mass-market merchants are highly competitive and uncertain. If we cannot compete effectively, we may not be profitable.

 

We may experience greater than expected product returns, which might adversely affect our sales and results of operations.

 

In the year ended December 31, 2021, product returns represented 2% of our sales. Products may be returned for various reasons, including expiration dates or lack of sufficient sales volume. Any increase in product returns could reduce our results of operations.

 

The purchase of many of our products is discretionary and may be negatively impacted by adverse trends in the general economy and make it more difficult for us to generate revenues.

 

Our business is affected by general economic conditions since our products are discretionary and we depend, to a significant extent, upon a number of factors relating to discretionary consumer spending. These factors include economic conditions and perceptions of such conditions by consumers, employment rates, the level of consumers’ disposable income, business conditions, interest rates, consumer debt levels and availability of credit. Consumer spending on our products may be adversely affected by changes in general economic conditions.

 

32
 

 

We may not be able to anticipate consumer preferences and trends within the diet and nutritional industry, which could negatively affect acceptance of our products by retailers and consumers and result in a significant decrease in our revenues.

 

Our products must appeal to a broad range of consumers, whose preferences cannot be predicted with certainty and are subject to rapid change. Our products will need to successfully meet constantly changing consumer demands. If our products are not successfully received by our private label distributors and their customers, our business, financial condition, results of operations and prospects may be harmed.

 

Risks Related to Our Management

 

Should we lose the services of Edgar Ward, our founder, Chief Executive Officer, President and sole Director, our financial condition and proposed expansion may be negatively impacted.

 

Our future depends on the continued contributions of Edgar Ward, our founder, Chief Executive Officer, President and sole Director who would be difficult to replace. The services of Mr. Ward are critical to the management of our business and operations. Additionally, we do not maintain key man life insurance on Mr. Ward. Should we lose the services of Mr. Ward, and be unable to replace his services with equally competent and experienced personnel, our operational goals and strategies would likely be adversely affected, which will negatively affect our revenues.

 

Edgar Ward, our founder, Chief Executive Officer, President and sole Director has voting control of the Company.

 

Edgar Ward, our founder, Chief Executive Officer, President and sole Director holds voting and dispositive control over 13.87% of our issued and outstanding common stock shares. Further he holds 100% of our issued and outstanding Series A Preferred stock. Each share of Series A Preferred Stock is entitled to 500,000 votes per share or an aggregate of 500,000,000 votes. Therefore, Edgar Ward effectively has voting control over the Company, which could lead to a conflict of interest where Mr. Ward’s interests do not align with those of ordinary shareholders of the Company.

 

Because we do not have an audit or compensation committee, shareholders will have to rely on the one member of our board of directors who is not independent to perform these functions.

 

We do not have an audit or compensation committee or board of directors as a whole that is composed of independent directors. These functions are performed by our sole director. Because our sole Director is not independent, there is a potential conflict between their or our interests and our shareholders’ interests since Edgar Ward, our sole Board Member, is also our Chief Executive Officer and President who will participate in discussions concerning management compensation and audit issues that may affect management decisions. Until we have an audit committee or independent directors, there may less oversight of management decisions and activities and little ability for minority shareholders to challenge or reverse those activities and decisions, even if they are not in the best interests of minority shareholders.

 

Our Vice-President devotes limited time to our business, which may negatively impact our plan of operations, implementation of our business plan and our potential profitability.

 

Neil Catania, our Vice-President currently devotes only ten (10) hours to our business each month. Our Chief Executive Officer and President, Edgar Ward, devotes full time to our business however, there is no assurance he will be able to do so in the future. Management time devoted to our business activities in the future may be inadequate to implement our plan of operations and develop a profitable business.

 

Risks Related to Our Common Stock

 

Our Chief Executive Officer, President and sole Director has voting control over all matters submitted to a vote of our common stockholders, which will prevent our minority shareholders from having the ability to control any of our corporate actions.

 

As of the date hereof, we had 174,968,516 shares of our common stock outstanding, each entitled to one vote per common share. Our Chief Executive Officer, President and sole Director, Edgar Ward, held 13.87% of our issued and outstanding common stock and 1,000 Series A Preferred which provide 500,000 votes per share or an aggregate of 500,000,000 votes on all matters submitted to our stockholders. As a result, Mr. Ward has voting control of the Company and has the ability to determine the outcome of all matters submitted to our stockholders for approval, including the election of directors. Mr. Ward’s control of our voting securities may make it impossible to complete some corporate transactions without his support and may prevent a change in our control. In addition, this ownership could discourage the acquisition of our common stock by potential investors and could have an anti-takeover effect, possibly depressing the trading price of our common stock.

 

33
 

 

We will, in the future, issue additional securities which would reduce investors’ percent of ownership and will cause dilution to our existing shareholders.

 

Our Articles of Incorporation authorize us to issue 499,990,000 shares of common stock. As of the date hereof, we had 174,968,516 shares of common stock outstanding. Accordingly, we may issue additional shares of common stock. The future issuance of common stock may result in substantial dilution in the percentage of our common stock held by our then existing shareholders. We may value any common stock issued in the future on an arbitrary basis including for services or acquisitions or other corporate actions that may have the effect of diluting the value of the shares held by our stockholders, and might have an adverse effect on any trading market for our common stock. Additionally, we are authorized to issue 10,000 shares of preferred stock, of which we currently have 1,000 shares of our Series A Preferred stock issued and outstanding and 20 shares of Series B Preferred stock issued and outstanding. Further, our board of directors may designate the rights, terms and preferences of our authorized but unissued preferred shares at our discretion including conversion and voting preferences without notice to our shareholders.

 

The sale of the additional shares of common stock could cause dilution as well as the value of our common stock to decline.

 

The sale of a substantial number of shares of our common stock, or anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish. Further, if we do sell or issue more common stock, any investors’ investment in the Company will be diluted. Dilution is the difference between what you pay for your stock and the net tangible book value per share immediately after the additional shares are sold by us. If dilution occurs, any investment in the Company’s common stock could seriously decline in value.

 

Our common stock is subject to the application of the “penny stock” rules which could adversely affect the market price of our common stock and increase transaction costs to sell those shares.

 

The SEC has adopted rule 3a51-1 which establishes the definition of a “penny stock,” for the purposes relevant to us, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, Rule 15g-9 requires:

 

  ● that a broker or dealer approve a person’s account for transactions in penny stocks, and
  ● the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased.
     
    In order to approve a person’s account for transactions in penny stocks, the broker or dealer must:
     
  ● obtain financial information and investment experience objectives of the person, and
  ● make a reasonable determination that the transactions in penny stocks are suitable for that person and the person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks.

 

The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prescribed by the SEC relating to the penny stock market, which, in highlight form:

 

  ● sets forth the basis on which the broker or dealer made the suitability determination and
  ● that the broker or dealer received a signed, written agreement from the investor prior to the transaction.

 

Generally, brokers may be less willing to execute transactions in securities subject to the “penny stock” rules. This may make it more difficult for investors to dispose of our common stock and cause a decline in the market value of our stock.

 

34
 

 

The market price for our common stock is particularly volatile which could lead to wide fluctuations in our share price. You may be unable to sell your common stock shares at or above your purchase price, or at all, which may result in substantial losses to you.

 

The market for our common stock is characterized by significant price volatility when compared to seasoned issuers, and we expect that our share price will continue to be more volatile than a seasoned issuer for the indefinite future. As a consequence of this enhanced risk, more risk-adverse investors may, under the fear of losing all or most of their investment in the event of negative news or lack of progress, be more inclined to sell their shares on the market more quickly and at greater discounts than would be the case with the stock of a seasoned issuer. Many of these factors are beyond our control and may decrease the market price of our common stock regardless of our operating performance. We cannot make any predictions or projections as to what the prevailing market price for our common stock shares will be at any time, or as to what effect the sale of shares or the availability of common stock shares for sale at any time will have on the prevailing market price.

 

FINRA sales practice requirements may also limit a stockholder’s ability to buy and sell our stock.

 

In addition to the “penny stock” rules described above, FINRA has adopted FINRA Rule 2111 that requires a broker-dealer to have reasonable grounds for believing that an investment is suitable for a customer before recommending the investment. Prior to recommending speculative low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. The FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.

 

We do not intend to pay dividends for the foreseeable future.

 

We have never declared or paid any cash dividends on our stock and do not intend to pay any cash dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the development of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our Board of Directors.

 

If we are unable to comply with the financial reporting requirements mandated by the SEC’s regulations, investors may lose confidence in our financial reporting and the price of our common stock, if a market ever does develop for it, could decline.

 

If we fail to maintain effective internal controls over financial reporting, our ability to produce timely, accurate and reliable periodic financial statements could be impaired. If we do not maintain adequate internal control over financial reporting, investors could lose confidence in the accuracy of our periodic reports filed under the Exchange Act. Additionally, our ability to obtain additional financing could be impaired or a lack of investor confidence in the reliability and accuracy of our public reporting could cause our stock price to decline.

 

Item 1B. Unresolved Staff Comments

 

Not Applicable.

 

Item 2. Properties

 

We lease an aggregate of 6,400 square feet of office and warehouse space at 6601 Lyons Rd, Suites L-6&7, Coconut Creek, FL 33073, with base rent at $6,100 per month from Lyons Corporate Park for our executive offices. Approximately 5,800 square feet is used for manufacturing, storage and distribution. The lease term has been renewed for a three year to expire in January of 2025.

 

On June 6, 2017, we entered into an agreement with Hillsboro Technology Center, LLC to lease an aggregate of 19,831 square feet at 448 Hillsboro Technology Drive, Deerfield Beach, FL 33441, with base rent at $14,447 per month plus 7.65% of common area and 13% of building operating expenses. We plan to use this location as a manufacturing, storage and distribution facility commencing in June 2022. The lease term commenced on January 1, 2018 and terminates eighty-six (86) months thereafter.

 

35
 

 

Item 3. Legal Proceedings

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. Litigations applicable to the Company are discussed as follows.

 

Ortiz v. the Company: Jose Ortiz v. Nutralife Biosciences, Inc. f/k/a Nutrafuels, Inc., Case No. CACE-29-017957, was filed in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida, on October 28, 2020. In this matter, Mr. Ortiz is seeking a judgment for damages, attorneys’ fees, and other costs relating to defendant’s purported breach of an employment agreement dated March 18, 2015. We do not believe that this claim is valued at greater than $5,000. Ortiz’ claim was filed on October 28, 2020, asserting improper discharge from employment, and failure to pay wages and benefits, however, we believe (and have filed summary judgment asserting) that the claim was filed too late, in contravention of the applicable statute of limitations.

 

Hamilton v. the Company: Hamilton & Associates Law Group, P.A. v. Nutralife Biosciences, Inc. f/k/a Nutrafuels, Inc., Case No. 50-2020-CA-008435, was filed in the Circuit Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida on August 9, 2020. In the suit, Hamilton & Associates Law Group, P.A. sets forth purported claims for breach of contract, and in the alternative, account stated, open account, unjust enrichment, and quantum meruit. Plaintiff requests a judgment for damages in the principal sum of $150,000, plus an award of attorneys’ fees and costs pursuant to a legal services agreement dated January 7, 2019, as well as pre-judgment interest and post-judgment interest. The Hamilton matter filed directly against the Company initially included a claim against Edgar Ward, but the individual claim has been dropped. The prior engagement agreement between the Hamilton law firm and the Company (for 2018) was in the nature of a flat fee engagement, in which shares were provided in lieu of cash payments. The Company maintains that the change in the engagement of the law firm (from 2018 to 2019) in terms of the nature of payment was not disclosed or explained adequately, and the Company was unaware of any claim that sums remained unpaid, as all fees were understood to be paid as a result of the shares of stock provided. The claim was filed on August 9, 2020, and is not set for trial, and only documentary discovery has been conducted to date.

 

Native American Partners v. the Company: Native American Partners LLC, including NAVF Holdings and NAVF-Pharma, subsidiary companies, and Best Darn Brands, LLC, and its subsidiaries v. Nutralife Biosciences Inc., Case No. CACE-20-009352, was filed in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida. This action was filed on June 5, 2020, against both the Company and Edgar Ward. However, the claim against Mr. Ward was later dropped. The claim asserted that the Company failed to comply with the confidentiality imposed by a non-disclosure agreement signed by plaintiff and defendant. Plaintiff claims that defendant proceeded with the development of a hand sanitizer product that was first revealed to defendant by the plaintiff, however, defendant asserted that the product produced was different (gel vs. spray) and that defendant had contemplated developing the product (the Covid 19 pandemic was already underway) well in advance of the signing of the NDA. In the Amended Complaint filed on July 9, 2020, plaintiffs demanded injunctive relief and damages for conversion, fraudulent misrepresentation, fraud in the inducement, equitable accounting, unjust enrichment, quantum meruit, breach of contract, and negligent misrepresentation. We obtained a dismissal of this Amended Complaint on February 8, 2021, based on the arbitration provision included in the written contract at issue between the parties. At this time, the plaintiffs have not filed another court action that we are aware of. We are also not yet aware of any arbitration initiated by the plaintiff.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

PART II

 

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

Market for Common Stock

 

Our common stock is quoted on the OTC Pink Limited Information Tier of OTC Markets under the symbol, “NLBS.” Our common stock shares were quoted with the symbol “NTFU” on the OTC Markets from May 19, 2014 until March 5, 2019. Trading in stocks quoted on the OTC Markets is often thin and is characterized by wide fluctuations in trading prices due to many factors that may have little to do with a company’s operations or business prospects. On March 23, 2022, the closing price of our common stock on the OTC Pink was $0.085 per share.

 

OTC Markets securities are not listed or traded on the floor of an organized national or regional stock exchange. Instead, OTC Markets securities transactions are conducted through a telephone and computer network connecting dealers in stocks. OTC Markets issuers are traditionally smaller companies that do not meet the financial and other listing requirements of a regional or national stock exchange.

 

Set forth below are the range of high and low prices for our common stock from the OTC Markets Pink Tier for the periods indicated. The quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions and may not necessarily represent actual transactions:

 

PERIOD  HIGH   LOW 
YEAR 2021          
First Quarter 03/31/21  $0.179   $0.085 
Second Quarter 06/30/21  $0.158   $0.090 
Third Quarter 09/30/21  $0.138   $0.056 
Fourth Quarter 12/31/21  $0.123   $0.073 
YEAR 2020          
First Quarter 03/31/20  $0.113   $0.007 
Second Quarter 06/30/20  $0.099   $0.035 
Third Quarter 09/30/20  $0.067   $0.021 
Fourth Quarter 12/31/20  $0.175   $0.037 

 

Transfer Agent

 

Our transfer agent is VStock Transfer LLC located at 18 Lafayette Place, Woodmere, NY 11598. Its telephone number is 212-828-8436 and its website is located at http://www.vstocktransfer.com. VStock Transfer is registered as a transfer agent with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.

 

36
 

 

Holders

 

As of the date hereof, we had 174,968,516 shares of common stock issued and outstanding. As of the date hereof, we had 141 record holders of our common stock. The number of record holders does not include beneficial owners of common stock whose shares are held in the names of banks, brokers, nominees or other fiduciaries.

 

Dividends

 

We have not paid any dividends to the holders of our common stock and we do not expect to pay any such dividends in the foreseeable future as we expect to retain our future earnings for use in the operation and expansion of our business.

 

Equity Compensation Plans

 

None.

 

Registration Rights

 

There are no agreements that require us to register securities under the Securities Act.

 

Stock Re-Purchases

 

We have not, and none of our affiliates have made re-purchases of shares of our common stock since our inception and we do not currently have any publicly-announced repurchase plans in effect.

 

Unregistered Securities

 

From March 2019 to present, we offered and sold the securities below which were not registered under the Securities Act of 1933, as amended. None of the issuances involved underwriters, underwriting discounts or commissions. We relied upon Sections 4(2) of the Securities Act, and Rule 506(b) of the Securities Act of 1933, as amended for the offer and sale of the securities.

 

We believed these exemptions were available because:

 

  ● We are not a blank check company;
  ● We filed a Form D, Notice of Sales, with the SEC;
  ● Sales were not made by general solicitation or advertising;
  ● All certificates had restrictive legends;
  ● Sales were made to persons with a pre-existing relationship to our Chief Executive Officer and Sole Director, Edgar Ward; and
  ● Sales were made to investors who represented that they were accredited investors.

 

On March 7, 2019, we issued 62,500 common shares to Austin Hunter for services rendered to us. We valued these shares at $.170 per share or an aggregate of $10,625.

 

On March 12, 2019, we issued 1,200,000 common shares to Bruce Burley for the purchase of certain assets. We value these shares at a price of $.177 per share or an aggregate of $212,760.

 

On March 12, 2019, we issued 300,000 common shares to Robert E. Borland Jr for the purchase of certain assets. We value these shares at a price of $.177 per share or an aggregate of $53,190.

 

On March 15, 2019, we issued 2,499,765 common shares to Orange Pumpkin Trust for a price of $.085 per share or an aggregate of $212,480.

 

37
 

 

On March 19, 2019, we issued 176,470 common shares to Antonio Morgado for services rendered to us. We valued these shares at $.085 per share or an aggregate of $15,000.

 

On March 22, 2019, we issued 117,647 common shares to Scott Mast for a price of $.085 per share or an aggregate of $10,000.

 

On March 22, 2019, we issued 117,647 common shares to Charles Mast for a price of $.085 per share or an aggregate of $10,000.

 

On April 2, 2019, we issued 2,352,941 common shares to Kahn Family Limited PT II in exchange for the aggregate principal and interest of $200,000 outstanding under a promissory note.

 

On April 2, 2019, we issued 200,000 common shares to Carmen Cortes for a price of $.085 per share or an aggregate of $17,000.

 

On April 9, 2019, we issued 117,647 common shares to Gerald Hersey for services rendered to us. We valued these shares at $.085 per share or an aggregate of $10,000.

 

On April 16, 2019, we issued 117,647 common shares to Gloria G. Ruiz for services rendered to us. We valued these shares at $.19 per share or an aggregate of $10,000.

 

On May 15, 2019, we issued 62,500 common shares to Sebastian Zagami for services rendered to us. We valued these shares at $.235 per share or an aggregate of $14,687.

 

On May 30, 2019, we issued 500,000 common shares to Owen Morgan for services rendered to us. We valued these shares at $.225 per share or an aggregate of $112,500.

 

On June 7, 2019, we issued 250,000 common shares to Nicholas Ward for services rendered to us. We valued these shares at $.195 per share or an aggregate of $48,750.

 

On June 7, 2019, we issued 62,500 common shares to Anthony Centorani for services rendered to us. We valued these shares at $.195 per share or an aggregate of $12,187.

 

On June 7, 2019, we issued 62,500 common shares to Robert Patrick Scott for services rendered to us. We valued these shares at $.195 per share or an aggregate of $12,187.

 

On June 7, 2019, we issued 62,500 common shares to Mary Ellen Mahon for services rendered to us. We valued these shares at $.195 per share or an aggregate of $12,187.

 

On June 7, 2019, we issued 62,500 common shares to John Gross for services rendered to us. We valued these shares at $.195 per share or an aggregate of $12,187.

 

On June 7, 2019, we issued 62,500 common shares to Esco Bell for services rendered to us. We valued these shares at $.195 per share or an aggregate of $12,187.

 

On June 7, 2019, we issued 62,500 common shares to Austin Hunter for services rendered to us. We valued these shares at $.195 per share or an aggregate of $12,187.

 

On June 7, 2019, we issued 62,500 common shares to Cooper Dodd for services rendered to us. We valued these shares at $.195 per share or an aggregate of $12,187.

 

On June 7, 2019, we issued 62,500 common shares to Karina Rodriguez for services rendered to us. We valued these shares at $.195 per share or an aggregate of $12,187.

 

On June 7, 2019, we issued 62,500 common shares to Liska Rodriguez for services rendered to us. We valued these shares at $.195 per share or an aggregate of $12,187.

 

On June 7, 2019, we issued 434,000 common shares to Sidnak Solutions Inc. for payment of the balance of invoices outstanding. We valued these shares at $.10 per share or an aggregate of $43,400.

 

38
 

 

On June 18, 2019, we issued 500,000 common shares to Brenda Hamilton for providing a pledge as collateral for a loan in the amount of $1,000,000 to us. We valued these shares at $.191 per share or an aggregate of $95,500.

 

On June 18, 2019, we issued 500,000 common shares to Kahn Family Limited PT II as additional consideration for a loan provided to us in the amount of $1,000,000 to us. We valued these shares at $.191 per share or an aggregate of $95,500.

 

On July 16, 2019, we issued 50,000 common shares to Milena Castaneda for services rendered to us We valued these shares at $.187 per share or an aggregate of $9,345.

 

On July 16, 2019, we issued 70,203 common shares to Paul R. Hermes in exchange for services rendered to us. We valued these shares at $.18 or an aggregate of $12,637.

 

On August 6, 2019, we issued 500,000 common shares to Sidnak Solutions, Inc. for the purchase raw materials. We valued these shares at $.10 per share or an aggregate of $50,000.

 

On August 28, 2019, we issued 470,588 shares of common shares to Barbara Ludwig for a price of $.085 per share or an aggregate of $40,000.

 

On September 6, 2019, we issued 248,948 shares of our common stock to Hamilton & Associates Law Group, P.A. for services rendered which we valued these shares at $.19 per share or an aggregate of $47,300.

 

On September 12, 2019, we issued 588,235 shares of our common stock to Gregory Ross for a price of $.085 per share or an aggregate of $50,000.

 

On September 13, 2019, we issued 588,240 shares of our common stock to Eileen Miller for a price of $.085 per share or an aggregate of $50,000.

 

On September 27, 2019, we issued 352,941 shares of our common stock to Rudolph Mass for a price of $.085 per share or an aggregate of $30,000.

 

On October 9, 2019, we issued 1,764,705 shares of our common stock to Randall Oostra for a price of $.085 per share or an aggregate of $150,000.

 

On October 9, 2019, we issued 1,764,705 shares of our common stock to Simon Guo for a price of $.085 per share or an aggregate of $150,000.

 

On December 3, 2019, we issued 218,800 shares of our common stock to EW STRATEGIES LLC for a price of $0.10 per share or aggregate of $21,880 as part of a promissory note agreement.

 

On December 3, 2019, we issued 200,000 shares of our common stock to Stephen O’Shaughnessy for a price of $0.10 per share or aggregate of $20,000 as part of a promissory note agreement.

 

On January 8, 2020, we issued 1,000,000 shares of our common stock to Gregory Ross for a price of $.105 per share or aggregate of $105,000 as part of a promissory note agreement.

 

On January 14, 2020, we issued 1,000,000 shares of our common stock to Walter Lundon for a price of $0.10 per share or aggregate of $100,000 as part of a promissory note agreement.

 

On January 23, 2020, we issued 500,000 shares of our common stock to Paul Botts for a price of $0.10 per share or aggregate of $50,000 as part of a promissory note agreement.

 

On February 12, 2020, we issued 350,000 shares of our common stock to Barbara Ludwig for a price of $.09 per share or an aggregate of $31,500 as part of a promissory note agreement.

 

On March 10, 2020 we issued 470,229 shares of our common stock to Brenda Hamilton in exchange for services rendered to us. We valued these shares at $.10 per share or an aggregate of $47,023.

 

On March 13, 2020, we issued 1,538,461 shares of our common stock to Gary Dailey for a price of $.065 per share or an aggregate of $100,000.

 

39
 

 

On March 16, 2020, we issued 400,000 shares of our common stock to Joseph Corso for a price of $0.069 per share or an aggregate of $27,600 as part of a promissory note agreement.

 

On April 7, 2020, we issued 384,615 shares of our common stock to Mark Muller for a price of $.065 per share or an aggregate of $25,000.

 

On August 21, 2020, we issued 80,000 shares of our common stock to Mohamad Hassan Ossiani for a price of $0.035 per share or aggregate of $2,800 as part of a promissory note agreement.

 

On September 8, 2020, we issued 100,000 shares of our common stock to James R. Stuart for a price of $0.045 per share or aggregate of $4,500 as part of a promissory note agreement.

 

On September 15, 2020, we issued 200,000 shares of our common stock to Nicholas Cirignano III for a price of $0.037 per share or aggregate of $7,400 as part of a promissory note agreement.

 

On September 15, 2020, we issued 400,000 shares of our common stock to Thomas Cirignano for a price of $0.037 per share or aggregate of $14,800 as part of a promissory note agreement.

 

On October 16, 2020, we issued 100,000 shares of our common stock to Pinnacle Medical Consulting LLC for a price of $0.059 per share or aggregate of $5,900 as part of a promissory note agreement.

 

On October 23, 2020, we issued 120,000 shares of our common stock to Frank Cannarozzo for a price of $0.09 per share or aggregate of $10,800 as part of a promissory note agreement.

 

On November 3, 2020, we issued 200,000 shares of our common stock to Kenneth Klimas for a price of $0.10 per share or aggregate of $20,000 as part of a promissory note agreement.

 

On November 17, 2020, we issued 100,000 shares of our common stock to Larraine Cullam for a price of $0.09 per share or aggregate of $9,000 as part of a promissory note agreement.

 

On December 28, 2020, we issued 12,500,000 shares of our common stock to 27 Health in exchange for 250 shares of Series X Convertible Preferred stock of Lord Global Corporation in connection with a stock purchase agreement. We valued the transaction at $383,326 using the Black-Scholes Merton valuation model.

 

On November 4, 2020, the Company issued 2 shares of its Series B Preferred stock to John Boldis in exchange for services rendered to us. We valued the shares at an aggregate of $45,469.

 

On November 4, 2020, the Company issued 2 shares of its Series B Preferred stock to Thomas Reid in exchange for services rendered to us. We valued the shares at an aggregate of 45,469.

 

On November 4, 2020, the Company issued 16 shares of its Series B Preferred stock to Draper, Inc. in exchange for services rendered to us. We valued these shares at an aggregate of $363,747.

 

On March 1, 2021, we issued 400,000 shares of our common stock to Joseph Corso for a price of $0.106 per share or aggregate of $42,400 as part of a promissory note agreement dated March 16, 2020.

 

On March 1, 2021, we issued 1,000,000 shares of our common stock to Gregory Ross for a price of $0.106 per share or aggregate of $106,000 as part of a promissory note agreement dated January 8, 2020.

 

On April 2, 2021, we issued 375,000 shares of our common stock to Glenn Morris for a price of $0.08 per share or an aggregate of $30,000.

 

On May 11, 2021, we issued 500,000 shares of our common stock to Frank Cannarozzo for a price of $0.08 per share or an aggregate of $40,000.

 

On June 1, 2021, we issued 475,000 shares of our common stock to Andrew O’Connor for a price of $0.08 per share or an aggregate of $38,000.

 

40
 

 

In March, 2021, the Company issued 10 shares of Series B Convertible Preferred Stock to three consultants, Thomas Reid, Draper Inc. and John Boldis as part of their compensation agreements. The consultant compensation was valued at $164,524 using the trading price of the equivalent common stock on the date of issuance.

 

In April 2021, the Company issued 2,000,000 warrants to Nicholas Ward, its Production Manager as compensation. The warrants have an exercise price of $0.1025 and expire 3 years after issuance.

 

In April through June 2021, the Company issued 2,412,000 shares of common stock and 9,650,000 warrants in exchange for $193,000 to Mitchell Pasin, Frank Cannarozzo, Glenn Morris, Andrew O’Connor and Kenneth Klimas. The warrants have an exercise price of $0.08 per share and expire 2 years after issuance.

 

In June 2021, the Company entered into two Note Exchange Agreements with Larraine Cullam and Eileen Miller. The note holders agreed to exchange their current notes that were in default, for new promissory notes, shares of common stock totalling 1,997,312, and warrants to acquire an aggregate of 7,989,250 shares of common stock. The warrants are exercisable at $0.08 per share and expire two years from the dates of the new promissory notes.

 

During the quarter ended September 30, 2021, the Company issued 1,937,500 shares of common stock and 7,750,000 warrants in exchange for cash totalling $155,000 to Jeffrey Vaughn, and Frank Cannarozzo. The warrants have an exercise price of $0.08 per share and expire two years after issuance.

 

In July 2021, the Company issued 1,000,000 shares of common stock with an aggregate value of $120,000 for consulting services to Kahn Family Limited PT II.

 

During the quarter ended September 30, 2021, the Company received proceeds aggregating $297,500 in connection with two convertible promissory notes issued to GC Capital Partners, LLC and Quick Capital, LLC with due dates ranging from August to September 2022. The notes contained original issue discounts totalling $30,000. Each noteholder has the right to convert any or all of the principal face amount of the notes to the Company’s common stock at a price of $0.08 per share.

 

During the quarter ended September 30, 2021, an aggregate of 4,187,500 warrants were issued to the above noteholders as additional consideration. The warrants are exercisable at $0.08 per share and expire three years from the date of each respective note.

 

In November, 2021 the Company entered into Note Exchange Agreement with Joseph Corso. The note holder agreed to exchange his current note that was in default for shares of common stock totaling 2,633,333, and warrants to acquire 2,633,333 shares of common stock. The warrants are exercisable at $0.08 per share and expire two years from the dates of the new promissory notes.

 

In December 2021, The Company issued 550,000 shares of common stock with an aggregate value of $55,000 for consulting services to David Hayek.

 

Our Securities

 

General

 

Our authorized capital stock consists of 499,990,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, $0.0001 par value per share. As of December 31, 2021, 171,398,834 shares of common stock are outstanding; and 1,000 shares of Series A Preferred stock and 27 shares of Series B Preferred stock are outstanding.

 

Common Stock

 

Each holder of our common stock is entitled to one vote for each share owned of record on all matters voted upon by shareholders, and a majority vote is required for actions to be taken by shareholders. The common stock has no preemptive rights, no cumulative voting rights and no redemption, sinking fund or conversion provisions.

 

41
 

 

Preferred Stock

 

The Company is authorized to issue 10,000,000 shares of preferred stock, $0.0001 par value per share and the Company’s Board of Directors is authorized to establish, from the authorized shares of preferred stock, one or more classes or series of shares, to designate each such class and series, and fix the rights and preferences of each such class of preferred stock, which shall have voting powers, preferences, participating, optional or other special rights, qualifications and limitations or restrictions as adopted by the Board of Directors prior to the issuance of any such preferred shares. We have designated 1,000 shares of Series A Preferred and 110 shares of Series B Preferred.

 

There are currently 1,000 shares of Series A Preferred stock and 27 shares of Series B Preferred stock issued and outstanding.

 

Series A Preferred

 

The Series A Shares have the following rights and preferences:

 

  ● Each one (1) share is entitled to 500,000 votes per share on all matters submitted to our common stockholders.
  ● The Series A Shares are not convertible into common shares;
  ● The holders of the Series A Shares are not entitled to receive dividends or any distribution upon our liquidation or dissolution;
  ● The holders of the Series A Shares cannot assign or sell the shares; and
  ● The Series A Shares are redeemable in whole by us for the price of $1,000 at the option of the holder.

 

So long as any of the Series A Shares are outstanding, we cannot take the following actions without the consent of the holders of 100% of the Series A Shares: amend, alter, waive or repeal, whether by merger consolidation, combination, reclassification or otherwise, the Articles of Incorporation or Bylaws; or create, authorize or issue any class, series or shares of any class of capital stock. The rights and preferences of the Series A Share cannot be amended without the consent of 100% of the holders of the Series A Shares.

 

Series B Preferred

 

We have designated one hundred and ten (110) shares of the preferred stock of the Company, par value $0.0001 as Series B Convertible Preferred Stock (the “Series B Preferred Stock”).

 

The shares of Series B Preferred Stock are convertible at a rate of 1 share of Series B Preferred Stock to 149,567 shares of common stock, par value $0.0001 per share of the Company (the “Common Stock”). Holders of Series B Preferred Stock of the Company may convert their shares of Series B Preferred Stock into Common Stock at any time following January 1, 2021 (the “Permitted Conversion Date”). The Series B Preferred Stock is subject to an ownership limitation, pursuant to which no holder of Series B Preferred Stock will be entitled to convert such investor’s shares of Series B Preferred Stock into shares of Common Stock if such conversion would result in ownership of more than 4.99% of the outstanding shares of Common Stock of the Company. Each share of Series B Preferred Stock will vote together with the holders of the Common Stock on any matter submitted to the shareholders of the Company. Each share of Series B Preferred Stock shall be entitled to a number of votes equal to the number of shares of Common Stock into which the Series B Preferred Stock may convert at the time such vote is made. The Series B Preferred Stock will participate in any dividends, distributions or payments to the holders of the Common Stock on an as-converted basis. The Series B Preferred Stock does not have any liquidation preference over the holders of Common Stock of the Company. Once issued, certain shares of the Series B Preferred Stock are redeemable at the election of the Company at any time prior to the Permitted Conversion Date pursuant to a separate written agreement between the holders of the Series B Preferred Stock and the Company.

 

Warrants

 

There are 80,837,314 outstanding warrants of the Company as of December 31, 2021. The warrants are exercisable at $0.08-$0.35 per share and expire two to three years from the date of each respective agreement.

 

Options

 

There are currently no options outstanding.

 

42
 

 

Item 6. Reserved

 

Not applicable.

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The financial data discussed below is derived from our audited consolidated financial statements for the fiscal years ended December 31, 2021 and 2020, which are found elsewhere in this Annual Report on Form 10-K. Our consolidated financial statements are prepared and presented in accordance with generally accepted accounting principles in the United States. The financial data discussed below is only a summary and investors should read the following discussion and analysis of our financial condition and results of our operations in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. Our actual results and the timing of events may differ materially from those contained in these forward-looking statements due to a number of factors, including those discussed in the section entitled “Risk Factors,” and elsewhere in this Annual Report on Form 10-K.

 

Overview

 

The Company was formed as a limited liability company in the state of Florida on April 1, 2010, to engage in the development and distribution of nutritional and dietary oral spray products. On December 3, 2012, we converted from a Limited Liability Company to a Florida Corporation.

 

We manufacture, market, and distribute alternative wellness solutions with a mission to build an enterprise solution within the health and wellness industry.

 

Our objective is to uncover breakthrough, nutrient-rich formulations, using the most effective ingredients and delivery systems available to the nutraceutical industry, and offer alternative wellness solutions that help improve the quality of life. Our distribution strategy includes selling to private label customers, retailers, distributors, and consumers through retail outlets.

 

Years Ended December 31, 2021 and 2020

 

We had sales of $626,619 and $1,255,784 for the years ended December 31, 2021 and 2020, respectively, or a 50.1% decrease. This decrease is directly related to the decrease in sales and production volume resulting from the shutdowns and business disruptions due to the pandemic and overall industry changes as a result.

 

Cost of sales was $543,031 compared to $745,934 for the years ended December 31, 2021 and 2020, respectively, or a 27.2% decrease. This decrease is directly related to the decrease in sales and production volume resulting from the shutdowns and business disruptions from the pandemic and overall industry changes.

 

Gross profit was $83,588 and $509,850 for the years ended December 31, 2021 and 2020, respectively, or a 83.6% decrease. This is the result of the disruptions in operations resulting from the pandemic and overall industry changes.

 

General and administrative expenses were $1,849,371 compared to $1,804,765 for the years ended December 31, 2021 and 2020, respectively, or a 2.5% increase. This increase is primarily due to the disruptions in the Company’s operations from the pandemic overall industry changes.

 

Stock based compensation was $2,569,514 and $501,707 for the years ended December 31, 2021 and 2020, respectively, or a 412.2% increase. This increase was a result of business development and operational efforts.

 

Finance costs were $1,849,286 compared to $916,835 for the years ended December 31, 2021 and 2020, respectively, an increase of $932,451.

 

We incurred a net loss of approximately $5,800,000 compared to $2,900,000 for the years ended December 31, 2021 and 2020, respectively.

  

43
 

 

Liquidity and Capital Resources

 

Historically, the Company’s primary cash needs have been related to working capital items, which the Company has largely funded through our revenues, working capital, cash on hand, and proceeds from the issuance of stock.

 

The Company through its efforts has secured new business and expects to see a surge in its revenue from multiple channels providing the necessary cash flows to support its operations and debt commitments.

 

Cash Flow Activities

 

As of December 31, 2021, the Company had a cash balance of $135,769. Failure to successfully continue to grow operational revenues could harm our profitability and adversely affect our financial condition and results of operations. We face all of the risks inherent in a new business, including the need for significant additional capital, management’s potential underestimation of initial and ongoing costs, and potential delays and other problems in connection with establishing sales channels.

 

We are continuing our plan to further grow and expand operations and seek sources of capital to pay our contractual obligations as they come due. Management believes that its current operating strategy will provide the opportunity for us to continue as a going concern as long as we are able to obtain additional financing; however, there is no assurance this will occur. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

 

Operating Activities

 

Our cash increased $135,027 for the year ended December 31, 2021. Cash used in operating activities is net loss adjusted for certain non-cash items and changes in certain assets and liabilities, such as those included in working capital.

 

For the year ended December 31, 2021, the Company’s operating activities used cash of $487,386, compared to the year ended December 31, 2020 which used cash of $1,284,240. For details of the operating cash flows refer to the consolidated statements of cash flows in Item 8 – Financial Information and Supplementary Data.

 

Investing Activities

 

For the year ended December 31, 2021, the Company’s investing activities used cash of $675,000 for a deposit on an equity and license agreement.

 

Financing Activities

 

During the year ended December 30, 2021, we received an aggregate of $243,275 from SBA financing, under the Paycheck Protection Program and CARES act.

 

We also received $725,050 from financing from debt, and $348,000 from the sale of common stock.

 

Critical Accounting Policies and Estimates

 

In preparing the financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the financial statements.

 

The preparation of the financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Our estimates and assumptions, including those related to the ability to continue as going concern, legal proceedings, the recoverability of inventory, long-lived assets, the fair value of stock-based compensation and the fair value of warrant liabilities are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.

  

44
 

 

Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made, and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:

 

Revenue Recognition: In general, we record revenue when persuasive evidence of an arrangement exists, services have been rendered or product delivery has occurred, the sales price to the customer is fixed or determinable, and collectability is reasonably assured. Provision for sales returns will be estimated based on the Company’s historical return experience.

 

Accounts Receivable and Allowance for Doubtful Accounts: Our accounts receivable are stated at estimated net realizable value. Accounts receivable are comprised of balances due from customers net of estimated allowances for uncollectible accounts. In determining collectability, historical trends are evaluated and specific customer issues are reviewed to arrive at appropriate allowances.

 

Long-Lived Assets: The carrying value of long-lived assets is reviewed annually and on a regular basis for the existence of facts and circumstances that may suggest impairment. If indicators of impairment are present, we determine whether the sum of the estimated undiscounted future cash flows attributable to the long-lived asset in question is less than its carrying amount. If less, we measure the amount of the impairment based on the amount that the carrying value of the impaired asset exceeds the discounted cash flows expected to result from the use and eventual disposal of the impaired assets.

 

Derivative Financial Instrument: The Company evaluates its convertible debt, options, warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be accounted for. The result of this accounting treatment is that under certain circumstances the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value measurement is recorded in the statement of operations as other income or expense. Upon conversion or exercise of the convertible note containing an embedded derivative instrument is marked to fair value at the conversion date and that the fair value is reclassified to equity. The shares issued upon conversion of this note are recorded at their fair value with a gain or loss recognition as applicable.

 

Equity instruments that are initially classified as equity that become subject to reclassification under this accounting standard are reclassified to liabilities at the fair value of the instruments on the reclassification date/

 

Share-Based Compensation: We record share-based compensation in accordance with FASB ASC 718, Stock Compensation. FASB ASC 718 requires that the cost resulting from all share-based transactions are recorded in the financial statements over the respective service periods. It establishes fair value as the measurement objective in accounting for share-based payment arrangements and requires all entities to apply a fair-value-based measurement in accounting for share-based payment transactions with employees. FASB ASC 718 also establishes fair value as the measurement objective for transactions in which an entity acquires goods or services from non-employees in share-based payment transactions.

 

Off-Balance Sheet Arrangements

 

We have not entered into any transaction, agreement or other contractual arrangement with an entity unconsolidated with us under whom we have:

 

  ● An obligation under a guarantee contract.
  ● A retained or contingent interest in assets transferred to the unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to such entity for such assets.
  ● Any obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument.
  ● Any obligation, including a contingent obligation, arising out of a variable interest in an unconsolidated entity that is held by us and material to us where such entity provides financing, liquidity, market risk or credit risk support to, or engages in leasing, hedging or research and development services with us.

 

We do not have any off-balance sheet arrangements or commitments that have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures, or capital resources that is material, other than those which may be disclosed in this Management’s Discussion and Analysis of Financial Condition and the audited Consolidated Financial Statements and related notes.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

Not required for smaller reporting companies.

 

45
 

 

Item 8. Financial Statements and Supplementary Data

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

Report of Independent Registered Accounting Firm (Rotenberg Meril Solomon Bertiger & Guttilla, PC, Saddle Brook, NJ, PCAOB ID:361) F-1
Consolidated Balance Sheets F-2
Consolidated Statements of Operations F-3
Consolidated Statements of Changes in Stockholders’ (Deficit) Equity F-4
Consolidated Statements of Cash Flows F-5
Notes to the Consolidated Financial Statements F-6

 

46
 

 

Report of Independent Registered Public Accounting Firm

 

To the Shareholders and Board of Directors of

NutraLife Biosciences, Inc.

Coconut Creek, Florida

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of NutraLife Biosciences, Inc. and Subsidiaries (the “Company”) as of December 31, 2021 and 2020, and the related consolidated statements of operations, stockholders’ (deficit) equity and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As disclosed in the financial statements, the Company has suffered substantial net losses in recent years, has negative working capital and has an accumulated deficit at December 31, 2021 and 2020 and is dependent on debt and equity financing to fund its operations, all of which raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans regarding these matters are disclosed in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.  

 

Critical Audit Matters

 

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the board of directors and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgements. We determined that there are no critical audit matters.

 

/s/ ROTENBERG MERIL SOLOMON BERTIGER & GUTTILLA, P.C.  
ROTENBERG MERIL SOLOMON BERTIGER & GUTTILLA, P.C.  

We have served as the Company's auditors since 2020.

 

Saddle Brook, New Jersey

April 11, 2022

  

 

F-1

 

 

NUTRALIFE BIOSCIENCES, INC.

Consolidated Balance Sheets

December 31,

 

   2021   2020 
         
Assets          
Current Assets:          
Cash and cash equivalents  $135,769   $742 
Accounts receivable, net of allowance for doubtful accounts in the amount of $0 and $0   44,198    154,193 
Inventories   309,334    567,527 
Prepaid and other current assets   28,997    - 
Total current assets   518,298    722,462 
           
Property and equipment, net   2,265,196    2,314,661 
           
Operating lease right-of-use assets   449,155    661,141 
Investment   383,326    383,326 
Deposit on equity and license agreement   675,000    - 
Intangible asset   525,150    590,118 
Other assets   35,000    35,000 
           
Total Assets  $4,851,125   $4,706,708 
           
Liabilities and Stockholders’ (Deficit) Equity          
           
Current Liabilities:          
Accounts payable   283,164   $173,925 
Accrued expenses (related party $148,552 and $91,048)   1,043,891    786,495 
Deferred revenue   70,521    - 
Customer deposits   -    22,700 
Liability for stock to be issued   265,500    265,500 
Current portion of SBA Note Payable   -    148,000 
Current portion of finance leases   17,161    20,000 
Current portion of operating lease liability   141,911    214,000 
Notes payable, net of unamortized discount of $200,524 and $206,542 (related party $1,000,000 and $1,000,000)   2,621,506    2,153,498 
Other current liability   

33,000

    

-

 
Revenue share agreements payable   725,000    - 
Total current liabilities   5,201,654    3,784,118 
           
Long-term Liabilities:          
           
Notes payable - SBA, net of current portion   10,000    106,700 
Operating lease liability, net of current portion   350,887    497,593 
Finance leases, net of current portion   1,114    17,187 
           
Total liabilities   5,563,655    4,405,598 
           
Stockholders’ (Deficit) Equity          
Preferred stock; $0.0001 par value, authorized 10,000 shares: 1,000 shares Series A issued and outstanding   1    1 
27 and 20 shares Series B issued and outstanding   -    - 
Common stock; $0.0001 par value, 499,990,000 authorized shares; 171,398,834 and 160,419,488 shares issued and outstanding   17,133    16,036 
Additional paid-in-capital   46,828,644    42,015,874 
Accumulated deficit   (47,558,308)   (41,730,801)
Total stockholders’ (deficit) equity   (712,530)   301,110 
           
Total Liabilities and Stockholders’ (Deficit) Equity  $4,851,125   $4,706,708 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-2

 

 

NUTRALIFE BIOSCIENCES, INC.

Consolidated Statements of Operations

Years Ended December 31,

 

   2021   2020 
         
Sales  $626,619   $1,255,784 
           
Cost of Sales   543,031    745,934 
           
Gross Profit    83,588    509,850 
           
Operating expenses          
           
Advertising and promotion   22,913    176,430 
Stock-based compensation   2,569,514    501,707 
General and administrative   1,849,371    1,804,765 
Depreciation and amortization   114,434    - 
           
Total operating expenses   4,556,232    2,482,902 
           
Loss from operations   (4,472,644)   (1,973,052)
           
Other Income (expense)          
           
Other income (expense)   6,448    (53)
Income from debt forgiveness   487,975    - 
Finance costs   (1,849,286)   (916,835)
           
Total other income (expense)   (1,354,863)   (916,888)
           
Loss before income taxes   (5,827,507)   (2,889,940)
Income tax expense   -    - 
           
Net loss  $(5,827,507)  $(2,889,940)
           
Net loss per weighted average common share - basic and diluted  $(0.04)  $(0.02)
           
Number of weighted average shares outstanding - basic and diluted   164,526,457    146,330,346 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-3

 

 

NUTRALIFE BIOSCIENCES, INC.

Consolidated Statements of Changes in Stockholders’ (Deficit) Equity

 

   Shares   Amount   Shares   Amount   Common   Common   Capital   Deficit   Equity 
   Preferred Stock                     
   Series A   Series B   Number   Par   Additional       Total 
   Number   Par   Number   Par   Shares   Amount   Paid-in   Accumulated   Stockholders’ 
   Shares   Amount   Shares   Amount   Common   Common   Capital   Deficit   Equity 
                                
Ending Balance, December 31, 2019   1,000   $1   $-   $-    140,976,183   $14,092   $40,415,885   $(38,840,861)  $1,589,117 
                                              
Preferred stock issued for services   -    -    20    -    -    -    454,684    -    454,684 
                                              
Shares issued for cash   -    -    -    -    1,923,076    192    124,808    -    125,000 
                                              
Shares issued in connection with debt financing   -    -    -    -    4,550,000    455    390,645    -    391,100 
                                              
Shares issued for services   -    -    -    -    470,229    47    46,976    -    47,023 
                                              
Beneficial conversion feature   -    -    -    -    -    -    51,900    -    51,900 
                                              
Warrants issued in connection with convertible debt   -    -    -    -    -         143,900    -    143,900 
                                              
Warrants issued for cash   -    -    -    -    -         5,000    -    5,000 
                                              
Investment in convertible preferred stock   -    -    -    -    12,500,000    1,250    382,076    -    383,326 
                                              
Net Loss                                      (2,889,940)   (2,889,940)
Ending Balance, December 31, 2020   1,000   $1    20   $-    160,419,488   $16,036   $42,015,874   $(41,730,801)  $301,110 
                                              
Preferred stock issued for services             10    -    -    -    164,524    -    164,524 
                                              
Conversion series B Preferred Stock to Common Stock   -    -    (3)   -    448,701    44    -    -    44 
                                              
Common stock and warrants issued for cash             -    -    4,350,000    435    347,565    -    348,000 
                                              
Common stock issued in connection with debt conversions and accrued interest             -    -    4,630,645    463    369,989    -    370,452 
                                              
Shares issued for services             -    -    1,550,000    155    174,845    -    175,000 
                                              
Warrants issued in connection with debt financing             -    -    -    -    1,525,857    -    1,525,857 
                                            - 
Warrants issued as compensation             -    -    -    -    2,229,990    -    2,229,990 
                                              
Net Loss                                      (5,827,507)   (5,827,507)
Ending Balance, December 31, 2021   1,000   $1    27   $-    171,398,834   $17,133   $46,828,644   $(47,558,308)  $(712,530)

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-4

 

 

NUTRALIFE BIOSCIENCES, INC.

Consolidated Statements of Cash Flows

Years Ended December 31,

 

   2021   2020 
OPERATING ACTIVITIES          
Net loss  $(5,827,507)  $(2,889,940)
Adjustments to reconcile net loss to net cash used in operating activities:          
Income from debt forgiveness   (487,975)   - 
Depreciation   49,465    61,986 
Stock-based compensation   2,569,514    501,707 
Warrants issued in connection with debt conversion   1,155,590    - 
Amortization of debt discount   438,235    671,319 
Amortization of right of use asset   211,986    267,754 
Amortization of intangible asset   64,968    64,968 
Bad debt recoveries   -    (1,500)
           
Changes in operating assets and liabilities:          
Accounts receivable   109,995    (140,894)
Inventories   258,193    (77,354)
Prepaid expenses   (28,997)   87,627 
Accounts payable   109,239    938 
Accrued expenses   302,882    373,301 
Deferred revenue   70,521    - 
Customer deposits   (22,700)   13,350 
Operating lease liabilities   

(218,795

)   

(217,502

)
Revenue share agreements payable   

725,000

    

-

 
Other current liability   33,000    - 
           
Net Cash Used in Operating Activities   (487,386)   (1,284,240)
           
INVESTING ACTIVITIES          
Deposit on equity and license agreement   (675,000)   - 
           
Net Cash Used in Investing Activities   (675,000)   - 
           
FINANCING ACTIVITIES          
Proceeds from SBA financing   243,275    254,700 
Proceeds from debt issuances   725,050    905,040 
Proceeds from warrants issued for cash   -    5,000 
Common shares issued for cash   348,000    125,000 
Payments on finance leases   (18,912)   (19,586)
           
Net Cash Provided by Financing Activities   1,297,413    1,270,154 
          
NET CHANGE IN CASH AND CASH EQUIVALENTS   135,027    (14,086)
           
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR   742    14,828 
           
CASH AND CASH EQUIVALENTS AT END OF YEAR  $135,769   $742 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION          
           
Cash paid for income taxes  $-   $- 
Cash paid for interest  $-   $- 
           
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES          
           
Shares issued in connection with debt  $-   $391,100 
Beneficial conversion feature  $-   $51,900 
Right of use asset addition under ASC 842  $-   $134,364 
Operating lease liabilities under ASC 842  $-   $134,364 
Debt and accrued interest converted to equity  $370,452   $- 
Warrants issued for the issuance of debt  $370,267   $143,900 
Investment in convertible preferred stock  $-   $383,326 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

F-5

 

 

NUTRALIFE BIOSCIENCES, INC.

Notes to the Consolidated Financial Statements

 

NOTE 1 - NATURE OF OPERATIONS

 

NutraLife BioSciences, Inc. (“We” or the “Company”) is the producer and distributor of nutritional supplements that uses micro molecular formulae and a utilization of an oral spray to provide faster and more efficient absorption. Our products are sold to private label distributers who sell the products we manufacture under their own brand name as well as under our own brand name.

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted (“GAAP”) in the United States of America as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and with the rules and regulations of the U.S Securities and Exchange Commission (“SEC”).

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Precision Analytic Testing, LLC, NutraDerma Technologies, Inc., PhytoChem Technologies, Inc., and TransDermalRX, Inc. We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates”, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending March 31, 2023 for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company will evaluate the impact of ASU 2016-13 on the Company’s consolidated financial statements in a future period closer to the date of adoption.

 

Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.

 

In August 2020, the FASB issued ASU 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which simplifies and clarifies certain calculation and presentation matters related to convertible equity and debt instruments. Specifically, ASU-2020-06 removes requirements to separately account for conversion features as a derivative under ASC Topic 815 and removing the requirement to account for beneficial conversion features on such instruments. Accounting Standards Update 2020-06 also provides clearer guidance surrounding disclosure of such instruments and provides specific guidance for how such instruments are to be incorporated in the calculation of Diluted EPS. The guidance under ASU 2020-06 is effective for fiscal years beginning after December 15, 2021,

 

F-6

 

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

 

including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted this standard using a modified retrospective approach effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.

 

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at December 31, 2021 consisted of a money market account.

 

Inventories

 

Inventories are stated at lower of cost or net realizable value utilizing the weighted average method of valuation and consist of raw materials and finished goods. The Company reduces inventory on hand to its net realizable value on an item-by-item basis when it is apparent that the expected realizable value of an inventory item falls below its original cost. A charge to cost of sales results when the estimated net realizable value of specific inventory items declines below cost. Management regularly reviews the Company’s inventories for such declines in value. Inventory consists of the following:

 

  

December 31, 2021

  

December 31, 2020

 
Raw Materials  $60,630   $356,901 
Finished Goods   248,704    210,626 
Inventories  $309,334   $567,527 

 

Allowance for Doubtful Accounts

 

We establish the existence of bad debts through a review of several factors including historical collection experience, current aging status of the customer accounts, and financial condition of our customers. The allowance for doubtful accounts is $0 as of both December 31, 2021 and 2020.

 

Property and Equipment

 

All property and equipment are recorded at cost and depreciated over their estimated useful lives, generally three, seven and twelve years, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Leasehold improvements are amortized over their estimated useful lives or the remaining term of the lease, whichever is shorter.

 

F-7

 

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

 

Impairment of Long-Lived Assets

 

A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.

 

Impairment charges would be included with costs and expenses in the Company’s consolidated statements of operations and would result in reduced carrying amounts of the related assets on the Company’s consolidated balance sheets. No adjustments were made to long-lived assets during the years ended December 31, 2021 and 2020, respectively.

 

Revenue Recognition

 

The Company accounts for revenue under the guidance of FASB ASC 606, “Revenue from Contracts from Customers” (“ASC 606”).

 

ASC 606 prescribes a five-step model that focuses on transfer of control and entitlement to payment when determining the amount of revenue to be recognized. Under the ASC 606 guidance, an entity is required to perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

The Company generates revenues from the sale of products. The product is invoiced, and the revenue is recognized upon shipment or once transfer of risk has passed to the customer, which is the point at which the Company has satisfied its performance obligation.

 

Payments received in advance from customers are recorded as customer deposits until earned, at which time revenue is recognized.

 

We recognize certain revenues under bill and hold arrangements with certain customers when the Company has fulfilled all of its performance obligations, the units are segregated for the specific customer only, and the goods are ready for physical transfer to the customer in accordance with their defined contract delivery schedule. For any requested bill and hold arrangement, we make an evaluation as to whether the bill and hold arrangement qualifies for revenue recognition. The customer must initiate the request for the bill and hold arrangement. The customer must make a fixed commitment to purchase the items. The risk of ownership is passed to the customer, and payment terms are not modified.

 

The Company’s revenues accounted for under ASC 606 do not require significant estimates or judgements based on the nature of the Company’s revenue. The Company’s contracts do not include multiple performance obligations or variable consideration. All of the Company’s sales resulted from contracts with customers for the years ended December 31, 2021 and 2020.

 

Shipping and Handling Costs

 

Shipping and handling costs are expensed as incurred and included in cost of sales. Billings for shipping and handling are reflected within sales in the accompanying consolidated statements of operations.

 

Income Taxes

 

The Company follows the provisions of ASC 740-10, “Accounting for Uncertain Income Tax Positions.” When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management

 

F-8

 

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

 

believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

The tax years 2018-2021 for the Company remain open for audit by federal and state tax authorities. The Company has received no notice of audit or any notifications from the IRS for any of the open tax years.

 

Net Loss Per Share

 

Basic loss per share excludes dilution and is computed by dividing the loss attributable to stockholders by the weighted-average number of shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the year and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. The following anti-dilutive equity and debt securities were excluded from the computation of net loss per share.

 

  

December 31, 2021

  

December 31, 2020

 
   (Shares)   (Shares) 
Warrants   80,837,314    30,560,598 
Series B Preferred Stock   4,038,309    - 
Convertible notes payable, and accrued interest   7,746,257    5,799,124 

 

   92,621,880    36,359,722 

 

Related Party Transactions

 

All transactions with related parties are in the normal course of operations and are measured at the exchange amount.

 

Leases

 

The Company accounts for leases FASB ASU 2016-02, “Leases” (“ASC 842”) and other associated standards, which defines a lease as any contract that conveys the right to use a specific asset for a period of time in exchange for consideration. ASC 842 requires the recognition of the right-of-use assets and related operating and finance lease liabilities on the balance sheet and the disclosure of key information about certain leasing arrangements. As permitted by ASC 842, the Company elected the adoption date of January 1, 2019, which is the initial date of application. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated. Under ASC 842, all leases are required to be recorded on the balance sheet and are classified as either operating leases or finance leases (formerly called capital leases). The lease classification affects the expense recognition in the income statement. Operating lease charges are recorded entirely in operating expenses. Finance lease charges are split, where amortization of the right-of-use asset is recorded in operating expenses and an implied interest component is recorded in interest expense.

 

Leases are classified as a finance lease if any of the following criteria are met:

 

  1. The lease transfers ownership of the underlying asset to the lessee by the end of the lease term.
  2. The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.
  3. The lease term is for the major part of the remaining economic life of the underlying asset.

 

F-9

 

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

 

  4. The present value of the sum of lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset.
  5. The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.

 

For any leases that do not meet the criteria identified above for finance leases, the Company treats such leases as operating leases. As of December 30, 2021, the Company has two finance leases and three operating leases.

 

Under the ASC 842 guidance, both finance and operating leases are reflected on the balance sheet as lease or “right-of-use” assets and lease liabilities. There are some exceptions, which the Company has elected in its accounting policies. For leases with terms of twelve months or less, or below the Company’s general capitalization policy threshold, the Company elects an accounting policy to not recognize lease assets and lease liabilities for all asset classes. The Company recognizes lease expense for such leases generally on a straight-line basis over the lease term.

 

The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and accounts for these options when they are reasonably certain to be exercised. Certain leases contain non-lease components, such as common area maintenance, which are generally accounted for separately. In general, the Company will assess if non-lease components are fixed and determinable, or variable, when determining if the component should be included in the lease liability. For purposes of calculating the present value of the lease obligations, the Company utilizes the implicit interest rate within the lease agreement when known and/or determinable, and otherwise utilizes its incremental borrowing rate at the time of the lease agreement. The related right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability.

 

Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense.

 

Intangible Asset

 

Intangible asset represents the value assigned to intellectual property and is amortized based on the economic benefit expected to be realized.

 

NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS

 

Our consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. We sustained significant losses and negative cash flows from operations. We incurred a net loss of approximately $5.8 million and $2.9 million for the years ended December 31, 2021 and 2020, respectively. We had cash used in operating activities of approximately $487 thousand for the year ended December 31, 2021, and have an accumulated deficit of approximately $48 million at December 31, 2021. These conditions raise substantial doubt about our ability to continue as a going concern.

 

In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in China and began to spread around the world in early 2020. In reaction to decreased supply of and increased demand for sanitizer products, the Company shifted its manufacturing to produce sanitizer products. The Company’s other business operations have been impacted negatively by COVID-19 due to government restrictions and the overall adverse effect on the global economy. The Company expects COVID-19 to continue to negatively impact its operating results and its ability to obtain financing.

 

F-10

 

 

NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS, CONTINUED

 

The Company is currently in the process of raising capital to complete and finalize the build-out of its facility in Deerfield Beach for the purpose of consolidating its operations. The structure of the capital raise is currently in

 

development. The Company is continuing its path to profitability through increased business development, marketing and sales of the Company’s multiple lines of topical, ingestible and skincare health and wellness products. The Company is also focused on completing an efficacy clinical study on its patented mosquito bug patch with plans upon a successful conclusion to launch globally in the very near future, adding to the Company’s suite of wellness products.

 

In January 2022, the Company entered into a license and ownership agreement in an effort to expand its sales and customer base. For the details of equity and license agreement refer to the Note 6-Investment.

 

The independent auditors’ report on our financial statements for the years ended December 31, 2021 and 2020 contain explanatory paragraphs expressing substantial doubt as to our ability to continue as a going concern.

 

Failure to successfully continue to grow operational revenues could harm our profitability and adversely affect our financial condition and results of operations. We face all of the risks inherent in a new business, including the need for significant additional capital, management’s potential underestimation of initial and ongoing costs, and potential delays and other problems in connection with establishing sales channels.

 

We are continuing our plan to further grow and expand operations and seek sources of capital to pay our contractual obligations as they come due. Management believes that its current operating strategy will provide the opportunity for us to continue as a going concern as long as we are able to obtain additional financing; however, there is no assurance this will occur. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

 

NOTE 4 – PROPERTY AND EQUIPMENT, NET

 

A summary of property and equipment at December 31, 2021 and 2020 is as follows:

 

   December 31, 2021   December 31, 2020 
Furniture and equipment  $1,959,694   $1,959,694 
Leasehold improvements   840,728    840,728 
Property and equipment, at cost   2,800,422    2,800,422 
Less: accumulated depreciation   (535,226)   (485,761)
Property and equipment,net  $2,265,196   $2,314,661 

 

Depreciation expense for the years ended December 31, 2021 and 2020 totaled $49,465 and $61,986, respectively.

 

NOTE 5 – INTANGIBLE ASSET

 

In February 2019, the Company acquired certain intellectual property consisting of patent rights. The aggregate purchase price paid in connection with the patent purchase was $714,640, consisting of $130,000 cash, and 3,300,000 shares of the Company’s common stock valued at $0.177 per share or an aggregate of $584,640. Of the 3,300,000 shares, 1,800,000 shares were provided at closing and 1,500,000 were to be provided one year thereafter. These shares have not been issued and the Company is in negotiations with the seller to extend the issuance of the shares. As such, the Company recognized a liability for stock to be issued of $265,500 at both December 31, 2021 and 2020. The acquired patent is amortized over its remaining estimated useful life of approximately 11 years. Amortization expense is $64,968 for both of the years ended December 31, 2021 and 2020. The estimated annual amortization expense for the next five years and thereafter is as follows:

 

      
2022  $65,000 
2023   65,000 
2024   65,000 
2025   65,000 
2026   65,000 
Thereafter   200,150 
Estimated amortization expenses  $525,150 

 

F-11

 

 

NOTE 5 – INTANGIBLE ASSET, CONTINUED

 

A summary of the intangible asset at December 31, 2021 and 2020 is as follows:

 

   December 31, 2021   December 31, 2020 
Patent  $714,640   $714,640 
Less: accumulated amortization   (189,490)   (124,522)
Total  $525,150   $590,118 

 

NOTE 6 – INVESTMENT

 

Distribution Agreement

 

On November 2, 2020 in connection with a manufacturing, distribution and sales agreement with a third party distributor (the “Distributor”), the Company issued 12.5 million of its common shares for 250 shares of non-trading convertible preferred stock of the Distributor. Each convertible preferred share is convertible into 1,000 shares of the Distributor’s common stock. The Distributor’s common shares are currently traded in the over the counter market. On the first business day following the 180-day anniversary of closing, if the share price of the Distributor is less than $4.00, the Distributor will provide the Company its common stock valued at $1 million, less 250,000 common shares, for no additional consideration. On the one-year anniversary of closing, if the share price of the Distributor is less than $4.00, the Distributor will provide the Company its common stock valued at $1 million, less 250,000 shares, less the number of shares provided on the 181st day anniversary, for no additional consideration.

 

As of December 31, 2021, the Company was entitled to 3,831,169 shares of the Distributor’s common stock. No shares have been received as of the date of the filing of this report.

 

The Company determined to initially value the convertible preferred stock investment using the Black-Scholes option pricing model using the following inputs: stock price: $4.00, exercise price: $4.00, expected term: one year, and risk free rate 0.17%.

 

The Company made this investment to realize strategic benefits for its business, rather than to generate income or capital gains. Because the Company owns less than 20% on an as converted basis of the Distributor, and cannot exercise significant influence over operating and financial policies of the Distributor, the Company accounts for the investment under ASC 321, “Equity Securities” (“ASC 321”). Under ASC 321, for each reporting period, the Company completes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired.

 

The investment balance as of both December 31, 2021 and 2020 was $383,326. There is no impairment recorded for the years ended December 31, 2021 and 2020.

 

Deposit on Equity and License Agreement

 

In November 2021, the Company negotiated terms of a non-exclusive sub-license agreement with a third party (the “Party”) whereby the Party will grant the Company a limited, non-exclusive authority to purchase, distribute, market, make, and sell products in which the Party has authorized the Company to produce on a case-by-case basis, for a period of three years from the effective date of the definitive agreement. In exchange for the license, the Company agreed to pay $450,000 along with a monthly license royalty fee of 20% of the final sales price of licensed items to the end buyer.

 

The terms also allow the Company to purchase an equivalent ownership interest of the Party for an initial funding of $225,000, with the option to increase its investment up to $6,000,000. The Company provided an initial funding fee of $225,000 in exchange for the permission to purchase an equivalent ownership interest of the Party, which should equal to the appropriate preferred purchase price, based upon the stated current valuation. The total payment of $675,000 as of December 31, 2021 is classified as a Deposit on Equity and License Agreement on the consolidated balance sheet.

 

In January 2022, the Company entered into a definitive agreement with the Party. The definitive agreement defined an initial term of three years from December 30, 2021, with options to renew. The Company made additional payments to the Party in January in the amount of $725,000 toward the license fee and to purchase an equivalent ownership interest. The total funding to the Party of $1,400,000 was allocated $500,000 for the license, and equity participation of $900,000.

 

F-12

 

 

NOTE 7 – ACCRUED EXPENSES

 

A summary of accrued expenses is as follows:

 

   December 31, 2021   December 31, 2020 
Officer – Bonus  $540,500   $400,000 
Accrued Expenses - Other   30,912    15,456 
Accrued Interest – Related Parties   148,552    91,048 
Accrued Interest   230,203    103,811 
Other Current Liabilities   93,724    52,849 
Accrued Rent   -    123,331 
Accrued expenses  $1,043,891   $786,495 

 

NOTE 8 – NOTES PAYABLE

 

Notes Payable

 

During the quarter ended March 31, 2020, the Company received proceeds aggregating $345,000 in connection with multiple short-term promissory notes with due dates ranging from February to June 2020. The notes had interest at 0% to 12% for the terms of the notes. Each noteholder had the right to convert all the outstanding principal and accrued unpaid interest to the Company’s common stock at a price ranging from $.085 to $.10 per share, prior to the maturity date. Additionally, an aggregate of 3,250,000 shares were issued to the noteholders as additional consideration. The notes also included a beneficial conversion feature (BCF). These notes are currently in default.

 

During the quarter ended September 30, 2020, the Company received proceeds aggregating $230,000 in connection with multiple short-term promissory notes each with a term of one year, maturing in August or September 2021. The notes bear interest at 18%. Four of the five notes were issued under a subscription agreement whereby in addition to the promissory note, the note holder is offered up to four shares of common stock for each one dollar of principal amount of the note at a price of $0.0001 per share. Under the subscription agreement, a total of 780,000 shares were issued.

 

During the quarter ended December 31, 2020, the Company received proceeds aggregating $330,040 in connection with multiple short-term promissory notes each with a term of one year, maturing in October through December 2021. The notes bear interest at 10% to 18%. Each note was issued under a subscription agreement whereby in addition to the promissory note, the note holder is offered up to four shares of common stock for each one dollar of principal amount of the note at a price of $0.0001 per share. Under the subscription agreement, a total of 520,000 shares were issued. Additionally, an aggregate of 6,800,000 warrants were issued to five of the noteholders as additional consideration. The warrants are exercisable at $0.08 per share and expire three years from the date of each respective note.

 

The Company allocated $314,100 of the gross proceeds of the 2020 convertible notes to the stock issuances and $75,200 of the gross proceeds of the subscription agreement notes to the stock issuances on a relative fair value basis, which has been recorded as a debt discount.

 

The Company allocated $143,900 of the gross proceeds of the 2020 subscription agreement notes to the warrants on a relative fair basis. The warrants’ relative fair value was calculated using the Black-Scholes Merton valuation model with the following inputs: an expected and contractual life of 36 months, as assumed volatility of 189.9%, zero dividend rate, and a risk free rate of 0.17% - 0.22%. The warrants are classified in equity as additional paid-in capital.

 

Because the effective conversion prices of the convertible notes were less than the fair value of the underlying common stock on the issuance date, the Company allocated $51,900, the intrinsic value of that beneficial conversion feature, to additional paid-in capital.

 

In January 2021, the Company entered into a Note Exchange Agreement whereby a note holder of the Company agreed to exchange their current note that was in default, for a new promissory note and a warrant to acquire 1,200,000

 

F-13

 

 

NOTE 8 – NOTES PAYABLE, CONTINUED

 

shares of common stock. The warrant is exercisable at $0.08 per share and expires three years from the date of the new promissory note.

 

During the year ended December 31, 2021, the Company received proceeds aggregating $725,050 in connection with multiple short-term promissory notes with due dates ranging from January to December 2022. The notes have original issue discounts totaling $61,950 and bear interest at 8% to 12% for the terms of the notes.

 

An aggregate of 12,787,500 warrants were issued to the noteholders as additional consideration. The warrants are exercisable at $0.08 per share and expire three years from the date of each respective note.

 

The warrants to purchase common stock issued to the noteholders were treated as debt discounts. The gross proceeds of the notes were allocated to debt and warrants issued on a relative far value basis.

 

The Company allocated $370,267 of the gross proceeds to the warrants on a relative fair basis. The warrants’ relative fair value was calculated using the Black-Scholes Merton valuation model with the following inputs: an expected and contractual life of two years, an assumed volatility ranging from 191.0%-245.56%, zero dividend rate, and risk free rate ranging from 0.18%-0.73%.

 

The debt discounts associated with the BCF, warrants, and common stock issuances are amortized through the earlier of the conversion of the notes into common stock, or the maturity date of the notes, on a straight-line basis which approximates the effective interest method due to the short-term nature of the notes. Amortization of the debt discount is reported as finance costs in the Statement of Operations.

 

During the year ended December 31, 2021, the Company entered into debt settlement agreements with three of its noteholders whereby the Company issued 4,630,645 shares of its common stock as well as warrants to acquire 10,622,583 shares of common stock. The warrants are exercisable at $0.08 per share and expire two years from the date of issuance, and were recorded as finance cost.

 

The amount converted was an aggregate of $325,010 of principal and $45,441 of accrued interest.

 

The warrants’ relative fair value of $1,155,590 was calculated using the Black-Scholes Merton valuation model with the following inputs: an expected and contractual life of 24 months, as assumed volatility of 226.19%-249.44%, zero dividend rate, and a risk free rate of 0.17% - 0.28%. The warrants are classified in equity as additional paid-in capital.

 

Debt Discounts

 

Total amortization associated with all debt discounts was $438,235 and $671,319 for the years ended December 31, 2021 and 2020, respectively.

 

Convertible Note Payable to Shareholder

 

In June 2019, the Company entered into an Investment Agreement that included a secured convertible 5.75% promissory note payable for $1,000,000 with a shareholder. The note is subject to a security agreement whereby the

 

F-14

 

 

NOTE 8 – NOTES PAYABLE, CONTINUED

 

first four Ennea Processors the Company has committed to commercialize and monetize will be secured as collateral for the note as well as current and future assets of the Company and its subsidiaries. The payment terms of the note were interest only payments from July 7, 2019 through December 7, 2019 and commencing January 7, 2020, the Company was to make equal monthly installment payments that include principal and interest through the Maturity Date of December 7, 2020.

 

Included in the Investment Agreement is a royalty agreement whereby the investor received 500,000 shares of the Company’s common stock and will be entitled to a royalty of 8.5% from the revenue generated from the “collateral processors” while the principal is outstanding and 5% thereafter on the first two collateral processors for a period of 10 years.

 

In addition to the collateral, the note is secured by a Pledge Agreement from a related-party that included a mortgage lien on certain real property as additional collateral.

 

The collateral processors are not yet in service. Therefore, revenue generated from them and the related royalties due cannot be estimated at this time and will be expensed as incurred in the future.

 

The Company is currently in default of this note, however, the parties are in negotiation to reach settlement terms.

 

Note Payable, SBA

 

On April 23, 2020, the Company received an aggregate of $254,700 related to its filing under the Paycheck Protection Program (“PPP”) and Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) from Trust Bank, N.A. (the “Lender”). The Company elected to treat the loan debt under ASB ASC 470. As such, the Company would derecognize the liability when the loan was forgiven and the Company was legally released from the loan. The PPP loan of $244,700 was forgiven on March 12, 2021 and recognized as other income.

 

On February 26, 2021, the Company received an aggregate of $243,275 related to its filing under the PPP and CARES Act from the Lender. The PPP loan of $243,275 was forgiven on November 26, 2021 and recognized as other income.

 

NOTE 9 – REVENUE SHARE AGREEMENTS

 

During the year ended December 31, 2021, the Company entered into two revenue share agreements with third party investors (“Investors”) and received an aggregate of $725,000. In accordance with the agreements, the proceeds were primarily used to fund the third party license agreement as described in Note 6. The proceeds are non-refundable. In exchange, the Investors are entitled to a percentage of revenue collected by the Company as a result of its investments, ranging from 1.3% to 60% until the Investors’ proceeds are repaid, and 0.83% to 49% thereafter, for a minimum of 60 months. The proceeds of $725,000 was recorded as a liability in the accompanying consolidated balance sheet.

 

NOTE 10 - STOCKHOLDERS’ EQUITY

 

During the quarter ended March 31, 2020, the Company issued 470,229 shares of common stock for services aggregating $47,023, valued using the trading price on the date of issuance.

 

The Company issued 1,923,076 shares of common stock for $.065 per share for an aggregate of $125,000, during 2020.

 

During 2020 the Company recorded $51,900 to additional paid-in capital resulting from the beneficial conversion feature.

 

In July 2020, the Company issued 740,740 warrants in exchange for cash proceeds of $5,000. The warrants have an exercise price of $0.10 and expire two years after issuance.

 

In November 2020, the Company issued 12,500,000 shares of common stock in exchange for 250 shares of nontradable Convertible Preferred Stock of the Distributor in connection with a distribution agreement. See Note 6.

 

F-15

 

 

NOTE 10 - STOCKHOLDERS’ EQUITY, CONTINUED

 

In January 2021, the Company issued 15,000,000 warrants to its Chief Executive Officer, President and sole Director as compensation. The warrants are exercisable at $0.1025 per share and expire three years from issuance.

 

In January 2021, the Company issued 7,500,000 warrants to its Vice President, Neil Catania, as compensation. The warrants are exercisable at $0.1025 per share and expire three years from issuance.

 

In April 2021, the Company issued 2,000,000 warrants to its Production Manager as compensation. The warrants are exercisable at $0.125 per share and expire three years from issuance.

 

The warrants issued as compensation were valued at $2,229,990, calculated using the Black-Scholes Merton valuation model with the following in puts: an expected and contractual life of three years, an assumed volatility ranging from 191.0% to 224.75%, zero dividend rate, and a risk free rate ranging from 0.22% to 0.36%.

 

In April through September 2021, the Company issued 4,350,000 shares of common stock and 17,400,000 warrants in exchange for cash totaling $348,000. The warrants have an exercise price of $0.08 per share and expire two years after issuance.

 

In July 2021, the Company issued 1,000,000 shares of common stock with an aggregate value of $120,000 for consulting services.

 

In December 2021, The Company issued 550,000 shares of common stock with an aggregate value of $55,000 for consulting services.

 

Preferred Stock

 

The Company’s board of directors is authorized to issue, at any time, without further stockholder approval, up to 10,000 shares of preferred stock. The board of directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.

 

Series A Preferred Stock (“Series A Preferred”)

 

On November 30, 2012, the board of directors of the Company created Series A Preferred. The Series A Preferred has the following rights and preferences:

 

  1. The shares are not entitled to dividends or liquidation preferences.
  2. Each share has voting rights equal to 500,000 shares of the Company’s common stock.
  3. So long as Series A Preferred shares are outstanding, the Company cannot take certain actions (as defined in the certificate of designation) without the consent of the holders of 100% of the Series A Preferred shares.

 

On November 30, 2012, Edgar Ward, the Company’s President, CEO, and director, was granted 1,000 shares of Series A Preferred for $1,000. At the option of Mr. Ward, the Series A Preferred shares are redeemable for $1,000.

 

As of December 31, 2021 and 2020, 1,000 shares of Series A Preferred are outstanding.

 

Series B Convertible Preferred Stock (“Series B Preferred”)

 

On September 30, 2020, the Company designated 110 shares of Preferred Stock as Series B Convertible Preferred Stock. A Series B Holder has the right from time to time, and at any time following January 1, 2021, to convert each outstanding share of Series B stock into shares of common stock at a rate of 149,567 shares of common stock for each share of Series B Preferred. Each share of Series B Preferred shall have a number of votes equal to the number of conversion shares which would be issuable as of the date of such vote. The Series B Preferred does not have any liquidation preferences. The Series B Preferred will participate in any dividends, distributions or payments to the holders of the common stock on an as-converted basis. The Series B Preferred is subject to an ownership limitation, pursuant to which no holder of Series B Preferred will be entitled to convert such investor’s shares of Series B Preferred Stock into shares of common stock if such conversion would result in ownership of more than 4.99% of the outstanding shares of common stock of the Company. Once issued, certain shares of the Series B Preferred are redeemable at the election of the Company at any time prior to the Permitted Conversion Date pursuant to separate written agreements that will be effectuated between holders of the Series B Preferred and the Company.

 

F-16

 

 

NOTE 10 - STOCKHOLDERS’ EQUITY, CONTINUED

 

In March 2021, the Company issued 10 shares of Series B Preferred to three consultants as part of their compensation agreements. The consultant compensation was valued at $164,524 using the trading price of the equivalent common stock on the date of issuance.

 

During the quarter ended September 30, 2021, three shares of Series B Preferred were converted to 448,701 shares of common stock.

 

As of December 31, 2021 and 2020, 27 and 20 shares, respectively, of Series B Preferred are outstanding.

 

NOTE 11 – LEASES

 

In conjunction with the new guidance for leases, as defined by the FASB with ASU 2016-02, Leases (Topic 842), the Company has designated the existing leases as operating as further described below:

 

The Company leases their office and warehouse facilities located in in Coconut Creek, Florida under a non-cancelable operating lease agreement. In January 2022, the lease term has been renewed for a three year to expire in January, 2025

 

In June 2017, the Company entered into a lease for an additional facility located in Deerfield Beach, Florida under a non-cancelable operating lease. The term of the lease is for 86 months beginning on January 1, 2018 and calls for yearly 3% increases to base rent, with monthly payments that commenced in March 2018.

 

In July and September of 2019, the Company’s wholly owned subsidiary, Phytochem, entered into two separate lease agreements for office and warehouse space located in Onalaska, Wisconsin, that commenced on August 1 and October 1, respectively. Each lease is for six-month terms with four (4) renewal options to extend for six additional months. The Company expects to occupy one of the spaces for the full term of the lease totaling 30 months. The Company terminated its lease on the other facility in May 2020, without penalty. The remaining lease calls for an annual 3% increase to base rent. In addition to rent, the Company pays certain insurance, maintenance, and other costs related to the rented spaces.

 

In June 2021, the Company entered into a verbal, month-to-month sub-lease agreement for the Wisconsin location. Rental income totalled $80,000 for the year ended December 31, 2021, and in included in general and administrative expenses.

 

As of December 31, 2021, in the consolidated balance sheet, the Company has recorded right-of-use assets of $449,155 and a lease liability of $492,798, of which $141,900 is reported as a current liability. The weighted average remaining lease term is 37 months and weighted average discount rate used is 10%.

 

The following table presents a reconciliation of the undiscounted future minimum lease payments remaining under the operating lease reported as operating lease liability on the consolidated balance sheet as of December 31, 2021:

 

     
Undiscounted future minimum lease payments:    
2022  $199,000 
2023   189,400 
2024   195,100 
Total undiscounted future minimum lease payments   583,500 
Less: amount representing imputed interest   (90,702)
Operating lease liability  $492,798 

 

F-17

 

 

Supplemental cash flow information related to leases is as follows, for the years ended December 31,

 

   2021   2020 
Cash paid for amounts included in the measurement of operating lease liabilities  $551,688   $262,214 

 

Lease expense for operating leases was approximately $386,000 and $442,000 for the years ended December 31, 2021 and 2020.

 

Finance Leases:

 

The Company has acquired certain equipment under agreements that are classified as finance leases. The cost of the equipment under finance leases is included in the balance sheet as property and equipment. The finance lease equipment was $110,372 as of December 31, 2021 and December 31, 2020, with related accumulated depreciation of $12,786 and $8,950, respectively.

 

Minimum lease payments required by these finance leases are as follows:

 

Undiscounted future minimum lease payments:

 

Undiscounted future minimum lease payments:    
2022  $17,000 
2023   2,100 
Total undiscounted future minimum lease payments   19,100 
Less: amount representing interest   (825)
Less: current portion   (17,161)
Present value of minimum lease payments, net of current portion  $1,114 

 

NOTE 12 – EQUITY WARRANTS

 

At December 31, our warrants outstanding are as follows:

 

By Exercise Price:  2021   2020 
Warrants - $0.08   42,020,833    8,000,000 
Warrants - $0.1025   24,500,000    - 
Warrants - $0.10   3,240,740    3,240,740 
Warrants - $0.20   10,352,941    13,302,941 
Warrants - $0.30   722,800    722,800 
Warrants - $0.35   -    5,294,117 
Total outstanding   80,837,314    30,560,598 

 

   Warrants 
Balance, January 1, 2020   21,819,858 
Warrants Issued   8,740,740 
Warrants Exercised   - 
Warrants Expired   - 
Balance, December 30, 2020   30,560,598 
Warrants Issued   66,510,083 
Warrants Exercised   (7,989,250)
Warrants Expired   (8,244,117)
Balance, December 30, 2021   80,837,314 

 

F-18

 

 

NOTE 13 - INCOME TAXES

 

The Company accounts for income taxes in accordance with FSB ASC 740 “Income Taxes”. Federal and state income taxes are calculated and recorded on the current period’s activity in accordance with the tax laws and regulations that are in effect. Deferred tax assets and liabilities are recognized based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rate in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assts will not be realized.

 

The components of the income tax provision are as follows at December 31, 2021 and 2020:

 

   2021   2020 
Current   -    - 
Deferred   -    - 
Total tax provision   -    - 

  

The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31, 2021 and 2020:

 

   2021   2020 
U.S. Federal statutory income tax rate   (21.0)%   (21.0)%
State income tax, net of federal benefit   (3.5)%   (3.5)%
           
Valuation allowance   24.5%   24.5%
Effective tax rate   0.0%   0.0%

 

The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31, 2021 and 2020:

 

Deferred tax assets  2021   2020 
Net operating loss carry forwards  $10,788,000   $9,843,000 
Accrued Wages   133,000    98,000 
Accrued Interest   93,000    - 
Less: valuation allowance   (11,014,000)   (9,941,000)
Total   -    - 
           
Deferred tax liabilities          
Stock based compensation   -    - 
Depreciation   -    - 
Net deferred tax asset  $-   $- 

 

The change in valuation allowance was $1,073,000 and $543,000 for the years ended December 31, 2021 and 2020, respectively. We recorded a 100% valuation allowance related to the deferred tax asset for the loss from operations.

 

The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which temporary differences become deductible. The Company has net operating loss carryforwards of approximately $44.0 million as of December 31, 2021, of which $32.6 million were incurred prior to 2018 that begin to expire in the year 2032 through 2036.

 

In accordance with the provisions of ASC 740: Income Taxes, we record a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At December 31, 2021 and 2020, we have no liabilities for uncertain tax positions. We continually evaluate expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

 

F-19

 

 

NOTE 14 - CONTINGENCIES

 

The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company’s financial position or results of operations.

 

Legal Proceedings:

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. Litigations applicable to the Company are discussed as follows.

 

Hamilton v. the Company: Hamilton & Associates Law Group, P.A. v. Nutralife Biosciences, Inc. f/k/a Nutrafuels, Inc., Case No. 50-2020-CA-008435, was filed in the Circuit Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida on August 9, 2020. In the suit, Hamilton & Associates Law Group, P.A. sets forth purported claims for breach of contract, and in the alternative, account stated, open account, unjust enrichment, and quantum meruit. Plaintiff requests a judgment for damages in the principal sum of $150,000, plus an award of attorneys’ fees and costs pursuant to a legal services agreement dated January 7, 2019, as well as pre-judgment interest and post-judgment interest. The Hamilton matter filed directly against the Company initially included a claim against Edgar Ward, but the individual claim has been dropped. The prior engagement agreement between the Hamilton law firm and the Company (for 2018) was in the nature of a flat fee engagement, in which shares were provided in lieu of cash payments. The Company maintains that the change in the engagement of the law firm (from 2018 to 2019) in terms of the nature of payment was not disclosed or explained adequately, and the Company was unaware of any claim that sums remained unpaid, as all fees were understood to be paid as a result of the shares of stock provided. The claim was filed on August 9, 2020, and is not set for trial, and only documentary discovery has been conducted to date.

 

Native American Partners v. the Company: Native American Partners LLC, including NAVF Holdings and NAVF-Pharma, subsidiary companies, and Best Darn Brands, LLC, and its subsidiaries v. Nutralife Biosciences Inc., Case No. CACE-20-009352, was filed in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida. This action was filed on June 5, 2020, against both the Company and Edgar Ward. However, the claim against Mr. Ward was later dropped. The claim asserted that the Company failed to comply with the confidentiality imposed by a non-disclosure agreement signed by plaintiff and defendant. Plaintiff claims that defendant proceeded with the development of a hand sanitizer product that was first revealed to defendant by the plaintiff, however, defendant asserted that the product produced was different (gel vs. spray) and that defendant had contemplated developing the product (the Covid 19 pandemic was already underway) well in advance of the signing of the NDA. In the Amended Complaint filed on July 9, 2020, plaintiffs demanded injunctive relief and damages for conversion, fraudulent misrepresentation, fraud in the inducement, equitable accounting, unjust enrichment, quantum meruit, breach of contract, and negligent misrepresentation. We obtained a dismissal of this Amended Complaint on February 8, 2021, based on the arbitration provision included in the written contract at issue between the parties. At this time, the plaintiffs have not filed another court action that we are aware of. We are also not yet aware of any arbitration initiated by the plaintiff.

 

Ortiz v. the Company: Jose Ortiz v. Nutralife Biosciences, Inc. f/k/a Nutrafuels, Inc., Case No. CACE-29-017957, was filed in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida, on October 28, 2020. In this matter, Mr. Ortiz is seeking a judgment for damages, attorneys’ fees, and other costs relating to defendant’s purported breach of an employment agreement dated March 18, 2015. We do not believe that this claim is valued at greater than $5,000. Ortiz’ claim was filed on October 28, 2020, asserting improper discharge from employment, and failure to pay wages and benefits, however, we believe (and have filed summary judgment asserting) that the claim was filed too late, in contravention of the applicable statute of limitations.

 

NOTE 15 - CONCENTRATIONS OF CREDIT RISK:

 

Cash

 

The Company maintains principally all cash balances with various financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent

 

upon daily bank balances and the respective strength of the financial institutions. The Company has not incurred any losses on these accounts. At both December 31, 2021 and 2020, there are no amounts in excess of insured limits.

 

Revenue

 

For the year ended December 31, 2021, two customers accounted for approximately 82% of sales. For the year ended December 31, 2020, two customers accounted for 28% of sales.

 

NOTE 16 - SUBSEQUENT EVENTS

 

In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in China, and began to spread around the world in early 2020. In reaction to decreased supply of and increased demand for sanitizer products, the Company shifted its manufacturing to produce sanitizer products. The Company’s other business operations have been impacted negatively by COVID-19 due to government restrictions and the overall adverse effect on the global economy. The Company expects COVID-19 to continue to negatively impact its operating results and its ability to obtain financing.

 

In January 2022, the Company received proceeds aggregating $110,000 in connection with two subscription agreements. Under the subscription agreements, a total of 1,375,000 shares of common stock and 1,375,000 warrants were issued. The warrants are exercisable at $0.08 per share and expire two years from the date of issuance.

 

In January 2022, the Company issued 1,100,000 shares of common stock for services aggregating $100,000.

 

In February 2022, the Company entered into a debt settlement agreement with its noteholder whereby the noteholder converted their two promissory notes into a revenue share agreement. The amount converted was an aggregate of $187,000 of principal and $18,700 of accrued interest. The total amount converted was $205,700.

 

In March 2022, the Company received proceeds of $15,000 in connection with the issuance of a promissory note with a due date in March 2023. The note bears interest at 20%.

 

F-20

 

 

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

 

Resignation of Independent Registered Public Accounting Firm

 

On September 11, 2020, Daszkal Bolton LLP (“Daszkal”) resigned its position as the independent registered public accounting firm of the Company.

 

Daszkal did not issue a report on the Company’s financial statements for the fiscal year ended December 31, 2019. Except as set forth herein, Daszkal’s report on the Company’s financial statements for the fiscal year ended December 31, 2018 did not contain an adverse opinion or a disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles, except that such report expressed substantial doubt regarding our ability to continue as a going concern.

 

Furthermore, during the Company’s two most recent fiscal years and through September 11, 2020, there have been no disagreements with Daszkal on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to Daszkal’s satisfaction, would have caused Daszkal to make reference to the subject matter of the disagreement in connection with its reports on the Company’s financial statements for such periods.

 

For the fiscal years ended December 31, 2019 and 2018 and through September 11, 2020, there were no “reportable events” as that term is described in Item 304(a)(1)(v) of Regulation S-K.

 

Engagement of New Independent Registered Accounting Firm

 

On September 16, 2020, the Company’s Board of Directors appointed Rotenberg Meril Solomon Bertiger & Guttilla, P.C. (“Rotenberg”) as the Company’s new independent registered accounting firm. During the Company’s two most recent fiscal years and through September 16, 2020, neither the Company nor anyone acting on the Company’s behalf consulted Rotenberg with respect to any of the matters or reportable events set forth in Item 304(a)(2)(i) and (ii) of Regulation S-K.

 

Item 9A. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

Pursuant to Rule 13a-15(b) under the Securities Exchange Act of 1934 (“Exchange Act”), we carried out an evaluation, with the participation of our management, including our CEO and sole Director, of the effectiveness of our disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, our CEO concluded that our disclosure controls and procedures were not effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our CEO as appropriate, to allow timely decisions regarding required disclosure for the reasons discussed below.

 

47

 

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Our internal control system was designed to, in general, provide reasonable assurance to our management and board regarding the preparation and fair presentation of published financial statements, but because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2021. The framework used by management in making that assessment was the criteria set forth in the document entitled “Internal Control – Integrated Framework” issued by the 2013 Committee of Sponsoring Organizations of the Treadway Commission. Based on that assessment, our President and Chief Financial Officer have determined and concluded that, as of December 31, 2021, our internal controls over financial reporting were not effective. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. In our assessment of the effectiveness of internal control our financial reporting as of December 31, 2021, we determined that the following items constituted a material weakness:

 

  ● We do not have an independent audit committee in place, which would provide oversight of our officers, operations and financial reporting function;
  ● We do not have anyone currently serving as our Chief Financial Officer;
  ● Our accounting department, which consists of a limited number of personnel, does not provide adequate segregation of duties; and
  ● We do not have effective controls over period end financial disclosure and reporting processes.

 

Management believes that the appointment of one or more outside directors, who shall be appointed to a fully functioning audit committee, will remedy the lack of a functioning audit committee and a lack of a majority of outside directors on our Board. Management plans to take action and implementing improvements to our controls and procedures when our financial position permits.

 

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to the permanent exemption of the Securities and Exchange Commission that permit us to provide only management’s report in this annual report.

 

Changes in Internal Control over Financial Reporting

 

No change in our system of internal control over financial reporting occurred during the period covered by this report, fourth quarter of the fiscal year ended December 31, 2021, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Item 9B. Other Information

 

None.

 

Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections

 

None.

 

PART III

 

Item 10. Directors, Executive Officers and Corporate Governance

 

The board of directors elect our executive officers annually. A majority vote of the directors who are in office are required to fill vacancies. Each director shall be elected for the term of one year, and until his successor is elected and qualified, or until his earlier resignation or removal. Our directors and executive officers are as follows:

 

Name   Age   Position
Edgar Ward   50   Chief Executive Officer, President, Director
Neil Catania   59   Vice President

 

48

 

 

Edgar Ward, Chief Executive Officer, President and Director

 

From April 1, 2010 to present, Edgar Ward has served as our Chief Executive Officer, President, and Director. Mr. Ward’s services to us include day to day operations of our manufacturing facility and management of our company.

 

As our chief executive officer, president and director Mr. Ward brings his experience in managing our day to day operations.

 

Neil Catania, Vice President

 

Neil Catania became our Vice-President on November 20, 2012. From May 2004 until present, Neil Catania has been the chief executive officer of TJM Investments DBA MND LLC, a financial services company located in New York.

 

Mr. Catania’s services to us include assisting Mr. Ward with our day to day operations. Neil Catania holds Series 7, Series 63, Series 24 and Series 55 licenses from the Financial Industry Regulatory Authority (“FINRA”).

 

As our Vice-President Mr. Catania brings his experience in the financial services industry and executive management to our day to day operations.

 

Involvement in Certain Legal Proceedings

 

No executive officer, member of the board of directors or control person of our Company has been involved in any legal proceeding listed in Item 401(f) of Regulation S-K in the past 10 years.

 

Committees

 

We do not have a standing nominating, compensation or audit committee. Rather, our sole director performs the functions of these committees. Additionally, because our common stock is not listed for trading or quotation on a national securities exchange, we are not required to have such committees.

 

Other Directorships

 

None of our other officers and directors are directors of other Securities and Exchange Commission reporting companies.

 

Conflicts of Interest

 

Our Chief Executive Officer, President, and sole Director, Edgar Ward devotes his full time to our business under the terms of his employment contract. Our only other executive officer, Neal Catania is not obligated to commit his full time and attention to our business; accordingly, he may encounter a conflict of interest in allocating his time between our operations and those of other businesses. Neal Catania spends on an average ten (10) hours each month to our business and is not contractually required to devote full time services to us. In the future, our officers and directors may engage in other business activities, investments and business opportunities that may be appropriate for presentation to us as well as other entities to which they owe a fiduciary duty. As a result, they may have conflicts of interest in determining to which entity a particular business opportunity should be presented. Our officers and directors may also in the future become affiliated with entities, engaged in business activities similar to those we intend to conduct. In general, officers and directors of a corporation are required to present business opportunities to a corporation if:

 

  ● the corporation could financially undertake the opportunity;
  ● the opportunity is within the corporation’s line of business; and
  ● it would be unfair to the corporation and its stockholders not to bring the opportunity to the attention of the corporation.

 

49

 

 

Code of Ethics

 

We have not yet adopted a code of ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting. We plan to adopt a Code of Ethics in the future, at the latest prior to our stock being listed on an exchange that requires us to have a formal Code of Ethics.

 

Director Independence

 

We do not have any independent directors, as such term is defined in the listing standards of The NASDAQ Stock Market, at this time. The Company is not quoted on any exchange that requires director independence requirements. For purposes of determining director independence, we have applied the definitions set out in NASDAQ Rule 4200(a)(15). See “Directors, Executive Officers and Corporate Governance”— “Director Independence.”

 

Family Relationships

 

None.

 

Compliance with Section 16(a) of the Exchange Act

 

Section 16(a) of the Exchange Act requires the Company’s directors and officers, and persons who beneficially own more than 10% of a registered class of the Company’s equity securities, to file reports of beneficial ownership and changes in beneficial ownership of the Company’s securities with the SEC on Forms 3, 4 and 5. Officers, directors and greater than 10% stockholders are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms they file.

 

Based solely on the Company’s review of the copies of the forms received by it during the fiscal year ended December 31, 2021, the Company believes that all person who, at any time during such fiscal year, was a director, officer or beneficial owner of more than 10% of the Company’s common stock failed to comply with all Section 16(a) filing requirements during such fiscal years.

 

Item 11. Executive Compensation

 

2021 Summary Compensation Table

 

The table below summarizes all compensation awarded to, earned by, or paid to our Principal Executive Officer, our two (2) most highly compensated executive officers who occupied such position at the end of our latest fiscal year that they were not executive officers at the end of our latest fiscal year, by us, or by any third party where the purpose of a transaction was to furnish compensation, for all services rendered in all capacities to us for the years ended December 31, 2021 and 2020.

 

Name  Position  Year  Salary   Bonus/
Stock Awards		   Options   Non-Equity Incentive Plan Compensation   Non-qualified deferred compensation   All other compensation   Total 
Edgar Ward (1)  Chief Executive Officer,  2021  $350,000                       $350,000(1)
   President, Director  2020  $350,000                             350,000(1)
Neil Catania (2)  Vice  2021  $5,000                            $5,000(2)
   President  2020  $15,000                             15,000(2)

 

(1) Under the terms of his employment agreement, Mr. Ward receives an annual salary of $250,000 and an annual cash bonus of $100,000. For the years ended December 31, 2021 and 2020, Edgar Ward received $159,000 and $111,500, of the annual compensation of $300,000 due him, respectively.
(2) For the years ended December 31, 2021 and 2020 Neil Catania received cash compensation of $5,000 and $15,000, respectively.

 

50

 

 

Edgar Ward is the sole member of our board of Directors. Mr. Ward is not compensated for his service as a director.

 

Our board of directors determines the compensation paid to our executive officers based upon the years of service to us, whether services are provided on a full-time basis and the experience and level of skill required. Because Mr. Ward is our sole director, he determines his own compensation for his services as our Chief Executive Officer and President.

 

We may award our officers and directors shares of common stock as non-cash compensation as determined by the board of directors from time to time. The board will base its decision to grant common stock as compensation on the level of skill required to perform the services rendered and time committed to providing services to us.

 

Outstanding Equity Awards at Fiscal Year-End

 

There were no outstanding equity awards at the 2021 fiscal year-end.

 

Compensation Plans

 

We have not adopted any compensation plan to provide for future compensation of any of our directors or executive officers.

 

Employment Agreements

 

On January 13, 2017, we entered into an employment agreement with our President and CEO, Edgar Ward. The term of this agreement began on January 13, 2017 and ends on January 1, 2027. Pursuant to this agreement, we agreed to compensate Mr. Ward for his services as an executive officer with a base salary of $250,000 per year and a bonus of $100,000 per year.

 

The Company is not currently party to any other employment agreements.

 

Item 12. Security Ownership of Certain Beneficial Owners and Management

 

At March 23, 2022, we had 174,968,516 shares of our common stock issued and outstanding, 1,000 shares of our Series A Preferred stock issued and outstanding, and 27 shares of our Series B Preferred issued and outstanding. The following table sets forth information regarding the beneficial ownership of our common stock, Series A Preferred stock and Series B Preferred stock as of March 23, 2022 by:

 

  ● each person known by us to be the beneficial owner of more than 5% of our common stock;
     
  ● each of our directors;
     
  ● each of our named executive officers; and
     
  ● our executive officers and directors as a group.

 

Unless otherwise indicated, the business address of each person listed is in care of the Company, 6601 Lyons Road, Suite L-6, Coconut Creek Florida 33037. The amounts and percentages of our common stock beneficially owned are reported on the basis of regulations of the SEC governing the determination of beneficial ownership of securities. Under the rules of the SEC, a person is deemed to be a “beneficial owner” of a security if that person has or shares “voting power,” which includes the power to vote or to direct the voting of such security, or “investment power,” which includes the power to dispose of or to direct the disposition of such security. A person is also deemed to be a beneficial owner of any securities of which that person has the right to acquire beneficial ownership within 60 days. Under these rules more than one person may be deemed a beneficial owner of the same securities and a person may be deemed to be a beneficial owner of securities as to which such person has no economic interest.

 

Unless otherwise indicated below, to the best of our knowledge each beneficial owner named in the table has sole voting and sole investment power with respect to all shares beneficially owned, subject to community property laws where applicable.

 

Common Stock  Direct   Indirect   Total   Percentage of Class(1) 
Name & Address of Beneficial Owner                    
Edgar Ward, Founder, Chief Executive Officer, President & Sole Director(3)   38,274,792(3)   1,000,000    39,274,792    24.43%
Neil Catania Vice President(9)   16,270,571    –    16,270,571    10.12%
All Executive Officers & Directors as a Group (2) Persons   54,545,363    1,000,000    55,545,363    34.56%
5% Holders                    
Kahn Family Limited PT II(4)   25,136,439    –    25,136,439    15.64%
NewLeaf Assets, LLC   15,764,705    –    15,764,705    9.01%
27 Health Inc. (6)   12,500,000    –    12,500,000    7.78%

 

51

 

 

Series A Preferred Stock  Direct   Indirect   Total   Percentage of Class(2) 
Name & Address of Beneficial Owner                    
Edgar Ward, Founder, Chief Executive Officer, President & Sole Director   1,000    0    1,000    100%
Neil Catania, Vice President   0    0    0    0 
All Executive Officers & Directors as a Group (2) Persons   1,000    0    1,000    100%
5% Holders                    
None.                    

 

Series B Preferred Stock  Direct   Indirect   Total   Percentage of Class(7) 
Name & Address of Beneficial Owner                    
Edgar Ward, Founder, Chief Executive Officer, President & Sole Director   0    0    0    0 
Neil Catania, Vice President   0    0    0    0 
All Executive Officers & Directors as a Group (2) Persons   0    0    0    0 
5% Holders                    
John Boldis   2    0    2    10.00%
Draper Inc.(8)   16    0    16    80.00%
Thomas Reid   2    0    2    10.00%

 

(1) Based upon 174,968,516 shares of common stock issued and outstanding as of March 23, 2022.
(2) Based upon 1,000 shares of Series A Preferred Stock issued and outstanding as of 1,000. Each share of Series A Preferred Stock is entitled to 500,000 votes per share or an aggregate of 500,000,000 votes.
(3) Our Founder, Chief Executive Officer, President and Director, Edgar Ward, holds all 1,000 shares of our Series A Preferred Stock which entitled him to an aggregate of 500,000,000 votes. Mr. Ward also holds 23,274,792 common shares directly and 1,000,000 shares indirectly which are held by Nicole Archon who is Mr. Ward’s fiancé. Mr. Ward also holds warrants for 15,000,000 common shares which are exercisable within 60 days of the date hereof.
(4) Kahn Family Limited PT II is a trust controlled by Harvey Kahn who has dispositive and voting power over the shares held by Kahn Family Limited PT II. Kahn Family Limited PT II also holds warrants to purchase 5,294,117 common shares which are exercisable within 60 days of the date hereof.
(6) 27 Health Inc. is owned and controlled by Joseph Frontiere, who has dispositive and voting power over the shares held by 27 Health Inc.
(7) Based upon 27 shares of our Series B Preferred issued and outstanding as of March 23, 2022. Each share of Series B Preferred Stock will vote together with the holders of the Common Stock on any matter submitted to the shareholders of the Company.
(8) Draper Inc. is owned and controlled by Denise Aversano, who has dispositive and voting control over the shares held by Draper Inc.
(9) Neil Catania holds warrants for 7,500,000 common shares which are exercisable within 60 days of the date hereof.

 

52

 

 

Item 13. Certain Relationships and Related Transactions, and Director Independence.

 

We do not have a written policy for the review, approval or ratification of transactions with related parties or conflicted transactions.

 

During the fiscal years ended December 31, 2021 and 2020, we had the following transactions with related persons.

 

As of December 31, 2021 and 2020, convertible notes payable to related parties, net of discounts totalled $1,000,000 and $1,000,000, respectively, and other notes payable to related parties, net of discounts, totalled $1,621,506 and $1,153,498, respectively.

 

Director Independence

 

We do not have any independent directors, as such term is defined in the listing standards of The NASDAQ Stock Market, at this time. The Company is not quoted on any exchange that requires director independence requirements. For purposes of determining director independence, we have applied the definitions set out in NASDAQ Rule 4200(a)(15). See “Directors, Executive Officers and Corporate Governance”— “Director Independence.”

 

Item 14. Principal Accounting Fees and Services

 

The following table sets forth the fees billed or to be billed to the Company for the years ended December 31, 2021 and 2020 for professional services rendered by our current independent registered public accounting firm Rotenberg was engaged by us effective as of September 16, 2020.

 

ACCOUNTING FEES AND SERVICES  2021   2020 
         
Audit fees  $80,000   $60,000 
Audit-related fees        - 
Tax fees        - 
All other fees        - 
           
Total  $80,000   $60,000 

 

Audit Fees

 

Audit fees to Rotenberg were for professional services rendered for the audit and reviews of our annual financial statements for the years ended December 31, 2021 and 2020.

 

Audit-Related Fees

 

None.

 

Tax Fees

 

None.

 

All Other Fees

 

None.

 

53

 

 

Pre-Approval of Services

 

We do not have an audit committee. As a result, our Board of Directors performs the duties of an audit committee. Our Board of Directors evaluates and approves in advance the scope and cost of the engagement of an auditor before the auditor renders the audit and non-audit services. We do not rely on pre-approval policies and procedures.

 

PART IV

 

Item 15. Exhibits and Financial Statement Schedules

 

EXHIBITS

 

Exhibit 3.1 Articles of Organization of Nutrafuels, LLC, a Florida Limited Liability Company (Incorporated by reference to Exhibit 3.1 to the Company’s Registration Statement on Form 10 filed with the SEC on November 1, 2017).
Exhibit 3.2 Certificate of Conversion from a Florida Limited Liability Company to a Florida Corporation (Incorporated by reference to Exhibit 3.2 to the Company’s Registration Statement on Form 10 filed with the SEC on November 1, 2017).
Exhibit 3.3 Articles of Incorporation of Nutrafuels, Inc., a Florida Corporation (Incorporated by reference to Exhibit 3.3 to the Company’s Registration Statement on Form 10 filed with the SEC on November 1, 2017).
Exhibit 3.4 Certificate of Designation of Series A Preferred Shares (Incorporated by reference to Exhibit 3.4 to the Company’s Registration Statement on Form 10 filed with the SEC on November 1, 2017).
Exhibit 3.5 Bylaws of Nutrafuels, Inc (Incorporated by reference to Exhibit 3.5 to the Company’s Registration Statement on Form 10 filed with the SEC on November 1, 2017).
Exhibit 3.6 Articles of Amendment to Articles of Incorporation (Incorporated by reference to Exhibit A of the Company’s Definitive Schedule 14C filed with the SEC on February 15, 2019).
Exhibit 3.7 Articles of Amendment (Certificate of Designations for Series B Preferred Stock) filed September 30, 2020 with the Florida Department of State. (Incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on November 5, 2020).
Exhibit 4.1 Common Stock Purchase Warrant issued December 4, 2020 to Russel S. Smith Jr. (Incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.2 Common Stock Purchase Warrant issued February 11, 2021 to Thomas Reid. (Incorporated by reference to Exhibit 4.2 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.3 Common Stock Purchase Warrant issued December 24, 2020 to Nicholas Cirignano II. (Incorporated by reference to Exhibit 4.3 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.4 Common Stock Purchase Warrant dated February 23, 2021 issued to Mark Wakeland. (Incorporated by reference to Exhibit 4.4 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.5 Common Stock Purchase Warrant dated issued December 24, 2020 to Kenneth Klimas. (Incorporated by reference to Exhibit 4.5 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.6 Common Stock Purchase Warrant issued January 27, 2021 to Frank Cannarozzo. (Incorporated by reference to Exhibit 4.6 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.7 Common Stock Purchase Warrant issued December 21, 2018 to Kahn Family Limited PT II. (Incorporated by reference to Exhibit 4.7 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.8 Common Stock Purchase Warrant issued October 11, 2018 to Forage Complete, LLC. (Incorporated by reference to Exhibit 4.8 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.9 Common Stock Purchase Warrant issued January 11, 2021 to Edgar Ward. (Incorporated by reference to Exhibit 4.9 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).

 

54

 

 

Exhibit 4.10 Common Stock Purchase Warrant issued July 31, 2018 to New Leaf Assets, LLC. (Incorporated by reference to Exhibit 4.10 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.11 Common Stock Purchase Warrant issued July 21, 2020 to Mitchell Pasin. (Incorporated by reference to Exhibit 4.11 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.12 Common Stock Purchase Warrant issued October 11, 2018 to FMG LLC. (Incorporated by reference to Exhibit 4.12 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.13 Common Stock Purchase Warrant issued January 11, 2021 to Gregory Ross. (Incorporated by reference to Exhibit 4.13 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.14 Common Stock Purchase Warrant issued January 11, 2021 to Gregory Ross. (Incorporated by reference to Exhibit 4.14 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 4.15* Description of Securities.
Exhibit 10.1 Employment Agreement with Edgar Ward, dated October 10, 2017 (Incorporated by reference to Exhibit 99.1 to the Company’s Registration Statement on Form 10 filed with the SEC on November 1, 2017).
Exhibit 10.2 Agreement with Neil Catania dated October 9, 2017 (Incorporated by reference to Exhibit 99.2 to the Company’s Registration Statement on Form 10 filed with the SEC on November 1, 2017).
Exhibit 10.3 Neil Catania Note Agreement in the amount of $160,000 (Incorporated by reference to Exhibit 99.23 to the Company’s Registration Statement on Form 10 filed with the SEC on November 1, 2017).
Exhibit 10.4 Neil Catania Note Agreement in the amount of $50,000 (Incorporated by reference to Exhibit 99.24 to the Company’s Registration Statement on Form 10 filed with the SEC on November 1, 2017).
Exhibit 10.5 Agreement between Owen Morgan & Phytochem Technologies, Inc. (Incorporated by reference to Exhibit 10.24 of the Company’s Current Report on Form 8-K filed with the SEC on February 7, 2019).
Exhibit 10.6 Agreement between Orlando Pharmacy Inc., and NutraLife BioSciences, Inc. (Incorporated by reference to Exhibit 10.25 of the Company’s Current Report on Form 8-K filed with the SEC on March 13, 2019).
Exbibit 10.7 Agreement with NewLeaf Assets LLS dated March 14 2019 (Incorporated by reference to Exhibit 10.26 of the Company’s Current Report on Form 8-K filed with the SEC on March 18, 2019).
Exhibit 10.8 Stock Purchase Agreement by and among the Company, Lord Global Corporation, and 27 Health, Inc. dated November 2, 2020. (Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the SEC on November 5, 2020).
Exhibit 10.9 Manufacturing, Distribution and Sales Agreement by and between the Company, 27 Health, Inc. dated November 2, 2020. (Incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the SEC on November 5, 2020).
Exhibit 10.10 June 6, 2019 Investment Agreement with the Company, Phytochem Technologies, Inc., Kahn Family Limited PT II. (Incorporated by reference to Exhibit 10.29 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.11 June 6, 2019 Note issued to Kahn Family Limited PT II. (Incorporated by reference to Exhibit 10.30 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.12 June 6, 2019 Security Agreement with the Company, Phytochem Technologies, Inc., Kahn Family Limited PT II. (Incorporated by reference to Exhibit 10.31 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.13 June 6, 2019 Purchaser Royalty Agreement with the Company, Phytochem Technologies, Inc., Kahn Family Limited PT II. (Incorporated by reference to Exhibit 10.32 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.14 June 6, 2019 Pledge Agreement with the Company, Phytochem Technologies, Inc., Kahn Family Limited PT II and Brenda Hamilton. (Incorporated by reference to Exhibit 10.33 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.15 June 6, 2019 Pledgor Royalty Agreement with the Company, Phytochem Technologies, Inc., and Brenda Hamilton. (Incorporated by reference to Exhibit 10.34 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).

 

55

 

 

Exhibit 10.16 November 13, 2019 Amended Investment Agreement with the Company, Phytochem Technologies, Inc., Kahn Family Limited PT II. (Incorporated by reference to Exhibit 10.35 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.17 November 13, 2019 Amended Note issued to Kahn Family Limited PT II. (Incorporated by reference to Exhibit 10.36 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.18 November 13, 2019 Amended Security Agreement with the Company, Phytochem Technologies, Inc., Kahn Family Limited PT II. (Incorporated by reference to Exhibit 10.37 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.19 November 13, 2919 Amended Purchaser Royalty Agreement with the Company, Phytochem Technologies, Inc., Kahn Family Limited PT II. (Incorporated by reference to Exhibit 10.38 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.20 November 13, 2019 Amended Pledge Agreement with the Company, Phytochem Technologies, Inc., Kahn Family Limited PT II and Brenda Hamilton. (Incorporated by reference to Exhibit 10.39 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.21 November 13, 2019 Amended Pledgor Royalty Agreement with the Company, Phytochem Technologies, Inc., and Brenda Hamilton. (Incorporated by reference to Exhibit 10.40 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.22 February 12, 2020 Convertible Promissory Note issued to Barbara Ludwig. (Incorporated by reference to Exhibit 10.41 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.23 October 14, 2019 Convertible Promissory Note issued to Dennis Poland and Amendment to Convertible Promissory Note dated December 31, 2019. (Incorporated by reference to Exhibit 10.42 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.24 October 22, 2019 Convertible Promissory Note issued to Eileen Miller. (Incorporated by reference to Exhibit 10.43 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.25 November 18, 2019 Convertible Promissory Note issued to EW Strategies LLC. (Incorporated by reference to Exhibit 10.44 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.26 December 31, 2019 Amendment to October 10, 2019 Convertible Promissory Note issued to Mike Farr. (Incorporated by reference to Exhibit 10.45 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.27 January 22, 2020 Convertible Promissory Note issued to Paul R. Botts. (Incorporated by reference to Exhibit 10.46 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.28 October 17, 2019 Convertible Promissory Note issued to Paul R. Botts. (Incorporated by reference to Exhibit 10.47 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.29 November 21, 2019 Convertible Promissory Note issued to Stephen O’Shaughnessy. (Incorporated by reference to Exhibit 10.48 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.30 January 8, 2020 Convertible Promissory Note issued to Walter Lundon. (Incorporated by reference to Exhibit 10.49 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.31 December 4, 2020 Subscription Agreement with Russel S. Smith Jr. (Incorporated by reference to Exhibit 10.50 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.32 December 4, 2020 Convertible Promissory Note issued to Russel S. Smith Jr. (Incorporated by reference to Exhibit 10.51 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.33 December 2, 2020 Promissory Note issued to Draper, Inc. (Incorporated by reference to Exhibit 10.52 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.34 December 2, 2020 Promissory Note issued to Carriage House. (Incorporated by reference to Exhibit 10.53 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).

 

56

 

 

Exhibit 10.35 October 22, 2020 Subscription Agreement with Frank Cannarozzo and October 22, 2020 Convertible Promissory Note issued to Frank Cannarozzo. (Incorporated by reference to Exhibit 10.54 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.36 September 8, 2020 Convertible Promissory Note issued to James R. Stuart. (Incorporated by reference to Exhibit 10.55 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.37 March 16, 2020 Convertible Promissory Note issued to Joseph Corso. (Incorporated by reference to Exhibit 10.56 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.38 November 17, 2020 Subscription Agreement with Larraine Cullam and November 17, 2020 Convertible Promissory Note issued to Larraine Cullam. (Incorporated by reference to Exhibit 10.57 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.39 August 21, 2020 Convertible Promissory Note issued to Mohamad Ossiani. (Incorporated by reference to Exhibit 10.58 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.40 September 11, 2020 Subscription Agreement with Nicholas Cirgnano III and September 11, 2020 Convertible Promissory Note issued to Nicholas Cirgnano III. (Incorporated by reference to Exhibit 10. 59 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.41 October 8, 2020 Convertible Promissory Note issued to Pinnacle Medical Consulting LLC. (Incorporated by reference to Exhibit 10.60 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.42 November 3, 2020 Convertible Promissory Note issued to Kenneth R. Klimas. (Incorporated by reference to Exhibit 10.61 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.43 November 2, 2020 Subscription Agreement with Kenneth R. Klimas. (Incorporated by reference to Exhibit 10.62 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.44 August 14, 2020 Convertible Promissory Note issued to Barbara Ludwig. (Incorporated by reference to Exhibit 10.63 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.45 February 11, 2021 Subscription Agreement with Thomas Reid. (Incorporated by reference to Exhibit 10.64 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.46 February 11, 2021 Convertible Promissory Note issued to Thomas Reid. (Incorporated by reference to Exhibit 10.65 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.47 Common Stock Purchase Warrant issued December 24, 2020 to Thomas Cirignano together with the Subscription Agreement for same with Thomas Cirignano. (Incorporated by reference to Exhibit 10.66 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.48 December 24, 2020 Subscription Agreement with Nicholas Cirignano II. (Incorporated by reference to Exhibit 10.67 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.49 December 24, 2020 Convertible Promissory Note issued to Nicholas Cirignano II. (Incorporated by reference to Exhibit 10.68 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.50 February 23, 2021 Subscription Agreement with Mark Wakeland. (Incorporated by reference to Exhibit 10.69 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.51 February 23, 2021 Convertible Promissory Note issued to Mark Wakeland. (Incorporated by reference to Exhibit 10.70 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.52 December 24, 2020 Convertible Promissory Note issued to Kenneth R. Klimas. (Incorporated by reference to Exhibit 10.71 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).

 

57

 

 

Exhibit 10.53 January 27, 2021 Subscription Agreement with Frank Cannarozzo. (Incorporated by reference to Exhibit 10.72 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.54 January 27, 2021 Convertible Promissory Note issued to Frank Cannarozzo. (Incorporated by reference to Exhibit 10.73 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.55 January 21, 2021 Convertible Promissory Note issued to Albert Klimas together with subscription for same. (Incorporated by reference to Exhibit 10.74 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.56 March 14, 2019 Settlement Agreement with New Leaf assets, LLC together with Stock Purchase Warrant issued on March 15, 2019. (Incorporated by reference to Exhibit 10.75 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.57 January 11, 2021 Convertible Promissory Note issued to Gregory Ross. (Incorporated by reference to Exhibit 10.76 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.58 January 11, 2021 Subscription Agreement with Gregory Ross. (Incorporated by reference to Exhibit 10.77 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.59 January 11, 2021 Note Exchange Agreement with Gregory Ross. (Incorporated by reference to Exhibit 10.78 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 10.60 January 11, 2021 Promissory Note issued to Gregory Ross. (Incorporated by reference to Exhibit 10.79 to the Company’s Annual Report on Form 10-K filed with the SEC on March 19, 2021).
Exhibit 16.1 Letter of Daszkal Bolton LLP to the Commission dated November 3, 2020. (Incorporated by reference to Exhibit 16.1 of the Company’s Current Report on Form 8-K filed with the SEC on November 3, 202).
Exhibit 21.1* List of subsidiaries of the registrant.
Exhibit 31.1* Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Exhibit 32.1* Certification of Principal Executive Officer and Principal Financial Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Exhibit 99.1 Form of Purchase Order (Incorporated by reference to Exhibit 99.4 to the Company’s Registration Statement on Form 10 filed with the SEC on November 1, 2017).
   
101.INS* Inline XBRL INSTANCE
   
101.SCH* Inline XBRL TAXONOMY EXTENSION SCHEMA
   
101.CAL* Inline XBRL TAXONOMY EXTENSION CALCULATION
   
101.DEF* Inline XBRL TAXONOMY EXTENSION DEFINITION
   
101.LAB* Inline XBRL TAXONOMY EXTENSION LABELS
   
101.PRE* Inline XBRL TAXONOMY EXTENSION PRESENTATION

 

*Filed herewith.

 

Item 16. Form 10-K Summary

 

None.

 

58

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NutraLife BioSciences, Inc.
     
Dated: April 11, 2022 By: /s/ Edgar Ward
    Edgar Ward
    Chief Executive Officer (principal executive, accounting, and financial officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Signature   Title   Date
         
/s/ Edgar Ward   Chief Executive Officer and Sole Director   April 11, 2022
Edgar Ward   (principal executive officer and principal financials and accounting officer)    

 

59

 

 EX-4.15 2 ex4-15.htm

 

Exhibit 4.15

 

Description of Securities

 

General

 

Our authorized capital stock consists of 499,990,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, $0.0001 par value per share, of which 160,740,200 shares of common stock are currently outstanding; and 1,000 shares of Series A Preferred stock and 20 shares of Series B Preferred stock are currently outstanding.

 

Common Stock

 

Each holder of our common stock is entitled to one vote for each share owned of record on all matters voted upon by shareholders, and a majority vote is required for actions to be taken by shareholders. The common stock has no preemptive rights, no cumulative voting rights and no redemption, sinking fund or conversion provisions.

 

Preferred Stock

 

The Company is authorized to issue 10,000,000 shares of preferred stock, $0.0001 par value per share and the Company’s Board of Directors is authorized to establish, from the authorized shares of preferred stock, one or more classes or series of shares, to designate each such class and series, and fix the rights and preferences of each such class of preferred stock, which shall have voting powers, preferences, participating, optional or other special rights, qualifications and limitations or restrictions as adopted by the Board of Directors prior to the issuance of any such preferred shares. We have designated 1,000 shares of Series A Preferred and 110 shares of Series B Preferred.

 

There are currently 1,000 shares of Series A Preferred stock and 20 shares of Series B Preferred stock issued and outstanding.

 

Series A Preferred

 

The Series A Shares have the following rights and preferences:

 

  ● Each one (1) share is entitled to 500,000 votes per share on all matters submitted to our common stockholders.
  ● The Series A Shares are not convertible into common shares;
  ● The holders of the Series A Shares are not entitled to receive dividends or any distribution upon our liquidation or dissolution;
  ● The holders of the Series A Shares cannot assign or sell the shares; and
  ● The Series A Shares are redeemable in whole by us for the price of $1,000 at the option of the holder.

 

So long as any of the Series A Shares are outstanding, we cannot take the following actions without the consent of the holders of 100% of the Series A Shares: amend, alter, waive or repeal, whether by merger consolidation, combination, reclassification or otherwise, the Articles of Incorporation or Bylaws; or create, authorize or issue any class, series or shares of any class of capital stock. The rights and preferences of the Series A Share cannot be amended without the consent of 100% of the holders of the Series A Shares.

 

 

 

 

Series B Preferred

 

We have designated one hundred and ten (110) shares of the preferred stock of the Company, par value $0.0001 as Series B Convertible Preferred Stock (the “Series B Preferred Stock”).

 

The shares of Series B Preferred Stock are convertible at a rate of 1 share of Series B Preferred Stock to 149,567 shares of common stock, par value $0.0001 per share of the Company (the “Common Stock”). Holders of Series B Preferred Stock of the Company may convert their shares of Series B Preferred Stock into Common Stock at any time following January 1, 2021 (the “Permitted Conversion Date”). The Series B Preferred Stock is subject to an ownership limitation, pursuant to which no holder of Series B Preferred Stock will be entitled to convert such investor’s shares of Series B Preferred Stock into shares of Common Stock if such conversion would result in ownership of more than 4.99% of the outstanding shares of Common Stock of the Company. Each share of Series B Preferred Stock will vote together with the holders of the Common Stock on any matter submitted to the shareholders of the Company. Each share of Series B Preferred Stock shall be entitled to a number of votes equal to the number of shares of Common Stock into which the Series B Preferred Stock may convert at the time such vote is made. The Series B Preferred Stock will participate in any dividends, distributions or payments to the holders of the Common Stock on an as-converted basis. The Series B Preferred Stock does not have any liquidation preference over the holders of Common Stock of the Company. Once issued, certain shares of the Series B Preferred Stock are redeemable at the election of the Company at any time prior to the Permitted Conversion Date pursuant to a separate written agreement between the holders of the Series B Preferred Stock and the Company.

 

Warrants

 

There are currently 78,203,981 outstanding warrants of the Company.

 

Options

 

There are currently 0 options outstanding.

 

 

 

 EX-21.1 3 ex21-1.htm

 

EXHIBIT 21.1

 

NutraLife BioSciences, Inc. currently has the following wholly owned subsidiaries:

 

  ● Precision Analytic Testing, LLC, a Florida limited liability company (“PAT”) formed on May 11, 2017;
  ● NutraDerma Technologies, Inc., (“NutraDerma”) a Florida corporation formed on January 28, 2019;
  ● PhytoChem Technologies, Inc., a Florida corporation (“PhytoChem”) formed on February 4, 2019; and
  ● TransDermalRX, Inc., a Florida corporation (“TransDermal”) formed on February 8, 2019.

 

 

 

 EX-31.1 4 ex31-1.htm

 

EXHIBIT 31.1

 

CERTIFICATIONS

 

I, Edgar Ward, certify that:

 

1. I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2021 of NutraLife BioSciences, Inc.;
   
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
   
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
   
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
     
  a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
     
  b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
     
  c. evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
     
  d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and;
     
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions);
     
  a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls.

 

Dated: April 11, 2022 /s/ Edgar Ward
  Edgar Ward
  Chief Executive Officer
  (principal executive officer, principal financial and accounting officer)

 

 

 

 EX-32.1 5 ex32-1.htm

 

EXHIBIT 32.1

 

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Annual Report on Form 10-K of NutraLife BioSciences, Inc. (the “Company”) for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission (the “Report”), I, Robert Stevens, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: April 11, 2022 /s/ Edgar Ward
  Edgar Ward
  Chief Executive Officer
  (principal executive officer, principal financial and accounting officer)

 

This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.

 

 

 GRAPHIC 6 form10-k_001.jpg begin 644 form10-k_001.jpg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end EX-101.SCH 7 nlbs-20211231.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - LIQUIDITY AND GOING CONCERN CONSIDERATIONS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PROPERTY AND EQUIPMENT, NET link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - INTANGIBLE ASSET link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - INVESTMENT link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - ACCRUED EXPENSES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - REVENUE SHARE AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - EQUITY WARRANTS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - CONCENTRATIONS OF CREDIT RISK link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - INTANGIBLE ASSET (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - ACCRUED EXPENSES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - EQUITY WARRANTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF INVENTORIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SCHEDULE OF ANTI-DILUTIVE EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - LIQUIDITY AND GOING CONCERN CONSIDERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - SCHEDULE OF ESTIMATE AMORTIZATION EXPENSE (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SCHEDULE OF INTANGIBLE ASSET (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - INTANGIBLE ASSET (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - INVESTMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - REVENUE SHARE AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - SCHEDULE OF OPERATING LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - SCHEDULE OF FINANCE LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - LEASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY FEDERAL INCOME TAX RATE (Details) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - CONCENTRATIONS OF CREDIT RISK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 nlbs-20211231_cal.xml INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 nlbs-20211231_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 nlbs-20211231_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Series A Preferred Stock [Member] Series B Preferred Stock [Member] Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Antidilutive Securities [Axis] Warrant [Member] Convertible Series B Preferred Stock [Member] Convertible Debt Securities [Member] Long-Lived Tangible Asset [Axis] Furniture and Fixtures [Member] Leasehold Improvements [Member] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Related Party [Axis] Distributor [Member] Convertible Preferred Stock [Member] Award Type [Axis] One Year Anniversary [Member] Measurement Input Type [Axis] Measurement Input, Expected Term [Member] Measurement Input, Risk Free Interest Rate [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Distribution Agreement [Member] License Agreement [Member] Statistical Measurement [Axis] Maximum [Member] Product and Service [Axis] License [Member] Trading Activity [Axis] Equity [Member] Short-term Debt, Type [Axis] Multiple Short Term Promissory Notes Payable [Member] Minimum [Member] Noteholders [Member] Debt Instrument [Axis] 2020 Convertibles Notes [Member] Subscription Agreement [Member] 2020 Subscription Agreement Notes [Member] Measurement Input, Option Volatility [Member] Debt Settlement Agreements [Member] Financial Instrument [Axis] Principal Amount [Member] Accrued Interest [Member] Secured Convertible 5.75% Promissory Note Payable [Member] Investment Agreement [Member] Long-term Debt, Type [Axis] Paycheck Protection Program [Member] Two Revenue Share Agreement [Member] Title of Individual [Axis] Third Party Investors [Member] Stock Purchase Agreement [Member] Legal Entity [Axis] Lord Global Corporation [Member] Series X Preferred Stock [Member] Chief Executive Officer President And Director [Member] Vice President [Member] Production Manager [Member] Measurement Input, Price Volatility [Member] Measurement Input, Expected Dividend Rate [Member] Edgar Ward [Member] Series B Convertible Preferred Stock [Member] Three Consultants [Member] Geographical [Axis] Coconut Creek, Florida [Member] Deerfield Beach, Florida [Member] Consolidated Entities [Axis] Phytochem [Member] Sub-Lease Agreement [Member] Exercise Price Range [Axis] Exercise Price 1 [Member] Exercise Price 2 [Member] Exercise Price 3 [Member] Exercise Price 4 [Member] Exercise Price 5 [Member] Exercise Price 6 [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Customer [Axis] Two Customers [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Two Subscription Agreement [Member] Debt Settlement Agreement [Member] Extinguishment of Debt [Axis] Principal [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents incorporated by reference ICFR Auditor Attestation Flag Auditor Name Auditor Location Auditor Firm ID Statement [Table] Statement [Line Items] Assets Current Assets: Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts in the amount of $0 and $0 Inventories Prepaid and other current assets Total current assets Property and equipment, net Operating lease right-of-use assets Investment Deposit on equity and license agreement Intangible asset Other assets Total Assets Liabilities and Stockholders’ (Deficit) Equity Current Liabilities: Accounts payable Accrued expenses (related party $148,552 and $91,048) Deferred revenue Customer deposits Liability for stock to be issued Current portion of SBA Note Payable Current portion of finance leases Current portion of operating lease liability Notes payable, net of unamortized discount of $200,524 and $206,542 (related party $1,000,000 and $1,000,000) Other current liability Revenue share agreements payable Total current liabilities Long-term Liabilities: Notes payable - SBA, net of current portion Operating lease liability, net of current portion Finance leases, net of current portion Total liabilities Stockholders’ (Deficit) Equity Preferred stock value Common stock; $0.0001 par value, 499,990,000 authorized shares; 171,398,834 and 160,419,488 shares issued and outstanding Additional paid-in-capital Accumulated deficit Total stockholders’ (deficit) equity Total Liabilities and Stockholders’ (Deficit) Equity Allowance for doubtful accounts Accrued expenses related party Notes payable, unamortized discount Notes payable related parties current Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Sales Cost of Sales Gross Profit Operating expenses Advertising and promotion Stock-based compensation General and administrative Depreciation and amortization Total operating expenses Loss from operations Other Income (expense) Other income (expense) Income from debt forgiveness Finance costs Total other income (expense) Loss before income taxes Income tax expense Net loss Net loss per weighted average common share - basic and diluted Number of weighted average shares outstanding - basic and diluted Beginning balance, value Beginning balance, shares Preferred stock issued for services Preferred stock issued for services, shares Shares issued for cash Shares issued for cash, shares Shares issued in connection with debt financing Shares issued in connection with debt financing, shares Shares issued for services Shares issued for services, shares Beneficial conversion feature Warrants issued in connection with debt financing Warrants issued for cash Investment in convertible preferred stock Investment in convertible preferred stock, shares Net Loss Conversion series B Preferred Stock to Common Stock Conversion series B Preferred Stock to Common Stock, shares Common stock and warrants issued for cash Common stock and warrants issued for cash, shares Common stock issued in connection with debt conversions and accrued interest Common stock issued in connection with debt conversions and accrued interest, shares Warrants issued as compensation Ending Balance, value Ending balance, shares Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Income from debt forgiveness Depreciation Warrants issued in connection with debt conversion Amortization of debt discount Amortization of right of use asset Amortization of intangible asset Bad debt recoveries Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses Accounts payable Accrued expenses Deferred revenue Customer deposits Operating lease liabilities Revenue share agreements payable Other current liability Net Cash Used in Operating Activities INVESTING ACTIVITIES Deposit on equity and license agreement Net Cash Used in Investing Activities FINANCING ACTIVITIES Proceeds from SBA financing Proceeds from debt issuances Proceeds from warrants issued for cash Common shares issued for cash Payments on finance leases Net Cash Provided by Financing Activities NET CHANGE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR CASH AND CASH EQUIVALENTS AT END OF YEAR SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid for income taxes Cash paid for interest SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES Shares issued in connection with debt Beneficial conversion feature Right of use asset addition under ASC 842 Operating lease liabilities under ASC 842 Debt and accrued interest converted to equity Warrants issued for the issuance of debt Investment in convertible preferred stock Organization, Consolidation and Presentation of Financial Statements [Abstract] NATURE OF OPERATIONS Accounting Policies [Abstract] BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES LIQUIDITY AND GOING CONCERN CONSIDERATIONS Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT, NET Goodwill and Intangible Assets Disclosure [Abstract] INTANGIBLE ASSET Investments, All Other Investments [Abstract] INVESTMENT Payables and Accruals [Abstract] ACCRUED EXPENSES Debt Disclosure [Abstract] NOTES PAYABLE Revenue Share Agreements REVENUE SHARE AGREEMENTS Equity [Abstract] STOCKHOLDERS’ EQUITY Leases LEASES Equity Warrants EQUITY WARRANTS Income Tax Disclosure [Abstract] INCOME TAXES Commitments and Contingencies Disclosure [Abstract] CONTINGENCIES Risks and Uncertainties [Abstract] CONCENTRATIONS OF CREDIT RISK Subsequent Events [Abstract] SUBSEQUENT EVENTS Basis of Presentation Principles of Consolidation Recent Accounting Pronouncements Use of Estimates Cash and Cash Equivalents Inventories Allowance for Doubtful Accounts Property and Equipment Impairment of Long-Lived Assets Revenue Recognition Shipping and Handling Costs Income Taxes Net Loss Per Share Related Party Transactions Leases Intangible Asset SCHEDULE OF INVENTORIES SCHEDULE OF ANTI-DILUTIVE EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE SCHEDULE OF PROPERTY AND EQUIPMENT SCHEDULE OF ESTIMATE AMORTIZATION EXPENSE SCHEDULE OF INTANGIBLE ASSET SCHEDULE OF ACCRUED EXPENSES SCHEDULE OF OPERATING LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES SCHEDULE OF FINANCE LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS SCHEDULE OF WARRANTS OUTSTANDING SCHEDULE OF WARRANTS ACTIVITY SCHEDULE OF INCOME TAX PROVISION SCHEDULE OF RECONCILIATION OF STATUTORY FEDERAL INCOME TAX RATE SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES Raw Materials Finished Goods Inventories Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Allowance for doubtful accounts Asset impairment charges Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net Cash Provided by (Used in) Operating Activities Retained Earnings (Accumulated Deficit) Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Property and equipment, at cost Less: accumulated depreciation Property and equipment,net Depreciation expense 2022 2023 2024 2025 2026 Thereafter Estimated amortization expenses Patent Less: accumulated amortization Schedule of Finite-Lived Intangible Assets [Table] Finite-Lived Intangible Assets [Line Items] Patent purchase price Payments to Acquire Intangible Assets Stock issued during period, shares, purchase of assets Shares issued, price per share Stock issued during period, value, purchase of assets Issuance of shares description Finite-Lived Intangible Asset, Useful Life Amortization of Intangible Assets Stock issued during period, shares Stock issued during period, shares, conversion of convertible securities Stock price Stock issued during period, value Exercise price Measurement inputs expected term Measurement input risk free interest rate Equity method investment, ownership percentage Investment Other than Temporary Impairment Losses, Investments License royalty fee Percentage of license royalty fee License fees Payments for participation liabilities Officer – Bonus Accrued Expenses - Other Accrued Interest – Related Parties Accrued Interest Other Current Liabilities Accrued Rent Accrued expenses Schedule of Short-term Debt [Table] Short-term Debt [Line Items] Proceeds from notes payable Debt instrument, maturity date, description Debt instrument interest rate Debt instrument interest rate Number of warrants issued Warrants exercise price Warrant expected term Proceeds from issuance of stock Warrant measurement inputs Beneficial conversion Original issue discounts Debt Conversion, Converted Instrument, Shares Issued Debt conversion, amount Fair Value of Warrants Amortization of Debt Discount (Premium) Notes payable to shareholders Debt description Debt forgiveness Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] [custom:RevenueReceived] [custom:RevenueShareAgreementsDescription] Schedule of Stock by Class [Table] Class of Stock [Line Items] Consulting services, shares Consulting services, value Stock issued during the period, shares Exercise, price per share Additional paid in capital, beneficial conversion feature Cash proceeds, exercise price Convertible preferred stock shares issued Warrants term Warrants issued as compensation Warrants and rights outstanding, measurement input Warrants and Rights Outstanding Preferred stock, shares authorized Preferred stock voting rights Preferred stock, redemption amount Equity ownership percentage Stock issued during the period for stock based compensation, shares Stock issued during the period for stock based compensation, value Conversion of stock Shares converted Schedule Of Operating Leases Undiscounted Future Minimum Lease Payments 2022 2023 2024 Total undiscounted future minimum lease payments Less: amount representing imputed interest Operating lease liability Schedule Of Supplemental Cash Flow Information Related To Leases Cash paid for amounts included in the measurement of operating lease liabilities 2022 2023 Total undiscounted future minimum lease payments Less: amount representing interest Less: current portion Present value of minimum lease payments, net of current portion Operating lease expiration description Description of operating lease Lessee, operating lease, term of contract Annual increases to base rent percent Proceeds from rent Operating Lease, Right-of-Use Asset Operating lease liability, current Weighted average remaining lease term Weighted average discount rate Operating lease expense Finance lease equipment Finance lease equipment, accumulated depreciation Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-based Payment Arrangement, Option, Exercise Price Range [Line Items] Exercise price Warrants outstanding Warrants outstanding, beginning balance Warrants Issued Warrants Exercised Warrants Expired Warrants outstanding, ending balance Current Deferred Total tax provision U.S. Federal statutory income tax rate State income tax, net of federal benefit Valuation allowance Effective tax rate Net operating loss carry forwards Accrued Wages Accrued Interest Less: valuation allowance Total Stock based compensation Depreciation Net deferred tax asset Change in valuation allowance Percentages of valuation allowance recorded Net operating loss carryforwards Operating loss carryforwards, expiration year Loss Contingencies [Table] Loss Contingencies [Line Items] Contingency principal amount Concentration Risk [Table] Concentration Risk [Line Items] Cash balances Concentration risk, percentage Subsequent Event [Table] Subsequent Event [Line Items] Proceeds from common stock Number of warrants exchange, shares Warrant expiration term Common stock, shares Common stock, value Debt conversion, total Debt instrument maturity date Liability for stock to be issued Accrued interest related parties current Revenue share agreements payable. Deposit on joint venture partnership. Beneficial conversion feature Right of use asset additions under asc842 Operating lease liabilities under asc842 Debt and accrued interest converted to equity Warrants issued for issuance of debt Investment in convertible preferred stock. Proceeds from revenue share agreements. Proceeds from joint venture agreement. Warrants Issued In Connection With Debt Conversion. Preferred stock issued for services. Shares issued in connection with debt financing Warrants issued for cash Warrants issued in connection with convertible debt. Common stock and warrants issued for cash Common stock issued in connection with debt conversions and accrued interest Stock issued during period value investment in convertible preferred stock. Stock issued during period shares preferred stock issued for services Shares issued in connection with debt financing, shares Stock issued during period shares investment in convertible preferred stock. Common stock and warrants issued for cash, shares Common stock issued in connection with debt conversions and accrued interest, shares Income From Debt Forgiveness. Related Party Transactions [Policy Text Block] Convertible Series B Preferred Stock [Member]. Issuance of shares description. Distributor [Member] One Year Anniversary [Member] Accrued expenses- other. Chief Executive Officer President andDirector [Member] Production manager [Member]. Noteholders [Member] Edgar Ward [Member] Payment of license fees. License Fee. Series B Convertible Preferred Stock [Member] Three Consultants [Member] Lessee Operating Leases And Financing Leases [Text Block] Operating lease expiration description. Coconut Creek, Florida [Member]. Deerfield Beach, Florida [Member] Annual increases to base rent percent. Phytochem [Member] Secured Convertible 5.75% Promissory Note Payable [Member] Investment Agreement [Member] Schedule Of Cash Flow Supplemental Lease Disclosures [Table Text Block] Cash paid for amounts included in the measurement of operating lease liabilities. Revenue Share Agreements [Text Block] Equity Warrants Disclosure [Text Block] Revenue received. Third Party Investors [Member] Two Revenue Share Agreement [Member] Exercise price 1 [Member] Exercise price 2 [Member] Exercise price 3 [Member] Exercise price 4 [Member] Exercise price 5 [Member] Schedule Of Warrants Activity [Table Text Block] Deferred tax liabilities, Stock based compensation. Deferred tax liabilities, Depreciation. Percentages of valuation allowance recorded. Operating loss carryforwards, expiration year. Former Attorney [Member] Two Customers [Member] Multiple Short Term Promissory Notes Payable [Member] Number of warrants exchange, shares. Two Subscription Agreement [Member] Debt Settlement Agreement [Member] Principal [Member] Accrued Interest [Member] Lord Global Corporation [Member] Distribution Agreement [Member] Exercise Price Six [Member] Shipping and Handling Costs [Policy Text Block] Convertible preferred stock measurement inputs term. License Agreement [Member] 2020 Convertibles Notes [Member] Subscription Agreement [Member] 2020 Subscription Agreement Notes [Member] 2021 Warrants [Member] Debt Settlement Agreements [Member] Principal Amount [Member] Paycheck Protection Program [Member] Revenue share agreements description. Long term debt current. Stock Purchase Agreement [Member] Series X Preferred Stock [Member] Amount of accrued interest related parties. Deposit on equity and license agreement. Deposit on equity and license agreement under investing activities. Percentage of license royalty fee. Deferred tax assets tax deferred expense reserves and accruals accrued interest. Revenue share agreements payable Sub-Lease Agreement [Member] Assets, Current Assets [Default Label] Liabilities, Current Liabilities Stockholders' Equity Attributable to Parent Liabilities and Equity Gross Profit Operating Expenses Operating Income (Loss) Debt Related Commitment Fees and Debt Issuance Costs Nonoperating Income (Expense) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares, Outstanding Increase (Decrease) in Accounts Receivable Increase (Decrease) in Inventories Increase (Decrease) in Prepaid Expense Increase (Decrease) in Accounts Payable Increase (Decrease) in Deferred Revenue Increase (Decrease) in Contract with Customer, Liability Revenue share agreements payable [Default Label] Increase (Decrease) in Other Current Liabilities Net Cash Provided by (Used in) Operating Activities DepositOnEquityAndLicenseAgreementUnderInvestingActivities Net Cash Provided by (Used in) Investing Activities Finance Lease, Principal Payments Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations BeneficialConversionFeature InvestmentInConvertiblePreferredStock Inventory, Policy [Policy Text Block] Lessee, Leases [Policy Text Block] Accounts Receivable, Allowance for Credit Loss Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Finite-Lived Intangible Assets, Accumulated Amortization Investments Debt Instrument, Convertible, Conversion Price Lessee, Operating Lease, Liability, to be Paid, Year One Lessee, Operating Lease, Liability, to be Paid, Year Two Lessee, Operating Lease, Liability, to be Paid, Year Three Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, to be Paid, Year One Finance Lease, Liability, to be Paid, Year Two Finance Lease, Liability, Payment, Due Finance Lease, Liability, Undiscounted Excess Amount Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedInterest Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Depreciation Deferred Tax Assets, Net EX-101.PRE 11 nlbs-20211231_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover - USD ($)
 12 Months Ended
Dec. 31, 2021
Mar. 23, 2022
Jun. 30, 2021
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2021    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2021    
Current Fiscal Year End Date --12-31    
Entity File Number 000-55144    
Entity Registrant Name NUTRALIFE BIOSCIENCES, INC    
Entity Central Index Key 0001563463    
Entity Tax Identification Number 46-1482900    
Entity Incorporation, State or Country Code FL    
Entity Address, Address Line One 6601 Lyons Road    
Entity Address, Address Line Two Suite L-6    
Entity Address, City or Town Coconut Creek    
Entity Address, State or Province FL    
Entity Address, Postal Zip Code 33073    
City Area Code 888    
Local Phone Number 509-8901    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 14,359,742
Entity Common Stock, Shares Outstanding   174,968,516  
Documents incorporated by reference NONE    
ICFR Auditor Attestation Flag false    
Auditor Name Rotenberg Meril Solomon Bertiger & Guttilla, PC    
Auditor Location Saddle Brook    
Auditor Firm ID 361    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Current Assets:    
Cash and cash equivalents $ 135,769 $ 742
Accounts receivable, net of allowance for doubtful accounts in the amount of $0 and $0 44,198 154,193
Inventories 309,334 567,527
Prepaid and other current assets 28,997
Total current assets 518,298 722,462
Property and equipment, net 2,265,196 2,314,661
Operating lease right-of-use assets 449,155 661,141
Investment 383,326 383,326
Deposit on equity and license agreement 675,000
Intangible asset 525,150 590,118
Other assets 35,000 35,000
Total Assets 4,851,125 4,706,708
Current Liabilities:    
Accounts payable 283,164 173,925
Accrued expenses (related party $148,552 and $91,048) 1,043,891 786,495
Deferred revenue 70,521
Customer deposits 22,700
Liability for stock to be issued 265,500 265,500
Current portion of SBA Note Payable 148,000
Current portion of finance leases 17,161 20,000
Current portion of operating lease liability 141,911 214,000
Notes payable, net of unamortized discount of $200,524 and $206,542 (related party $1,000,000 and $1,000,000) 2,621,506 2,153,498
Other current liability 33,000
Revenue share agreements payable 725,000
Total current liabilities 5,201,654 3,784,118
Long-term Liabilities:    
Notes payable - SBA, net of current portion 10,000 106,700
Operating lease liability, net of current portion 350,887 497,593
Finance leases, net of current portion 1,114 17,187
Total liabilities 5,563,655 4,405,598
Stockholders’ (Deficit) Equity    
Preferred stock value 1 1
Common stock; $0.0001 par value, 499,990,000 authorized shares; 171,398,834 and 160,419,488 shares issued and outstanding 17,133 16,036
Additional paid-in-capital 46,828,644 42,015,874
Accumulated deficit (47,558,308) (41,730,801)
Total stockholders’ (deficit) equity (712,530) 301,110
Total Liabilities and Stockholders’ (Deficit) Equity 4,851,125 4,706,708
Series A Preferred Stock [Member]    
Stockholders’ (Deficit) Equity    
Preferred stock value 1 1
Series B Preferred Stock [Member]    
Stockholders’ (Deficit) Equity    
Preferred stock value
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Allowance for doubtful accounts $ 0 $ 0
Accrued expenses related party 148,552 91,048
Notes payable, unamortized discount 200,524 206,542
Notes payable related parties current $ 1,000,000 $ 1,000,000
Preferred Stock, Par or Stated Value Per Share   $ 0.0001
Preferred Stock, Shares Authorized   10,000
Common stock, shares par value $ 0.0001 $ 0.0001
Common stock, shares authorized 499,990,000 499,990,000
Common stock, shares issued 171,398,834 160,419,488
Common stock, shares outstanding 171,398,834 160,419,488
Series A Preferred Stock [Member]    
Preferred stock, shares issued   1,000
Preferred stock, shares outstanding 1,000 1,000
Series B Preferred Stock [Member]    
Preferred stock, shares issued 27 20
Preferred stock, shares outstanding 27 20
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]    
Sales $ 626,619 $ 1,255,784
Cost of Sales 543,031 745,934
Gross Profit 83,588 509,850
Operating expenses    
Advertising and promotion 22,913 176,430
Stock-based compensation 2,569,514 501,707
General and administrative 1,849,371 1,804,765
Depreciation and amortization 114,434
Total operating expenses 4,556,232 2,482,902
Loss from operations (4,472,644) (1,973,052)
Other Income (expense)    
Other income (expense) 6,448 (53)
Income from debt forgiveness 487,975
Finance costs (1,849,286) (916,835)
Total other income (expense) (1,354,863) (916,888)
Loss before income taxes (5,827,507) (2,889,940)
Income tax expense
Net loss $ (5,827,507) $ (2,889,940)
Net loss per weighted average common share - basic and diluted $ (0.04) $ (0.02)
Number of weighted average shares outstanding - basic and diluted 164,526,457 146,330,346
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Changes in Stockholders' (Deficit) Equity - USD ($)
Series A Preferred Stock [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Beginning balance, value at Dec. 31, 2019 $ 1 $ 14,092 $ 40,415,885 $ (38,840,861) $ 1,589,117
Beginning balance, shares at Dec. 31, 2019 1,000 140,976,183      
Preferred stock issued for services 454,684 454,684
Preferred stock issued for services, shares   20        
Shares issued for cash $ 192 124,808 125,000
Shares issued for cash, shares     1,923,076      
Shares issued in connection with debt financing $ 455 390,645 391,100
Shares issued in connection with debt financing, shares     4,550,000      
Shares issued for services $ 47 46,976 47,023
Shares issued for services, shares     470,229      
Beneficial conversion feature 51,900 51,900
Warrants issued in connection with debt financing   143,900 143,900
Warrants issued for cash   5,000 5,000
Investment in convertible preferred stock $ 1,250 382,076 383,326
Investment in convertible preferred stock, shares     12,500,000      
Net Loss         (2,889,940) (2,889,940)
Ending Balance, value at Dec. 31, 2020 $ 1 $ 16,036 42,015,874 (41,730,801) 301,110
Ending balance, shares at Dec. 31, 2020 1,000 20 160,419,488      
Preferred stock issued for services   164,524 164,524
Preferred stock issued for services, shares   10        
Shares issued for services   $ 155 174,845 175,000
Shares issued for services, shares     1,550,000      
Warrants issued in connection with debt financing   1,525,857 1,525,857
Net Loss         (5,827,507) (5,827,507)
Conversion series B Preferred Stock to Common Stock $ 44 44
Conversion series B Preferred Stock to Common Stock, shares   (3) 448,701      
Common stock and warrants issued for cash   $ 435 347,565 348,000
Common stock and warrants issued for cash, shares     4,350,000      
Common stock issued in connection with debt conversions and accrued interest   $ 463 369,989 370,452
Common stock issued in connection with debt conversions and accrued interest, shares     4,630,645      
Warrants issued as compensation   2,229,990 2,229,990
Ending Balance, value at Dec. 31, 2021 $ 1 $ 17,133 $ 46,828,644 $ (47,558,308) $ (712,530)
Ending balance, shares at Dec. 31, 2021 1,000 27 171,398,834      
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
OPERATING ACTIVITIES    
Net loss $ (5,827,507) $ (2,889,940)
Adjustments to reconcile net loss to net cash used in operating activities:    
Income from debt forgiveness (487,975)
Depreciation 49,465 61,986
Stock-based compensation 2,569,514 501,707
Warrants issued in connection with debt conversion 1,155,590
Amortization of debt discount 438,235 671,319
Amortization of right of use asset 211,986 267,754
Amortization of intangible asset 64,968 64,968
Bad debt recoveries (1,500)
Changes in operating assets and liabilities:    
Accounts receivable (109,995) 140,894
Inventories (258,193) 77,354
Prepaid expenses 28,997 (87,627)
Accounts payable 109,239 938
Accrued expenses 302,882 373,301
Deferred revenue 70,521
Customer deposits (22,700) 13,350
Operating lease liabilities (218,795) (217,502)
Revenue share agreements payable 725,000
Other current liability 33,000
Net Cash Used in Operating Activities (487,386) (1,284,240)
INVESTING ACTIVITIES    
Deposit on equity and license agreement (675,000)
Net Cash Used in Investing Activities (675,000)
FINANCING ACTIVITIES    
Proceeds from SBA financing 243,275 254,700
Proceeds from debt issuances 725,050 905,040
Proceeds from warrants issued for cash 5,000
Common shares issued for cash 348,000 125,000
Payments on finance leases (18,912) (19,586)
Net Cash Provided by Financing Activities 1,297,413 1,270,154
NET CHANGE IN CASH AND CASH EQUIVALENTS 135,027 (14,086)
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR 742 14,828
CASH AND CASH EQUIVALENTS AT END OF YEAR 135,769 742
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION    
Cash paid for income taxes
Cash paid for interest
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES    
Shares issued in connection with debt 391,100
Beneficial conversion feature 51,900
Right of use asset addition under ASC 842 134,364
Operating lease liabilities under ASC 842 134,364
Debt and accrued interest converted to equity 370,452
Warrants issued for the issuance of debt 370,267 143,900
Investment in convertible preferred stock $ 383,326
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.22.1
NATURE OF OPERATIONS
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS

NOTE 1 - NATURE OF OPERATIONS

 

NutraLife BioSciences, Inc. (“We” or the “Company”) is the producer and distributor of nutritional supplements that uses micro molecular formulae and a utilization of an oral spray to provide faster and more efficient absorption. Our products are sold to private label distributers who sell the products we manufacture under their own brand name as well as under our own brand name.

 
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.22.1
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted (“GAAP”) in the United States of America as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and with the rules and regulations of the U.S Securities and Exchange Commission (“SEC”).

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Precision Analytic Testing, LLC, NutraDerma Technologies, Inc., PhytoChem Technologies, Inc., and TransDermalRX, Inc. We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.

 

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates”, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending March 31, 2023 for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company will evaluate the impact of ASU 2016-13 on the Company’s consolidated financial statements in a future period closer to the date of adoption.

 

Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.

 

In August 2020, the FASB issued ASU 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which simplifies and clarifies certain calculation and presentation matters related to convertible equity and debt instruments. Specifically, ASU-2020-06 removes requirements to separately account for conversion features as a derivative under ASC Topic 815 and removing the requirement to account for beneficial conversion features on such instruments. Accounting Standards Update 2020-06 also provides clearer guidance surrounding disclosure of such instruments and provides specific guidance for how such instruments are to be incorporated in the calculation of Diluted EPS. The guidance under ASU 2020-06 is effective for fiscal years beginning after December 15, 2021,

 

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

 

including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted this standard using a modified retrospective approach effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.

 

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

 

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at December 31, 2021 consisted of a money market account.

 

Inventories

 

Inventories are stated at lower of cost or net realizable value utilizing the weighted average method of valuation and consist of raw materials and finished goods. The Company reduces inventory on hand to its net realizable value on an item-by-item basis when it is apparent that the expected realizable value of an inventory item falls below its original cost. A charge to cost of sales results when the estimated net realizable value of specific inventory items declines below cost. Management regularly reviews the Company’s inventories for such declines in value. Inventory consists of the following:

 

  

December 31, 2021

  

December 31, 2020

 
Raw Materials  $60,630   $356,901 
Finished Goods   248,704    210,626 
Inventories  $309,334   $567,527 

 

Allowance for Doubtful Accounts

 

We establish the existence of bad debts through a review of several factors including historical collection experience, current aging status of the customer accounts, and financial condition of our customers. The allowance for doubtful accounts is $0 as of both December 31, 2021 and 2020.

 

Property and Equipment

 

All property and equipment are recorded at cost and depreciated over their estimated useful lives, generally three, seven and twelve years, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Leasehold improvements are amortized over their estimated useful lives or the remaining term of the lease, whichever is shorter.

 

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

 

Impairment of Long-Lived Assets

 

A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.

 

Impairment charges would be included with costs and expenses in the Company’s consolidated statements of operations and would result in reduced carrying amounts of the related assets on the Company’s consolidated balance sheets. No adjustments were made to long-lived assets during the years ended December 31, 2021 and 2020, respectively.

 

Revenue Recognition

 

The Company accounts for revenue under the guidance of FASB ASC 606, “Revenue from Contracts from Customers” (“ASC 606”).

 

ASC 606 prescribes a five-step model that focuses on transfer of control and entitlement to payment when determining the amount of revenue to be recognized. Under the ASC 606 guidance, an entity is required to perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

The Company generates revenues from the sale of products. The product is invoiced, and the revenue is recognized upon shipment or once transfer of risk has passed to the customer, which is the point at which the Company has satisfied its performance obligation.

 

Payments received in advance from customers are recorded as customer deposits until earned, at which time revenue is recognized.

 

We recognize certain revenues under bill and hold arrangements with certain customers when the Company has fulfilled all of its performance obligations, the units are segregated for the specific customer only, and the goods are ready for physical transfer to the customer in accordance with their defined contract delivery schedule. For any requested bill and hold arrangement, we make an evaluation as to whether the bill and hold arrangement qualifies for revenue recognition. The customer must initiate the request for the bill and hold arrangement. The customer must make a fixed commitment to purchase the items. The risk of ownership is passed to the customer, and payment terms are not modified.

 

The Company’s revenues accounted for under ASC 606 do not require significant estimates or judgements based on the nature of the Company’s revenue. The Company’s contracts do not include multiple performance obligations or variable consideration. All of the Company’s sales resulted from contracts with customers for the years ended December 31, 2021 and 2020.

 

Shipping and Handling Costs

 

Shipping and handling costs are expensed as incurred and included in cost of sales. Billings for shipping and handling are reflected within sales in the accompanying consolidated statements of operations.

 

Income Taxes

 

The Company follows the provisions of ASC 740-10, “Accounting for Uncertain Income Tax Positions.” When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management

 

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

 

believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

The tax years 2018-2021 for the Company remain open for audit by federal and state tax authorities. The Company has received no notice of audit or any notifications from the IRS for any of the open tax years.

 

Net Loss Per Share

 

Basic loss per share excludes dilution and is computed by dividing the loss attributable to stockholders by the weighted-average number of shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the year and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. The following anti-dilutive equity and debt securities were excluded from the computation of net loss per share.

 

  

December 31, 2021

  

December 31, 2020

 
   (Shares)   (Shares) 
Warrants   80,837,314    30,560,598 
Series B Preferred Stock   4,038,309    - 
Convertible notes payable, and accrued interest   7,746,257    5,799,124 

 

   92,621,880    36,359,722 

 

Related Party Transactions

 

All transactions with related parties are in the normal course of operations and are measured at the exchange amount.

 

Leases

 

The Company accounts for leases FASB ASU 2016-02, “Leases” (“ASC 842”) and other associated standards, which defines a lease as any contract that conveys the right to use a specific asset for a period of time in exchange for consideration. ASC 842 requires the recognition of the right-of-use assets and related operating and finance lease liabilities on the balance sheet and the disclosure of key information about certain leasing arrangements. As permitted by ASC 842, the Company elected the adoption date of January 1, 2019, which is the initial date of application. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated. Under ASC 842, all leases are required to be recorded on the balance sheet and are classified as either operating leases or finance leases (formerly called capital leases). The lease classification affects the expense recognition in the income statement. Operating lease charges are recorded entirely in operating expenses. Finance lease charges are split, where amortization of the right-of-use asset is recorded in operating expenses and an implied interest component is recorded in interest expense.

 

Leases are classified as a finance lease if any of the following criteria are met:

 

  1. The lease transfers ownership of the underlying asset to the lessee by the end of the lease term.
  2. The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.
  3. The lease term is for the major part of the remaining economic life of the underlying asset.

 

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

 

  4. The present value of the sum of lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset.
  5. The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.

 

For any leases that do not meet the criteria identified above for finance leases, the Company treats such leases as operating leases. As of December 30, 2021, the Company has two finance leases and three operating leases.

 

Under the ASC 842 guidance, both finance and operating leases are reflected on the balance sheet as lease or “right-of-use” assets and lease liabilities. There are some exceptions, which the Company has elected in its accounting policies. For leases with terms of twelve months or less, or below the Company’s general capitalization policy threshold, the Company elects an accounting policy to not recognize lease assets and lease liabilities for all asset classes. The Company recognizes lease expense for such leases generally on a straight-line basis over the lease term.

 

The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and accounts for these options when they are reasonably certain to be exercised. Certain leases contain non-lease components, such as common area maintenance, which are generally accounted for separately. In general, the Company will assess if non-lease components are fixed and determinable, or variable, when determining if the component should be included in the lease liability. For purposes of calculating the present value of the lease obligations, the Company utilizes the implicit interest rate within the lease agreement when known and/or determinable, and otherwise utilizes its incremental borrowing rate at the time of the lease agreement. The related right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability.

 

Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense.

 

Intangible Asset

 

Intangible asset represents the value assigned to intellectual property and is amortized based on the economic benefit expected to be realized.

 
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.22.1
LIQUIDITY AND GOING CONCERN CONSIDERATIONS
 12 Months Ended
Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
LIQUIDITY AND GOING CONCERN CONSIDERATIONS

NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS

 

Our consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. We sustained significant losses and negative cash flows from operations. We incurred a net loss of approximately $5.8 million and $2.9 million for the years ended December 31, 2021 and 2020, respectively. We had cash used in operating activities of approximately $487 thousand for the year ended December 31, 2021, and have an accumulated deficit of approximately $48 million at December 31, 2021. These conditions raise substantial doubt about our ability to continue as a going concern.

 

In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in China and began to spread around the world in early 2020. In reaction to decreased supply of and increased demand for sanitizer products, the Company shifted its manufacturing to produce sanitizer products. The Company’s other business operations have been impacted negatively by COVID-19 due to government restrictions and the overall adverse effect on the global economy. The Company expects COVID-19 to continue to negatively impact its operating results and its ability to obtain financing.

 

 

NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS, CONTINUED

 

The Company is currently in the process of raising capital to complete and finalize the build-out of its facility in Deerfield Beach for the purpose of consolidating its operations. The structure of the capital raise is currently in

 

development. The Company is continuing its path to profitability through increased business development, marketing and sales of the Company’s multiple lines of topical, ingestible and skincare health and wellness products. The Company is also focused on completing an efficacy clinical study on its patented mosquito bug patch with plans upon a successful conclusion to launch globally in the very near future, adding to the Company’s suite of wellness products.

 

In January 2022, the Company entered into a license and ownership agreement in an effort to expand its sales and customer base. For the details of equity and license agreement refer to the Note 6-Investment.

 

The independent auditors’ report on our financial statements for the years ended December 31, 2021 and 2020 contain explanatory paragraphs expressing substantial doubt as to our ability to continue as a going concern.

 

Failure to successfully continue to grow operational revenues could harm our profitability and adversely affect our financial condition and results of operations. We face all of the risks inherent in a new business, including the need for significant additional capital, management’s potential underestimation of initial and ongoing costs, and potential delays and other problems in connection with establishing sales channels.

 

We are continuing our plan to further grow and expand operations and seek sources of capital to pay our contractual obligations as they come due. Management believes that its current operating strategy will provide the opportunity for us to continue as a going concern as long as we are able to obtain additional financing; however, there is no assurance this will occur. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.22.1
PROPERTY AND EQUIPMENT, NET
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT, NET

NOTE 4 – PROPERTY AND EQUIPMENT, NET

 

A summary of property and equipment at December 31, 2021 and 2020 is as follows:

 

   December 31, 2021   December 31, 2020 
Furniture and equipment  $1,959,694   $1,959,694 
Leasehold improvements   840,728    840,728 
Property and equipment, at cost   2,800,422    2,800,422 
Less: accumulated depreciation   (535,226)   (485,761)
Property and equipment,net  $2,265,196   $2,314,661 

 

Depreciation expense for the years ended December 31, 2021 and 2020 totaled $49,465 and $61,986, respectively.

 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.1
INTANGIBLE ASSET
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
INTANGIBLE ASSET

NOTE 5 – INTANGIBLE ASSET

 

In February 2019, the Company acquired certain intellectual property consisting of patent rights. The aggregate purchase price paid in connection with the patent purchase was $714,640, consisting of $130,000 cash, and 3,300,000 shares of the Company’s common stock valued at $0.177 per share or an aggregate of $584,640. Of the 3,300,000 shares, 1,800,000 shares were provided at closing and 1,500,000 were to be provided one year thereafter. These shares have not been issued and the Company is in negotiations with the seller to extend the issuance of the shares. As such, the Company recognized a liability for stock to be issued of $265,500 at both December 31, 2021 and 2020. The acquired patent is amortized over its remaining estimated useful life of approximately 11 years. Amortization expense is $64,968 for both of the years ended December 31, 2021 and 2020. The estimated annual amortization expense for the next five years and thereafter is as follows:

 

      
2022  $65,000 
2023   65,000 
2024   65,000 
2025   65,000 
2026   65,000 
Thereafter   200,150 
Estimated amortization expenses  $525,150 

 

 

NOTE 5 – INTANGIBLE ASSET, CONTINUED

 

A summary of the intangible asset at December 31, 2021 and 2020 is as follows:

 

   December 31, 2021   December 31, 2020 
Patent  $714,640   $714,640 
Less: accumulated amortization   (189,490)   (124,522)
Total  $525,150   $590,118 

 
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.22.1
INVESTMENT
 12 Months Ended
Dec. 31, 2021
Investments, All Other Investments [Abstract]  
INVESTMENT

NOTE 6 – INVESTMENT

 

Distribution Agreement

 

On November 2, 2020 in connection with a manufacturing, distribution and sales agreement with a third party distributor (the “Distributor”), the Company issued 12.5 million of its common shares for 250 shares of non-trading convertible preferred stock of the Distributor. Each convertible preferred share is convertible into 1,000 shares of the Distributor’s common stock. The Distributor’s common shares are currently traded in the over the counter market. On the first business day following the 180-day anniversary of closing, if the share price of the Distributor is less than $4.00, the Distributor will provide the Company its common stock valued at $1 million, less 250,000 common shares, for no additional consideration. On the one-year anniversary of closing, if the share price of the Distributor is less than $4.00, the Distributor will provide the Company its common stock valued at $1 million, less 250,000 shares, less the number of shares provided on the 181st day anniversary, for no additional consideration.

 

As of December 31, 2021, the Company was entitled to 3,831,169 shares of the Distributor’s common stock. No shares have been received as of the date of the filing of this report.

 

The Company determined to initially value the convertible preferred stock investment using the Black-Scholes option pricing model using the following inputs: stock price: $4.00, exercise price: $4.00, expected term: one year, and risk free rate 0.17%.

 

The Company made this investment to realize strategic benefits for its business, rather than to generate income or capital gains. Because the Company owns less than 20% on an as converted basis of the Distributor, and cannot exercise significant influence over operating and financial policies of the Distributor, the Company accounts for the investment under ASC 321, “Equity Securities” (“ASC 321”). Under ASC 321, for each reporting period, the Company completes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired.

 

The investment balance as of both December 31, 2021 and 2020 was $383,326. There is no impairment recorded for the years ended December 31, 2021 and 2020.

 

Deposit on Equity and License Agreement

 

In November 2021, the Company negotiated terms of a non-exclusive sub-license agreement with a third party (the “Party”) whereby the Party will grant the Company a limited, non-exclusive authority to purchase, distribute, market, make, and sell products in which the Party has authorized the Company to produce on a case-by-case basis, for a period of three years from the effective date of the definitive agreement. In exchange for the license, the Company agreed to pay $450,000 along with a monthly license royalty fee of 20% of the final sales price of licensed items to the end buyer.

 

The terms also allow the Company to purchase an equivalent ownership interest of the Party for an initial funding of $225,000, with the option to increase its investment up to $6,000,000. The Company provided an initial funding fee of $225,000 in exchange for the permission to purchase an equivalent ownership interest of the Party, which should equal to the appropriate preferred purchase price, based upon the stated current valuation. The total payment of $675,000 as of December 31, 2021 is classified as a Deposit on Equity and License Agreement on the consolidated balance sheet.

 

In January 2022, the Company entered into a definitive agreement with the Party. The definitive agreement defined an initial term of three years from December 30, 2021, with options to renew. The Company made additional payments to the Party in January in the amount of $725,000 toward the license fee and to purchase an equivalent ownership interest. The total funding to the Party of $1,400,000 was allocated $500,000 for the license, and equity participation of $900,000.

 

 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.22.1
ACCRUED EXPENSES
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
ACCRUED EXPENSES

NOTE 7 – ACCRUED EXPENSES

 

A summary of accrued expenses is as follows:

 

   December 31, 2021   December 31, 2020 
Officer – Bonus  $540,500   $400,000 
Accrued Expenses - Other   30,912    15,456 
Accrued Interest – Related Parties   148,552    91,048 
Accrued Interest   230,203    103,811 
Other Current Liabilities   93,724    52,849 
Accrued Rent   -    123,331 
Accrued expenses  $1,043,891   $786,495 

 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.22.1
NOTES PAYABLE
 12 Months Ended
Dec. 31, 2021
Debt Disclosure [Abstract]  
NOTES PAYABLE

NOTE 8 – NOTES PAYABLE

 

Notes Payable

 

During the quarter ended March 31, 2020, the Company received proceeds aggregating $345,000 in connection with multiple short-term promissory notes with due dates ranging from February to June 2020. The notes had interest at 0% to 12% for the terms of the notes. Each noteholder had the right to convert all the outstanding principal and accrued unpaid interest to the Company’s common stock at a price ranging from $.085 to $.10 per share, prior to the maturity date. Additionally, an aggregate of 3,250,000 shares were issued to the noteholders as additional consideration. The notes also included a beneficial conversion feature (BCF). These notes are currently in default.

 

During the quarter ended September 30, 2020, the Company received proceeds aggregating $230,000 in connection with multiple short-term promissory notes each with a term of one year, maturing in August or September 2021. The notes bear interest at 18%. Four of the five notes were issued under a subscription agreement whereby in addition to the promissory note, the note holder is offered up to four shares of common stock for each one dollar of principal amount of the note at a price of $0.0001 per share. Under the subscription agreement, a total of 780,000 shares were issued.

 

During the quarter ended December 31, 2020, the Company received proceeds aggregating $330,040 in connection with multiple short-term promissory notes each with a term of one year, maturing in October through December 2021. The notes bear interest at 10% to 18%. Each note was issued under a subscription agreement whereby in addition to the promissory note, the note holder is offered up to four shares of common stock for each one dollar of principal amount of the note at a price of $0.0001 per share. Under the subscription agreement, a total of 520,000 shares were issued. Additionally, an aggregate of 6,800,000 warrants were issued to five of the noteholders as additional consideration. The warrants are exercisable at $0.08 per share and expire three years from the date of each respective note.

 

The Company allocated $314,100 of the gross proceeds of the 2020 convertible notes to the stock issuances and $75,200 of the gross proceeds of the subscription agreement notes to the stock issuances on a relative fair value basis, which has been recorded as a debt discount.

 

The Company allocated $143,900 of the gross proceeds of the 2020 subscription agreement notes to the warrants on a relative fair basis. The warrants’ relative fair value was calculated using the Black-Scholes Merton valuation model with the following inputs: an expected and contractual life of 36 months, as assumed volatility of 189.9%, zero dividend rate, and a risk free rate of 0.17% - 0.22%. The warrants are classified in equity as additional paid-in capital.

 

Because the effective conversion prices of the convertible notes were less than the fair value of the underlying common stock on the issuance date, the Company allocated $51,900, the intrinsic value of that beneficial conversion feature, to additional paid-in capital.

 

In January 2021, the Company entered into a Note Exchange Agreement whereby a note holder of the Company agreed to exchange their current note that was in default, for a new promissory note and a warrant to acquire 1,200,000

 

 

NOTE 8 – NOTES PAYABLE, CONTINUED

 

shares of common stock. The warrant is exercisable at $0.08 per share and expires three years from the date of the new promissory note.

 

During the year ended December 31, 2021, the Company received proceeds aggregating $725,050 in connection with multiple short-term promissory notes with due dates ranging from January to December 2022. The notes have original issue discounts totaling $61,950 and bear interest at 8% to 12% for the terms of the notes.

 

An aggregate of 12,787,500 warrants were issued to the noteholders as additional consideration. The warrants are exercisable at $0.08 per share and expire three years from the date of each respective note.

 

The warrants to purchase common stock issued to the noteholders were treated as debt discounts. The gross proceeds of the notes were allocated to debt and warrants issued on a relative far value basis.

 

The Company allocated $370,267 of the gross proceeds to the warrants on a relative fair basis. The warrants’ relative fair value was calculated using the Black-Scholes Merton valuation model with the following inputs: an expected and contractual life of two years, an assumed volatility ranging from 191.0%-245.56%, zero dividend rate, and risk free rate ranging from 0.18%-0.73%.

 

The debt discounts associated with the BCF, warrants, and common stock issuances are amortized through the earlier of the conversion of the notes into common stock, or the maturity date of the notes, on a straight-line basis which approximates the effective interest method due to the short-term nature of the notes. Amortization of the debt discount is reported as finance costs in the Statement of Operations.

 

During the year ended December 31, 2021, the Company entered into debt settlement agreements with three of its noteholders whereby the Company issued 4,630,645 shares of its common stock as well as warrants to acquire 10,622,583 shares of common stock. The warrants are exercisable at $0.08 per share and expire two years from the date of issuance, and were recorded as finance cost.

 

The amount converted was an aggregate of $325,010 of principal and $45,441 of accrued interest.

 

The warrants’ relative fair value of $1,155,590 was calculated using the Black-Scholes Merton valuation model with the following inputs: an expected and contractual life of 24 months, as assumed volatility of 226.19%-249.44%, zero dividend rate, and a risk free rate of 0.17% - 0.28%. The warrants are classified in equity as additional paid-in capital.

 

Debt Discounts

 

Total amortization associated with all debt discounts was $438,235 and $671,319 for the years ended December 31, 2021 and 2020, respectively.

 

Convertible Note Payable to Shareholder

 

In June 2019, the Company entered into an Investment Agreement that included a secured convertible 5.75% promissory note payable for $1,000,000 with a shareholder. The note is subject to a security agreement whereby the

 

 

NOTE 8 – NOTES PAYABLE, CONTINUED

 

first four Ennea Processors the Company has committed to commercialize and monetize will be secured as collateral for the note as well as current and future assets of the Company and its subsidiaries. The payment terms of the note were interest only payments from July 7, 2019 through December 7, 2019 and commencing January 7, 2020, the Company was to make equal monthly installment payments that include principal and interest through the Maturity Date of December 7, 2020.

 

Included in the Investment Agreement is a royalty agreement whereby the investor received 500,000 shares of the Company’s common stock and will be entitled to a royalty of 8.5% from the revenue generated from the “collateral processors” while the principal is outstanding and 5% thereafter on the first two collateral processors for a period of 10 years.

 

In addition to the collateral, the note is secured by a Pledge Agreement from a related-party that included a mortgage lien on certain real property as additional collateral.

 

The collateral processors are not yet in service. Therefore, revenue generated from them and the related royalties due cannot be estimated at this time and will be expensed as incurred in the future.

 

The Company is currently in default of this note, however, the parties are in negotiation to reach settlement terms.

 

Note Payable, SBA

 

On April 23, 2020, the Company received an aggregate of $254,700 related to its filing under the Paycheck Protection Program (“PPP”) and Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) from Trust Bank, N.A. (the “Lender”). The Company elected to treat the loan debt under ASB ASC 470. As such, the Company would derecognize the liability when the loan was forgiven and the Company was legally released from the loan. The PPP loan of $244,700 was forgiven on March 12, 2021 and recognized as other income.

 

On February 26, 2021, the Company received an aggregate of $243,275 related to its filing under the PPP and CARES Act from the Lender. The PPP loan of $243,275 was forgiven on November 26, 2021 and recognized as other income.

 
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUE SHARE AGREEMENTS
 12 Months Ended
Dec. 31, 2021
Revenue Share Agreements  
REVENUE SHARE AGREEMENTS

NOTE 9 – REVENUE SHARE AGREEMENTS

 

During the year ended December 31, 2021, the Company entered into two revenue share agreements with third party investors (“Investors”) and received an aggregate of $725,000. In accordance with the agreements, the proceeds were primarily used to fund the third party license agreement as described in Note 6. The proceeds are non-refundable. In exchange, the Investors are entitled to a percentage of revenue collected by the Company as a result of its investments, ranging from 1.3% to 60% until the Investors’ proceeds are repaid, and 0.83% to 49% thereafter, for a minimum of 60 months. The proceeds of $725,000 was recorded as a liability in the accompanying consolidated balance sheet.

 
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS’ EQUITY
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 10 - STOCKHOLDERS’ EQUITY

 

During the quarter ended March 31, 2020, the Company issued 470,229 shares of common stock for services aggregating $47,023, valued using the trading price on the date of issuance.

 

The Company issued 1,923,076 shares of common stock for $.065 per share for an aggregate of $125,000, during 2020.

 

During 2020 the Company recorded $51,900 to additional paid-in capital resulting from the beneficial conversion feature.

 

In July 2020, the Company issued 740,740 warrants in exchange for cash proceeds of $5,000. The warrants have an exercise price of $0.10 and expire two years after issuance.

 

In November 2020, the Company issued 12,500,000 shares of common stock in exchange for 250 shares of nontradable Convertible Preferred Stock of the Distributor in connection with a distribution agreement. See Note 6.

 

 

NOTE 10 - STOCKHOLDERS’ EQUITY, CONTINUED

 

In January 2021, the Company issued 15,000,000 warrants to its Chief Executive Officer, President and sole Director as compensation. The warrants are exercisable at $0.1025 per share and expire three years from issuance.

 

In January 2021, the Company issued 7,500,000 warrants to its Vice President, Neil Catania, as compensation. The warrants are exercisable at $0.1025 per share and expire three years from issuance.

 

In April 2021, the Company issued 2,000,000 warrants to its Production Manager as compensation. The warrants are exercisable at $0.125 per share and expire three years from issuance.

 

The warrants issued as compensation were valued at $2,229,990, calculated using the Black-Scholes Merton valuation model with the following in puts: an expected and contractual life of three years, an assumed volatility ranging from 191.0% to 224.75%, zero dividend rate, and a risk free rate ranging from 0.22% to 0.36%.

 

In April through September 2021, the Company issued 4,350,000 shares of common stock and 17,400,000 warrants in exchange for cash totaling $348,000. The warrants have an exercise price of $0.08 per share and expire two years after issuance.

 

In July 2021, the Company issued 1,000,000 shares of common stock with an aggregate value of $120,000 for consulting services.

 

In December 2021, The Company issued 550,000 shares of common stock with an aggregate value of $55,000 for consulting services.

 

Preferred Stock

 

The Company’s board of directors is authorized to issue, at any time, without further stockholder approval, up to 10,000 shares of preferred stock. The board of directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.

 

Series A Preferred Stock (“Series A Preferred”)

 

On November 30, 2012, the board of directors of the Company created Series A Preferred. The Series A Preferred has the following rights and preferences:

 

  1. The shares are not entitled to dividends or liquidation preferences.
  2. Each share has voting rights equal to 500,000 shares of the Company’s common stock.
  3. So long as Series A Preferred shares are outstanding, the Company cannot take certain actions (as defined in the certificate of designation) without the consent of the holders of 100% of the Series A Preferred shares.

 

On November 30, 2012, Edgar Ward, the Company’s President, CEO, and director, was granted 1,000 shares of Series A Preferred for $1,000. At the option of Mr. Ward, the Series A Preferred shares are redeemable for $1,000.

 

As of December 31, 2021 and 2020, 1,000 shares of Series A Preferred are outstanding.

 

Series B Convertible Preferred Stock (“Series B Preferred”)

 

On September 30, 2020, the Company designated 110 shares of Preferred Stock as Series B Convertible Preferred Stock. A Series B Holder has the right from time to time, and at any time following January 1, 2021, to convert each outstanding share of Series B stock into shares of common stock at a rate of 149,567 shares of common stock for each share of Series B Preferred. Each share of Series B Preferred shall have a number of votes equal to the number of conversion shares which would be issuable as of the date of such vote. The Series B Preferred does not have any liquidation preferences. The Series B Preferred will participate in any dividends, distributions or payments to the holders of the common stock on an as-converted basis. The Series B Preferred is subject to an ownership limitation, pursuant to which no holder of Series B Preferred will be entitled to convert such investor’s shares of Series B Preferred Stock into shares of common stock if such conversion would result in ownership of more than 4.99% of the outstanding shares of common stock of the Company. Once issued, certain shares of the Series B Preferred are redeemable at the election of the Company at any time prior to the Permitted Conversion Date pursuant to separate written agreements that will be effectuated between holders of the Series B Preferred and the Company.

 

 

NOTE 10 - STOCKHOLDERS’ EQUITY, CONTINUED

 

In March 2021, the Company issued 10 shares of Series B Preferred to three consultants as part of their compensation agreements. The consultant compensation was valued at $164,524 using the trading price of the equivalent common stock on the date of issuance.

 

During the quarter ended September 30, 2021, three shares of Series B Preferred were converted to 448,701 shares of common stock.

 

As of December 31, 2021 and 2020, 27 and 20 shares, respectively, of Series B Preferred are outstanding.

 
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.22.1
LEASES
 12 Months Ended
Dec. 31, 2021
Leases  
LEASES

NOTE 11 – LEASES

 

In conjunction with the new guidance for leases, as defined by the FASB with ASU 2016-02, Leases (Topic 842), the Company has designated the existing leases as operating as further described below:

 

The Company leases their office and warehouse facilities located in in Coconut Creek, Florida under a non-cancelable operating lease agreement. In January 2022, the lease term has been renewed for a three year to expire in January, 2025

 

In June 2017, the Company entered into a lease for an additional facility located in Deerfield Beach, Florida under a non-cancelable operating lease. The term of the lease is for 86 months beginning on January 1, 2018 and calls for yearly 3% increases to base rent, with monthly payments that commenced in March 2018.

 

In July and September of 2019, the Company’s wholly owned subsidiary, Phytochem, entered into two separate lease agreements for office and warehouse space located in Onalaska, Wisconsin, that commenced on August 1 and October 1, respectively. Each lease is for six-month terms with four (4) renewal options to extend for six additional months. The Company expects to occupy one of the spaces for the full term of the lease totaling 30 months. The Company terminated its lease on the other facility in May 2020, without penalty. The remaining lease calls for an annual 3% increase to base rent. In addition to rent, the Company pays certain insurance, maintenance, and other costs related to the rented spaces.

 

In June 2021, the Company entered into a verbal, month-to-month sub-lease agreement for the Wisconsin location. Rental income totalled $80,000 for the year ended December 31, 2021, and in included in general and administrative expenses.

 

As of December 31, 2021, in the consolidated balance sheet, the Company has recorded right-of-use assets of $449,155 and a lease liability of $492,798, of which $141,900 is reported as a current liability. The weighted average remaining lease term is 37 months and weighted average discount rate used is 10%.

 

The following table presents a reconciliation of the undiscounted future minimum lease payments remaining under the operating lease reported as operating lease liability on the consolidated balance sheet as of December 31, 2021:

 

     
Undiscounted future minimum lease payments:    
2022  $199,000 
2023   189,400 
2024   195,100 
Total undiscounted future minimum lease payments   583,500 
Less: amount representing imputed interest   (90,702)
Operating lease liability  $492,798 

 

 

Supplemental cash flow information related to leases is as follows, for the years ended December 31,

 

   2021   2020 
Cash paid for amounts included in the measurement of operating lease liabilities  $551,688   $262,214 

 

Lease expense for operating leases was approximately $386,000 and $442,000 for the years ended December 31, 2021 and 2020.

 

Finance Leases:

 

The Company has acquired certain equipment under agreements that are classified as finance leases. The cost of the equipment under finance leases is included in the balance sheet as property and equipment. The finance lease equipment was $110,372 as of December 31, 2021 and December 31, 2020, with related accumulated depreciation of $12,786 and $8,950, respectively.

 

Minimum lease payments required by these finance leases are as follows:

 

Undiscounted future minimum lease payments:

 

Undiscounted future minimum lease payments:    
2022  $17,000 
2023   2,100 
Total undiscounted future minimum lease payments   19,100 
Less: amount representing interest   (825)
Less: current portion   (17,161)
Present value of minimum lease payments, net of current portion  $1,114 

 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.22.1
EQUITY WARRANTS
 12 Months Ended
Dec. 31, 2021
Equity Warrants  
EQUITY WARRANTS

NOTE 12 – EQUITY WARRANTS

 

At December 31, our warrants outstanding are as follows:

 

By Exercise Price:  2021   2020 
Warrants - $0.08   42,020,833    8,000,000 
Warrants - $0.1025   24,500,000    - 
Warrants - $0.10   3,240,740    3,240,740 
Warrants - $0.20   10,352,941    13,302,941 
Warrants - $0.30   722,800    722,800 
Warrants - $0.35   -    5,294,117 
Total outstanding   80,837,314    30,560,598 

 

   Warrants 
Balance, January 1, 2020   21,819,858 
Warrants Issued   8,740,740 
Warrants Exercised   - 
Warrants Expired   - 
Balance, December 30, 2020   30,560,598 
Warrants Issued   66,510,083 
Warrants Exercised   (7,989,250)
Warrants Expired   (8,244,117)
Balance, December 30, 2021   80,837,314 

 

 
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 13 - INCOME TAXES

 

The Company accounts for income taxes in accordance with FSB ASC 740 “Income Taxes”. Federal and state income taxes are calculated and recorded on the current period’s activity in accordance with the tax laws and regulations that are in effect. Deferred tax assets and liabilities are recognized based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rate in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assts will not be realized.

 

The components of the income tax provision are as follows at December 31, 2021 and 2020:

 

   2021   2020 
Current   -    - 
Deferred   -    - 
Total tax provision   -    - 

  

The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31, 2021 and 2020:

 

   2021   2020 
U.S. Federal statutory income tax rate   (21.0)%   (21.0)%
State income tax, net of federal benefit   (3.5)%   (3.5)%
           
Valuation allowance   24.5%   24.5%
Effective tax rate   0.0%   0.0%

 

The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31, 2021 and 2020:

 

Deferred tax assets  2021   2020 
Net operating loss carry forwards  $10,788,000   $9,843,000 
Accrued Wages   133,000    98,000 
Accrued Interest   93,000    - 
Less: valuation allowance   (11,014,000)   (9,941,000)
Total   -    - 
           
Deferred tax liabilities          
Stock based compensation   -    - 
Depreciation   -    - 
Net deferred tax asset  $-   $- 

 

The change in valuation allowance was $1,073,000 and $543,000 for the years ended December 31, 2021 and 2020, respectively. We recorded a 100% valuation allowance related to the deferred tax asset for the loss from operations.

 

The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which temporary differences become deductible. The Company has net operating loss carryforwards of approximately $44.0 million as of December 31, 2021, of which $32.6 million were incurred prior to 2018 that begin to expire in the year 2032 through 2036.

 

In accordance with the provisions of ASC 740: Income Taxes, we record a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At December 31, 2021 and 2020, we have no liabilities for uncertain tax positions. We continually evaluate expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.

 

 
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.22.1
CONTINGENCIES
 12 Months Ended
Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
CONTINGENCIES

NOTE 14 - CONTINGENCIES

 

The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company’s financial position or results of operations.

 

Legal Proceedings:

 

From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. Litigations applicable to the Company are discussed as follows.

 

Hamilton v. the Company: Hamilton & Associates Law Group, P.A. v. Nutralife Biosciences, Inc. f/k/a Nutrafuels, Inc., Case No. 50-2020-CA-008435, was filed in the Circuit Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida on August 9, 2020. In the suit, Hamilton & Associates Law Group, P.A. sets forth purported claims for breach of contract, and in the alternative, account stated, open account, unjust enrichment, and quantum meruit. Plaintiff requests a judgment for damages in the principal sum of $150,000, plus an award of attorneys’ fees and costs pursuant to a legal services agreement dated January 7, 2019, as well as pre-judgment interest and post-judgment interest. The Hamilton matter filed directly against the Company initially included a claim against Edgar Ward, but the individual claim has been dropped. The prior engagement agreement between the Hamilton law firm and the Company (for 2018) was in the nature of a flat fee engagement, in which shares were provided in lieu of cash payments. The Company maintains that the change in the engagement of the law firm (from 2018 to 2019) in terms of the nature of payment was not disclosed or explained adequately, and the Company was unaware of any claim that sums remained unpaid, as all fees were understood to be paid as a result of the shares of stock provided. The claim was filed on August 9, 2020, and is not set for trial, and only documentary discovery has been conducted to date.

 

Native American Partners v. the Company: Native American Partners LLC, including NAVF Holdings and NAVF-Pharma, subsidiary companies, and Best Darn Brands, LLC, and its subsidiaries v. Nutralife Biosciences Inc., Case No. CACE-20-009352, was filed in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida. This action was filed on June 5, 2020, against both the Company and Edgar Ward. However, the claim against Mr. Ward was later dropped. The claim asserted that the Company failed to comply with the confidentiality imposed by a non-disclosure agreement signed by plaintiff and defendant. Plaintiff claims that defendant proceeded with the development of a hand sanitizer product that was first revealed to defendant by the plaintiff, however, defendant asserted that the product produced was different (gel vs. spray) and that defendant had contemplated developing the product (the Covid 19 pandemic was already underway) well in advance of the signing of the NDA. In the Amended Complaint filed on July 9, 2020, plaintiffs demanded injunctive relief and damages for conversion, fraudulent misrepresentation, fraud in the inducement, equitable accounting, unjust enrichment, quantum meruit, breach of contract, and negligent misrepresentation. We obtained a dismissal of this Amended Complaint on February 8, 2021, based on the arbitration provision included in the written contract at issue between the parties. At this time, the plaintiffs have not filed another court action that we are aware of. We are also not yet aware of any arbitration initiated by the plaintiff.

 

Ortiz v. the Company: Jose Ortiz v. Nutralife Biosciences, Inc. f/k/a Nutrafuels, Inc., Case No. CACE-29-017957, was filed in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida, on October 28, 2020. In this matter, Mr. Ortiz is seeking a judgment for damages, attorneys’ fees, and other costs relating to defendant’s purported breach of an employment agreement dated March 18, 2015. We do not believe that this claim is valued at greater than $5,000. Ortiz’ claim was filed on October 28, 2020, asserting improper discharge from employment, and failure to pay wages and benefits, however, we believe (and have filed summary judgment asserting) that the claim was filed too late, in contravention of the applicable statute of limitations.

 
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.22.1
CONCENTRATIONS OF CREDIT RISK
 12 Months Ended
Dec. 31, 2021
Risks and Uncertainties [Abstract]  
CONCENTRATIONS OF CREDIT RISK

NOTE 15 - CONCENTRATIONS OF CREDIT RISK:

 

Cash

 

The Company maintains principally all cash balances with various financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent

 

upon daily bank balances and the respective strength of the financial institutions. The Company has not incurred any losses on these accounts. At both December 31, 2021 and 2020, there are no amounts in excess of insured limits.

 

Revenue

 

For the year ended December 31, 2021, two customers accounted for approximately 82% of sales. For the year ended December 31, 2020, two customers accounted for 28% of sales.

 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS
 12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 16 - SUBSEQUENT EVENTS

 

In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in China, and began to spread around the world in early 2020. In reaction to decreased supply of and increased demand for sanitizer products, the Company shifted its manufacturing to produce sanitizer products. The Company’s other business operations have been impacted negatively by COVID-19 due to government restrictions and the overall adverse effect on the global economy. The Company expects COVID-19 to continue to negatively impact its operating results and its ability to obtain financing.

 

In January 2022, the Company received proceeds aggregating $110,000 in connection with two subscription agreements. Under the subscription agreements, a total of 1,375,000 shares of common stock and 1,375,000 warrants were issued. The warrants are exercisable at $0.08 per share and expire two years from the date of issuance.

 

In January 2022, the Company issued 1,100,000 shares of common stock for services aggregating $100,000.

 

In February 2022, the Company entered into a debt settlement agreement with its noteholder whereby the noteholder converted their two promissory notes into a revenue share agreement. The amount converted was an aggregate of $187,000 of principal and $18,700 of accrued interest. The total amount converted was $205,700.

 

In March 2022, the Company received proceeds of $15,000 in connection with the issuance of a promissory note with a due date in March 2023. The note bears interest at 20%.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.22.1
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted (“GAAP”) in the United States of America as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and with the rules and regulations of the U.S Securities and Exchange Commission (“SEC”).

 
Principles of Consolidation

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Precision Analytic Testing, LLC, NutraDerma Technologies, Inc., PhytoChem Technologies, Inc., and TransDermalRX, Inc. We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.

 
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates”, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending March 31, 2023 for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company will evaluate the impact of ASU 2016-13 on the Company’s consolidated financial statements in a future period closer to the date of adoption.

 

Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.

 

In August 2020, the FASB issued ASU 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which simplifies and clarifies certain calculation and presentation matters related to convertible equity and debt instruments. Specifically, ASU-2020-06 removes requirements to separately account for conversion features as a derivative under ASC Topic 815 and removing the requirement to account for beneficial conversion features on such instruments. Accounting Standards Update 2020-06 also provides clearer guidance surrounding disclosure of such instruments and provides specific guidance for how such instruments are to be incorporated in the calculation of Diluted EPS. The guidance under ASU 2020-06 is effective for fiscal years beginning after December 15, 2021,

 

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

 

including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted this standard using a modified retrospective approach effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.

 

Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.

 
Use of Estimates

Use of Estimates

 

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

 
Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at December 31, 2021 consisted of a money market account.

 
Inventories

Inventories

 

Inventories are stated at lower of cost or net realizable value utilizing the weighted average method of valuation and consist of raw materials and finished goods. The Company reduces inventory on hand to its net realizable value on an item-by-item basis when it is apparent that the expected realizable value of an inventory item falls below its original cost. A charge to cost of sales results when the estimated net realizable value of specific inventory items declines below cost. Management regularly reviews the Company’s inventories for such declines in value. Inventory consists of the following:

 

  

December 31, 2021

  

December 31, 2020

 
Raw Materials  $60,630   $356,901 
Finished Goods   248,704    210,626 
Inventories  $309,334   $567,527 

 
Allowance for Doubtful Accounts

Allowance for Doubtful Accounts

 

We establish the existence of bad debts through a review of several factors including historical collection experience, current aging status of the customer accounts, and financial condition of our customers. The allowance for doubtful accounts is $0 as of both December 31, 2021 and 2020.

 
Property and Equipment

Property and Equipment

 

All property and equipment are recorded at cost and depreciated over their estimated useful lives, generally three, seven and twelve years, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Leasehold improvements are amortized over their estimated useful lives or the remaining term of the lease, whichever is shorter.

 

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

 
Impairment of Long-Lived Assets

Impairment of Long-Lived Assets

 

A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.

 

Impairment charges would be included with costs and expenses in the Company’s consolidated statements of operations and would result in reduced carrying amounts of the related assets on the Company’s consolidated balance sheets. No adjustments were made to long-lived assets during the years ended December 31, 2021 and 2020, respectively.

 
Revenue Recognition

Revenue Recognition

 

The Company accounts for revenue under the guidance of FASB ASC 606, “Revenue from Contracts from Customers” (“ASC 606”).

 

ASC 606 prescribes a five-step model that focuses on transfer of control and entitlement to payment when determining the amount of revenue to be recognized. Under the ASC 606 guidance, an entity is required to perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.

 

The Company generates revenues from the sale of products. The product is invoiced, and the revenue is recognized upon shipment or once transfer of risk has passed to the customer, which is the point at which the Company has satisfied its performance obligation.

 

Payments received in advance from customers are recorded as customer deposits until earned, at which time revenue is recognized.

 

We recognize certain revenues under bill and hold arrangements with certain customers when the Company has fulfilled all of its performance obligations, the units are segregated for the specific customer only, and the goods are ready for physical transfer to the customer in accordance with their defined contract delivery schedule. For any requested bill and hold arrangement, we make an evaluation as to whether the bill and hold arrangement qualifies for revenue recognition. The customer must initiate the request for the bill and hold arrangement. The customer must make a fixed commitment to purchase the items. The risk of ownership is passed to the customer, and payment terms are not modified.

 

The Company’s revenues accounted for under ASC 606 do not require significant estimates or judgements based on the nature of the Company’s revenue. The Company’s contracts do not include multiple performance obligations or variable consideration. All of the Company’s sales resulted from contracts with customers for the years ended December 31, 2021 and 2020.

 
Shipping and Handling Costs

Shipping and Handling Costs

 

Shipping and handling costs are expensed as incurred and included in cost of sales. Billings for shipping and handling are reflected within sales in the accompanying consolidated statements of operations.

 
Income Taxes

Income Taxes

 

The Company follows the provisions of ASC 740-10, “Accounting for Uncertain Income Tax Positions.” When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management

 

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

 

believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.

 

The tax years 2018-2021 for the Company remain open for audit by federal and state tax authorities. The Company has received no notice of audit or any notifications from the IRS for any of the open tax years.

 
Net Loss Per Share

Net Loss Per Share

 

Basic loss per share excludes dilution and is computed by dividing the loss attributable to stockholders by the weighted-average number of shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the year and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. The following anti-dilutive equity and debt securities were excluded from the computation of net loss per share.

 

  

December 31, 2021

  

December 31, 2020

 
   (Shares)   (Shares) 
Warrants   80,837,314    30,560,598 
Series B Preferred Stock   4,038,309    - 
Convertible notes payable, and accrued interest   7,746,257    5,799,124 

 

   92,621,880    36,359,722 

 
Related Party Transactions

Related Party Transactions

 

All transactions with related parties are in the normal course of operations and are measured at the exchange amount.

 
Leases

Leases

 

The Company accounts for leases FASB ASU 2016-02, “Leases” (“ASC 842”) and other associated standards, which defines a lease as any contract that conveys the right to use a specific asset for a period of time in exchange for consideration. ASC 842 requires the recognition of the right-of-use assets and related operating and finance lease liabilities on the balance sheet and the disclosure of key information about certain leasing arrangements. As permitted by ASC 842, the Company elected the adoption date of January 1, 2019, which is the initial date of application. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated. Under ASC 842, all leases are required to be recorded on the balance sheet and are classified as either operating leases or finance leases (formerly called capital leases). The lease classification affects the expense recognition in the income statement. Operating lease charges are recorded entirely in operating expenses. Finance lease charges are split, where amortization of the right-of-use asset is recorded in operating expenses and an implied interest component is recorded in interest expense.

 

Leases are classified as a finance lease if any of the following criteria are met:

 

  1. The lease transfers ownership of the underlying asset to the lessee by the end of the lease term.
  2. The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.
  3. The lease term is for the major part of the remaining economic life of the underlying asset.

 

 

NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED

 

  4. The present value of the sum of lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset.
  5. The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.

 

For any leases that do not meet the criteria identified above for finance leases, the Company treats such leases as operating leases. As of December 30, 2021, the Company has two finance leases and three operating leases.

 

Under the ASC 842 guidance, both finance and operating leases are reflected on the balance sheet as lease or “right-of-use” assets and lease liabilities. There are some exceptions, which the Company has elected in its accounting policies. For leases with terms of twelve months or less, or below the Company’s general capitalization policy threshold, the Company elects an accounting policy to not recognize lease assets and lease liabilities for all asset classes. The Company recognizes lease expense for such leases generally on a straight-line basis over the lease term.

 

The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and accounts for these options when they are reasonably certain to be exercised. Certain leases contain non-lease components, such as common area maintenance, which are generally accounted for separately. In general, the Company will assess if non-lease components are fixed and determinable, or variable, when determining if the component should be included in the lease liability. For purposes of calculating the present value of the lease obligations, the Company utilizes the implicit interest rate within the lease agreement when known and/or determinable, and otherwise utilizes its incremental borrowing rate at the time of the lease agreement. The related right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability.

 

Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense.

 
Intangible Asset

Intangible Asset

 

Intangible asset represents the value assigned to intellectual property and is amortized based on the economic benefit expected to be realized.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.22.1
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
SCHEDULE OF INVENTORIES

 

  

December 31, 2021

  

December 31, 2020

 
Raw Materials  $60,630   $356,901 
Finished Goods   248,704    210,626 
Inventories  $309,334   $567,527 
SCHEDULE OF ANTI-DILUTIVE EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE

 

  

December 31, 2021

  

December 31, 2020

 
   (Shares)   (Shares) 
Warrants   80,837,314    30,560,598 
Series B Preferred Stock   4,038,309    - 
Convertible notes payable, and accrued interest   7,746,257    5,799,124 

 

   92,621,880    36,359,722 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.22.1
PROPERTY AND EQUIPMENT, NET (Tables)
 12 Months Ended
Dec. 31, 2021
Property, Plant and Equipment [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT

A summary of property and equipment at December 31, 2021 and 2020 is as follows:

 

   December 31, 2021   December 31, 2020 
Furniture and equipment  $1,959,694   $1,959,694 
Leasehold improvements   840,728    840,728 
Property and equipment, at cost   2,800,422    2,800,422 
Less: accumulated depreciation   (535,226)   (485,761)
Property and equipment,net  $2,265,196   $2,314,661 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.22.1
INTANGIBLE ASSET (Tables)
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
SCHEDULE OF ESTIMATE AMORTIZATION EXPENSE

 

      
2022  $65,000 
2023   65,000 
2024   65,000 
2025   65,000 
2026   65,000 
Thereafter   200,150 
Estimated amortization expenses  $525,150 
SCHEDULE OF INTANGIBLE ASSET

A summary of the intangible asset at December 31, 2021 and 2020 is as follows:

 

   December 31, 2021   December 31, 2020 
Patent  $714,640   $714,640 
Less: accumulated amortization   (189,490)   (124,522)
Total  $525,150   $590,118 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.22.1
ACCRUED EXPENSES (Tables)
 12 Months Ended
Dec. 31, 2021
Payables and Accruals [Abstract]  
SCHEDULE OF ACCRUED EXPENSES

A summary of accrued expenses is as follows:

 

   December 31, 2021   December 31, 2020 
Officer – Bonus  $540,500   $400,000 
Accrued Expenses - Other   30,912    15,456 
Accrued Interest – Related Parties   148,552    91,048 
Accrued Interest   230,203    103,811 
Other Current Liabilities   93,724    52,849 
Accrued Rent   -    123,331 
Accrued expenses  $1,043,891   $786,495 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.22.1
LEASES (Tables)
 12 Months Ended
Dec. 31, 2021
Leases  
SCHEDULE OF OPERATING LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS

The following table presents a reconciliation of the undiscounted future minimum lease payments remaining under the operating lease reported as operating lease liability on the consolidated balance sheet as of December 31, 2021:

 

     
Undiscounted future minimum lease payments:    
2022  $199,000 
2023   189,400 
2024   195,100 
Total undiscounted future minimum lease payments   583,500 
Less: amount representing imputed interest   (90,702)
Operating lease liability  $492,798 
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES

Supplemental cash flow information related to leases is as follows, for the years ended December 31,

 

   2021   2020 
Cash paid for amounts included in the measurement of operating lease liabilities  $551,688   $262,214 
SCHEDULE OF FINANCE LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS

Undiscounted future minimum lease payments:

 

Undiscounted future minimum lease payments:    
2022  $17,000 
2023   2,100 
Total undiscounted future minimum lease payments   19,100 
Less: amount representing interest   (825)
Less: current portion   (17,161)
Present value of minimum lease payments, net of current portion  $1,114 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.22.1
EQUITY WARRANTS (Tables)
 12 Months Ended
Dec. 31, 2021
Equity Warrants  
SCHEDULE OF WARRANTS OUTSTANDING

At December 31, our warrants outstanding are as follows:

 

By Exercise Price:  2021   2020 
Warrants - $0.08   42,020,833    8,000,000 
Warrants - $0.1025   24,500,000    - 
Warrants - $0.10   3,240,740    3,240,740 
Warrants - $0.20   10,352,941    13,302,941 
Warrants - $0.30   722,800    722,800 
Warrants - $0.35   -    5,294,117 
Total outstanding   80,837,314    30,560,598 
SCHEDULE OF WARRANTS ACTIVITY

 

   Warrants 
Balance, January 1, 2020   21,819,858 
Warrants Issued   8,740,740 
Warrants Exercised   - 
Warrants Expired   - 
Balance, December 30, 2020   30,560,598 
Warrants Issued   66,510,083 
Warrants Exercised   (7,989,250)
Warrants Expired   (8,244,117)
Balance, December 30, 2021   80,837,314 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
SCHEDULE OF INCOME TAX PROVISION

The components of the income tax provision are as follows at December 31, 2021 and 2020:

 

   2021   2020 
Current   -    - 
Deferred   -    - 
Total tax provision   -    - 
SCHEDULE OF RECONCILIATION OF STATUTORY FEDERAL INCOME TAX RATE

The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31, 2021 and 2020:

 

   2021   2020 
U.S. Federal statutory income tax rate   (21.0)%   (21.0)%
State income tax, net of federal benefit   (3.5)%   (3.5)%
           
Valuation allowance   24.5%   24.5%
Effective tax rate   0.0%   0.0%
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES

The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31, 2021 and 2020:

 

Deferred tax assets  2021   2020 
Net operating loss carry forwards  $10,788,000   $9,843,000 
Accrued Wages   133,000    98,000 
Accrued Interest   93,000    - 
Less: valuation allowance   (11,014,000)   (9,941,000)
Total   -    - 
           
Deferred tax liabilities          
Stock based compensation   -    - 
Depreciation   -    - 
Net deferred tax asset  $-   $- 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF INVENTORIES (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Raw Materials $ 60,630 $ 356,901
Finished Goods 248,704 210,626
Inventories $ 309,334 $ 567,527
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF ANTI-DILUTIVE EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE (Details) - shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities 92,621,880 36,359,722
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities 80,837,314 30,560,598
Convertible Series B Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities 4,038,309
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive Securities 7,746,257 5,799,124
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.22.1
BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Accounting Policies [Abstract]    
Allowance for doubtful accounts $ 0 $ 0
Asset impairment charges $ 0 $ 0
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.22.1
LIQUIDITY AND GOING CONCERN CONSIDERATIONS (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ 5,800,000 $ 2,900,000
Net Cash Provided by (Used in) Operating Activities 487,386 1,284,240
Retained Earnings (Accumulated Deficit) $ 47,558,308 $ 41,730,801
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost $ 2,800,422 $ 2,800,422
Less: accumulated depreciation (535,226) (485,761)
Property and equipment,net 2,265,196 2,314,661
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost 1,959,694 1,959,694
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property and equipment, at cost $ 840,728 $ 840,728
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.22.1
PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 49,465 $ 61,986
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF ESTIMATE AMORTIZATION EXPENSE (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]    
2022 $ 65,000  
2023 65,000  
2024 65,000  
2025 65,000  
2026 65,000  
Thereafter 200,150  
Estimated amortization expenses $ 525,150 $ 590,118
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF INTANGIBLE ASSET (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]    
Patent $ 714,640 $ 714,640
Less: accumulated amortization (189,490) (124,522)
Estimated amortization expenses $ 525,150 $ 590,118
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.22.1
INTANGIBLE ASSET (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Feb. 28, 2019
Dec. 31, 2021
Dec. 31, 2020
Finite-Lived Intangible Assets [Line Items]      
Patent purchase price   $ 714,640 $ 714,640
Liability for stock to be issued   265,500 265,500
Amortization of Intangible Assets   $ 64,968 $ 64,968
Patents [Member]      
Finite-Lived Intangible Assets [Line Items]      
Patent purchase price $ 714,640    
Payments to Acquire Intangible Assets $ 130,000    
Finite-Lived Intangible Asset, Useful Life   11 years  
Patents [Member] | Common Stock [Member]      
Finite-Lived Intangible Assets [Line Items]      
Stock issued during period, shares, purchase of assets 3,300,000    
Shares issued, price per share $ 0.177    
Stock issued during period, value, purchase of assets $ 584,640    
Issuance of shares description Of the 3,300,000 shares, 1,800,000 shares were provided at closing and 1,500,000 were to be provided one year thereafter    
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.22.1
INVESTMENT (Details Narrative)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 02, 2020
USD ($)
$ / shares
shares
Nov. 30, 2021
USD ($)
Sep. 30, 2021
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
shares
Stock issued during period, value         $ 125,000
Equity method investment, ownership percentage       20.00%  
Distribution Agreement [Member]          
Investment       $ 383,326 383,326
Other than Temporary Impairment Losses, Investments         $ 0
License Agreement [Member]          
Investment       675,000  
License royalty fee   $ 450,000      
Percentage of license royalty fee   20.00%      
License fees   $ 225,000   725,000  
Payments for participation liabilities       1,400,000  
License Agreement [Member] | Equity [Member]          
Payments for participation liabilities       900,000  
License Agreement [Member] | License [Member]          
Payments for participation liabilities       500,000  
License Agreement [Member] | Maximum [Member]          
Investment       $ 6,000,000  
Common Stock [Member]          
Stock issued during period, shares | shares     4,350,000   1,923,076
Stock issued during period, shares, conversion of convertible securities | shares       448,701  
Stock issued during period, value         $ 192
Convertible Preferred Stock [Member]          
Stock price | $ / shares $ 4.00        
Exercise price | $ / shares $ 4.00        
Convertible Preferred Stock [Member] | Measurement Input, Expected Term [Member]          
Measurement inputs expected term 1 year        
Convertible Preferred Stock [Member] | Measurement Input, Risk Free Interest Rate [Member]          
Measurement input risk free interest rate 0.17        
Distributor [Member]          
Stock issued during period, shares | shares 12,500,000        
Distributor [Member] | Common Stock [Member]          
Stock issued during period, shares | shares 250,000     3,831,169  
Issuance of shares description On the first business day following the 180-day anniversary of closing, if the share price of the Distributor is less than $4.00, the Distributor will provide the Company its common stock valued at $1 million, less 250,000 common shares, for no additional consideration. On the one-year anniversary of closing, if the share price of the Distributor is less than $4.00, the Distributor will provide the Company its common stock valued at $1 million, less 250,000 shares, less the number of shares provided on the 181st day anniversary, for no additional consideration        
Stock price | $ / shares $ 4.00        
Stock issued during period, value $ 1,000,000        
Distributor [Member] | Common Stock [Member] | One Year Anniversary [Member]          
Stock issued during period, shares | shares 250,000        
Stock price | $ / shares $ 4.00        
Stock issued during period, value $ 1,000,000        
Distributor [Member] | Convertible Preferred Stock [Member]          
Stock issued during period, shares | shares 250        
Stock issued during period, shares, conversion of convertible securities | shares 1,000        
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF ACCRUED EXPENSES (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Officer – Bonus $ 540,500 $ 400,000
Accrued Expenses - Other 30,912 15,456
Accrued Interest – Related Parties 148,552 91,048
Accrued Interest 230,203 103,811
Other Current Liabilities 93,724 52,849
Accrued Rent 123,331
Accrued expenses $ 1,043,891 $ 786,495
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.22.1
NOTES PAYABLE (Details Narrative)
 3 Months Ended 4 Months Ended 12 Months Ended
Nov. 26, 2021
USD ($)
Mar. 12, 2021
USD ($)
Feb. 26, 2021
USD ($)
Apr. 23, 2020
USD ($)
Jun. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
shares
Mar. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Dec. 31, 2021
USD ($)
$ / shares
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Sep. 30, 2021
$ / shares
shares
Apr. 30, 2021
Mar. 31, 2021
Jan. 31, 2021
$ / shares
shares
Jul. 31, 2020
shares
Short-term Debt [Line Items]                              
Proceeds from notes payable                 $ 243,275 $ 254,700          
Beneficial conversion                   51,900          
Amortization of Debt Discount (Premium)                 438,235 671,319          
Notes payable to shareholders               $ 1,000,000 $ 1,000,000 1,000,000          
Paycheck Protection Program [Member]                              
Short-term Debt [Line Items]                              
Proceeds from notes payable     $ 243,275 $ 254,700                      
Debt forgiveness $ 243,275 $ 244,700                          
Warrant [Member]                              
Short-term Debt [Line Items]                              
Number of warrants issued | shares                     17,400,000     1,200,000 740,740
Warrants exercise price | $ / shares                     $ 0.08     $ 0.08  
Warrant expected term                 24 months   2 years   3 years    
Fair Value of Warrants                 $ 1,155,590            
Subscription Agreement [Member]                              
Short-term Debt [Line Items]                              
Proceeds from issuance of stock                   75,200          
Debt Settlement Agreements [Member]                              
Short-term Debt [Line Items]                              
Number of warrants issued | shares                 10,622,583            
Warrants exercise price | $ / shares                 $ 0.08            
Warrant expected term                 2 years            
Debt Conversion, Converted Instrument, Shares Issued | shares                 4,630,645            
Debt Settlement Agreements [Member] | Principal Amount [Member]                              
Short-term Debt [Line Items]                              
Debt conversion, amount                 $ 325,010            
Debt Settlement Agreements [Member] | Accrued Interest [Member]                              
Short-term Debt [Line Items]                              
Debt conversion, amount                 45,441            
2020 Convertibles Notes [Member]                              
Short-term Debt [Line Items]                              
Proceeds from issuance of stock                   314,100          
2020 Subscription Agreement Notes [Member]                              
Short-term Debt [Line Items]                              
Proceeds from issuance of stock                   $ 143,900          
2020 Subscription Agreement Notes [Member] | Measurement Input, Expected Term [Member]                              
Short-term Debt [Line Items]                              
Warrant expected term               36 months   36 months          
2020 Subscription Agreement Notes [Member] | Measurement Input, Option Volatility [Member]                              
Short-term Debt [Line Items]                              
Warrant measurement inputs               1.899   1.899          
Noteholders [Member]                              
Short-term Debt [Line Items]                              
Stock issued during period, shares | shares             3,250,000                
Proceeds from issuance of stock                 $ 370,267            
Noteholders [Member] | Warrant [Member]                              
Short-term Debt [Line Items]                              
Number of warrants issued | shares                 12,787,500            
Warrants exercise price | $ / shares                 $ 0.08            
Warrant expected term                 3 years            
Noteholders [Member] | Measurement Input, Expected Term [Member]                              
Short-term Debt [Line Items]                              
Warrant expected term                 2 years            
Multiple Short Term Promissory Notes Payable [Member]                              
Short-term Debt [Line Items]                              
Stock issued during period, shares | shares                   520,000          
Minimum [Member] | Measurement Input, Option Volatility [Member] | Warrant [Member]                              
Short-term Debt [Line Items]                              
Warrant measurement inputs                 2.2619            
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Warrant [Member]                              
Short-term Debt [Line Items]                              
Warrant measurement inputs                 0.0017     0.22      
Minimum [Member] | 2020 Subscription Agreement Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]                              
Short-term Debt [Line Items]                              
Warrant measurement inputs               0.0017   0.0017          
Minimum [Member] | Noteholders [Member] | Measurement Input, Option Volatility [Member]                              
Short-term Debt [Line Items]                              
Warrant measurement inputs                 1.910            
Minimum [Member] | Noteholders [Member] | Measurement Input, Risk Free Interest Rate [Member]                              
Short-term Debt [Line Items]                              
Warrant measurement inputs               0.0073 0.0018 0.0073          
Maximum [Member] | Measurement Input, Option Volatility [Member] | Warrant [Member]                              
Short-term Debt [Line Items]                              
Warrant measurement inputs                 2.4944            
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Warrant [Member]                              
Short-term Debt [Line Items]                              
Warrant measurement inputs                 0.0028     0.36      
Maximum [Member] | 2020 Subscription Agreement Notes [Member] | Measurement Input, Risk Free Interest Rate [Member]                              
Short-term Debt [Line Items]                              
Warrant measurement inputs               0.0022   0.0022          
Maximum [Member] | Noteholders [Member] | Measurement Input, Option Volatility [Member]                              
Short-term Debt [Line Items]                              
Warrant measurement inputs                 2.4556            
Multiple Short Term Promissory Notes Payable [Member]                              
Short-term Debt [Line Items]                              
Proceeds from notes payable           $ 230,000 $ 345,000 $ 330,040 $ 725,050            
Debt instrument, maturity date, description           a term of one year, maturing in August or September 2021 due dates ranging from February to June 2020 a term of one year, maturing in October through December 2021              
Debt instrument interest rate           18.00%                  
Debt instrument interest rate | $ / shares           $ 0.0001   $ 0.0001   $ 0.0001          
Stock issued during period, shares | shares           780,000                  
Number of warrants issued | shares               6,800,000   6,800,000          
Warrants exercise price | $ / shares               $ 0.08   $ 0.08          
Warrant expected term               3 years   3 years          
Original issue discounts                 $ 61,950            
Multiple Short Term Promissory Notes Payable [Member] | Minimum [Member]                              
Short-term Debt [Line Items]                              
Debt instrument interest rate             0.00% 10.00% 8.00% 10.00%          
Debt instrument interest rate | $ / shares             $ 0.085                
Multiple Short Term Promissory Notes Payable [Member] | Maximum [Member]                              
Short-term Debt [Line Items]                              
Debt instrument interest rate             12.00% 18.00% 12.00% 18.00%          
Debt instrument interest rate | $ / shares             $ 0.10                
Secured Convertible 5.75% Promissory Note Payable [Member] | Investment Agreement [Member]                              
Short-term Debt [Line Items]                              
Debt instrument interest rate         5.75%                    
Notes payable to shareholders         $ 1,000,000                    
Debt description         Included in the Investment Agreement is a royalty agreement whereby the investor received 500,000 shares of the Company’s common stock and will be entitled to a royalty of 8.5% from the revenue generated from the “collateral processors” while the principal is outstanding and 5% thereafter on the first two collateral processors for a period of 10 years                    
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUE SHARE AGREEMENTS (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Revenue share agreements payable $ 725,000
Two Revenue Share Agreement [Member] | Third Party Investors [Member]    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
[custom:RevenueReceived] $ 725,000  
[custom:RevenueShareAgreementsDescription] In exchange, the Investors are entitled to a percentage of revenue collected by the Company as a result of its investments, ranging from 1.3% to 60% until the Investors’ proceeds are repaid, and 0.83% to 49% thereafter, for a minimum of 60 months.  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS’ EQUITY (Details Narrative)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 31, 2021
USD ($)
shares
Nov. 30, 2012
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Jul. 31, 2021
USD ($)
shares
Apr. 30, 2021
USD ($)
$ / shares
shares
Nov. 30, 2020
shares
Jul. 31, 2020
USD ($)
$ / shares
shares
Sep. 30, 2021
USD ($)
$ / shares
shares
Mar. 31, 2020
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2020
USD ($)
$ / shares
shares
Jan. 31, 2021
$ / shares
shares
Sep. 30, 2020
shares
Class of Stock [Line Items]                          
Consulting services, shares     550,000 1,000,000                  
Consulting services, value | $     $ 55,000 $ 120,000           $ 175,000 $ 47,023    
Stock issued during period, value | $                     125,000    
Additional paid in capital, beneficial conversion feature | $                     $ 51,900    
Preferred stock, shares authorized                     10,000    
Equity ownership percentage     20.00%             20.00%      
Chief Executive Officer President And Director [Member]                          
Class of Stock [Line Items]                          
Number of warrants issued                       15,000,000  
Warrants exercise price | $ / shares                       $ 0.1025  
Warrants term                       3 years  
Vice President [Member]                          
Class of Stock [Line Items]                          
Number of warrants issued                       7,500,000  
Warrants exercise price | $ / shares                       $ 0.1025  
Warrants term                       3 years  
Production Manager [Member]                          
Class of Stock [Line Items]                          
Number of warrants issued         2,000,000                
Warrants exercise price | $ / shares         $ 0.125                
Warrants term         3 years                
Common Stock [Member]                          
Class of Stock [Line Items]                          
Consulting services, shares                   1,550,000 470,229    
Consulting services, value | $                   $ 155 $ 47    
Stock issued during the period, shares               4,350,000     1,923,076    
Exercise, price per share | $ / shares                     $ 0.065    
Stock issued during period, value | $                     $ 192    
Additional paid in capital, beneficial conversion feature | $                        
Shares converted               448,701          
Warrant [Member]                          
Class of Stock [Line Items]                          
Exercise, price per share | $ / shares             $ 0.10            
Number of warrants issued             740,740 17,400,000       1,200,000  
Cash proceeds, exercise price | $             $ 5,000            
Warrants exercise price | $ / shares               $ 0.08       $ 0.08  
Warrants term 3 years   24 months         2 years   24 months      
Warrants issued as compensation | $                   $ 1,155,590      
Warrants and Rights Outstanding | $               $ 348,000          
Warrant [Member] | Measurement Input, Price Volatility [Member]                          
Class of Stock [Line Items]                          
Warrants issued as compensation | $         $ 2,229,990                
Warrant [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]                          
Class of Stock [Line Items]                          
Warrants and rights outstanding, measurement input         191.0                
Warrant [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]                          
Class of Stock [Line Items]                          
Warrants and rights outstanding, measurement input         224.75                
Warrant [Member] | Measurement Input, Expected Dividend Rate [Member]                          
Class of Stock [Line Items]                          
Warrants and rights outstanding, measurement input         0                
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]                          
Class of Stock [Line Items]                          
Warrants and rights outstanding, measurement input     0.0017   0.22         0.0017      
Warrant [Member] | Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]                          
Class of Stock [Line Items]                          
Warrants and rights outstanding, measurement input     0.0028   0.36         0.0028      
Common Stock [Member]                          
Class of Stock [Line Items]                          
Consulting services, shares                 470,229        
Consulting services, value | $                 $ 47,023        
Series X Preferred Stock [Member] | Stock Purchase Agreement [Member] | Lord Global Corporation [Member]                          
Class of Stock [Line Items]                          
Stock issued during the period, shares           12,500,000              
Convertible preferred stock shares issued           250              
Preferred Stock [Member] | Maximum [Member]                          
Class of Stock [Line Items]                          
Preferred stock, shares authorized               10,000          
Series A Preferred Stock [Member]                          
Class of Stock [Line Items]                          
Preferred stock voting rights   Each share has voting rights equal to 500,000 shares of the Company’s common stock                      
Preferred stock, shares outstanding     1,000             1,000 1,000    
Series A Preferred Stock [Member] | Edgar Ward [Member]                          
Class of Stock [Line Items]                          
Stock issued during the period, shares   1,000                      
Stock issued during period, value | $   $ 1,000                      
Preferred stock, redemption amount | $   $ 1,000                      
Series B Convertible Preferred Stock [Member]                          
Class of Stock [Line Items]                          
Convertible preferred stock shares issued                         149,567
Preferred stock, shares authorized                         110
Equity ownership percentage                         4.99%
Series B Preferred Stock [Member]                          
Class of Stock [Line Items]                          
Preferred stock, shares outstanding     27             27 20    
Conversion of stock               3          
Series B Preferred Stock [Member] | Three Consultants [Member]                          
Class of Stock [Line Items]                          
Stock issued during the period for stock based compensation, shares 10                        
Stock issued during the period for stock based compensation, value | $ $ 164,524                        
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF OPERATING LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS (Details)
Dec. 31, 2021
USD ($)
Leases  
2022 $ 199,000
2023 189,400
2024 195,100
Total undiscounted future minimum lease payments 583,500
Less: amount representing imputed interest (90,702)
Operating lease liability $ 492,798
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Leases    
Cash paid for amounts included in the measurement of operating lease liabilities $ 551,688 $ 262,214
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF FINANCE LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Leases    
2022 $ 17,000  
2023 2,100  
Total undiscounted future minimum lease payments 19,100  
Less: amount representing interest (825)  
Less: current portion (17,161) $ (20,000)
Present value of minimum lease payments, net of current portion $ 1,114 $ 17,187
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.22.1
LEASES (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2022
Jun. 30, 2017
Sep. 30, 2019
Dec. 31, 2021
Dec. 31, 2020
Operating Lease, Right-of-Use Asset       $ 449,155 $ 661,141
Operating lease liability       492,798  
Operating lease liability, current       $ 141,911 214,000
Weighted average remaining lease term       37 months  
Weighted average discount rate       10.00%  
Operating lease expense       $ 386,000 442,000
Finance lease equipment       110,372 110,372
Finance lease equipment, accumulated depreciation       12,786 $ 8,950
Sub-Lease Agreement [Member]          
Proceeds from rent       $ 80,000  
Phytochem [Member]          
Description of operating lease     In July and September of 2019, the Company’s wholly owned subsidiary, Phytochem, entered into two separate lease agreements for office and warehouse space located in Onalaska, Wisconsin, that commenced on August 1 and October 1, respectively. Each lease is for six-month terms with four (4) renewal options to extend for six additional months. The Company expects to occupy one of the spaces for the full term of the lease totaling 30 months. The Company terminated its lease on the other facility in May 2020, without penalty. The remaining lease calls for an annual 3% increase to base rent. In addition to rent, the Company pays certain insurance, maintenance, and other costs related to the rented spaces    
Lessee, operating lease, term of contract     30 months    
Annual increases to base rent percent     3.00%    
Coconut Creek, Florida [Member]          
Operating lease expiration description expire in January, 2025   The Company terminated its lease on the other facility in May 2020, without penalty    
Deerfield Beach, Florida [Member]          
Description of operating lease   the Company entered into a lease for an additional facility located in Deerfield Beach, Florida under a non-cancelable operating lease. The term of the lease is for      
Lessee, operating lease, term of contract   86 months      
Annual increases to base rent percent   3.00%      
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF WARRANTS OUTSTANDING (Details) - $ / shares
Dec. 31, 2021
Dec. 31, 2020
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]    
Warrants outstanding 80,837,314 30,560,598
Exercise Price 1 [Member]    
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]    
Exercise price $ 0.08  
Warrants outstanding 42,020,833 8,000,000
Exercise Price 2 [Member]    
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]    
Exercise price $ 0.1025  
Warrants outstanding 24,500,000
Exercise Price 3 [Member]    
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]    
Exercise price $ 0.10  
Warrants outstanding 3,240,740 3,240,740
Exercise Price 4 [Member]    
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]    
Exercise price $ 0.20  
Warrants outstanding 10,352,941 13,302,941
Exercise Price 5 [Member]    
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]    
Exercise price $ 0.30  
Warrants outstanding 722,800 722,800
Exercise Price 6 [Member]    
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]    
Exercise price $ 0.35  
Warrants outstanding 5,294,117
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF WARRANTS ACTIVITY (Details) - Warrant [Member] - shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Warrants outstanding, beginning balance 30,560,598 21,819,858
Warrants Issued 66,510,083 8,740,740
Warrants Exercised (7,989,250)
Warrants Expired (8,244,117)
Warrants outstanding, ending balance 80,837,314 30,560,598
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF INCOME TAX PROVISION (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Current
Deferred
Total tax provision
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF RECONCILIATION OF STATUTORY FEDERAL INCOME TAX RATE (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
U.S. Federal statutory income tax rate (21.00%) (21.00%)
State income tax, net of federal benefit (3.50%) (3.50%)
Valuation allowance 24.50% 24.50%
Effective tax rate 0.00% 0.00%
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.22.1
SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) - USD ($)
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Net operating loss carry forwards $ 10,788,000 $ 9,843,000
Accrued Wages 133,000 98,000
Accrued Interest 93,000
Less: valuation allowance (11,014,000) (9,941,000)
Total
Stock based compensation
Depreciation
Net deferred tax asset
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.22.1
INCOME TAXES (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Change in valuation allowance $ 1,073,000 $ 543,000
Percentages of valuation allowance recorded 100.00%  
Net operating loss carryforwards $ 44,000,000.0 $ 32,600,000
Operating loss carryforwards, expiration year expire in the year 2032 through 2036  
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.22.1
CONTINGENCIES (Details Narrative)
 12 Months Ended
Dec. 31, 2021
USD ($)
Loss Contingencies [Line Items]  
Contingency principal amount $ 150,000
Maximum [Member]  
Loss Contingencies [Line Items]  
Contingency principal amount $ 5,000
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.22.1
CONCENTRATIONS OF CREDIT RISK (Details Narrative) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Concentration Risk [Line Items]    
Cash balances $ 0 $ 0
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]    
Concentration Risk [Line Items]    
Concentration risk, percentage 82.00% 28.00%
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.22.1
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 4 Months Ended 12 Months Ended
Mar. 31, 2022
Feb. 28, 2022
Jan. 31, 2022
Dec. 31, 2021
Jul. 31, 2021
Mar. 31, 2022
Sep. 30, 2021
Sep. 30, 2020
Mar. 31, 2020
Dec. 31, 2020
Dec. 31, 2021
Dec. 31, 2020
Mar. 31, 2021
Jan. 31, 2021
Subsequent Event [Line Items]                            
Proceeds from common stock                     $ 348,000 $ 125,000    
Common stock, shares       550,000 1,000,000                  
Common stock, value       $ 55,000 $ 120,000           175,000 47,023    
Proceeds from notes payable                     243,275 $ 254,700    
Multiple Short Term Promissory Notes Payable [Member]                            
Subsequent Event [Line Items]                            
Stock issued during period, shares               780,000            
Warrants exercise price                   $ 0.08   $ 0.08    
Warrant expiration term                   3 years   3 years    
Proceeds from notes payable               $ 230,000 $ 345,000 $ 330,040 $ 725,050      
Debt instrument interest rate               18.00%            
Common Stock [Member]                            
Subsequent Event [Line Items]                            
Stock issued during period, shares             4,350,000         1,923,076    
Common stock, shares                     1,550,000 470,229    
Common stock, value                     $ 155 $ 47    
Warrant [Member]                            
Subsequent Event [Line Items]                            
Warrants exercise price             $ 0.08             $ 0.08
Warrant expiration term       24 months     2 years       24 months   3 years  
Subsequent Event [Member] | Multiple Short Term Promissory Notes Payable [Member]                            
Subsequent Event [Line Items]                            
Proceeds from notes payable           $ 15,000                
Debt instrument maturity date Mar. 31, 2023                          
Debt instrument interest rate 20.00%         20.00%                
Subsequent Event [Member] | Debt Settlement Agreement [Member]                            
Subsequent Event [Line Items]                            
Debt conversion, total   $ 205,700                        
Subsequent Event [Member] | Debt Settlement Agreement [Member] | Principal [Member]                            
Subsequent Event [Line Items]                            
Debt conversion, total   187,000                        
Subsequent Event [Member] | Debt Settlement Agreement [Member] | Accrued Interest [Member]                            
Subsequent Event [Line Items]                            
Debt conversion, total   $ 18,700                        
Subsequent Event [Member] | Common Stock [Member]                            
Subsequent Event [Line Items]                            
Common stock, shares     1,100,000                      
Common stock, value     $ 100,000                      
Subsequent Event [Member] | Common Stock [Member] | Two Subscription Agreement [Member]                            
Subsequent Event [Line Items]                            
Proceeds from common stock     $ 110,000                      
Stock issued during period, shares     1,375,000                      
Subsequent Event [Member] | Warrant [Member] | Two Subscription Agreement [Member]                            
Subsequent Event [Line Items]                            
Number of warrants exchange, shares     1,375,000                      
Warrants exercise price     $ 0.08                      
Warrant expiration term     2 years                      
XML 69 form10-k_htm.xml IDEA: XBRL DOCUMENT 0001563463 2021-01-01 2021-12-31 0001563463 2021-06-30 0001563463 2022-03-23 0001563463 2021-12-31 0001563463 2020-12-31 0001563463 us-gaap:SeriesAPreferredStockMember 2021-12-31 0001563463 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001563463 us-gaap:SeriesBPreferredStockMember 2021-12-31 0001563463 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001563463 2020-01-01 2020-12-31 0001563463 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001563463 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2019-12-31 0001563463 us-gaap:CommonStockMember 2019-12-31 0001563463 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001563463 us-gaap:RetainedEarningsMember 2019-12-31 0001563463 2019-12-31 0001563463 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001563463 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-12-31 0001563463 us-gaap:CommonStockMember 2020-12-31 0001563463 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001563463 us-gaap:RetainedEarningsMember 2020-12-31 0001563463 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001563463 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001563463 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001563463 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001563463 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001563463 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001563463 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001563463 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001563463 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001563463 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001563463 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001563463 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2021-12-31 0001563463 us-gaap:CommonStockMember 2021-12-31 0001563463 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001563463 us-gaap:RetainedEarningsMember 2021-12-31 0001563463 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001563463 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001563463 NLBS:ConvertibleSeriesBPreferredStockMember 2021-01-01 2021-12-31 0001563463 NLBS:ConvertibleSeriesBPreferredStockMember 2020-01-01 2020-12-31 0001563463 us-gaap:ConvertibleDebtSecuritiesMember 2021-01-01 2021-12-31 0001563463 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-12-31 0001563463 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001563463 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001563463 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001563463 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001563463 us-gaap:PatentsMember 2019-02-28 0001563463 us-gaap:PatentsMember 2019-02-01 2019-02-28 0001563463 us-gaap:PatentsMember us-gaap:CommonStockMember 2019-02-01 2019-02-28 0001563463 us-gaap:PatentsMember us-gaap:CommonStockMember 2019-02-28 0001563463 us-gaap:PatentsMember 2021-01-01 2021-12-31 0001563463 NLBS:DistributorMember 2020-11-01 2020-11-02 0001563463 NLBS:DistributorMember us-gaap:ConvertiblePreferredStockMember 2020-11-01 2020-11-02 0001563463 NLBS:DistributorMember us-gaap:CommonStockMember 2020-11-01 2020-11-02 0001563463 NLBS:DistributorMember us-gaap:CommonStockMember 2020-11-02 0001563463 NLBS:OneYearAnniversaryMember NLBS:DistributorMember us-gaap:CommonStockMember 2020-11-02 0001563463 NLBS:OneYearAnniversaryMember NLBS:DistributorMember us-gaap:CommonStockMember 2020-11-01 2020-11-02 0001563463 NLBS:DistributorMember us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001563463 us-gaap:ConvertiblePreferredStockMember 2020-11-02 0001563463 us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertiblePreferredStockMember 2020-11-01 2020-11-02 0001563463 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertiblePreferredStockMember 2020-11-02 0001563463 NLBS:DistributionAgreementMember 2021-12-31 0001563463 NLBS:DistributionAgreementMember 2020-12-31 0001563463 NLBS:DistributionAgreementMember 2020-01-01 2020-12-31 0001563463 NLBS:LicenseAgreementMember 2021-11-01 2021-11-30 0001563463 srt:MaximumMember NLBS:LicenseAgreementMember 2021-12-31 0001563463 NLBS:LicenseAgreementMember 2021-12-31 0001563463 NLBS:LicenseAgreementMember 2021-01-01 2021-12-31 0001563463 us-gaap:LicenseMember NLBS:LicenseAgreementMember 2021-01-01 2021-12-31 0001563463 us-gaap:EquityMember NLBS:LicenseAgreementMember 2021-01-01 2021-12-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2020-01-01 2020-03-31 0001563463 srt:MinimumMember NLBS:MultipleShortTermPromissoryNotePayableMember 2020-03-31 0001563463 srt:MaximumMember NLBS:MultipleShortTermPromissoryNotePayableMember 2020-03-31 0001563463 NLBS:NoteholdersMember 2020-01-01 2020-03-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2020-07-01 2020-09-30 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2020-09-30 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2020-09-01 2020-12-31 0001563463 srt:MinimumMember NLBS:MultipleShortTermPromissoryNotePayableMember 2020-12-31 0001563463 srt:MaximumMember NLBS:MultipleShortTermPromissoryNotePayableMember 2020-12-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2020-12-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2020-01-01 2020-12-31 0001563463 NLBS:TwoThousandTwentyConvertiblesNotesMember 2020-01-01 2020-12-31 0001563463 NLBS:SubscriptionAgreementMember 2020-01-01 2020-12-31 0001563463 NLBS:TwoThousandTwentySubscriptionAgreementNotesMember 2020-01-01 2020-12-31 0001563463 NLBS:TwoThousandTwentySubscriptionAgreementNotesMember us-gaap:MeasurementInputExpectedTermMember 2020-12-31 0001563463 NLBS:TwoThousandTwentySubscriptionAgreementNotesMember us-gaap:MeasurementInputOptionVolatilityMember 2020-12-31 0001563463 srt:MinimumMember NLBS:TwoThousandTwentySubscriptionAgreementNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001563463 srt:MaximumMember NLBS:TwoThousandTwentySubscriptionAgreementNotesMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-31 0001563463 us-gaap:WarrantMember 2021-01-31 0001563463 us-gaap:WarrantMember 2021-03-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2021-01-01 2021-12-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember 2021-12-31 0001563463 srt:MinimumMember NLBS:MultipleShortTermPromissoryNotePayableMember 2021-12-31 0001563463 srt:MaximumMember NLBS:MultipleShortTermPromissoryNotePayableMember 2021-12-31 0001563463 NLBS:NoteholdersMember us-gaap:WarrantMember 2021-12-31 0001563463 NLBS:NoteholdersMember 2021-01-01 2021-12-31 0001563463 us-gaap:MeasurementInputExpectedTermMember NLBS:NoteholdersMember 2021-12-31 0001563463 srt:MinimumMember us-gaap:MeasurementInputOptionVolatilityMember NLBS:NoteholdersMember 2021-12-31 0001563463 srt:MaximumMember us-gaap:MeasurementInputOptionVolatilityMember NLBS:NoteholdersMember 2021-12-31 0001563463 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember NLBS:NoteholdersMember 2021-12-31 0001563463 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember NLBS:NoteholdersMember 2020-12-31 0001563463 NLBS:DebtSettlementAgreementsMember 2021-01-01 2021-12-31 0001563463 NLBS:DebtSettlementAgreementsMember 2021-12-31 0001563463 NLBS:PrincipalAmountMember NLBS:DebtSettlementAgreementsMember 2021-01-01 2021-12-31 0001563463 NLBS:AccruedInterestMember NLBS:DebtSettlementAgreementsMember 2021-01-01 2021-12-31 0001563463 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001563463 us-gaap:WarrantMember 2021-12-31 0001563463 srt:MinimumMember us-gaap:MeasurementInputOptionVolatilityMember us-gaap:WarrantMember 2021-12-31 0001563463 srt:MaximumMember us-gaap:MeasurementInputOptionVolatilityMember us-gaap:WarrantMember 2021-12-31 0001563463 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-12-31 0001563463 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-12-31 0001563463 NLBS:SecuredConvertibleFivePointSevenFivePercentagePromissoryNotePayableMember NLBS:InvestmentAgreementMember 2019-06-30 0001563463 NLBS:SecuredConvertibleFivePointSevenFivePercentagePromissoryNotePayableMember NLBS:InvestmentAgreementMember 2019-06-28 2019-06-30 0001563463 NLBS:PaycheckProtectionProgramMember 2020-04-22 2020-04-23 0001563463 NLBS:PaycheckProtectionProgramMember 2021-03-11 2021-03-12 0001563463 NLBS:PaycheckProtectionProgramMember 2021-02-25 2021-02-26 0001563463 NLBS:PaycheckProtectionProgramMember 2021-11-25 2021-11-26 0001563463 NLBS:ThirdPartyInvestorsMember NLBS:TwoRevenueShareAgreementMember 2021-01-01 2021-12-31 0001563463 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001563463 us-gaap:WarrantMember 2020-07-31 0001563463 us-gaap:WarrantMember 2020-07-01 2020-07-31 0001563463 NLBS:SeriesXPreferredStockMember NLBS:StockPurchaseAgreementMember NLBS:LordGlobalCorporationMember 2020-11-01 2020-11-30 0001563463 NLBS:SeriesXPreferredStockMember NLBS:StockPurchaseAgreementMember NLBS:LordGlobalCorporationMember 2020-11-30 0001563463 NLBS:ChiefExecutiveOfficerPresidentAndDirectorMember 2021-01-31 0001563463 srt:VicePresidentMember 2021-01-31 0001563463 NLBS:ProductionManagerMember 2021-04-30 0001563463 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-04-01 2021-04-30 0001563463 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-04-30 0001563463 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember us-gaap:WarrantMember 2021-04-30 0001563463 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:WarrantMember 2021-04-30 0001563463 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-04-30 0001563463 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:WarrantMember 2021-04-30 0001563463 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001563463 us-gaap:WarrantMember 2021-09-30 0001563463 2021-07-01 2021-07-31 0001563463 2021-12-01 2021-12-31 0001563463 srt:MaximumMember us-gaap:PreferredStockMember 2021-09-30 0001563463 us-gaap:SeriesAPreferredStockMember 2012-11-29 2012-11-30 0001563463 NLBS:EdgarWardMember us-gaap:SeriesAPreferredStockMember 2012-11-29 2012-11-30 0001563463 NLBS:EdgarWardMember us-gaap:SeriesAPreferredStockMember 2012-11-30 0001563463 NLBS:SeriesBConvertiblePreferredStockMember 2020-09-30 0001563463 NLBS:ThreeConsultantsMember us-gaap:SeriesBPreferredStockMember 2021-03-29 2021-03-31 0001563463 us-gaap:SeriesBPreferredStockMember 2021-07-01 2021-09-30 0001563463 NLBS:CoconutCreekFloridaMember 2022-01-01 2022-01-31 0001563463 NLBS:DeerfieldBeachFloridaMember 2017-06-01 2017-06-30 0001563463 NLBS:DeerfieldBeachFloridaMember 2017-06-30 0001563463 NLBS:PhytochemMember 2019-07-01 2019-09-30 0001563463 NLBS:PhytochemMember 2019-09-30 0001563463 NLBS:CoconutCreekFloridaMember 2019-07-01 2019-09-30 0001563463 NLBS:SubLeaseAgreementMember 2021-01-01 2021-12-31 0001563463 NLBS:ExercisePriceOneMember 2021-12-31 0001563463 NLBS:ExercisePriceOneMember 2020-12-31 0001563463 NLBS:ExercisePriceTwoMember 2021-12-31 0001563463 NLBS:ExercisePriceTwoMember 2020-12-31 0001563463 NLBS:ExercisePriceThreeMember 2021-12-31 0001563463 NLBS:ExercisePriceThreeMember 2020-12-31 0001563463 NLBS:ExercisePriceFourMember 2021-12-31 0001563463 NLBS:ExercisePriceFourMember 2020-12-31 0001563463 NLBS:ExercisePriceFiveMember 2021-12-31 0001563463 NLBS:ExercisePriceFiveMember 2020-12-31 0001563463 NLBS:ExercisePriceSixMember 2021-12-31 0001563463 NLBS:ExercisePriceSixMember 2020-12-31 0001563463 us-gaap:WarrantMember 2019-12-31 0001563463 us-gaap:WarrantMember 2020-01-01 2020-12-31 0001563463 us-gaap:WarrantMember 2020-12-31 0001563463 srt:MaximumMember 2021-01-01 2021-12-31 0001563463 NLBS:TwoCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001563463 NLBS:TwoCustomersMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001563463 us-gaap:CommonStockMember us-gaap:SubsequentEventMember NLBS:TwoSubscriptionAgreementMember 2022-01-01 2022-01-31 0001563463 us-gaap:WarrantMember us-gaap:SubsequentEventMember NLBS:TwoSubscriptionAgreementMember 2022-01-01 2022-01-31 0001563463 us-gaap:WarrantMember us-gaap:SubsequentEventMember NLBS:TwoSubscriptionAgreementMember 2022-01-31 0001563463 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2022-01-01 2022-01-31 0001563463 NLBS:PrincipalMember us-gaap:SubsequentEventMember NLBS:DebtSettlementAgreementMember 2022-02-01 2022-02-28 0001563463 NLBS:AccruedInterestMember us-gaap:SubsequentEventMember NLBS:DebtSettlementAgreementMember 2022-02-01 2022-02-28 0001563463 us-gaap:SubsequentEventMember NLBS:DebtSettlementAgreementMember 2022-02-01 2022-02-28 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember us-gaap:SubsequentEventMember 2022-01-01 2022-03-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember us-gaap:SubsequentEventMember 2022-03-01 2022-03-31 0001563463 NLBS:MultipleShortTermPromissoryNotePayableMember us-gaap:SubsequentEventMember 2022-03-31 iso4217:USD shares iso4217:USD shares pure 0001563463 false FY 2023-03-31 10-K true 2021-12-31 --12-31 2021 false 000-55144 NUTRALIFE BIOSCIENCES, INC FL 46-1482900 6601 Lyons Road Suite L-6 Coconut Creek FL 33073 888 509-8901 No No Yes Yes Non-accelerated Filer true false false false 14359742 174968516 NONE Rotenberg Meril Solomon Bertiger & Guttilla, PC Saddle Brook 361 135769 742 0 0 44198 154193 309334 567527 28997 518298 722462 2265196 2314661 449155 661141 383326 383326 675000 525150 590118 35000 35000 4851125 4706708 283164 173925 148552 91048 1043891 786495 70521 22700 265500 265500 148000 17161 20000 141911 214000 200524 206542 1000000 1000000 2621506 2153498 33000 725000 5201654 3784118 10000 106700 350887 497593 1114 17187 5563655 4405598 0.0001 10000 1000 1000 1 1 27 27 20 20 1 1 0.0001 0.0001 499990000 499990000 171398834 171398834 160419488 160419488 17133 16036 46828644 42015874 -47558308 -41730801 -712530 301110 4851125 4706708 626619 1255784 543031 745934 83588 509850 22913 176430 2569514 501707 1849371 1804765 114434 4556232 2482902 -4472644 -1973052 6448 -53 487975 1849286 916835 -1354863 -916888 -5827507 -2889940 -5827507 -2889940 -0.04 -0.02 164526457 146330346 1000 1 140976183 14092 40415885 -38840861 1589117 20 454684 454684 1923076 192 124808 125000 4550000 455 390645 391100 470229 47 46976 47023 51900 51900 143900 143900 5000 5000 12500000 1250 382076 383326 -2889940 -2889940 1000 1 20 160419488 16036 42015874 -41730801 301110 1000 1 20 160419488 16036 42015874 -41730801 301110 10 164524 164524 -3 448701 44 44 4350000 435 347565 348000 4630645 463 369989 370452 1550000 155 174845 175000 1525857 1525857 2229990 2229990 -5827507 -5827507 1000 1 27 171398834 17133 46828644 -47558308 -712530 1000 1 27 171398834 17133 46828644 -47558308 -712530 -5827507 -2889940 487975 49465 61986 2569514 501707 1155590 438235 671319 211986 267754 64968 64968 -1500 109995 -140894 258193 -77354 -28997 87627 109239 938 302882 373301 70521 -22700 13350 -218795 -217502 725000 33000 -487386 -1284240 675000 -675000 243275 254700 725050 905040 5000 348000 125000 18912 19586 1297413 1270154 135027 -14086 742 14828 135769 742 391100 51900 134364 134364 370452 370267 143900 383326 <p id="xdx_808_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_zg5s4UPwGjH3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_825_zlzFZ3toOPa6">NATURE OF OPERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">NutraLife BioSciences, Inc. (“We” or the “Company”) is the producer and distributor of nutritional supplements that uses micro molecular formulae and a utilization of an oral spray to provide faster and more efficient absorption. Our products are sold to private label distributers who sell the products we manufacture under their own brand name as well as under our own brand name.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_808_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zrMM9cBqkM6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_82A_zdS1LbIaroJj">BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p> <p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zooqH1QNwWtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zoA5flt0qOki">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted (“GAAP”) in the United States of America as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and with the rules and regulations of the U.S Securities and Exchange Commission (“SEC”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_z3ugdFrWPOz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z8n4R41CO2rk">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Precision Analytic Testing, LLC, NutraDerma Technologies, Inc., PhytoChem Technologies, Inc., and TransDermalRX, Inc. We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8b7ORBMpj1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zAGTl6fgQVse">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates”, which amended the effective date of the various topics. As the Company is a </span>smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending March 31, 2023 for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company will evaluate the impact of ASU 2016-13 on the Company’s consolidated financial statements in a future period closer to the date of adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which simplifies and clarifies certain calculation and presentation matters related to convertible equity and debt instruments. Specifically, ASU-2020-06 removes requirements to separately account for conversion features as a derivative under ASC Topic 815 and removing the requirement to account for beneficial conversion features on such instruments. Accounting Standards Update 2020-06 also provides clearer guidance surrounding disclosure of such instruments and provides specific guidance for how such instruments are to be incorporated in the calculation of Diluted EPS. The guidance under ASU 2020-06 is effective for fiscal years beginning after December 15, 2021,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted this standard using a modified retrospective approach effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--UseOfEstimates_zX8cStYsByPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zhrl9R6rwG31">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBY3LDtRQE4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86C_znlOvHgknH4h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash and Cash Equivalents</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at December 31, 2021 consisted of a money market account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--InventoryPolicyTextBlock_zJPV1H81LTvc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zzd3iPYiXYnk">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at lower of cost or net realizable value utilizing the weighted average method of valuation and consist of raw materials and finished goods. The Company reduces inventory on hand to its net realizable value on an item-by-item basis when it is apparent that the expected realizable value of an inventory item falls below its original cost. A charge to cost of sales results when the estimated net realizable value of specific inventory items declines below cost. Management regularly reviews the Company’s inventories for such declines in value. Inventory consists of the following:</span></p> <p id="xdx_89E_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zIVBfQISpxyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zvolVc1FYZ3g" style="display: none">SCHEDULE OF INVENTORIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20211231_z6fjoSRl0Wkd" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td><td> </td><td> </td> <td colspan="2" id="xdx_494_20201231_zqzUViHB9WE4" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31, 2020</p></td><td> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_pp0p0_maINzLxS_zHN1HWUVLwN3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Raw Materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">60,630</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">356,901</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maINzLxS_zvxuPUMBiTQg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finished Goods</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">248,704</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">210,626</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryNet_iTI_pp0p0_mtINzLxS_zPfb09udQOwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">309,334</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">567,527</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_z2aU7tkyub82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zpEG8vw6gIga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zclWNTvaB886">Allowance for Doubtful Accounts</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We establish the existence of bad debts through a review of several factors including historical collection experience, current aging status of the customer accounts, and financial condition of our customers. The allowance for doubtful accounts is $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20211231_z3MVzHwTna5a" title="Allowance for doubtful accounts"><span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20201231_zQ949VQeakMf" title="Allowance for doubtful accounts">0</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of both December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zRw1kivOok33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_ziIita3ooR68">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All property and equipment are recorded at cost and depreciated over their estimated useful lives, generally three, seven and twelve years, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Leasehold improvements are amortized over their estimated useful lives or the remaining term of the lease, whichever is shorter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z5YHxOULbcy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z85NEPTikRmf">Impairment of Long-Lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment charges would be included with costs and expenses in the Company’s consolidated statements of operations and would result in reduced carrying amounts of the related assets on the Company’s consolidated balance sheets. <span id="xdx_90F_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20210101__20211231_zF616u0PL299" title="Asset impairment charges"><span id="xdx_901_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20200101__20201231_zEe74yP8hgNe" title="Asset impairment charges">No</span></span> adjustments were made to long-lived assets during the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z4hIsWOC4wyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zhCrrpBRElAc">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for revenue under the guidance of FASB ASC 606, “Revenue from Contracts from Customers” (“ASC 606”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 606 prescribes a five-step model that focuses on transfer of control and entitlement to payment when determining the amount of revenue to be recognized. Under the ASC 606 guidance, an entity is required to perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenues from the sale of products. The product is invoiced, and the revenue is recognized upon shipment or once transfer of risk has passed to the customer, which is the point at which the Company has satisfied its performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments received in advance from customers are recorded as customer deposits until earned, at which time revenue is recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize certain revenues under bill and hold arrangements with certain customers when the Company has fulfilled all of its performance obligations, the units are segregated for the specific customer only, and the goods are ready for physical transfer to the customer in accordance with their defined contract delivery schedule. For any requested bill and hold arrangement, we make an evaluation as to whether the bill and hold arrangement qualifies for revenue recognition. The customer must initiate the request for the bill and hold arrangement. The customer must make a fixed commitment to purchase the items. The risk of ownership is passed to the customer, and payment terms are not modified.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenues accounted for under ASC 606 do not require significant estimates or judgements based on the nature of the Company’s revenue. The Company’s contracts do not include multiple performance obligations or variable consideration. All of the Company’s sales resulted from contracts with customers for the years ended December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zuTTQFEOgZu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zmhf6fVKv0qb">Shipping and Handling Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping and handling costs are expensed as incurred and included in cost of sales. Billings for shipping and handling are reflected within sales in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_z786jW0xNMse" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zfIP0HQfSMu9">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the provisions of ASC 740-10, “Accounting for Uncertain Income Tax Positions.” When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax years 2018-2021 for the Company remain open for audit by federal and state tax authorities. The Company has received no notice of audit or any notifications from the IRS for any of the open tax years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zstJakCrsEu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zTKTOyKw3eH9">Net Loss Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share excludes dilution and is computed by dividing the loss attributable to stockholders by the weighted-average number of shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the year and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. The following anti-dilutive equity and debt securities were excluded from the computation of net loss per share.</span></p> <p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zm50nKd7Vnkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zmXkN6W05i98" style="display: none">SCHEDULE OF ANTI-DILUTIVE EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31, 2020</p></td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(Shares)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Shares)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zU5FM71BjJs6" style="width: 18%; text-align: right" title="Antidilutive Securities">80,837,314</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQFbIJzWNvmj" style="width: 18%; text-align: right" title="Antidilutive Securities">30,560,598</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesBPreferredStockMember_zfDj5fTXm4wi" style="text-align: right" title="Antidilutive Securities">4,038,309</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesBPreferredStockMember_z4wWuOwPGVK8" style="text-align: right" title="Antidilutive Securities"><span style="-sec-ix-hidden: xdx2ixbrl0679">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes payable, and accrued interest</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zKDRZxD1fYp9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive Securities">7,746,257</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zIN8kzrx1Uil" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive Securities">5,799,124</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><p style="margin-top: 0; margin-bottom: 0"/> <p style="margin-top: 0; margin-bottom: 0"> <span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zZZtPAVa0utb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive Securities">92,621,880</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_zepdWZuYNUyf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive Securities">36,359,722</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A7_zlR2NuiwHJje" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_ecustom--RelatedPartyTransactionsPolicyTextBlock_zQnKyyz6DJ4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_z1F3mj7Xl9R3">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All transactions with related parties are in the normal course of operations and are measured at the exchange amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_zMzcVv8aW2fh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zOcRkLaKjhCe">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for leases FASB ASU 2016-02, “Leases” (“ASC 842”) and other associated standards, which defines a lease as any contract that conveys the right to use a specific asset for a period of time in exchange for consideration. ASC 842 requires the recognition of the right-of-use assets and related operating and finance lease liabilities on the balance sheet and the disclosure of key information about certain leasing arrangements. As permitted by ASC 842, the Company elected the adoption date of January 1, 2019, which is the initial date of application. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated. Under ASC 842, all leases are required to be recorded on the balance sheet and are classified as either operating leases or finance leases (formerly called capital leases). The lease classification affects the expense recognition in the income statement. Operating lease charges are recorded entirely in operating expenses. Finance lease charges are split, where amortization of the right-of-use asset is recorded in operating expenses and an implied interest component is recorded in interest expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases are classified as a finance lease if any of the following criteria are met:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease transfers ownership of the underlying asset to the lessee by the end of the lease term.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease term is for the major part of the remaining economic life of the underlying asset.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The present value of the sum of lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For any leases that do not meet the criteria identified above for finance leases, the Company treats such leases as operating leases. As of December 30, 2021, the Company has two finance leases and three operating leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the ASC 842 guidance, both finance and operating leases are reflected on the balance sheet as lease or “right-of-use” assets and lease liabilities. There are some exceptions, which the Company has elected in its accounting policies. For leases with terms of twelve months or less, or below the Company’s general capitalization policy threshold, the Company elects an accounting policy to not recognize lease assets and lease liabilities for all asset classes. The Company recognizes lease expense for such leases generally on a straight-line basis over the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and accounts for these options when they are reasonably certain to be exercised. Certain leases contain non-lease components, such as common area maintenance, which are generally accounted for separately. In general, the Company will assess if non-lease components are fixed and determinable, or variable, when determining if the component should be included in the lease liability. For purposes of calculating the present value of the lease obligations, the Company utilizes the implicit interest rate within the lease agreement when known and/or determinable, and otherwise utilizes its incremental borrowing rate at the time of the lease agreement. The related right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zsVhJVmpgFxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zrcRKNt6ztW8">Intangible Asset</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible asset represents the value assigned to intellectual property and is amortized based on the economic benefit expected to be realized.</span></p> <p id="xdx_857_zscBybnyu8h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zooqH1QNwWtk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zoA5flt0qOki">Basis of Presentation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted (“GAAP”) in the United States of America as promulgated by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and with the rules and regulations of the U.S Securities and Exchange Commission (“SEC”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--ConsolidationPolicyTextBlock_z3ugdFrWPOz8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_z8n4R41CO2rk">Principles of Consolidation</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries: Precision Analytic Testing, LLC, NutraDerma Technologies, Inc., PhytoChem Technologies, Inc., and TransDermalRX, Inc. We operate as one reportable segment. All intercompany transactions and balances have been eliminated in consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_846_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z8b7ORBMpj1g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zAGTl6fgQVse">Recent Accounting Pronouncements</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, “Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates”, which amended the effective date of the various topics. As the Company is a </span>smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending March 31, 2023 for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company will evaluate the impact of ASU 2016-13 on the Company’s consolidated financial statements in a future period closer to the date of adoption.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Effective January 1, 2021, the Company adopted ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, the FASB issued ASU 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” which simplifies and clarifies certain calculation and presentation matters related to convertible equity and debt instruments. Specifically, ASU-2020-06 removes requirements to separately account for conversion features as a derivative under ASC Topic 815 and removing the requirement to account for beneficial conversion features on such instruments. Accounting Standards Update 2020-06 also provides clearer guidance surrounding disclosure of such instruments and provides specific guidance for how such instruments are to be incorporated in the calculation of Diluted EPS. The guidance under ASU 2020-06 is effective for fiscal years beginning after December 15, 2021,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. The Company adopted this standard using a modified retrospective approach effective January 1, 2021. The adoption of this standard did not have a material impact on the Company’s consolidated financial statements and related disclosures.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--UseOfEstimates_zX8cStYsByPi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zhrl9R6rwG31">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBY3LDtRQE4j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span id="xdx_86C_znlOvHgknH4h" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash and Cash Equivalents</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers all highly liquid debt instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at December 31, 2021 consisted of a money market account.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84B_eus-gaap--InventoryPolicyTextBlock_zJPV1H81LTvc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zzd3iPYiXYnk">Inventories</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories are stated at lower of cost or net realizable value utilizing the weighted average method of valuation and consist of raw materials and finished goods. The Company reduces inventory on hand to its net realizable value on an item-by-item basis when it is apparent that the expected realizable value of an inventory item falls below its original cost. A charge to cost of sales results when the estimated net realizable value of specific inventory items declines below cost. Management regularly reviews the Company’s inventories for such declines in value. Inventory consists of the following:</span></p> <p id="xdx_89E_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zIVBfQISpxyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zvolVc1FYZ3g" style="display: none">SCHEDULE OF INVENTORIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20211231_z6fjoSRl0Wkd" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td><td> </td><td> </td> <td colspan="2" id="xdx_494_20201231_zqzUViHB9WE4" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31, 2020</p></td><td> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_pp0p0_maINzLxS_zHN1HWUVLwN3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Raw Materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">60,630</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">356,901</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maINzLxS_zvxuPUMBiTQg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finished Goods</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">248,704</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">210,626</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryNet_iTI_pp0p0_mtINzLxS_zPfb09udQOwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">309,334</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">567,527</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AF_z2aU7tkyub82" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zIVBfQISpxyj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_zvolVc1FYZ3g" style="display: none">SCHEDULE OF INVENTORIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_494_20211231_z6fjoSRl0Wkd" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td><td> </td><td> </td> <td colspan="2" id="xdx_494_20201231_zqzUViHB9WE4" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31, 2020</p></td><td> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryRawMaterials_iI_pp0p0_maINzLxS_zHN1HWUVLwN3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Raw Materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">60,630</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">356,901</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maINzLxS_zvxuPUMBiTQg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finished Goods</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">248,704</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">210,626</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--InventoryNet_iTI_pp0p0_mtINzLxS_zPfb09udQOwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">309,334</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">567,527</td><td style="text-align: left"> </td></tr> </table> 60630 356901 248704 210626 309334 567527 <p id="xdx_841_eus-gaap--ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_zpEG8vw6gIga" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_866_zclWNTvaB886">Allowance for Doubtful Accounts</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We establish the existence of bad debts through a review of several factors including historical collection experience, current aging status of the customer accounts, and financial condition of our customers. The allowance for doubtful accounts is $<span id="xdx_90D_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20211231_z3MVzHwTna5a" title="Allowance for doubtful accounts"><span id="xdx_90A_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_pp0p0_c20201231_zQ949VQeakMf" title="Allowance for doubtful accounts">0</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of both December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zRw1kivOok33" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_ziIita3ooR68">Property and Equipment</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All property and equipment are recorded at cost and depreciated over their estimated useful lives, generally three, seven and twelve years, using the straight-line method. Upon sale or retirement, the cost and related accumulated depreciation are eliminated from their respective accounts, and the resulting gain or loss is included in the results of operations. Repairs and maintenance charges, which do not increase the useful lives of the assets, are charged to operations as incurred. Leasehold improvements are amortized over their estimated useful lives or the remaining term of the lease, whichever is shorter.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z5YHxOULbcy6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_z85NEPTikRmf">Impairment of Long-Lived Assets</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A long-lived asset is tested for impairment whenever events or changes in circumstances indicate that its carrying value amount may not be recoverable. An impairment loss is recognized when the carrying amount of the asset exceeds the sum of the undiscounted cash flows resulting from its use and eventual disposition. The impairment loss is measured as the amount by which the carrying amount of the long-lived assets exceeds its fair value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment charges would be included with costs and expenses in the Company’s consolidated statements of operations and would result in reduced carrying amounts of the related assets on the Company’s consolidated balance sheets. <span id="xdx_90F_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20210101__20211231_zF616u0PL299" title="Asset impairment charges"><span id="xdx_901_eus-gaap--AssetImpairmentCharges_pp0p0_do_c20200101__20201231_zEe74yP8hgNe" title="Asset impairment charges">No</span></span> adjustments were made to long-lived assets during the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 <p id="xdx_84B_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_z4hIsWOC4wyl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zhCrrpBRElAc">Revenue Recognition</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounts for revenue under the guidance of FASB ASC 606, “Revenue from Contracts from Customers” (“ASC 606”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 606 prescribes a five-step model that focuses on transfer of control and entitlement to payment when determining the amount of revenue to be recognized. Under the ASC 606 guidance, an entity is required to perform the following five steps: (1) identify the contract(s) with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when (or as) the entity satisfies a performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company generates revenues from the sale of products. The product is invoiced, and the revenue is recognized upon shipment or once transfer of risk has passed to the customer, which is the point at which the Company has satisfied its performance obligation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payments received in advance from customers are recorded as customer deposits until earned, at which time revenue is recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize certain revenues under bill and hold arrangements with certain customers when the Company has fulfilled all of its performance obligations, the units are segregated for the specific customer only, and the goods are ready for physical transfer to the customer in accordance with their defined contract delivery schedule. For any requested bill and hold arrangement, we make an evaluation as to whether the bill and hold arrangement qualifies for revenue recognition. The customer must initiate the request for the bill and hold arrangement. The customer must make a fixed commitment to purchase the items. The risk of ownership is passed to the customer, and payment terms are not modified.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s revenues accounted for under ASC 606 do not require significant estimates or judgements based on the nature of the Company’s revenue. The Company’s contracts do not include multiple performance obligations or variable consideration. All of the Company’s sales resulted from contracts with customers for the years ended December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_847_ecustom--ShippingAndHandlingCostsPolicyTextBlock_zuTTQFEOgZu7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_zmhf6fVKv0qb">Shipping and Handling Costs</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping and handling costs are expensed as incurred and included in cost of sales. Billings for shipping and handling are reflected within sales in the accompanying consolidated statements of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--IncomeTaxPolicyTextBlock_z786jW0xNMse" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zfIP0HQfSMu9">Income Taxes</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company follows the provisions of ASC 740-10, “Accounting for Uncertain Income Tax Positions.” When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for unrecognized tax benefits in the accompanying consolidated balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The tax years 2018-2021 for the Company remain open for audit by federal and state tax authorities. The Company has received no notice of audit or any notifications from the IRS for any of the open tax years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84A_eus-gaap--EarningsPerSharePolicyTextBlock_zstJakCrsEu4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zTKTOyKw3eH9">Net Loss Per Share</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic loss per share excludes dilution and is computed by dividing the loss attributable to stockholders by the weighted-average number of shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that shared in the earnings of the Company. Diluted loss per share is computed by dividing the loss available to stockholders by the weighted average number of shares outstanding for the year and dilutive potential shares outstanding unless consideration of such dilutive potential shares would result in anti-dilution. The following anti-dilutive equity and debt securities were excluded from the computation of net loss per share.</span></p> <p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zm50nKd7Vnkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zmXkN6W05i98" style="display: none">SCHEDULE OF ANTI-DILUTIVE EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31, 2020</p></td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(Shares)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Shares)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zU5FM71BjJs6" style="width: 18%; text-align: right" title="Antidilutive Securities">80,837,314</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQFbIJzWNvmj" style="width: 18%; text-align: right" title="Antidilutive Securities">30,560,598</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesBPreferredStockMember_zfDj5fTXm4wi" style="text-align: right" title="Antidilutive Securities">4,038,309</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesBPreferredStockMember_z4wWuOwPGVK8" style="text-align: right" title="Antidilutive Securities"><span style="-sec-ix-hidden: xdx2ixbrl0679">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes payable, and accrued interest</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zKDRZxD1fYp9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive Securities">7,746,257</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zIN8kzrx1Uil" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive Securities">5,799,124</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><p style="margin-top: 0; margin-bottom: 0"/> <p style="margin-top: 0; margin-bottom: 0"> <span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zZZtPAVa0utb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive Securities">92,621,880</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_zepdWZuYNUyf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive Securities">36,359,722</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A7_zlR2NuiwHJje" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zm50nKd7Vnkj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B4_zmXkN6W05i98" style="display: none">SCHEDULE OF ANTI-DILUTIVE EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31, 2021</p></td><td> </td><td> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">December 31, 2020</p></td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" style="text-align: center">(Shares)</td><td> </td><td> </td> <td colspan="2" style="text-align: center">(Shares)</td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Warrants</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zU5FM71BjJs6" style="width: 18%; text-align: right" title="Antidilutive Securities">80,837,314</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zQFbIJzWNvmj" style="width: 18%; text-align: right" title="Antidilutive Securities">30,560,598</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series B Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesBPreferredStockMember_zfDj5fTXm4wi" style="text-align: right" title="Antidilutive Securities">4,038,309</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesBPreferredStockMember_z4wWuOwPGVK8" style="text-align: right" title="Antidilutive Securities"><span style="-sec-ix-hidden: xdx2ixbrl0679">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Convertible notes payable, and accrued interest</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zKDRZxD1fYp9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive Securities">7,746,257</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_zIN8kzrx1Uil" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive Securities">5,799,124</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><p style="margin-top: 0; margin-bottom: 0"/> <p style="margin-top: 0; margin-bottom: 0"> <span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p></td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20211231_zZZtPAVa0utb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive Securities">92,621,880</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20201231_zepdWZuYNUyf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Antidilutive Securities">36,359,722</td><td style="text-align: left"> </td></tr> </table> 80837314 30560598 4038309 7746257 5799124 92621880 36359722 <p id="xdx_848_ecustom--RelatedPartyTransactionsPolicyTextBlock_zQnKyyz6DJ4h" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_z1F3mj7Xl9R3">Related Party Transactions</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All transactions with related parties are in the normal course of operations and are measured at the exchange amount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--LesseeLeasesPolicyTextBlock_zMzcVv8aW2fh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zOcRkLaKjhCe">Leases</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for leases FASB ASU 2016-02, “Leases” (“ASC 842”) and other associated standards, which defines a lease as any contract that conveys the right to use a specific asset for a period of time in exchange for consideration. ASC 842 requires the recognition of the right-of-use assets and related operating and finance lease liabilities on the balance sheet and the disclosure of key information about certain leasing arrangements. As permitted by ASC 842, the Company elected the adoption date of January 1, 2019, which is the initial date of application. As a result, the consolidated balance sheet prior to January 1, 2019 was not restated. Under ASC 842, all leases are required to be recorded on the balance sheet and are classified as either operating leases or finance leases (formerly called capital leases). The lease classification affects the expense recognition in the income statement. Operating lease charges are recorded entirely in operating expenses. Finance lease charges are split, where amortization of the right-of-use asset is recorded in operating expenses and an implied interest component is recorded in interest expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases are classified as a finance lease if any of the following criteria are met:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease transfers ownership of the underlying asset to the lessee by the end of the lease term.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The lease term is for the major part of the remaining economic life of the underlying asset.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The present value of the sum of lease payments and any residual value guaranteed by the lessee equals or exceeds substantially all of the fair value of the underlying asset.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For any leases that do not meet the criteria identified above for finance leases, the Company treats such leases as operating leases. As of December 30, 2021, the Company has two finance leases and three operating leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under the ASC 842 guidance, both finance and operating leases are reflected on the balance sheet as lease or “right-of-use” assets and lease liabilities. There are some exceptions, which the Company has elected in its accounting policies. For leases with terms of twelve months or less, or below the Company’s general capitalization policy threshold, the Company elects an accounting policy to not recognize lease assets and lease liabilities for all asset classes. The Company recognizes lease expense for such leases generally on a straight-line basis over the lease term.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and accounts for these options when they are reasonably certain to be exercised. Certain leases contain non-lease components, such as common area maintenance, which are generally accounted for separately. In general, the Company will assess if non-lease components are fixed and determinable, or variable, when determining if the component should be included in the lease liability. For purposes of calculating the present value of the lease obligations, the Company utilizes the implicit interest rate within the lease agreement when known and/or determinable, and otherwise utilizes its incremental borrowing rate at the time of the lease agreement. The related right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease expense for operating leases consists of the lease payments plus any initial direct costs and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zsVhJVmpgFxg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zrcRKNt6ztW8">Intangible Asset</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible asset represents the value assigned to intellectual property and is amortized based on the economic benefit expected to be realized.</span></p> <p id="xdx_80D_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zFjIMSnj3E2g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 - <span id="xdx_82C_zgWZ2LpsJ0pa">LIQUIDITY AND GOING CONCERN CONSIDERATIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. We sustained significant losses and negative cash flows from operations. We incurred a net loss of approximately $<span id="xdx_901_eus-gaap--ProfitLoss_pn5n6_c20210101__20211231_znjPtxJlqdR6">5.8</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million and $<span id="xdx_90A_eus-gaap--ProfitLoss_pn5n6_c20200101__20201231_zAVV9I0zb0m7">2.9 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million for the years ended December 31, 2021 and 2020, respectively. We had cash used in operating activities of approximately $<span id="xdx_903_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iN_pn3n3_di_c20210101__20211231_zYU4B0RSKIyg">487</span> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">thousand</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> for the year ended December 31, 2021, and have an accumulated deficit of approximately $<span id="xdx_90E_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn6n6_di_c20211231_z5gZ5oHMPGU">48 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million at December 31, 2021. These conditions raise substantial doubt about our ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in China and began to spread around the world in early 2020. In reaction to decreased supply of and increased demand for sanitizer products, the Company shifted its manufacturing to produce sanitizer products. The Company’s other business operations have been impacted negatively by COVID-19 due to government restrictions and the overall adverse effect on the global economy. The Company expects COVID-19 to continue to negatively impact its operating results and its ability to obtain financing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 - LIQUIDITY AND GOING CONCERN CONSIDERATIONS, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is currently in the process of raising capital to complete and finalize the build-out of its facility in Deerfield Beach for the purpose of consolidating its operations. The structure of the capital raise is currently in</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">development. The Company is continuing its path to profitability through increased business development, marketing and sales of the Company’s multiple lines of topical, ingestible and skincare health and wellness products. The Company is also focused on completing an efficacy clinical study on its patented mosquito bug patch with plans upon a successful conclusion to launch globally in the very near future, adding to the Company’s suite of wellness products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2022, the Company entered into a license and ownership agreement in an effort to expand its sales and customer base. For the details of equity and license agreement refer to the Note 6-Investment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The independent auditors’ report on our financial statements for the years ended December 31, 2021 and 2020 contain explanatory paragraphs expressing substantial doubt as to our ability to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to successfully continue to grow operational revenues could harm our profitability and adversely affect our financial condition and results of operations. We face all of the risks inherent in a new business, including the need for significant additional capital, management’s potential underestimation of initial and ongoing costs, and potential delays and other problems in connection with establishing sales channels.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are continuing our plan to further grow and expand operations and seek sources of capital to pay our contractual obligations as they come due. Management believes that its current operating strategy will provide the opportunity for us to continue as a going concern as long as we are able to obtain additional financing; however, there is no assurance this will occur. The accompanying consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5800000 2900000 -487000 -48000000 <p id="xdx_80A_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zG1rtItzBv04" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_82F_zWdOUtA3nwZc">PROPERTY AND EQUIPMENT, NET</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zQVpR2euSqi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of property and equipment at December 31, 2021 and 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zYw3swNlr7C4" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20211231_zh01F7ReYV43" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20201231_zdkcmL6EIyBb" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zZsjzITyuQVj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Furniture and equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,959,694</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,959,694</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zbtCbISoaUn5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">840,728</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">840,728</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzUWD_zt752pOptnIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment, at cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,800,422</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,800,422</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzUWD_zBAe93BEvsg9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(535,226</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(485,761</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzUWD_zALi66B4M2Nl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment,net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,265,196</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,314,661</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zi3GAfwCP0A3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation expense for the years ended December 31, 2021 and 2020 totaled $<span id="xdx_908_eus-gaap--Depreciation_pp0p0_c20210101__20211231_zDzaZ6qdQ23h" title="Depreciation expense">49,465</span> and $<span id="xdx_902_eus-gaap--Depreciation_pp0p0_c20200101__20201231_z9YkkS6arAwj" title="Depreciation expense">61,986</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zQVpR2euSqi4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of property and equipment at December 31, 2021 and 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zYw3swNlr7C4" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20211231_zh01F7ReYV43" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20201231_zdkcmL6EIyBb" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zZsjzITyuQVj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Furniture and equipment</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,959,694</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,959,694</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zbtCbISoaUn5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">840,728</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">840,728</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzUWD_zt752pOptnIi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Property and equipment, at cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,800,422</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,800,422</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzUWD_zBAe93BEvsg9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(535,226</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(485,761</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzUWD_zALi66B4M2Nl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment,net</span></td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,265,196</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,314,661</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1959694 1959694 840728 840728 2800422 2800422 535226 485761 2265196 2314661 49465 61986 <p id="xdx_80D_eus-gaap--IntangibleAssetsDisclosureTextBlock_zTE2uELgHtvb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_82C_z4F4CKtZkn5i">INTANGIBLE ASSET</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2019, the Company acquired certain intellectual property consisting of patent rights. The aggregate purchase price paid in connection with the patent purchase was $<span id="xdx_90E_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_c20190228__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zns3YKYzBVke" title="Patent purchase price">714,640</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, consisting of $<span id="xdx_905_eus-gaap--PaymentsToAcquireIntangibleAssets_pp0p0_c20190201__20190228__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zZ4EpMza4jkh">130,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cash, and <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesPurchaseOfAssets_c20190201__20190228__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqj0k9oeV7Wd" title="Stock issued during period, shares, purchase of assets">3,300,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of the Company’s common stock valued at $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_c20190228__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJO0wYqhzoG8" title="Shares issued, price per share">0.177 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share or an aggregate of $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValuePurchaseOfAssets_pp0p0_c20190201__20190228__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znE7S1GCrUib" title="Stock issued during period, value, purchase of assets">584,640</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. <span id="xdx_907_ecustom--IssuanceOfSharesDescription_c20190201__20190228__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zo8AJVXVLmOc" title="Issuance of shares description">Of the 3,300,000 shares, 1,800,000 shares were provided at closing and 1,500,000 were to be provided one year thereafter</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. These shares have not been issued and the Company is in negotiations with the seller to extend the issuance of the shares. As such, the Company recognized a liability for stock to be issued of $<span id="xdx_901_ecustom--LiabilityForStockToBeIssued_iI_pp0p0_c20211231_zHhhtiNaDOBb" title="Liability for stock to be issued"><span id="xdx_90E_ecustom--LiabilityForStockToBeIssued_iI_pp0p0_c20201231_zsqTnWEKaII" title="Liability for stock to be issued">265,500</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at both December 31, 2021 and 2020. The acquired patent is amortized over its remaining estimated useful life of approximately <span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7Fy8YP6o44d">11 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years. Amortization expense is $<span id="xdx_903_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210101__20211231_z7u3T90tLtK8"><span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200101__20201231_zaj0cDH8xCEf">64,968</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for both of the years ended December 31, 2021 and 2020. The estimated annual amortization expense for the next five years and thereafter is as follows:</span></p> <p id="xdx_893_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zLh3up1VUuX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zd1gX68HcW8c" style="display: none">SCHEDULE OF ESTIMATE AMORTIZATION EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20211231_zdxCmSxVO3Ug" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_maFLIANzwtY_maFLIANz2rU_zOccTmOaohva" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">2022</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">65,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANzwtY_maFLIANz2rU_zDkoTajGnAL" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANzwtY_maFLIANz2rU_zjLnz4zTwnQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANzwtY_maFLIANz2rU_zuNsQ7liEvfe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_maFLIANzwtY_maFLIANz2rU_zLfd4IBu4zp6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANzwtY_maFLIANz2rU_zjgbbiZ40hUh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Thereafter</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,150</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANz2rU_zWTAqyOB1Ceb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated amortization expenses</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">525,150</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AD_ztCIphjoDsDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – INTANGIBLE ASSET, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_z3Cb0xHlq6N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the intangible asset at December 31, 2021 and 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zhCSQatMsR0c" style="display: none">SCHEDULE OF INTANGIBLE ASSET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211231_zIPNZcmAxm6h" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20201231_zPkhZwwqdyBj" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_maIANEGzt6b_zf2E8Z5Lpxm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Patent</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">714,640</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">714,640</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msIANEGzt6b_zezaSy6VXgd1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(189,490</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(124,522</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtIANEGzt6b_zQQDMKwEiP43" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">525,150</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">590,118</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AD_zW5ZaxThV2z9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 714640 130000 3300000 0.177 584640 Of the 3,300,000 shares, 1,800,000 shares were provided at closing and 1,500,000 were to be provided one year thereafter 265500 265500 P11Y 64968 64968 <p id="xdx_893_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zLh3up1VUuX3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BB_zd1gX68HcW8c" style="display: none">SCHEDULE OF ESTIMATE AMORTIZATION EXPENSE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 50%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20211231_zdxCmSxVO3Ug" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_maFLIANzwtY_maFLIANz2rU_zOccTmOaohva" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 70%; text-align: left">2022</td><td style="width: 10%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">65,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0_maFLIANzwtY_maFLIANz2rU_zDkoTajGnAL" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_maFLIANzwtY_maFLIANz2rU_zjLnz4zTwnQ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2024</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_maFLIANzwtY_maFLIANz2rU_zuNsQ7liEvfe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2025</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_pp0p0_maFLIANzwtY_maFLIANz2rU_zLfd4IBu4zp6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2026</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_maFLIANzwtY_maFLIANz2rU_zjgbbiZ40hUh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Thereafter</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">200,150</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANz2rU_zWTAqyOB1Ceb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated amortization expenses</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">525,150</td><td style="text-align: left"> </td></tr> </table> 65000 65000 65000 65000 65000 200150 525150 <p id="xdx_895_eus-gaap--ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_z3Cb0xHlq6N8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of the intangible asset at December 31, 2021 and 2020 is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zhCSQatMsR0c" style="display: none">SCHEDULE OF INTANGIBLE ASSET</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20211231_zIPNZcmAxm6h" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_493_20201231_zPkhZwwqdyBj" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40F_eus-gaap--FiniteLivedPatentsGross_iI_pp0p0_maIANEGzt6b_zf2E8Z5Lpxm1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%">Patent</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">714,640</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">714,640</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msIANEGzt6b_zezaSy6VXgd1" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(189,490</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(124,522</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtIANEGzt6b_zQQDMKwEiP43" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">525,150</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">590,118</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> 714640 714640 189490 124522 525150 590118 <p id="xdx_801_eus-gaap--InvestmentTextBlock_zP26rWChpgg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 – <span id="xdx_822_zsv2JPN8fXOk">INVESTMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Distribution Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 2, 2020 in connection with a manufacturing, distribution and sales agreement with a third party distributor (the “Distributor”), the Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pn5n6_c20201101__20201102__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorMember_z6CLvfo64BZ4" title="Stock issued during period, shares">12.5</span> million of its common shares for <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201101__20201102__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorMember__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z3SCvZLwdfQ8" title="Stock issued during period, shares">250</span> shares of non-trading convertible preferred stock of the Distributor. Each convertible preferred share is convertible into <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20201101__20201102__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorMember__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zbdkanAOJmOl" title="Stock issued during period, shares, conversion of convertible securities">1,000</span> shares of the Distributor’s common stock. The Distributor’s common shares are currently traded in the over the counter market. <span id="xdx_909_ecustom--IssuanceOfSharesDescription_c20201101__20201102__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zr7SY3wTWaH3" title="Issuance of shares description">On the first business day following the 180-day anniversary of closing, if the share price of the Distributor is less than $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20201102__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_za6CCaiSSxU5" title="Stock price">4.00</span>, the Distributor will provide the Company its common stock valued at $<span id="xdx_905_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn6n6_c20201101__20201102__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkiJvLaVrV74" title="Stock issued during period, value">1</span> million, less <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201101__20201102__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zn9gijwQwrf" title="Stock issued during period, shares">250,000</span> common shares, for no additional consideration. On the one-year anniversary of closing, if the share price of the Distributor is less than $<span id="xdx_902_eus-gaap--SharePrice_iI_c20201102__us-gaap--AwardTypeAxis__custom--OneYearAnniversaryMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znF7ciKhRUFk" title="Stock price">4.00</span>, the Distributor will provide the Company its common stock valued at $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn6n6_c20201101__20201102__us-gaap--AwardTypeAxis__custom--OneYearAnniversaryMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlB5HsPe1ij7" title="Stock issued during period, value">1</span> million, less <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201101__20201102__us-gaap--AwardTypeAxis__custom--OneYearAnniversaryMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ0DjwE12385" title="Stock issued during period, shares">250,000</span> shares, less the number of shares provided on the 181st day anniversary, for no additional consideration</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">As of December 31, 2021, the Company was entitled to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DistributorMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTrMHQMkDRl4">3,831,169</span> shares of the Distributor’s common stock. No shares have been received as of the date of the filing of this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company determined to initially value the convertible preferred stock investment using the Black-Scholes option pricing model using the following inputs: stock price: $<span id="xdx_90D_eus-gaap--SharePrice_iI_c20201102__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_zEIDKx4dronb" title="Stock price">4.00</span>, exercise price: $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20201102__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember_z9XtlJmDECLl" title="Exercise price">4.00</span>, expected term: <span id="xdx_905_ecustom--ConvertiblePreferredStockMeasurementInputsTerm_dc_c20201101__20201102__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zepfN0PnMblg" title="Measurement inputs expected term">one year</span>, and risk free rate <span id="xdx_902_eus-gaap--AlternativeInvestmentMeasurementInput_iI_pid_uPure_c20201102__us-gaap--StatementClassOfStockAxis__us-gaap--ConvertiblePreferredStockMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zeTbRuPUCWS4" title="Measurement input risk free interest rate">0.17</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company made this investment to realize strategic benefits for its business, rather than to generate income or capital gains. Because the Company owns less than <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20211231_zeBE5VdAEqwh" title="Equity method investment, ownership percentage">20</span>% on an as converted basis of the Distributor, and cannot exercise significant influence over operating and financial policies of the Distributor, the Company accounts for the investment under ASC 321, “Equity Securities” (“ASC 321”). Under ASC 321, for each reporting period, the Company completes a qualitative assessment considering impairment indicators to evaluate whether the investment is impaired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The investment balance as of both December 31, 2021 and 2020 was $<span id="xdx_907_eus-gaap--Investments_iI_pp0p0_c20211231__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zPRnv1FQeb1j" title="Investment"><span id="xdx_900_eus-gaap--Investments_iI_pp0p0_c20201231__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zClrVf4boYIj" title="Investment">383,326</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. There is <span id="xdx_900_eus-gaap--ImpairmentOfInvestments_pp0p0_do_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zicZyyz8OVrd"><span id="xdx_900_eus-gaap--ImpairmentOfInvestments_pp0p0_do_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--DistributionAgreementMember_zqf6PpdNnOt1">no</span> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment recorded for the years ended December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Deposit on Equity and</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"> License Agreement</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2021, the Company negotiated terms of a non-exclusive sub-license agreement with a third party (the “Party”) whereby the Party will grant the Company a limited, non-exclusive authority to purchase, distribute, market, make, and sell products in which the Party has authorized the Company to produce on a case-by-case basis, for a period of three years from the effective date of the definitive agreement. In exchange for the license, the Company agreed to pay $<span id="xdx_900_eus-gaap--RoyaltyExpense_c20211101__20211130__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zuPo1Bx31oOh" title="License royalty fee">450,000</span> along with a monthly license royalty fee of <span id="xdx_90E_ecustom--PercentageOfLicenseRoyaltyFee_pid_dp_uPure_c20211101__20211130__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zQsPmPyLw456" title="Percentage of license royalty fee">20</span>% of the final sales price of licensed items to the end buyer.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The terms also allow the Company to purchase an equivalent ownership interest of the Party for an initial funding of $<span id="xdx_901_ecustom--LicenseFee_c20211101__20211130__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zZl9AB2Rmo1a" title="License fees">225,000</span>, with the option to increase its investment up to $<span id="xdx_90F_eus-gaap--Investments_iI_pp0p0_c20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--RangeAxis__srt--MaximumMember_zz109OANJdng" title="Investment">6,000,000</span>. The Company provided an initial funding fee of $<span id="xdx_905_ecustom--LicenseFee_c20211101__20211130__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zpL6tle4Tfi7" title="License fees">225,000</span> in exchange for the permission to purchase an equivalent ownership interest of the Party, which should equal to the appropriate preferred purchase price, based upon the stated current valuation. The total payment of $<span id="xdx_90D_eus-gaap--Investments_iI_pp0p0_c20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zjyKXqk33Qsi" title="Investment">675,000</span> as of December 31, 2021 is classified as a Deposit on Equity and License Agreement on the consolidated balance sheet.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2022, the Company entered into a definitive agreement with the Party. The definitive agreement defined an initial term of three years from December 30, 2021, with options to renew. The Company made additional payments to the Party in January in the amount of $<span id="xdx_906_ecustom--LicenseFee_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zxTiz8rhQdVb" title="License fees">725,000</span> toward the license fee and to purchase an equivalent ownership interest. The total funding to the Party of $<span id="xdx_900_eus-gaap--PaymentsForParticipationLiabilities_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember_zPjy9lUWVzT2" title="Payments for participation liabilities">1,400,000</span> was allocated $<span id="xdx_900_eus-gaap--PaymentsForParticipationLiabilities_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zIG1L3wL1IK9" title="Payments for participation liabilities">500,000</span> for the license, and equity participation of $<span id="xdx_90C_eus-gaap--PaymentsForParticipationLiabilities_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__us-gaap--TradingActivityByTypeAxis__us-gaap--EquityMember_zqb2dO3CIgZ6" title="Payments for participation liabilities">900,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 12500000 250 1000 On the first business day following the 180-day anniversary of closing, if the share price of the Distributor is less than $4.00, the Distributor will provide the Company its common stock valued at $1 million, less 250,000 common shares, for no additional consideration. On the one-year anniversary of closing, if the share price of the Distributor is less than $4.00, the Distributor will provide the Company its common stock valued at $1 million, less 250,000 shares, less the number of shares provided on the 181st day anniversary, for no additional consideration 4.00 1000000 250000 4.00 1000000 250000 3831169 4.00 4.00 P1Y 0.17 0.20 383326 383326 0 450000 0.20 225000 6000000 225000 675000 725000 1400000 500000 900000 <p id="xdx_80F_eus-gaap--AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_z56thBlu0d8b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_828_zxVwPHQPpoQe">ACCRUED EXPENSES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zEzgjANRsnR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of accrued expenses is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_z8l2qTkxzKN8" style="display: none">SCHEDULE OF ACCRUED EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_491_20211231_zsUMwNPUn3S3" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td> </td><td> </td> <td colspan="2" id="xdx_496_20201231_znpuWcv5URb8" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td> </td></tr> <tr id="xdx_40C_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCzTRC_zQZsAaoDhHc4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Officer – Bonus</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">540,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--OtherAccruedExpensesCurrent_iI_pp0p0_maALCzTRC_zDhFrZh6PFbd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Expenses - Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,912</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,456</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccruedInterestRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_maALCzTRC_zKdBvG5npQYb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued Interest – Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">148,552</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91,048</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_maALCzTRC_z0phRa1VrfRl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">230,203</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103,811</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzTRC_zuoWED7Q01T4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Current Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,724</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,849</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedRentCurrent_iI_pp0p0_maALCzTRC_zzVi1LE3Hsnh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Rent</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0849"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">123,331</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzTRC_zEI4lBJuNUY8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,043,891</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">786,495</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8AA_z8ribkbE9Xz4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89B_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zEzgjANRsnR" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A summary of accrued expenses is as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_z8l2qTkxzKN8" style="display: none">SCHEDULE OF ACCRUED EXPENSES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_491_20211231_zsUMwNPUn3S3" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2021</td><td> </td><td> </td> <td colspan="2" id="xdx_496_20201231_znpuWcv5URb8" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td> </td></tr> <tr id="xdx_40C_eus-gaap--AccruedBonusesCurrent_iI_pp0p0_maALCzTRC_zQZsAaoDhHc4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Officer – Bonus</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">540,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">400,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--OtherAccruedExpensesCurrent_iI_pp0p0_maALCzTRC_zDhFrZh6PFbd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Expenses - Other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,912</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,456</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--AccruedInterestRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_maALCzTRC_zKdBvG5npQYb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued Interest – Related Parties</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">148,552</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91,048</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--InterestPayableCurrentAndNoncurrent_iI_pp0p0_maALCzTRC_z0phRa1VrfRl" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">230,203</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">103,811</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCzTRC_zuoWED7Q01T4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other Current Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,724</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,849</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccruedRentCurrent_iI_pp0p0_maALCzTRC_zzVi1LE3Hsnh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Rent</td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0849"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">123,331</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCzTRC_zEI4lBJuNUY8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued expenses</span></td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,043,891</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">786,495</td><td style="text-align: left"> </td></tr> </table> 540500 400000 30912 15456 148552 91048 230203 103811 93724 52849 123331 1043891 786495 <p id="xdx_803_eus-gaap--DebtDisclosureTextBlock_zS6KGe2w1bAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_826_zXMBFMeTKOS8">NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Notes Payable</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the quarter ended March 31, 2020, the Company received proceeds aggregating $<span id="xdx_90B_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20200101__20200331__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zFlVsH6F4Tgd" title="Proceeds from notes payable">345,000</span> in connection with multiple short-term promissory notes with <span id="xdx_903_eus-gaap--DebtInstrumentMaturityDateDescription_c20200101__20200331__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zi3axN52vPhb" title="Debt instrument, maturity date, description">due dates ranging from February to June 2020</span>. The notes had interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200331__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember__srt--RangeAxis__srt--MinimumMember_zAuRWJ0fUuA5" title="Debt instrument interest rate">0</span>% to <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200331__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember__srt--RangeAxis__srt--MaximumMember_zV3VKBPNwrRl" title="Debt instrument interest rate">12</span>% for the terms of the notes. Each noteholder had the right to convert all the outstanding principal and accrued unpaid interest to the Company’s common stock at a price ranging from $<span id="xdx_90D_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20200331__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember__srt--RangeAxis__srt--MinimumMember_zsGurT7PDXFd" title="Debt conversion price per share">.085</span> to $<span id="xdx_90E_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20200331__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember__srt--RangeAxis__srt--MaximumMember_zTe3a8kJEqP5" title="Debt conversion price per share">.10</span> per share, prior to the maturity date. Additionally, an aggregate of <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20200331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholdersMember_pdd" title="Stock issued during period, shares">3,250,000</span> shares were issued to the noteholders as additional consideration. The notes also included a beneficial conversion feature (BCF). These notes are currently in default.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the quarter ended September 30, 2020, the Company received proceeds aggregating $<span id="xdx_90C_eus-gaap--ProceedsFromNotesPayable_c20200701__20200930__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zPzUsBjf91jc" title="Proceeds from notes payable">230,000</span> in connection with multiple short-term promissory notes each with <span id="xdx_908_eus-gaap--DebtInstrumentMaturityDateDescription_c20200701__20200930__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zmUsFQFJhjlk" title="Debt instrument, maturity date, description">a term of one year, maturing in August or September 2021</span>. The notes bear interest at <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20200930__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zoC1wv36a9Re" title="Debt instrument interest rate">18</span>%. Four of the five notes were issued under a subscription agreement whereby in addition to the promissory note, the note holder is offered up to four shares of common stock for each one dollar of principal amount of the note at a price of $<span id="xdx_900_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20200930__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_ztCVU2zz5xlj" title="Debt instrument conversion price per share">0.0001</span> per share. Under the subscription agreement, a total of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200701__20200930__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zcrsRdg7awPd" title="Stock issued during period, shares">780,000</span> shares were issued.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the quarter ended December 31, 2020, the Company received proceeds aggregating $<span id="xdx_903_eus-gaap--ProceedsFromNotesPayable_c20200901__20201231__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zEMT3KZ8mbdb" title="Proceeds from notes payable">330,040</span> in connection with multiple short-term promissory notes each with <span id="xdx_905_eus-gaap--DebtInstrumentMaturityDateDescription_c20200901__20201231__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zjkvW9ds60i7" title="Debt instrument, maturity date, description">a term of one year, maturing in October through December 2021</span>. The notes bear interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember__srt--RangeAxis__srt--MinimumMember_zQtrhY395EZ3" title="Debt instrument interest rate">10</span>% to <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember__srt--RangeAxis__srt--MaximumMember_zVlmfJIJv5u8" title="Debt instrument interest rate">18</span>%. Each note was issued under a subscription agreement whereby in addition to the promissory note, the note holder is offered up to four shares of common stock for each one dollar of principal amount of the note at a price of $<span id="xdx_902_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_z4IwxpyzQfh1" title="Debt instrument interest rate">0.0001</span> per share. Under the subscription agreement, a total of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MultipleShortTermPromissoryNotePayableMember_zswgCu80832k" title="Stock issued during period, shares">520,000</span> shares were issued. Additionally, an aggregate of<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zb23I1XJ3dP9" title="Number of warrrants issued"> 6,800,000</span> warrants were issued to five of the noteholders as additional consideration. The warrants are exercisable at $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zJCu1PpiGXB" title="Warrents exercise price">0.08</span> per share and expire <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20201231__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_znFyitmX75qa" title="Warrant expiration term">three years</span> from the date of each respective note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company allocated $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyConvertiblesNotesMember_zh9aR8cd6rmk" title="Proceeds from issuance of stock">314,100</span> of the gross proceeds of the 2020 convertible notes to the stock issuances and $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20200101__20201231__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementMember_zbnzzyQiAc7h" title="Proceeds from issuance of stock">75,200</span> of the gross proceeds of the subscription agreement notes to the stock issuances on a relative fair value basis, which has been recorded as a debt discount.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company allocated $<span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20200101__20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentySubscriptionAgreementNotesMember_zZepv1AKwp37">143,900</span> of the gross proceeds of the 2020 subscription agreement notes to the warrants on a relative fair basis. The warrants’ relative fair value was calculated using the Black-Scholes Merton valuation model with the following inputs: an expected and contractual life of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentySubscriptionAgreementNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zfSPgiFLcog6" title="Warrant expected term">36</span> months, as assumed volatility of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentySubscriptionAgreementNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zaTjxWnQGCq2" title="Warrant measurement input">189.9</span>%, zero dividend rate, and a risk free rate of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentySubscriptionAgreementNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zVxHzBRMDjse" title="Warrant measurement input">0.17</span>% - <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20201231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentySubscriptionAgreementNotesMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zA6GZirNACXk" title="Warrant measurement input">0.22</span>%. The warrants are classified in equity as additional paid-in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because the effective conversion prices of the convertible notes were less than the fair value of the underlying common stock on the issuance date, the Company allocated $<span id="xdx_906_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_c20200101__20201231_zTqe1VNPyOT5" title="Beneficial conversion">51,900</span>, the intrinsic value of that beneficial conversion feature, to additional paid-in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company entered into a Note Exchange Agreement whereby a note holder of the Company agreed to exchange their current note that was in default, for a new promissory note and a warrant to acquire <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqVuKL7VYOmk" title="Warrant issued">1,200,000</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – NOTES PAYABLE, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. The warrant is exercisable at $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210131__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zA7IGaoRAQf3" title="Warrants exercise price">0.08</span> per share and expires <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLQdLyhojQy4" title="Warrant expiration term">three years</span> from the date of the new promissory note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company received proceeds aggregating $<span id="xdx_90E_eus-gaap--ProceedsFromNotesPayable_c20210101__20211231__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zMXsRTHTdxdj">725,050</span> in connection with multiple short-term promissory notes with due dates ranging from January to December 2022. The notes have original issue discounts totaling $<span id="xdx_90D_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zfbx2zKJh2W9" title="Original issue discounts">61,950</span> and bear interest at <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember__srt--RangeAxis__srt--MinimumMember_zmuJNVbMyQh7" title="Debt instrument interest rate">8</span>% to <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember__srt--RangeAxis__srt--MaximumMember_z9DuYnnUr6ek" title="Debt instrument interest rate">12</span>% for the terms of the notes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An aggregate of <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholdersMember_zHUGFb26CmRf" title="Number of warrants issued">12,787,500</span> warrants were issued to the noteholders as additional consideration. The warrants are exercisable at $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholdersMember_zDAfuBZFUivi" title="Warrants exercise price">0.08</span> per share and expire <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholdersMember_zWbF9SFQC4P3">three years</span> from the date of each respective note.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants to purchase common stock issued to the noteholders were treated as debt discounts. The gross proceeds of the notes were allocated to debt and warrants issued on a relative far value basis.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company allocated $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20210101__20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholdersMember_zsiL8tEFizec">370,267 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the gross proceeds to the warrants on a relative fair basis. The warrants’ relative fair value was calculated using the Black-Scholes Merton valuation model with the following inputs: an expected and contractual life of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholdersMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zy0W86vQh3m4">two years</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, an assumed volatility ranging from <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholdersMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_z6HbhSnWZEgc">191.0</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%-<span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholdersMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zv16UDHOiTFf">245.56</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%, zero dividend rate, and risk free rate ranging from <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholdersMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zQ9AsT6a38b7">0.18</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%-<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20201231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--NoteholdersMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zSABRkwVctQ7">0.73</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The debt discounts associated with the BCF, warrants, and common stock issuances are amortized through the earlier of the conversion of the notes into common stock, or the maturity date of the notes, on a straight-line basis which approximates the effective interest method due to the short-term nature of the notes. Amortization of the debt discount is reported as finance costs in the Statement of Operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company entered into debt settlement agreements with three of its noteholders whereby the Company issued <span id="xdx_904_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--DebtSettlementAgreementsMember_zktEdKQf6mR8">4,630,645 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock as well as warrants to acquire <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_c20211231__us-gaap--TypeOfArrangementAxis__custom--DebtSettlementAgreementsMember_zHxGdHpysUD5">10,622,583 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. The warrants are exercisable at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--TypeOfArrangementAxis__custom--DebtSettlementAgreementsMember_zE42hSSVIP5h">0.08 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share and expire <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20211231__us-gaap--TypeOfArrangementAxis__custom--DebtSettlementAgreementsMember_zdW27LO24Y4c">two years</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">from the date of issuance, and were recorded as finance cost.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amount converted was an aggregate of $<span id="xdx_90B_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--DebtSettlementAgreementsMember__us-gaap--FinancialInstrumentAxis__custom--PrincipalAmountMember_zFgwNTqKcQB5" title="Debt conversion, amount">325,010</span> of principal and $<span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--DebtSettlementAgreementsMember__us-gaap--FinancialInstrumentAxis__custom--AccruedInterestMember_zZM8c3gdnK05">45,441</span> of accrued interest.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants’ relative fair value of $<span id="xdx_904_eus-gaap--FairValueAdjustmentOfWarrants_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYxfl5asxHR8" title="Fair Value of Warrants">1,155,590</span> was calculated using the Black-Scholes Merton valuation model with the following inputs: an expected and contractual life of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtM_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWCv4KdLeGE2" title="Warrant expected term">24</span> months, as assumed volatility of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MinimumMember_zSNa5QlVBwf2" title="Warrant measurement inputs">226.19</span>%-<span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember__srt--RangeAxis__srt--MaximumMember_zJ38YgTe4bKf">249.44</span>%, zero dividend rate, and a risk free rate of <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zEb6eb21ieF4">0.17</span>% - <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dp_uPure_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zfdacf01Pdzk">0.28</span>%. The warrants are classified in equity as additional paid-in capital.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Debt Discounts</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total amortization associated with all debt discounts was $<span id="xdx_902_eus-gaap--AmortizationOfDebtDiscountPremium_c20210101__20211231_zWY30qResvqh">438,235 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90A_eus-gaap--AmortizationOfDebtDiscountPremium_c20200101__20201231_zliI6FKKrh2b">671,319 </span>for the years ended December 31, 2021 and 2020, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Convertible Note Payable to Shareholder</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2019, the Company entered into an Investment Agreement that included a secured convertible <span id="xdx_904_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20190630__us-gaap--ShortTermDebtTypeAxis__custom--SecuredConvertibleFivePointSevenFivePercentagePromissoryNotePayableMember__us-gaap--TypeOfArrangementAxis__custom--InvestmentAgreementMember_ziuHE7ynqva1" title="Debt instrument interest rate">5.75</span>% promissory note payable for $<span id="xdx_903_eus-gaap--NotesPayableRelatedPartiesClassifiedCurrent_iI_pp0p0_c20190630__us-gaap--ShortTermDebtTypeAxis__custom--SecuredConvertibleFivePointSevenFivePercentagePromissoryNotePayableMember__us-gaap--TypeOfArrangementAxis__custom--InvestmentAgreementMember_zNkE5G145qWg" title="Notes payable to shareholders">1,000,000</span> with a shareholder. The note is subject to a security agreement whereby the</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – NOTES PAYABLE, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">first four Ennea Processors the Company has committed to commercialize and monetize will be secured as collateral for the note as well as current and future assets of the Company and its subsidiaries. The payment terms of the note were interest only payments from July 7, 2019 through December 7, 2019 and commencing January 7, 2020, the Company was to make equal monthly installment payments that include principal and interest through the Maturity Date of December 7, 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentDescription_c20190628__20190630__us-gaap--ShortTermDebtTypeAxis__custom--SecuredConvertibleFivePointSevenFivePercentagePromissoryNotePayableMember__us-gaap--TypeOfArrangementAxis__custom--InvestmentAgreementMember_zQSpXYiLUjPl" title="Debt description">Included in the Investment Agreement is a royalty agreement whereby the investor received 500,000 shares of the Company’s common stock and will be entitled to a royalty of 8.5% from the revenue generated from the “collateral processors” while the principal is outstanding and 5% thereafter on the first two collateral processors for a period of 10 years</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In addition to the collateral, the note is secured by a Pledge Agreement from a related-party that included a mortgage lien on certain real property as additional collateral.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The collateral processors are not yet in service. Therefore, revenue generated from them and the related royalties due cannot be estimated at this time and will be expensed as incurred in the future.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is currently in default of this note, however, the parties are in negotiation to reach settlement terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Note Payable, SBA</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 23, 2020, the Company received an aggregate of $<span id="xdx_90D_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20200422__20200423__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember_zLFwVxi1IyW4">254,700 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">related to its filing under the Paycheck Protection Program (“PPP”) and Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) from Trust Bank, N.A. (the “Lender”). The Company elected to treat the loan debt under ASB ASC 470. As such, the Company would derecognize the liability when the loan was forgiven and the Company was legally released from the loan. The PPP loan of $<span id="xdx_90F_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20210311__20210312__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember_zOnZCRz5Qskc">244,700 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was forgiven on March 12, 2021 and recognized as other income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On February 26, 2021, the Company received an aggregate of $<span id="xdx_90A_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20210225__20210226__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember_zCw0hiEo79Zd" title="Proceeds from notes payable">243,275</span> related to its filing under the PPP and CARES Act from the Lender. The PPP loan of $<span id="xdx_904_eus-gaap--DebtInstrumentDecreaseForgiveness_pp0p0_c20211125__20211126__us-gaap--LongtermDebtTypeAxis__custom--PaycheckProtectionProgramMember_z4H3BViD5r2" title="Debt forgiveness">243,275</span> was forgiven on November 26, 2021 and recognized as other income.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 345000 due dates ranging from February to June 2020 0 0.12 0.085 0.10 3250000 230000 a term of one year, maturing in August or September 2021 0.18 0.0001 780000 330040 a term of one year, maturing in October through December 2021 0.10 0.18 0.0001 520000 6800000 0.08 P3Y 314100 75200 143900 P36M 1.899 0.0017 0.0022 51900 1200000 0.08 P3Y 725050 61950 0.08 0.12 12787500 0.08 P3Y 370267 P2Y 1.910 2.4556 0.0018 0.0073 4630645 10622583 0.08 P2Y 325010 45441 1155590 P24M 2.2619 2.4944 0.0017 0.0028 438235 671319 0.0575 1000000 Included in the Investment Agreement is a royalty agreement whereby the investor received 500,000 shares of the Company’s common stock and will be entitled to a royalty of 8.5% from the revenue generated from the “collateral processors” while the principal is outstanding and 5% thereafter on the first two collateral processors for a period of 10 years 254700 244700 243275 243275 <p id="xdx_807_ecustom--RevenueShareAgreementsTextBlock_zF4Dwd5JdV1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_821_zHaJ2S6ChtW3">REVENUE SHARE AGREEMENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company entered into two revenue share agreements with third party investors (“Investors”) and received an aggregate of $<span id="xdx_90B_ecustom--RevenueReceived_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoRevenueShareAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorsMember_zU4u12qU7Vhh">725,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the agreements, the proceeds were primarily used to fund the third party license agreement as described in Note 6. The proceeds are non-refundable. <span id="xdx_900_ecustom--RevenueShareAgreementsDescription_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--TwoRevenueShareAgreementMember__srt--TitleOfIndividualAxis__custom--ThirdPartyInvestorsMember_zVEZr3yKHetk">In exchange, the Investors are entitled to a percentage of revenue collected by the Company as a result of its investments, ranging from 1.3% to 60% until the Investors’ proceeds are repaid, and 0.83% to 49% thereafter, for a minimum of 60 months.</span> The proceeds of $<span id="xdx_906_ecustom--RevenueShareAgreementsPayable_iI_c20211231_z8i8fdhywq8j" title="Revenue share agreements payable">725,000</span> was recorded as a liability in the accompanying consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 725000 In exchange, the Investors are entitled to a percentage of revenue collected by the Company as a result of its investments, ranging from 1.3% to 60% until the Investors’ proceeds are repaid, and 0.83% to 49% thereafter, for a minimum of 60 months. 725000 <p id="xdx_80C_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zcpLf4ODoyMc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 - <span id="xdx_821_zlXL6JnRwl5f">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the quarter ended March 31, 2020, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200101__20200331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zlyzjJrQaTR4" title="Common stock, shares">470,229</span> shares of common stock for services aggregating $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20200101__20200331__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember_zOtUmay1Eifi" title="Common stock, value">47,023</span>, valued using the trading price on the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company issued <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHeF9ZzOGhI6" title="Common stock, shares">1,923,076</span> shares of common stock for $<span id="xdx_90C_eus-gaap--SaleOfStockPricePerShare_iI_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztRkWnfcPiLj" title="Common stock, price per share">.065</span> per share for an aggregate of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20200101__20201231_z67pedstHK56" title="Common stock, value">125,000</span>, during 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2020 the Company recorded $<span id="xdx_908_eus-gaap--AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature_c20200101__20201231_zUaDiIMByGi6" title="Additional paid in capital, beneficial conversion feature">51,900</span> to additional paid-in capital resulting from the beneficial conversion feature.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2020, the Company issued <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20200731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR618urZU2ub" title="Warrants issued during period for cash">740,740</span> warrants in exchange for cash proceeds of $<span id="xdx_90B_eus-gaap--ProceedsFromWarrantExercises_c20200701__20200731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDhhCY3aUge6" title="Cash proceeds, exercise price">5,000</span>. The warrants have an exercise price of $<span id="xdx_907_eus-gaap--SaleOfStockPricePerShare_iI_c20200731__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zP8qtFCmw8nl" title="Exercise, price per share">0.10</span> and expire two years after issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In November 2020, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201101__20201130__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--LordGlobalCorporationMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_zYYR22sYlOm7">12,500,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock in exchange for <span id="xdx_909_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20201130__us-gaap--TypeOfArrangementAxis__custom--StockPurchaseAgreementMember__dei--LegalEntityAxis__custom--LordGlobalCorporationMember__us-gaap--StatementClassOfStockAxis__custom--SeriesXPreferredStockMember_ziGCq8tYcaF2">250 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of nontradable Convertible Preferred Stock of the Distributor in connection with a distribution agreement. See Note 6.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 - STOCKHOLDERS’ EQUITY, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company issued <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210131__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerPresidentAndDirectorMember_zdCQ6aHV9jlc" title="Number of warrants issued">15,000,000</span> warrants to its Chief Executive Officer, President and sole Director as compensation. The warrants are exercisable at $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210131__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerPresidentAndDirectorMember_zDZqhHs0E9Zh" title="Warrants exercise price">0.1025</span> per share and expire <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210131__srt--TitleOfIndividualAxis__custom--ChiefExecutiveOfficerPresidentAndDirectorMember_zZXMTEncMI6i">three years</span> from issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2021, the Company issued <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210131__srt--TitleOfIndividualAxis__srt--VicePresidentMember_zwDkOhZa0iN9" title="Number of warrants issued">7,500,000</span> warrants to its Vice President, Neil Catania, as compensation. The warrants are exercisable at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210131__srt--TitleOfIndividualAxis__srt--VicePresidentMember_zayac98AA3Kk" title="Warrants exercise price">0.1025</span> per share and expire <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210131__srt--TitleOfIndividualAxis__srt--VicePresidentMember_zSTTj0R7I3Si">three years</span> from issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April 2021, the Company issued <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210430__srt--TitleOfIndividualAxis__custom--ProductionManagerMember_zHK6evzKlRr5" title="Number of warrants issued">2,000,000</span> warrants to its Production Manager as compensation. The warrants are exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210430__srt--TitleOfIndividualAxis__custom--ProductionManagerMember_zsPo109Y9QE6" title="Warrants exercise price">0.125</span> per share and expire <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210430__srt--TitleOfIndividualAxis__custom--ProductionManagerMember_zkb53ByGUxj6" title="Warrant expiration term">three years</span> from issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The warrants issued as compensation were valued at $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210401__20210430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zi07icCwD9A7" title="Warrants issued as compensation">2,229,990</span>, calculated using the Black-Scholes Merton valuation model with the following in puts: an expected and contractual life of three years, an assumed volatility ranging from <span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210430__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ze9ZXmEC4w2g" title="Warrants and rights outstanding, measurement input">191.0</span>% to <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210430__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDhQFDIiNCc2" title="Warrants and rights outstanding, measurement input">224.75</span>%, <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_dc_uPure_c20210430__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRZV0xE4Zxi2" title="Warrants and rights outstanding, measurement input">zero</span> dividend rate, and a risk free rate ranging from <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210430__srt--RangeAxis__srt--MinimumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zEDkO4hFWTX8" title="Warrants and rights outstanding, measurement input">0.22</span>% to <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20210430__srt--RangeAxis__srt--MaximumMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLwNgp9OpuOc" title="Warrants and rights outstanding, measurement input">0.36</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April through September 2021, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqKkfrLXACGd" title="Common stock, shares">4,350,000</span> shares of common stock and <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQSJGkrMInhg" title="Number of warrants issued">17,400,000</span> warrants in exchange for cash totaling $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstanding_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0">348,000</span>. The warrants have an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zL6j1kHgOgq9" title="Warrants exercise price">0.08</span> per share and expire <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvEgRubv7aHc" title="Warrants term">two years</span> after issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2021, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210701__20210731_zkVPkbyDJIl4" title="Consulting services, shares">1,000,000</span> shares of common stock with an aggregate value of $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20210701__20210731_zJXtBpCFNb9j" title="Consulting services, value">120,000</span> for consulting services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, The Company issued <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20211201__20211231_z6XDbudWGgKe" title="Consulting services, shares">550,000</span> shares of common stock with an aggregate value of $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_pp0p0_c20211201__20211231_ze7FSdWmYaL7" title="Consulting services, value">55,000</span> for consulting services.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Preferred Stock</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s board of directors is authorized to issue, at any time, without further stockholder approval, up to <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20210930__us-gaap--StatementClassOfStockAxis__us-gaap--PreferredStockMember__srt--RangeAxis__srt--MaximumMember_zddsRzm8R9Kg" title="Preferred stock, shares authorized">10,000</span> shares of preferred stock. The board of directors has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series A Preferred Stock (“Series A Preferred”)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 30, 2012, the board of directors of the Company created Series A Preferred. The Series A Preferred has the following rights and preferences:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares are not entitled to dividends or liquidation preferences.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--PreferredStockVotingRights_c20121129__20121130__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zYoqI3ubSh9b" title="Preferred stock voting rights">Each share has voting rights equal to 500,000 shares of the Company’s common stock</span>.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">So long as Series A Preferred shares are outstanding, the Company cannot take certain actions (as defined in the certificate of designation) without the consent of the holders of 100% of the Series A Preferred shares.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 30, 2012, Edgar Ward, the Company’s President, CEO, and director, was granted <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20121129__20121130__srt--TitleOfIndividualAxis__custom--EdgarWardMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z5UO8tNxPfxc" title="Stock issued during the period, shares">1,000</span> shares of Series A Preferred for $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20121129__20121130__srt--TitleOfIndividualAxis__custom--EdgarWardMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z48e43wGm569" title="Stock issued during period, value">1,000</span>. At the option of Mr. Ward, the Series A Preferred shares are redeemable for $<span id="xdx_903_eus-gaap--PreferredStockRedemptionAmount_iI_pp0p0_c20121130__srt--TitleOfIndividualAxis__custom--EdgarWardMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z86PTQ6sjP78" title="Preferred stock, redemption amount">1,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, <span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zvRV2BsQJTG9" title="Preferred stock, shares outstanding"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zW1BUO6ZYWte" title="Preferred stock, shares outstanding">1,000</span></span> shares of Series A Preferred are outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Series B Convertible Preferred Stock (“Series B Preferred”)</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 30, 2020, the Company designated <span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_iI_c20200930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zni2NZhghh8b" title="Preferred stock, shares authorized">110</span> shares of Preferred Stock as Series B Convertible Preferred Stock. A Series B Holder has the right from time to time, and at any time following January 1, 2021, to convert each outstanding share of Series B stock into shares of common stock at a rate of <span id="xdx_900_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20200930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zNNehLsooO5k" title="Convertible preferred stock shares issued">149,567</span> shares of common stock for each share of Series B Preferred. Each share of Series B Preferred shall have a number of votes equal to the number of conversion shares which would be issuable as of the date of such vote. The Series B Preferred does not have any liquidation preferences. The Series B Preferred will participate in any dividends, distributions or payments to the holders of the common stock on an as-converted basis. The Series B Preferred is subject to an ownership limitation, </span><span style="font-family: Times New Roman, Times, Serif">pursuant to which no holder of Series B Preferred will be entitled to convert such investor’s shares of Series B Preferred Stock into shares of common stock if such conversion would result in ownership of more than <span id="xdx_90A_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_uPure_c20200930__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zxwosoVM6mPb" title="Equity ownership percentage">4.99</span>% of the outstanding shares of common stock of the Company. Once issued, certain shares of the Series B Preferred are redeemable at the election of the Company at any time prior to the Permitted Conversion Date pursuant to separate written agreements that will be effectuated between holders of the Series B Preferred and the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 - STOCKHOLDERS’ EQUITY, CONTINUED</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b/></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company issued <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20210329__20210331__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z5G7QwQyze7b" title="Stock issued during the period for stock based compensation, shares">10</span> shares of Series B Preferred to three consultants as part of their compensation agreements. The consultant compensation was valued at $<span id="xdx_909_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_pp0p0_c20210329__20210331__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z9Td6JknTJO6" title="Stock issued during the period for stock based compensation, value">164,524</span> using the trading price of the equivalent common stock on the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the quarter ended September 30, 2021, <span id="xdx_902_eus-gaap--ConversionOfStockSharesIssued1_dc_c20210701__20210930__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zvCbR6n0drE" title="Conversion of stock">three</span> shares of Series B Preferred were converted to <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20210701__20210930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zStUhWrWGQik" title="Shares converted">448,701</span> shares of common stock.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021 and 2020, <span id="xdx_908_eus-gaap--PreferredStockSharesOutstanding_iI_c20211231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z1f7I5DBliph" title="Preferred stock, shares outstanding">27</span> and <span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_iI_c20201231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_z2A7CtPxYFbh" title="Preferred stock, shares outstanding">20</span> shares, respectively, of Series B Preferred are outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 470229 47023 1923076 0.065 125000 51900 740740 5000 0.10 12500000 250 15000000 0.1025 P3Y 7500000 0.1025 P3Y 2000000 0.125 P3Y 2229990 191.0 224.75 0 0.22 0.36 4350000 17400000 348000 0.08 P2Y 1000000 120000 550000 55000 10000 Each share has voting rights equal to 500,000 shares of the Company’s common stock 1000 1000 1000 1000 1000 110 149567 0.0499 10 164524 3 448701 27 20 <p id="xdx_80B_ecustom--LesseeOperatingLeasesAndFinancingLeasesTextBlock_zxr8luxt0S34" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11 – <span id="xdx_820_zCCV5UyTvrR5">LEASES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In conjunction with the new guidance for leases, as defined by the FASB with ASU 2016-02, <i>Leases</i> (Topic 842), the Company has designated the existing leases as operating as further described below:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company leases their office and warehouse facilities located in in Coconut Creek, Florida under a non-cancelable operating lease agreement. In January 2022, the lease term has been renewed for a three year to <span id="xdx_907_ecustom--LesseeOperatingLeaseExpirrationDescription_c20220101__20220131__srt--StatementGeographicalAxis__custom--CoconutCreekFloridaMember_z0Jt2XpLDmYj" title="Operating lease expiration description">expire in January, 2025</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2017, <span id="xdx_904_eus-gaap--DescriptionOfLesseeLeasingArrangementsOperatingLeases_c20170601__20170630__srt--StatementGeographicalAxis__custom--DeerfieldBeachFloridaMember_zdvnfixFUd5l" title="Description of operating lease">the Company entered into a lease for an additional facility located in Deerfield Beach, Florida under a non-cancelable operating lease. The term of the lease is for <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20170630__srt--StatementGeographicalAxis__custom--DeerfieldBeachFloridaMember_zaeaMVW6dLY8">86</span> months</span> beginning on January 1, 2018 and calls for yearly <span id="xdx_908_ecustom--AnnualIncreasesToBaseRentPercent_iI_dp_uPure_c20170630__srt--StatementGeographicalAxis__custom--DeerfieldBeachFloridaMember_zqVYQfHaIulc" style="font: 10pt Times New Roman, Times, Serif" title="Annual increases to base rent percent">3</span>% increases to base rent, with monthly payments that commenced in March 2018</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DescriptionOfLesseeLeasingArrangementsOperatingLeases_c20190701__20190930__srt--ConsolidatedEntitiesAxis__custom--PhytochemMember_zAMUOudMoWsg" title="Description of operating lease">In July and September of 2019, the Company’s wholly owned subsidiary, Phytochem, entered into two separate lease agreements for office and warehouse space located in Onalaska, Wisconsin, that commenced on August 1 and October 1, respectively. Each lease is for six-month terms with four (4) renewal options to extend for six additional months. The Company expects to occupy one of the spaces for the full term of the lease totaling <span id="xdx_90E_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtM_c20190930__srt--ConsolidatedEntitiesAxis__custom--PhytochemMember_zBbRkQK4vT6a" title="Lessee, operating lease, term of contract">30</span> months. <span id="xdx_90B_ecustom--LesseeOperatingLeaseExpirrationDescription_c20190701__20190930__srt--StatementGeographicalAxis__custom--CoconutCreekFloridaMember_zcBEhPgHVu1d" title="Operating lease expiration description">The Company terminated its lease on the other facility in May 2020, without penalty</span>. The remaining lease calls for an annual <span id="xdx_905_ecustom--AnnualIncreasesToBaseRentPercent_iI_pid_dp_uPure_c20190930__srt--ConsolidatedEntitiesAxis__custom--PhytochemMember_z2kQmYZcKVp5" title="Annual increases to base rent percent">3</span>% increase to base rent. In addition to rent, the Company pays certain insurance, maintenance, and other costs related to the rented spaces</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">In June 2021, the Company entered into a verbal, month-to-month sub-lease agreement for the Wisconsin location. Rental income totalled $<span id="xdx_908_eus-gaap--ProceedsFromRentsReceived_c20210101__20211231__us-gaap--TypeOfArrangementAxis__custom--SubLeaseAgreementMember_zDtSxoNCYD0a" title="Proceeds from rent">80,000</span> for the year ended December 31, 2021, and in included in general and administrative expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2021, in the consolidated balance sheet, the Company has recorded right-of-use assets of $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_c20211231_zDRjScfG7xa2">449,155</span> and a lease liability of $<span id="xdx_90F_eus-gaap--OperatingLeaseLiability_iI_pp0p0_c20211231_zWX2AzkZugFe" title="Operating lease liability">492,798</span>, of which $<span id="xdx_90B_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pn2p0_c20211231_zrZstIOSlUa7" title="Operating lease liability, current">141,900</span> is reported as a current liability. The weighted average remaining lease term is <span id="xdx_900_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtM_c20211231_zRk75e5f4Kdl" title="Weighted average remaining lease term">37</span> months and weighted average discount rate used is <span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pid_dp_uPure_c20211231_zVlNiXBXpU0a" title="Weighted average discount rate">10</span>%.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJHId8urnkTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of the undiscounted future minimum lease payments remaining under the operating lease reported as operating lease liability on the consolidated balance sheet as of December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_ziisvQ6bQUM4" style="display: none">SCHEDULE OF OPERATING LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" id="xdx_492_20211231_zB2EfwikQqY3" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Undiscounted future minimum lease payments:</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzv1I_zFrEvlaGyAlf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">199,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzv1I_zp7D3TJdOT7c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzv1I_zOJOg12xabAd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">195,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzv1I_maOLLzZMh_zYmkiwTpoGUl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total undiscounted future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">583,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_maOLLzZMh_zXTqO0pv1yV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: amount representing imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90,702</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zuAEalot7aOf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">492,798</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A8_zAi92h9u0OXl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_ecustom--ScheduleOfCashFlowSupplementalLeaseDisclosuresTableTextBlock_zz6i844Yvh74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to leases is as follows, for the years ended December 31,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zkUDgkA6Udxb" style="display: none">SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_492_20210101__20211231_zD5IPVMa7XQl" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" id="xdx_495_20200101__20201231_zY7DPnacwh21" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td> </td></tr> <tr id="xdx_405_ecustom--CashPaidForMeasurementofOperatingLeaseLiabilities_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Cash paid for amounts included in the measurement of operating lease liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">551,688</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">262,214</td><td style="width: 1%; text-align: left"> </td></tr> </table> <p id="xdx_8AA_zGkHxsBWv0ui" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease expense for operating leases was approximately $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_pp0p0_c20210101__20211231_z8Fo7gkwyVV7" title="Operating lease expense">386,000</span> and $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20200101__20201231_zwpyJeg6ZRl9" title="Operating lease expense">442,000</span> for the years ended December 31, 2021 and 2020.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Finance Leases:</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has acquired certain equipment under agreements that are classified as finance leases. The cost of the equipment under finance leases is included in the balance sheet as property and equipment. The finance lease equipment was $<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_iI_pp0p0_c20211231_z8J0ll2EEPxj" title="Finance lease equipment"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_iI_pp0p0_c20201231_zr1OTFt6u0c3" title="Finance lease equipment">110,372</span></span> as of December 31, 2021 and December 31, 2020, with related accumulated depreciation of $<span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_iI_pp0p0_c20211231_zLKGgoD6b6V5" title="Finance lease equipment, accumulated depreciation">12,786</span> and $<span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization_iI_pp0p0_c20201231_zTcnOGWE5j6g" title="Finance lease equipment, accumulated depreciation">8,950</span>, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Minimum lease payments required by these finance leases are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zgjTHP3JDzW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undiscounted future minimum lease payments:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zJnUXIa6r47k" style="display: none">SCHEDULE OF FINANCE LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td>Undiscounted future minimum lease payments:</td><td> </td> <td colspan="2" id="xdx_49D_20211231_zbRaY0by0zm4" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maFLLPDzAAO_zRyDiWATllj6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">17,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maFLLPDzAAO_zwDiVDIa144c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pp0p0_mtFLLPDzAAO_zzRt2Agbui18" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total undiscounted future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,100</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zy2T203DB46e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(825</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pp0p0_di_zOXcBrkHw4Nl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,161</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_iTI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of minimum lease payments, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zMWNmDEPjHBi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify"> </p> expire in January, 2025 the Company entered into a lease for an additional facility located in Deerfield Beach, Florida under a non-cancelable operating lease. The term of the lease is for P86M 0.03 In July and September of 2019, the Company’s wholly owned subsidiary, Phytochem, entered into two separate lease agreements for office and warehouse space located in Onalaska, Wisconsin, that commenced on August 1 and October 1, respectively. Each lease is for six-month terms with four (4) renewal options to extend for six additional months. The Company expects to occupy one of the spaces for the full term of the lease totaling 30 months. The Company terminated its lease on the other facility in May 2020, without penalty. The remaining lease calls for an annual 3% increase to base rent. In addition to rent, the Company pays certain insurance, maintenance, and other costs related to the rented spaces P30M The Company terminated its lease on the other facility in May 2020, without penalty 0.03 80000 449155 492798 141900 P37M 0.10 <p id="xdx_896_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zJHId8urnkTb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table presents a reconciliation of the undiscounted future minimum lease payments remaining under the operating lease reported as operating lease liability on the consolidated balance sheet as of December 31, 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_ziisvQ6bQUM4" style="display: none">SCHEDULE OF OPERATING LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.5in"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" id="xdx_492_20211231_zB2EfwikQqY3" style="text-align: justify"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Undiscounted future minimum lease payments:</td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzv1I_zFrEvlaGyAlf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">199,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPzv1I_zp7D3TJdOT7c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2023</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">189,400</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPzv1I_zOJOg12xabAd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">195,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzv1I_maOLLzZMh_zYmkiwTpoGUl" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Total undiscounted future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">583,500</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_maOLLzZMh_zXTqO0pv1yV7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: amount representing imputed interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(90,702</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zuAEalot7aOf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 2.5pt">Operating lease liability</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">492,798</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 199000 189400 195100 583500 90702 492798 <p id="xdx_893_ecustom--ScheduleOfCashFlowSupplementalLeaseDisclosuresTableTextBlock_zz6i844Yvh74" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supplemental cash flow information related to leases is as follows, for the years ended December 31,</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zkUDgkA6Udxb" style="display: none">SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_492_20210101__20211231_zD5IPVMa7XQl" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td> </td><td> </td> <td colspan="2" id="xdx_495_20200101__20201231_zY7DPnacwh21" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td> </td></tr> <tr id="xdx_405_ecustom--CashPaidForMeasurementofOperatingLeaseLiabilities_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Cash paid for amounts included in the measurement of operating lease liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">551,688</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">262,214</td><td style="width: 1%; text-align: left"> </td></tr> </table> 551688 262214 386000 442000 110372 110372 12786 8950 <p id="xdx_892_eus-gaap--FinanceLeaseLiabilityMaturityTableTextBlock_zgjTHP3JDzW8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undiscounted future minimum lease payments:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zJnUXIa6r47k" style="display: none">SCHEDULE OF FINANCE LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"> <tr style="vertical-align: bottom"> <td>Undiscounted future minimum lease payments:</td><td> </td> <td colspan="2" id="xdx_49D_20211231_zbRaY0by0zm4" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_40D_eus-gaap--FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maFLLPDzAAO_zRyDiWATllj6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">17,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--FinanceLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maFLLPDzAAO_zwDiVDIa144c" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,100</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--FinanceLeaseLiabilityPaymentsDue_iTI_pp0p0_mtFLLPDzAAO_zzRt2Agbui18" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Total undiscounted future minimum lease payments</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,100</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--FinanceLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zy2T203DB46e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(825</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--FinanceLeaseLiabilityCurrent_iNI_pp0p0_di_zOXcBrkHw4Nl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,161</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_407_eus-gaap--FinanceLeaseLiabilityNoncurrent_iTI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Present value of minimum lease payments, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,114</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 17000 2100 19100 825 17161 1114 <p id="xdx_80C_ecustom--EquityWarrantsDisclosureTextBlock_zmUh7ndq554c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 12 – <span id="xdx_82E_zATQgQi3roy2">EQUITY WARRANTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zdNjxKHwHbbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, our warrants outstanding are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z4mh7JYscXg6" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">By Exercise Price:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants - $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_ztcwxUtEh0e1" title="Exercise price">0.08</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFUBwdJHJygf" style="width: 16%; text-align: right" title="Warrants outstanding">42,020,833</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zNoY1xyy8BX7" style="width: 16%; text-align: right" title="Warrants outstanding">8,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zw7ku9RIElle" title="Exercise price">0.1025</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zcRQr7b7kvsl" style="text-align: right" title="Warrants outstanding">24,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zrT3h0mwBne9" style="text-align: right" title="Warrants outstanding"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants - $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWPOLDJiVYD" title="Exercise price">0.10</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zipOFWarYzml" style="text-align: right" title="Warrants outstanding">3,240,740</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zcAl35XkhOde" style="text-align: right" title="Warrants outstanding">3,240,740</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants - $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_ztkRmsEm3L5e" title="Exercise price">0.20</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbtop1mrl2n5" style="text-align: right" title="Warrants outstanding">10,352,941</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zPawR6mJ4Rg9" style="text-align: right" title="Warrants outstanding">13,302,941</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zfgEzxbjiGAf" title="Exercise price">0.30</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zeT2JYzvHet6" style="text-align: right" title="Warrants outstanding">722,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7nHQKUJ1xi5" style="text-align: right" title="Warrants outstanding">722,800</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Warrants - $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zZ0gVFCwdBPe" title="Exercise price">0.35</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zCQTEGtZzYlh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z1gBIFxKcpDb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding">5,294,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231_z3Aa10wH4oU5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding">80,837,314</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231_zVz1aVdPXUOa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding">30,560,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zjNhRBFAhOea" style="display: none; margin-top: 0; margin-bottom: 0"> </p> <p id="xdx_89A_ecustom--ScheduleOfWarrantsActivityTableTextBlock_zcWiSUCzACdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zMD2qipIdVXa" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 80%; font-weight: bold">Balance, January 1, 2020</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201230__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztKIz3y4u728" style="width: 16%; font-weight: bold; text-align: right" title="Warrants outstanding, beginning balance">21,819,858</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuyAHhyqtGR9" style="text-align: right" title="Warrants Issued">8,740,740</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqDhs0p89k81" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1196">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfACklntQWx5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1198">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt">Balance, December 30, 2020</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXkuIf4XL4ul" style="padding-bottom: 1.5pt; font-weight: bold; text-align: right" title="Warrants outstanding, beginning balance">30,560,598</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNCM458Clfk2" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Issued">66,510,083</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zijb3oLIoS8c" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Exercised">(7,989,250</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaMfZedmuYof" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Expired">(8,244,117</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-weight: bold">Balance, December 30, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAoxliEy0e7j" style="font-weight: bold; text-align: right" title="Warrants outstanding, ending balance">80,837,314</td><td style="font-weight: bold; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zG0kwlcMX1Nl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_890_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zdNjxKHwHbbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At December 31, our warrants outstanding are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z4mh7JYscXg6" style="display: none">SCHEDULE OF WARRANTS OUTSTANDING</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">By Exercise Price:</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Warrants - $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_ztcwxUtEh0e1" title="Exercise price">0.08</span></td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zFUBwdJHJygf" style="width: 16%; text-align: right" title="Warrants outstanding">42,020,833</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zNoY1xyy8BX7" style="width: 16%; text-align: right" title="Warrants outstanding">8,000,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zw7ku9RIElle" title="Exercise price">0.1025</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zcRQr7b7kvsl" style="text-align: right" title="Warrants outstanding">24,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zrT3h0mwBne9" style="text-align: right" title="Warrants outstanding"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1160">-</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants - $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zWPOLDJiVYD" title="Exercise price">0.10</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zipOFWarYzml" style="text-align: right" title="Warrants outstanding">3,240,740</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceThreeMember_zcAl35XkhOde" style="text-align: right" title="Warrants outstanding">3,240,740</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Warrants - $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_ztkRmsEm3L5e" title="Exercise price">0.20</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zbtop1mrl2n5" style="text-align: right" title="Warrants outstanding">10,352,941</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFourMember_zPawR6mJ4Rg9" style="text-align: right" title="Warrants outstanding">13,302,941</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants - $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zfgEzxbjiGAf" title="Exercise price">0.30</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_zeT2JYzvHet6" style="text-align: right" title="Warrants outstanding">722,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceFiveMember_z7nHQKUJ1xi5" style="text-align: right" title="Warrants outstanding">722,800</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Warrants - $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zZ0gVFCwdBPe" title="Exercise price">0.35</span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_zCQTEGtZzYlh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding"><span style="-sec-ix-hidden: xdx2ixbrl1182">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceSixMember_z1gBIFxKcpDb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants outstanding">5,294,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total outstanding</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20211231_z3Aa10wH4oU5" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding">80,837,314</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20201231_zVz1aVdPXUOa" style="border-bottom: Black 2.5pt double; text-align: right" title="Warrants outstanding">30,560,598</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 0.08 42020833 8000000 0.1025 24500000 0.10 3240740 3240740 0.20 10352941 13302941 0.30 722800 722800 0.35 5294117 80837314 30560598 <p id="xdx_89A_ecustom--ScheduleOfWarrantsActivityTableTextBlock_zcWiSUCzACdc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zMD2qipIdVXa" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; width: 80%; font-weight: bold">Balance, January 1, 2020</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20201230__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ztKIz3y4u728" style="width: 16%; font-weight: bold; text-align: right" title="Warrants outstanding, beginning balance">21,819,858</td><td style="width: 1%; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Warrants Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuyAHhyqtGR9" style="text-align: right" title="Warrants Issued">8,740,740</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Warrants Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zqDhs0p89k81" style="text-align: right" title="Warrants Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1196">-</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20200101__20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfACklntQWx5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1198">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt">Balance, December 30, 2020</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXkuIf4XL4ul" style="padding-bottom: 1.5pt; font-weight: bold; text-align: right" title="Warrants outstanding, beginning balance">30,560,598</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zNCM458Clfk2" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Issued">66,510,083</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zijb3oLIoS8c" style="padding-bottom: 1.5pt; text-align: right" title="Warrants Exercised">(7,989,250</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Warrants Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaMfZedmuYof" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrants Expired">(8,244,117</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; font-weight: bold">Balance, December 30, 2021</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAoxliEy0e7j" style="font-weight: bold; text-align: right" title="Warrants outstanding, ending balance">80,837,314</td><td style="font-weight: bold; text-align: left"> </td></tr> </table> 21819858 8740740 30560598 66510083 7989250 8244117 80837314 <p id="xdx_801_eus-gaap--IncomeTaxDisclosureTextBlock_z7sdrUT2A9Jh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 13 - <span id="xdx_820_z2uIau7mMR8a">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.2pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company accounts for income taxes in accordance with FSB ASC 740 “Income Taxes”. Federal and state income taxes are calculated and recorded on the current period’s activity in accordance with the tax laws and regulations that are in effect. Deferred tax assets and liabilities are recognized based on the differences between the financial statement carrying amounts and the tax bases of assets and liabilities, using enacted tax rate in effect in the years the differences are expected to reverse. Deferred income tax benefit (expense) results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all deferred tax assts will not be realized.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zncxY8vN715i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the income tax provision are as follows at December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zwrOzbQtPsIe" style="display: none">SCHEDULE OF INCOME TAX PROVISION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210101__20211231_zyQit0mHFyxf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200101__20201231_zZvk2AHK9Fi1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_maITEBz5TN_z6w9XKyL3Jx" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Current</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1214"> </span></td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1215"> </span></td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxExpenseBenefit_maITEBz5TN_zxCIqMWhDQmi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1217"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1218"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBz5TN_zI6L67SAjy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1220"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1221"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8AC_zZYpe942Fubb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z9BuSmHVpkSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B9_zO6niBDrhXWl" style="display: none">SCHEDULE OF RECONCILIATION OF STATUTORY FEDERAL INCOME TAX RATE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210101__20211231_zy5G9DM8DxO" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200101__20201231_zC47hxiyyi4g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_zXfgY5YFOPPj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">U.S. Federal statutory income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_uPure_zctxz9DWlpp4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3.5</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3.5</td><td style="text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_z5MbLhx0iJJb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">24.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">24.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zGKUagkxsYsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Effective tax rate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> </table> <p id="xdx_8A7_zg04iN4VSQtj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLkcfLqZfdXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zGwce3AKMsYc" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Deferred tax assets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231_zUCFvElzK0Zc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20201231_zJTXIE7aIHfl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTANz0hQ_zTuNPFilQUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">10,788,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,843,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pp0p0_maDTANz0hQ_ziHeqPU7eKS" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Wages</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedInterest_iI_pp0p0_maDTANz0hQ_zDs9jbSrPefk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1246"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANz0hQ_ziVfyxDlkVxk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,014,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,941,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANz0hQ_zCu7Wp2JGPq4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1251"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1252"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Deferred tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--StockBasedCompensationDeferredTaxLiabilities_iI_pp0p0_maDTALNzX8I_zpkYM5MDZtP7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock based compensation</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1254"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1255"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DepreciationDeferredTaxLiabilities_iI_pp0p0_maDTALNzX8I_zB3pDUkzrol6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1257"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1258"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzX8I_zTaoVm0Dmu0e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1260">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zHLng6jAYQLd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The change in valuation allowance was $<span id="xdx_909_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20210101__20211231_zg0Xh0VUyel1" title="Change in valuation allowance">1,073,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90A_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0p0_c20200101__20201231_zfWf1iWrGrfg" title="Change in valuation allowance">543,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the years ended December 31, 2021 and 2020, respectively. We recorded a <span id="xdx_905_ecustom--PercentagesOfValuationAllowanceRecorded_pid_dp_uPure_c20210101__20211231_zRJk0E7YIeH1">100</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">% valuation allowance related to the deferred tax asset for the loss from operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which temporary differences become deductible. The Company has net operating loss carryforwards of approximately $<span id="xdx_904_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20211231_zNb8wfrHW0hh" title="Net operating loss carryforwards">44.0 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million as of December 31, 2021, of which $<span id="xdx_90B_eus-gaap--OperatingLossCarryforwards_iI_pn5n6_c20201231_zaxcvZVQ8gv9" title="Net operating loss carryforwards">32.6</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">million were incurred prior to 2018 that begin to <span id="xdx_908_ecustom--OperatingLossCarryforwardsExpirationYear_c20210101__20211231_z5xYd24YOm42">expire in the year 2032 through 2036</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with the provisions of ASC 740: Income Taxes, we record a liability for uncertain tax positions when it is probable that a loss has been incurred and the amount can be reasonably estimated. At December 31, 2021 and 2020, we have no liabilities for uncertain tax positions. We continually evaluate expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89E_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zncxY8vN715i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The components of the income tax provision are as follows at December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B5_zwrOzbQtPsIe" style="display: none">SCHEDULE OF INCOME TAX PROVISION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210101__20211231_zyQit0mHFyxf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200101__20201231_zZvk2AHK9Fi1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_405_eus-gaap--CurrentIncomeTaxExpenseBenefit_maITEBz5TN_z6w9XKyL3Jx" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Current</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1214"> </span></td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1215"> </span></td><td style="width: 16%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DeferredIncomeTaxExpenseBenefit_maITEBz5TN_zxCIqMWhDQmi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Deferred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1217"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1218"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--IncomeTaxExpenseBenefit_iT_pp0p0_mtITEBz5TN_zI6L67SAjy9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total tax provision</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1220"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1221"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_897_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z9BuSmHVpkSe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following is a reconciliation of the effective income tax rate with the statutory income tax rate at December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B9_zO6niBDrhXWl" style="display: none">SCHEDULE OF RECONCILIATION OF STATUTORY FEDERAL INCOME TAX RATE</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20210101__20211231_zy5G9DM8DxO" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200101__20201231_zC47hxiyyi4g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_iN_pid_dpi_uPure_zXfgY5YFOPPj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">U.S. Federal statutory income tax rate</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">(21.0</td><td style="width: 1%; text-align: left">)%</td></tr> <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_iN_pid_dpi_uPure_zctxz9DWlpp4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">State income tax, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3.5</td><td style="text-align: left">)%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3.5</td><td style="text-align: left">)%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_z5MbLhx0iJJb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">24.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">24.5</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr id="xdx_40E_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_uPure_zGKUagkxsYsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Effective tax rate</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">0.0</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> </table> 0.210 0.210 0.035 0.035 0.245 0.245 0.000 0.000 <p id="xdx_892_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zLkcfLqZfdXh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The net deferred tax assets and liabilities included in the financial statements consist of the following amounts at December 31, 2021 and 2020:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_zGwce3AKMsYc" style="display: none">SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Deferred tax assets</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20211231_zUCFvElzK0Zc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_496_20201231_zJTXIE7aIHfl" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_maDTANz0hQ_zTuNPFilQUD7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Net operating loss carry forwards</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">10,788,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">9,843,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_iI_pp0p0_maDTANz0hQ_ziHeqPU7eKS" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued Wages</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">133,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">98,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedInterest_iI_pp0p0_maDTANz0hQ_zDs9jbSrPefk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued Interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">93,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1246"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_msDTANz0hQ_ziVfyxDlkVxk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(11,014,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,941,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DeferredTaxAssetsNet_iTI_pp0p0_mtDTANz0hQ_zCu7Wp2JGPq4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1251"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1252"> </span></td><td style="border-bottom: Black 2.5pt double; text-align: right">-</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left">Deferred tax liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--StockBasedCompensationDeferredTaxLiabilities_iI_pp0p0_maDTALNzX8I_zpkYM5MDZtP7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock based compensation</td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1254"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1255"> </span></td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DepreciationDeferredTaxLiabilities_iI_pp0p0_maDTALNzX8I_zB3pDUkzrol6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Depreciation</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1257"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl1258"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iTI_pp0p0_mtDTALNzX8I_zTaoVm0Dmu0e" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Net deferred tax asset</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1260">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1261">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 10788000 9843000 133000 98000 93000 11014000 9941000 1073000 543000 1 44000000.0 32600000 expire in the year 2032 through 2036 <p id="xdx_802_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zYEwSodUik2f" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 14 - <span><span id="xdx_823_zX16boVN7pkl">CONTINGENCIES</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to asserted claims and liabilities that arise in the ordinary course of business. The Company maintains insurance policies to mitigate potential losses from these actions. In the opinion of management, the amount of the ultimate liability with respect to those actions will not materially affect the Company’s financial position or results of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"/></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Legal Proceedings:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, we may become involved in various lawsuits and legal proceedings, which arise, in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. Litigations applicable to the Company are discussed as follows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Hamilton v. the Company:</span></i> Hamilton &amp; Associates Law Group, P.A. v. Nutralife Biosciences, Inc. f/k/a Nutrafuels, Inc., Case No. 50-2020-CA-008435, was filed in the Circuit Court of the Fifteenth Judicial Circuit in and for Palm Beach County, Florida on August 9, 2020. In the suit, Hamilton &amp; Associates Law Group, P.A. sets forth purported claims for breach of contract, and in the alternative, account stated, open account, unjust enrichment, and quantum meruit. Plaintiff requests a judgment for damages in the principal sum of $<span id="xdx_908_eus-gaap--LossContingencyDamagesPaidValue_c20210101__20211231_zo352EfeIyme" title="Contingency principal amount">150,000</span>, plus an award of attorneys’ fees and costs pursuant to a legal services agreement dated January 7, 2019, as well as pre-judgment interest and post-judgment interest. The Hamilton matter filed directly against the Company initially included a claim against Edgar Ward, but the individual claim has been dropped. The prior engagement agreement between the Hamilton law firm and the Company (for 2018) was in the nature of a flat fee engagement, in which shares were provided in lieu of cash payments. The Company maintains that the change in the engagement of the law firm (from 2018 to 2019) in terms of the nature of payment was not disclosed or explained adequately, and the Company was unaware of any claim that sums remained unpaid, as all fees were understood to be paid as a result of the shares of stock provided. The claim was filed on August 9, 2020, and is not set for trial, and only documentary discovery has been conducted to date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Native American Partners v. the Company</span></i>: Native American Partners LLC, including NAVF Holdings and NAVF-Pharma, subsidiary companies, and Best Darn Brands, LLC, and its subsidiaries v. Nutralife Biosciences Inc., Case No. CACE-20-009352, was filed in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida. This action was filed on June 5, 2020, against both the Company and Edgar Ward. However, the claim against Mr. Ward was later dropped. The claim asserted that the Company failed to comply with the confidentiality imposed by a non-disclosure agreement signed by plaintiff and defendant. Plaintiff claims that defendant proceeded with the development of a hand sanitizer product that was first revealed to defendant by the plaintiff, however, defendant asserted that the product produced was different (gel vs. spray) and that defendant had contemplated developing the product (the Covid 19 pandemic was already underway) well in advance of the signing of the NDA. In the Amended Complaint filed on July 9, 2020, plaintiffs demanded injunctive relief and damages for conversion, fraudulent misrepresentation, fraud in the inducement, equitable accounting, unjust enrichment, quantum meruit, breach of contract, and negligent misrepresentation. We obtained a dismissal of this Amended Complaint on February 8, 2021, based on the arbitration provision included in the written contract at issue between the parties. At this time, the plaintiffs have not filed another court action that we are aware of. We are also not yet aware of any arbitration initiated by the plaintiff.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Ortiz v. the Company</span>:</i> Jose Ortiz v. Nutralife Biosciences, Inc. f/k/a Nutrafuels, Inc., Case No. CACE-29-017957, was filed in the Circuit Court of the Seventeenth Judicial Circuit in and for Broward County, Florida, on October 28, 2020. In this matter, Mr. Ortiz is seeking a judgment for damages, attorneys’ fees, and other costs relating to defendant’s purported breach of an employment agreement dated March 18, 2015. We do not believe that this claim is valued at greater than $<span id="xdx_903_eus-gaap--LossContingencyDamagesPaidValue_c20210101__20211231__srt--RangeAxis__srt--MaximumMember_zGGIMDlH5xq5" title="Contingency principal amount">5,000</span>. Ortiz’ claim was filed on October 28, 2020, asserting improper discharge from employment, and failure to pay wages and benefits, however, we believe (and have filed summary judgment asserting) that the claim was filed too late, in contravention of the applicable statute of limitations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 150000 5000 <p id="xdx_807_eus-gaap--ConcentrationRiskDisclosureTextBlock_zT4kMf1Fsjvi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 15 - <span id="xdx_823_zwvmcgV8Skee">CONCENTRATIONS OF CREDIT RISK</span>:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Cash</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company maintains principally all cash balances with various financial institutions which, at times, may exceed the amount insured by the Federal Deposit Insurance Corporation. The exposure to the Company is solely dependent</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon daily bank balances and the respective strength of the financial institutions. The Company has not incurred any losses on these accounts. At both December 31, 2021 and 2020, there are <span id="xdx_906_eus-gaap--CashUninsuredAmount_iI_do_c20211231_zL7OQcKdBOq8" title="Cash balances"><span id="xdx_904_eus-gaap--CashUninsuredAmount_iI_do_c20201231_zPErgvfXTnOi" title="Cash balances">no</span></span> amounts in excess of insured limits.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Revenue</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2021, two customers accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zsLbtHtmWL4a" title="Concentration risk, percentage">82</span>% of sales. For the year ended December 31, 2020, two customers accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20200101__20201231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_z65Y0VJjmKlk" title="Concentration risk, percentage">28</span>% of sales.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 0 0.82 0.28 <p id="xdx_80A_eus-gaap--SubsequentEventsTextBlock_zC8xaTVVCnRc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 16 - <span id="xdx_829_zwaZeiwXM5Sa">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in China, and began to spread around the world in early 2020. In reaction to decreased supply of and increased demand for sanitizer products, the Company shifted its manufacturing to produce sanitizer products. The Company’s other business operations have been impacted negatively by COVID-19 due to government restrictions and the overall adverse effect on the global economy. The Company expects COVID-19 to continue to negatively impact its operating results and its ability to obtain financing.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2022, the Company received proceeds aggregating $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20220101__20220131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--TwoSubscriptionAgreementMember_zHxI9qZaHsi9" title="Proceeds from common stock">110,000</span> in connection with two subscription agreements. Under the subscription agreements, a total of <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220101__20220131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--TypeOfArrangementAxis__custom--TwoSubscriptionAgreementMember_zp4MyOwIhzIi" title="Stock issued during period, shares">1,375,000</span> shares of common stock and <span id="xdx_90D_ecustom--NumberOfWarrantsExchangeShares_c20220101__20220131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--TwoSubscriptionAgreementMember_z9TCBPGiFJwk" title="Number of warrants exchange, shares">1,375,000</span> warrants were issued. The warrants are exercisable at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--TypeOfArrangementAxis__custom--TwoSubscriptionAgreementMember_zIfS2dR8ORVh" title="Warrants exercise price">0.08</span> per share and expire <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dc_c20220131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--TwoSubscriptionAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zV9lPDVq4BG6" title="Warrant expiration term">two years</span> from the date of issuance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2022, the Company issued <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220101__20220131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZRWifuS7pAl" title="Common stock, shares">1,100,000</span> shares of common stock for services aggregating $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_c20220101__20220131__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwKfLSFXtGti" title="Common stock, value">100,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2022, the Company entered into a debt settlement agreement with its noteholder whereby the noteholder converted their two promissory notes into a revenue share agreement. The amount converted was an aggregate of $<span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--DebtSettlementAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ExtinguishmentOfDebtAxis__custom--PrincipalMember_z4mKp5tbMXl7" title="Debt conversion, principal">187,000</span> of principal and $<span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220201__20220228__us-gaap--TypeOfArrangementAxis__custom--DebtSettlementAgreementMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ExtinguishmentOfDebtAxis__custom--AccruedInterestMember_zmgZJOvcmW37" title="Debt conversion, accrued interest">18,700</span> of accrued interest. The total amount converted was $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220201__20220228__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--DebtSettlementAgreementMember_zWChdZFJqYB4" title="Debt conversion, total">205,700</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2022, the Company received proceeds of $<span id="xdx_903_eus-gaap--ProceedsFromNotesPayable_pp0p0_c20220101__20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zeoVjfcbHAKi" title="Proceeds from notes payable">15,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in connection with the issuance of a promissory note with a due date in <span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_ddxL_c20220301__20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zLiO111PAXNe" title="Debt instrument maturity date::XDX::Mar.%2031%2C%202023"><span style="-sec-ix-hidden: xdx2ixbrl1313">March 2023</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The note bears interest at <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20220331__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--ShortTermDebtTypeAxis__custom--MultipleShortTermPromissoryNotePayableMember_zqfeH7MwHdL" title="Debt instrument interest rate">20</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.</span></p> 110000 1375000 1375000 0.08 P2Y 1100000 100000 187000 18700 205700 15000 0.20 EXCEL 70 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 72 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 73 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 178 316 1 false 70 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://nutralifebiosciences.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://nutralifebiosciences.com/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://nutralifebiosciences.com/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://nutralifebiosciences.com/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity Sheet http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity Consolidated Statements of Changes in Stockholders' (Deficit) Equity Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Cash Flows Sheet http://nutralifebiosciences.com/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 00000007 - Disclosure - NATURE OF OPERATIONS Sheet http://nutralifebiosciences.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 7 false false R8.htm 00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - LIQUIDITY AND GOING CONCERN CONSIDERATIONS Sheet http://nutralifebiosciences.com/role/LiquidityAndGoingConcernConsiderations LIQUIDITY AND GOING CONCERN CONSIDERATIONS Notes 9 false false R10.htm 00000010 - Disclosure - PROPERTY AND EQUIPMENT, NET Sheet http://nutralifebiosciences.com/role/PropertyAndEquipmentNet PROPERTY AND EQUIPMENT, NET Notes 10 false false R11.htm 00000011 - Disclosure - INTANGIBLE ASSET Sheet http://nutralifebiosciences.com/role/IntangibleAsset INTANGIBLE ASSET Notes 11 false false R12.htm 00000012 - Disclosure - INVESTMENT Sheet http://nutralifebiosciences.com/role/Investment INVESTMENT Notes 12 false false R13.htm 00000013 - Disclosure - ACCRUED EXPENSES Sheet http://nutralifebiosciences.com/role/AccruedExpenses ACCRUED EXPENSES Notes 13 false false R14.htm 00000014 - Disclosure - NOTES PAYABLE Notes http://nutralifebiosciences.com/role/NotesPayable NOTES PAYABLE Notes 14 false false R15.htm 00000015 - Disclosure - REVENUE SHARE AGREEMENTS Sheet http://nutralifebiosciences.com/role/RevenueShareAgreements REVENUE SHARE AGREEMENTS Notes 15 false false R16.htm 00000016 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://nutralifebiosciences.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 16 false false R17.htm 00000017 - Disclosure - LEASES Sheet http://nutralifebiosciences.com/role/Leases LEASES Notes 17 false false R18.htm 00000018 - Disclosure - EQUITY WARRANTS Sheet http://nutralifebiosciences.com/role/EquityWarrants EQUITY WARRANTS Notes 18 false false R19.htm 00000019 - Disclosure - INCOME TAXES Sheet http://nutralifebiosciences.com/role/IncomeTaxes INCOME TAXES Notes 19 false false R20.htm 00000020 - Disclosure - CONTINGENCIES Sheet http://nutralifebiosciences.com/role/Contingencies CONTINGENCIES Notes 20 false false R21.htm 00000021 - Disclosure - CONCENTRATIONS OF CREDIT RISK Sheet http://nutralifebiosciences.com/role/ConcentrationsOfCreditRisk CONCENTRATIONS OF CREDIT RISK Notes 21 false false R22.htm 00000022 - Disclosure - SUBSEQUENT EVENTS Sheet http://nutralifebiosciences.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 22 false false R23.htm 00000023 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 23 false false R24.htm 00000024 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 24 false false R25.htm 00000025 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables) Sheet http://nutralifebiosciences.com/role/PropertyAndEquipmentNetTables PROPERTY AND EQUIPMENT, NET (Tables) Tables http://nutralifebiosciences.com/role/PropertyAndEquipmentNet 25 false false R26.htm 00000026 - Disclosure - INTANGIBLE ASSET (Tables) Sheet http://nutralifebiosciences.com/role/IntangibleAssetTables INTANGIBLE ASSET (Tables) Tables http://nutralifebiosciences.com/role/IntangibleAsset 26 false false R27.htm 00000027 - Disclosure - ACCRUED EXPENSES (Tables) Sheet http://nutralifebiosciences.com/role/AccruedExpensesTables ACCRUED EXPENSES (Tables) Tables http://nutralifebiosciences.com/role/AccruedExpenses 27 false false R28.htm 00000028 - Disclosure - LEASES (Tables) Sheet http://nutralifebiosciences.com/role/LeasesTables LEASES (Tables) Tables http://nutralifebiosciences.com/role/Leases 28 false false R29.htm 00000029 - Disclosure - EQUITY WARRANTS (Tables) Sheet http://nutralifebiosciences.com/role/EquityWarrantsTables EQUITY WARRANTS (Tables) Tables http://nutralifebiosciences.com/role/EquityWarrants 29 false false R30.htm 00000030 - Disclosure - INCOME TAXES (Tables) Sheet http://nutralifebiosciences.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://nutralifebiosciences.com/role/IncomeTaxes 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF INVENTORIES (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfInventoriesDetails SCHEDULE OF INVENTORIES (Details) Details 31 false false R32.htm 00000032 - Disclosure - SCHEDULE OF ANTI-DILUTIVE EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfAnti-dilutiveExcludedFromComputationOfNetLossPerShareDetails SCHEDULE OF ANTI-DILUTIVE EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE (Details) Details 32 false false R33.htm 00000033 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 33 false false R34.htm 00000034 - Disclosure - LIQUIDITY AND GOING CONCERN CONSIDERATIONS (Details Narrative) Sheet http://nutralifebiosciences.com/role/LiquidityAndGoingConcernConsiderationsDetailsNarrative LIQUIDITY AND GOING CONCERN CONSIDERATIONS (Details Narrative) Details http://nutralifebiosciences.com/role/LiquidityAndGoingConcernConsiderations 34 false false R35.htm 00000035 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails SCHEDULE OF PROPERTY AND EQUIPMENT (Details) Details 35 false false R36.htm 00000036 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative) Sheet http://nutralifebiosciences.com/role/PropertyAndEquipmentNetDetailsNarrative PROPERTY AND EQUIPMENT, NET (Details Narrative) Details http://nutralifebiosciences.com/role/PropertyAndEquipmentNetTables 36 false false R37.htm 00000037 - Disclosure - SCHEDULE OF ESTIMATE AMORTIZATION EXPENSE (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails SCHEDULE OF ESTIMATE AMORTIZATION EXPENSE (Details) Details 37 false false R38.htm 00000038 - Disclosure - SCHEDULE OF INTANGIBLE ASSET (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfIntangibleAssetDetails SCHEDULE OF INTANGIBLE ASSET (Details) Details 38 false false R39.htm 00000039 - Disclosure - INTANGIBLE ASSET (Details Narrative) Sheet http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative INTANGIBLE ASSET (Details Narrative) Details http://nutralifebiosciences.com/role/IntangibleAssetTables 39 false false R40.htm 00000040 - Disclosure - INVESTMENT (Details Narrative) Sheet http://nutralifebiosciences.com/role/InvestmentDetailsNarrative INVESTMENT (Details Narrative) Details http://nutralifebiosciences.com/role/Investment 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails SCHEDULE OF ACCRUED EXPENSES (Details) Details 41 false false R42.htm 00000042 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://nutralifebiosciences.com/role/NotesPayable 42 false false R43.htm 00000043 - Disclosure - REVENUE SHARE AGREEMENTS (Details Narrative) Sheet http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative REVENUE SHARE AGREEMENTS (Details Narrative) Details http://nutralifebiosciences.com/role/RevenueShareAgreements 43 false false R44.htm 00000044 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://nutralifebiosciences.com/role/StockholdersEquity 44 false false R45.htm 00000045 - Disclosure - SCHEDULE OF OPERATING LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfOperatingLeasesUndiscountedFutureMinimumLeasePaymentsDetails SCHEDULE OF OPERATING LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS (Details) Details 45 false false R46.htm 00000046 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details) Details 46 false false R47.htm 00000047 - Disclosure - SCHEDULE OF FINANCE LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfFinanceLeasesUndiscountedFutureMinimumLeasePaymentsDetails SCHEDULE OF FINANCE LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS (Details) Details 47 false false R48.htm 00000048 - Disclosure - LEASES (Details Narrative) Sheet http://nutralifebiosciences.com/role/LeasesDetailsNarrative LEASES (Details Narrative) Details http://nutralifebiosciences.com/role/LeasesTables 48 false false R49.htm 00000049 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails SCHEDULE OF WARRANTS OUTSTANDING (Details) Details 49 false false R50.htm 00000050 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfWarrantsActivityDetails SCHEDULE OF WARRANTS ACTIVITY (Details) Details 50 false false R51.htm 00000051 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfIncomeTaxProvisionDetails SCHEDULE OF INCOME TAX PROVISION (Details) Details 51 false false R52.htm 00000052 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY FEDERAL INCOME TAX RATE (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateDetails SCHEDULE OF RECONCILIATION OF STATUTORY FEDERAL INCOME TAX RATE (Details) Details 52 false false R53.htm 00000053 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) Sheet http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details) Details 53 false false R54.htm 00000054 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://nutralifebiosciences.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://nutralifebiosciences.com/role/IncomeTaxesTables 54 false false R55.htm 00000055 - Disclosure - CONTINGENCIES (Details Narrative) Sheet http://nutralifebiosciences.com/role/ContingenciesDetailsNarrative CONTINGENCIES (Details Narrative) Details http://nutralifebiosciences.com/role/Contingencies 55 false false R56.htm 00000056 - Disclosure - CONCENTRATIONS OF CREDIT RISK (Details Narrative) Sheet http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative CONCENTRATIONS OF CREDIT RISK (Details Narrative) Details http://nutralifebiosciences.com/role/ConcentrationsOfCreditRisk 56 false false R57.htm 00000057 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://nutralifebiosciences.com/role/SubsequentEvents 57 false false All Reports Book All Reports form10-k.htm ex21-1.htm ex31-1.htm ex32-1.htm ex4-15.htm nlbs-20211231.xsd nlbs-20211231_cal.xml nlbs-20211231_def.xml nlbs-20211231_lab.xml nlbs-20211231_pre.xml form10-k_001.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 76 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-k.htm": { "axisCustom": 0, "axisStandard": 26, "contextCount": 178, "dts": { "calculationLink": { "local": [ "nlbs-20211231_cal.xml" ] }, "definitionLink": { "local": [ "nlbs-20211231_def.xml" ] }, "inline": { "local": [ "form10-k.htm" ] }, "labelLink": { "local": [ "nlbs-20211231_lab.xml" ] }, "presentationLink": { "local": [ "nlbs-20211231_pre.xml" ] }, "schema": { "local": [ "nlbs-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 517, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 61, "http://nutralifebiosciences.com/20211231": 44, "http://xbrl.sec.gov/dei/2021q4": 3, "total": 108 }, "keyCustom": 51, "keyStandard": 265, "memberCustom": 40, "memberStandard": 25, "nsprefix": "NLBS", "nsuri": "http://nutralifebiosciences.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://nutralifebiosciences.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - PROPERTY AND EQUIPMENT, NET", "role": "http://nutralifebiosciences.com/role/PropertyAndEquipmentNet", "shortName": "PROPERTY AND EQUIPMENT, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - INTANGIBLE ASSET", "role": "http://nutralifebiosciences.com/role/IntangibleAsset", "shortName": "INTANGIBLE ASSET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - INVESTMENT", "role": "http://nutralifebiosciences.com/role/Investment", "shortName": "INVESTMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - ACCRUED EXPENSES", "role": "http://nutralifebiosciences.com/role/AccruedExpenses", "shortName": "ACCRUED EXPENSES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - NOTES PAYABLE", "role": "http://nutralifebiosciences.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "NLBS:RevenueShareAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - REVENUE SHARE AGREEMENTS", "role": "http://nutralifebiosciences.com/role/RevenueShareAgreements", "shortName": "REVENUE SHARE AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "NLBS:RevenueShareAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "role": "http://nutralifebiosciences.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "NLBS:LesseeOperatingLeasesAndFinancingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - LEASES", "role": "http://nutralifebiosciences.com/role/Leases", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "NLBS:LesseeOperatingLeasesAndFinancingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "NLBS:EquityWarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - EQUITY WARRANTS", "role": "http://nutralifebiosciences.com/role/EquityWarrants", "shortName": "EQUITY WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "NLBS:EquityWarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - INCOME TAXES", "role": "http://nutralifebiosciences.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "role": "http://nutralifebiosciences.com/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - CONTINGENCIES", "role": "http://nutralifebiosciences.com/role/Contingencies", "shortName": "CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - CONCENTRATIONS OF CREDIT RISK", "role": "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRisk", "shortName": "CONCENTRATIONS OF CREDIT RISK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - SUBSEQUENT EVENTS", "role": "http://nutralifebiosciences.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)", "role": "http://nutralifebiosciences.com/role/PropertyAndEquipmentNetTables", "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - INTANGIBLE ASSET (Tables)", "role": "http://nutralifebiosciences.com/role/IntangibleAssetTables", "shortName": "INTANGIBLE ASSET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - ACCRUED EXPENSES (Tables)", "role": "http://nutralifebiosciences.com/role/AccruedExpensesTables", "shortName": "ACCRUED EXPENSES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "NLBS:LesseeOperatingLeasesAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - LEASES (Tables)", "role": "http://nutralifebiosciences.com/role/LeasesTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "NLBS:LesseeOperatingLeasesAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "NLBS:EquityWarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - EQUITY WARRANTS (Tables)", "role": "http://nutralifebiosciences.com/role/EquityWarrantsTables", "shortName": "EQUITY WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "NLBS:EquityWarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - INCOME TAXES (Tables)", "role": "http://nutralifebiosciences.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF INVENTORIES (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfInventoriesDetails", "shortName": "SCHEDULE OF INVENTORIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SCHEDULE OF ANTI-DILUTIVE EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfAnti-dilutiveExcludedFromComputationOfNetLossPerShareDetails", "shortName": "SCHEDULE OF ANTI-DILUTIVE EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - LIQUIDITY AND GOING CONCERN CONSIDERATIONS (Details Narrative)", "role": "http://nutralifebiosciences.com/role/LiquidityAndGoingConcernConsiderationsDetailsNarrative", "shortName": "LIQUIDITY AND GOING CONCERN CONSIDERATIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)", "role": "http://nutralifebiosciences.com/role/PropertyAndEquipmentNetDetailsNarrative", "shortName": "PROPERTY AND EQUIPMENT, NET (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - SCHEDULE OF ESTIMATE AMORTIZATION EXPENSE (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails", "shortName": "SCHEDULE OF ESTIMATE AMORTIZATION EXPENSE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SCHEDULE OF INTANGIBLE ASSET (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfIntangibleAssetDetails", "shortName": "SCHEDULE OF INTANGIBLE ASSET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - INTANGIBLE ASSET (Details Narrative)", "role": "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative", "shortName": "INTANGIBLE ASSET (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-02-28_us-gaap_PatentsMember", "decimals": "0", "lang": null, "name": "us-gaap:FiniteLivedPatentsGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations", "role": "http://nutralifebiosciences.com/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2020-01-012020-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - INVESTMENT (Details Narrative)", "role": "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "shortName": "INVESTMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:InvestmentTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31_custom_DistributionAgreementMember", "decimals": "0", "lang": null, "name": "us-gaap:Investments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - SCHEDULE OF ACCRUED EXPENSES (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails", "shortName": "SCHEDULE OF ACCRUED EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccruedBonusesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromNotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - NOTES PAYABLE (Details Narrative)", "role": "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-02-252021-02-26_custom_PaycheckProtectionProgramMember", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "NLBS:RevenueShareAgreementsPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - REVENUE SHARE AGREEMENTS (Details Narrative)", "role": "http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative", "shortName": "REVENUE SHARE AGREEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "NLBS:RevenueShareAgreementsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-012021-12-31_custom_TwoRevenueShareAgreementMember_custom_ThirdPartyInvestorsMember", "decimals": "0", "lang": null, "name": "NLBS:RevenueReceived", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-12-012021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "role": "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-01-31_custom_ChiefExecutiveOfficerPresidentAndDirectorMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "NLBS:LesseeOperatingLeasesAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - SCHEDULE OF OPERATING LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfOperatingLeasesUndiscountedFutureMinimumLeasePaymentsDetails", "shortName": "SCHEDULE OF OPERATING LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "NLBS:LesseeOperatingLeasesAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "NLBS:ScheduleOfCashFlowSupplementalLeaseDisclosuresTableTextBlock", "NLBS:LesseeOperatingLeasesAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "NLBS:CashPaidForMeasurementofOperatingLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails", "shortName": "SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "NLBS:ScheduleOfCashFlowSupplementalLeaseDisclosuresTableTextBlock", "NLBS:LesseeOperatingLeasesAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "NLBS:CashPaidForMeasurementofOperatingLeaseLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "NLBS:LesseeOperatingLeasesAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - SCHEDULE OF FINANCE LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfFinanceLeasesUndiscountedFutureMinimumLeasePaymentsDetails", "shortName": "SCHEDULE OF FINANCE LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "NLBS:LesseeOperatingLeasesAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - LEASES (Details Narrative)", "role": "http://nutralifebiosciences.com/role/LeasesDetailsNarrative", "shortName": "LEASES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "NLBS:LesseeOperatingLeasesAndFinancingLeasesTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "NLBS:EquityWarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - SCHEDULE OF WARRANTS OUTSTANDING (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails", "shortName": "SCHEDULE OF WARRANTS OUTSTANDING (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "NLBS:EquityWarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Changes in Stockholders' (Deficit) Equity", "role": "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "shortName": "Consolidated Statements of Changes in Stockholders' (Deficit) Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_SeriesAPreferredStockMember_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "NLBS:ScheduleOfWarrantsActivityTableTextBlock", "NLBS:EquityWarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfWarrantsActivityDetails", "shortName": "SCHEDULE OF WARRANTS ACTIVITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "NLBS:ScheduleOfWarrantsActivityTableTextBlock", "NLBS:EquityWarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2019-12-31_us-gaap_WarrantMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R51": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - SCHEDULE OF INCOME TAX PROVISION (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfIncomeTaxProvisionDetails", "shortName": "SCHEDULE OF INCOME TAX PROVISION (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R52": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - SCHEDULE OF RECONCILIATION OF STATUTORY FEDERAL INCOME TAX RATE (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateDetails", "shortName": "SCHEDULE OF RECONCILIATION OF STATUTORY FEDERAL INCOME TAX RATE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)", "role": "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails", "shortName": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - INCOME TAXES (Details Narrative)", "role": "http://nutralifebiosciences.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesPaidValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - CONTINGENCIES (Details Narrative)", "role": "http://nutralifebiosciences.com/role/ContingenciesDetailsNarrative", "shortName": "CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LossContingencyDamagesPaidValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - CONCENTRATIONS OF CREDIT RISK (Details Narrative)", "role": "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative", "shortName": "CONCENTRATIONS OF CREDIT RISK (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "p", "us-gaap:ConcentrationRiskDisclosureTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashUninsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "role": "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2022-01-012022-03-31_us-gaap_SubsequentEventMember_custom_MultipleShortTermPromissoryNotePayableMember", "decimals": "0", "lang": null, "name": "us-gaap:ProceedsFromNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Cash Flows", "role": "http://nutralifebiosciences.com/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": "0", "lang": null, "name": "NLBS:WarrantsIssuedInConnectionWithDebtConversion", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - NATURE OF OPERATIONS", "role": "http://nutralifebiosciences.com/role/NatureOfOperations", "shortName": "NATURE OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies", "shortName": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - LIQUIDITY AND GOING CONCERN CONSIDERATIONS", "role": "http://nutralifebiosciences.com/role/LiquidityAndGoingConcernConsiderations", "shortName": "LIQUIDITY AND GOING CONCERN CONSIDERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-k.htm", "contextRef": "From2021-01-01to2021-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 70, "tag": { "NLBS_AccruedInterestMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued Interest [Member]", "label": "Accrued Interest [Member]" } } }, "localname": "AccruedInterestMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_AccruedInterestRelatedPartiesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued interest related parties current", "label": "Accrued expenses related party" } } }, "localname": "AccruedInterestRelatedPartiesCurrent", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "NLBS_AccruedInterestRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued interest related parties.", "label": "Accrued Interest \u2013 Related Parties" } } }, "localname": "AccruedInterestRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "NLBS_AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithConvertibleDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants issued in connection with convertible debt.", "label": "Warrants issued in connection with debt financing" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithConvertibleDebt", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "NLBS_AnnualIncreasesToBaseRentPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Annual increases to base rent percent.", "label": "Annual increases to base rent percent" } } }, "localname": "AnnualIncreasesToBaseRentPercent", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "NLBS_BeneficialConversionFeature": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Beneficial conversion feature", "label": "BeneficialConversionFeature", "verboseLabel": "Beneficial conversion feature" } } }, "localname": "BeneficialConversionFeature", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NLBS_CashPaidForMeasurementofOperatingLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash paid for amounts included in the measurement of operating lease liabilities.", "label": "Cash paid for amounts included in the measurement of operating lease liabilities" } } }, "localname": "CashPaidForMeasurementofOperatingLeaseLiabilities", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfSupplementalCashFlowInformationRelatedToLeasesDetails" ], "xbrltype": "monetaryItemType" }, "NLBS_ChiefExecutiveOfficerPresidentAndDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief Executive Officer President andDirector [Member]", "label": "Chief Executive Officer President And Director [Member]" } } }, "localname": "ChiefExecutiveOfficerPresidentAndDirectorMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_CoconutCreekFloridaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Coconut Creek, Florida [Member].", "label": "Coconut Creek, Florida [Member]" } } }, "localname": "CoconutCreekFloridaMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_CommonStockAndWarrantsIssuedForCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock and warrants issued for cash", "label": "Common stock and warrants issued for cash" } } }, "localname": "CommonStockAndWarrantsIssuedForCash", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "NLBS_CommonStockAndWarrantsIssuedForCashShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock and warrants issued for cash, shares", "label": "Common stock and warrants issued for cash, shares" } } }, "localname": "CommonStockAndWarrantsIssuedForCashShares", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "NLBS_CommonStockIssuedInConnectionWithDebtConversionsAndAccruedInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Common stock issued in connection with debt conversions and accrued interest", "label": "Common stock issued in connection with debt conversions and accrued interest" } } }, "localname": "CommonStockIssuedInConnectionWithDebtConversionsAndAccruedInterest", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "NLBS_CommonStockIssuedInConnectionWithDebtConversionsAndAccruedInterestShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock issued in connection with debt conversions and accrued interest, shares", "label": "Common stock issued in connection with debt conversions and accrued interest, shares" } } }, "localname": "CommonStockIssuedInConnectionWithDebtConversionsAndAccruedInterestShares", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "NLBS_ConvertiblePreferredStockMeasurementInputsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible preferred stock measurement inputs term.", "label": "Measurement inputs expected term" } } }, "localname": "ConvertiblePreferredStockMeasurementInputsTerm", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "durationItemType" }, "NLBS_ConvertibleSeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible Series B Preferred Stock [Member].", "label": "Convertible Series B Preferred Stock [Member]" } } }, "localname": "ConvertibleSeriesBPreferredStockMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAnti-dilutiveExcludedFromComputationOfNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "NLBS_DebtAndAccruedInterestConvertedToEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt and accrued interest converted to equity", "label": "Debt and accrued interest converted to equity" } } }, "localname": "DebtAndAccruedInterestConvertedToEquity", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NLBS_DebtSettlementAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Settlement Agreement [Member]", "label": "Debt Settlement Agreement [Member]" } } }, "localname": "DebtSettlementAgreementMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_DebtSettlementAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Settlement Agreements [Member]", "label": "Debt Settlement Agreements [Member]" } } }, "localname": "DebtSettlementAgreementsMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_DeerfieldBeachFloridaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deerfield Beach, Florida [Member]", "label": "Deerfield Beach, Florida [Member]" } } }, "localname": "DeerfieldBeachFloridaMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedInterest": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets tax deferred expense reserves and accruals accrued interest.", "label": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedInterest", "verboseLabel": "Accrued Interest" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedInterest", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "NLBS_DepositOnEquityAndLicenseAgreement": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposit on equity and license agreement.", "label": "Deposit on equity and license agreement" } } }, "localname": "DepositOnEquityAndLicenseAgreement", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "NLBS_DepositOnEquityAndLicenseAgreementUnderInvestingActivities": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deposit on equity and license agreement under investing activities.", "label": "DepositOnEquityAndLicenseAgreementUnderInvestingActivities", "negatedLabel": "Deposit on equity and license agreement" } } }, "localname": "DepositOnEquityAndLicenseAgreementUnderInvestingActivities", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NLBS_DepreciationDeferredTaxLiabilities": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities, Depreciation.", "label": "Deferred tax liabilities: Depreciation", "verboseLabel": "Depreciation" } } }, "localname": "DepreciationDeferredTaxLiabilities", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "NLBS_DisclosureEquityWarrantsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Warrants" } } }, "localname": "DisclosureEquityWarrantsAbstract", "nsuri": "http://nutralifebiosciences.com/20211231", "xbrltype": "stringItemType" }, "NLBS_DisclosureLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases", "terseLabel": "Schedule Of Supplemental Cash Flow Information Related To Leases", "verboseLabel": "Schedule Of Operating Leases Undiscounted Future Minimum Lease Payments" } } }, "localname": "DisclosureLeasesAbstract", "nsuri": "http://nutralifebiosciences.com/20211231", "xbrltype": "stringItemType" }, "NLBS_DisclosureRevenueShareAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue Share Agreements" } } }, "localname": "DisclosureRevenueShareAgreementsAbstract", "nsuri": "http://nutralifebiosciences.com/20211231", "xbrltype": "stringItemType" }, "NLBS_DistributionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distribution Agreement [Member]", "label": "Distribution Agreement [Member]" } } }, "localname": "DistributionAgreementMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_DistributorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Distributor [Member]", "label": "Distributor [Member]" } } }, "localname": "DistributorMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_EdgarWardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Edgar Ward [Member]", "label": "Edgar Ward [Member]" } } }, "localname": "EdgarWardMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_EquityWarrantsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Warrants Disclosure [Text Block]", "label": "EQUITY WARRANTS" } } }, "localname": "EquityWarrantsDisclosureTextBlock", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/EquityWarrants" ], "xbrltype": "textBlockItemType" }, "NLBS_ExercisePriceFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price 5 [Member]", "label": "Exercise Price 5 [Member]" } } }, "localname": "ExercisePriceFiveMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "NLBS_ExercisePriceFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price 4 [Member]", "label": "Exercise Price 4 [Member]" } } }, "localname": "ExercisePriceFourMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "NLBS_ExercisePriceOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price 1 [Member]", "label": "Exercise Price 1 [Member]" } } }, "localname": "ExercisePriceOneMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "NLBS_ExercisePriceSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Six [Member]", "label": "Exercise Price 6 [Member]" } } }, "localname": "ExercisePriceSixMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "NLBS_ExercisePriceThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price 3 [Member]", "label": "Exercise Price 3 [Member]" } } }, "localname": "ExercisePriceThreeMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "NLBS_ExercisePriceTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price 2 [Member]", "label": "Exercise Price 2 [Member]" } } }, "localname": "ExercisePriceTwoMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "NLBS_IncomeFromDebtForgiveness": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income From Debt Forgiveness.", "label": "Income from debt forgiveness", "negatedLabel": "Income from debt forgiveness" } } }, "localname": "IncomeFromDebtForgiveness", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows", "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "NLBS_IncreaseDecreaseInRevenueShareAgreementsPayable": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revenue share agreements payable", "label": "Revenue share agreements payable [Default Label]", "verboseLabel": "Revenue share agreements payable" } } }, "localname": "IncreaseDecreaseInRevenueShareAgreementsPayable", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NLBS_InvestmentAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment Agreement [Member]", "label": "Investment Agreement [Member]" } } }, "localname": "InvestmentAgreementMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_InvestmentInConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment in convertible preferred stock.", "label": "InvestmentInConvertiblePreferredStock", "verboseLabel": "Investment in convertible preferred stock" } } }, "localname": "InvestmentInConvertiblePreferredStock", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NLBS_IssuanceOfSharesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of shares description.", "label": "Issuance of shares description" } } }, "localname": "IssuanceOfSharesDescription", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative", "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "NLBS_LesseeOperatingLeaseExpirrationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease expiration description.", "label": "Operating lease expiration description" } } }, "localname": "LesseeOperatingLeaseExpirrationDescription", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "NLBS_LesseeOperatingLeasesAndFinancingLeasesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee Operating Leases And Financing Leases [Text Block]", "label": "LEASES" } } }, "localname": "LesseeOperatingLeasesAndFinancingLeasesTextBlock", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "NLBS_LiabilityForStockToBeIssued": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Liability for stock to be issued", "label": "Liability for stock to be issued" } } }, "localname": "LiabilityForStockToBeIssued", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "NLBS_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement [Member]", "label": "License Agreement [Member]" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_LicenseFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License Fee.", "label": "License fees" } } }, "localname": "LicenseFee", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "NLBS_LongTermDebtsCurrent": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Long term debt current.", "label": "Current portion of SBA Note Payable" } } }, "localname": "LongTermDebtsCurrent", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "NLBS_LordGlobalCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lord Global Corporation [Member]", "label": "Lord Global Corporation [Member]" } } }, "localname": "LordGlobalCorporationMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_MultipleShortTermPromissoryNotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Multiple Short Term Promissory Notes Payable [Member]", "label": "Multiple Short Term Promissory Notes Payable [Member]" } } }, "localname": "MultipleShortTermPromissoryNotePayableMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_NoteholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noteholders [Member]", "label": "Noteholders [Member]" } } }, "localname": "NoteholdersMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_NumberOfWarrantsExchangeShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants exchange, shares.", "label": "Number of warrants exchange, shares" } } }, "localname": "NumberOfWarrantsExchangeShares", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "NLBS_OneYearAnniversaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Year Anniversary [Member]", "label": "One Year Anniversary [Member]" } } }, "localname": "OneYearAnniversaryMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_OperatingLeaseLiabilitiesUnderAsc842": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating lease liabilities under asc842", "label": "Operating lease liabilities under ASC 842" } } }, "localname": "OperatingLeaseLiabilitiesUnderAsc842", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NLBS_OperatingLossCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards, expiration year.", "label": "Operating loss carryforwards, expiration year" } } }, "localname": "OperatingLossCarryforwardsExpirationYear", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "stringItemType" }, "NLBS_OtherAccruedExpensesCurrent": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued expenses- other.", "label": "Accrued Expenses - Other" } } }, "localname": "OtherAccruedExpensesCurrent", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "NLBS_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck Protection Program [Member]", "label": "Paycheck Protection Program [Member]" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_PercentageOfLicenseRoyaltyFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of license royalty fee.", "label": "Percentage of license royalty fee" } } }, "localname": "PercentageOfLicenseRoyaltyFee", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "percentItemType" }, "NLBS_PercentagesOfValuationAllowanceRecorded": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentages of valuation allowance recorded.", "label": "Percentages of valuation allowance recorded" } } }, "localname": "PercentagesOfValuationAllowanceRecorded", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "percentItemType" }, "NLBS_PhytochemMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Phytochem [Member]", "label": "Phytochem [Member]" } } }, "localname": "PhytochemMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_PrincipalAmountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principal Amount [Member]", "label": "Principal Amount [Member]" } } }, "localname": "PrincipalAmountMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_PrincipalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Principal [Member]", "label": "Principal [Member]" } } }, "localname": "PrincipalMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_ProductionManagerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Production manager [Member].", "label": "Production Manager [Member]" } } }, "localname": "ProductionManagerMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_RelatedPartyTransactionsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party Transactions [Policy Text Block]", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsPolicyTextBlock", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "NLBS_RevenueReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revenue received.", "label": "[custom:RevenueReceived]" } } }, "localname": "RevenueReceived", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "NLBS_RevenueShareAgreementsDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue share agreements description.", "label": "[custom:RevenueShareAgreementsDescription]" } } }, "localname": "RevenueShareAgreementsDescription", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "NLBS_RevenueShareAgreementsPayable": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue share agreements payable.", "label": "Revenue share agreements payable" } } }, "localname": "RevenueShareAgreementsPayable", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "NLBS_RevenueShareAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue Share Agreements [Text Block]", "label": "REVENUE SHARE AGREEMENTS" } } }, "localname": "RevenueShareAgreementsTextBlock", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/RevenueShareAgreements" ], "xbrltype": "textBlockItemType" }, "NLBS_RightOfUseAssetAdditionsUnderAsc842": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Right of use asset additions under asc842", "label": "Right of use asset addition under ASC 842" } } }, "localname": "RightOfUseAssetAdditionsUnderAsc842", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NLBS_ScheduleOfCashFlowSupplementalLeaseDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Cash Flow Supplemental Lease Disclosures [Table Text Block]", "label": "SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO LEASES" } } }, "localname": "ScheduleOfCashFlowSupplementalLeaseDisclosuresTableTextBlock", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "NLBS_ScheduleOfWarrantsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Warrants Activity [Table Text Block]", "label": "SCHEDULE OF WARRANTS ACTIVITY" } } }, "localname": "ScheduleOfWarrantsActivityTableTextBlock", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/EquityWarrantsTables" ], "xbrltype": "textBlockItemType" }, "NLBS_SecuredConvertibleFivePointSevenFivePercentagePromissoryNotePayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Secured Convertible 5.75% Promissory Note Payable [Member]", "label": "Secured Convertible 5.75% Promissory Note Payable [Member]" } } }, "localname": "SecuredConvertibleFivePointSevenFivePercentagePromissoryNotePayableMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_SeriesBConvertiblePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B Convertible Preferred Stock [Member]", "label": "Series B Convertible Preferred Stock [Member]" } } }, "localname": "SeriesBConvertiblePreferredStockMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_SeriesXPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series X Preferred Stock [Member]", "label": "Series X Preferred Stock [Member]" } } }, "localname": "SeriesXPreferredStockMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_SharesIssuedInConnectionWithDebtFinancing": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Shares issued in connection with debt financing", "label": "Shares issued in connection with debt financing" } } }, "localname": "SharesIssuedInConnectionWithDebtFinancing", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "NLBS_SharesIssuedInConnectionWithDebtFinancingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares issued in connection with debt financing, shares", "label": "Shares issued in connection with debt financing, shares" } } }, "localname": "SharesIssuedInConnectionWithDebtFinancingShares", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "NLBS_ShippingAndHandlingCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shipping and Handling Costs [Policy Text Block]", "label": "Shipping and Handling Costs" } } }, "localname": "ShippingAndHandlingCostsPolicyTextBlock", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "NLBS_StockBasedCompensationDeferredTaxLiabilities": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities, Stock based compensation.", "label": "Stock based compensation" } } }, "localname": "StockBasedCompensationDeferredTaxLiabilities", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "NLBS_StockIssuedDuringPeriodSharesInvestmentInConvertiblePreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares investment in convertible preferred stock.", "label": "Investment in convertible preferred stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesInvestmentInConvertiblePreferredStock", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "NLBS_StockIssuedDuringPeriodSharesPreferredStockIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares preferred stock issued for services", "label": "Preferred stock issued for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesPreferredStockIssuedForServices", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "NLBS_StockIssuedDuringPeriodValueInvestmentInConvertiblePreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock issued during period value investment in convertible preferred stock.", "label": "Investment in convertible preferred stock" } } }, "localname": "StockIssuedDuringPeriodValueInvestmentInConvertiblePreferredStock", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "NLBS_StockIssuedDuringPeriodValuePreferredStockIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Preferred stock issued for services.", "label": "Preferred stock issued for services" } } }, "localname": "StockIssuedDuringPeriodValuePreferredStockIssuedForServices", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "NLBS_StockPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Purchase Agreement [Member]", "label": "Stock Purchase Agreement [Member]" } } }, "localname": "StockPurchaseAgreementMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_SubLeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sub-Lease Agreement [Member]", "label": "Sub-Lease Agreement [Member]" } } }, "localname": "SubLeaseAgreementMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_SubscriptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Agreement [Member]", "label": "Subscription Agreement [Member]" } } }, "localname": "SubscriptionAgreementMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_ThirdPartyInvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Party Investors [Member]", "label": "Third Party Investors [Member]" } } }, "localname": "ThirdPartyInvestorsMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_ThreeConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Three Consultants [Member]", "label": "Three Consultants [Member]" } } }, "localname": "ThreeConsultantsMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_TwoCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Customers [Member]", "label": "Two Customers [Member]" } } }, "localname": "TwoCustomersMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_TwoRevenueShareAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Revenue Share Agreement [Member]", "label": "Two Revenue Share Agreement [Member]" } } }, "localname": "TwoRevenueShareAgreementMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_TwoSubscriptionAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Subscription Agreement [Member]", "label": "Two Subscription Agreement [Member]" } } }, "localname": "TwoSubscriptionAgreementMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_TwoThousandTwentyConvertiblesNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Convertibles Notes [Member]", "label": "2020 Convertibles Notes [Member]" } } }, "localname": "TwoThousandTwentyConvertiblesNotesMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_TwoThousandTwentySubscriptionAgreementNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Subscription Agreement Notes [Member]", "label": "2020 Subscription Agreement Notes [Member]" } } }, "localname": "TwoThousandTwentySubscriptionAgreementNotesMember", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "NLBS_WarrantsIssuedForCash": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants issued for cash", "label": "Warrants issued for cash" } } }, "localname": "WarrantsIssuedForCash", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "NLBS_WarrantsIssuedForIssuanceOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrants issued for issuance of debt", "label": "Warrants issued for the issuance of debt" } } }, "localname": "WarrantsIssuedForIssuanceOfDebt", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "NLBS_WarrantsIssuedInConnectionWithDebtConversion": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Warrants Issued In Connection With Debt Conversion.", "label": "Warrants issued in connection with debt conversion" } } }, "localname": "WarrantsIssuedInConnectionWithDebtConversion", "nsuri": "http://nutralifebiosciences.com/20211231", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r565", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r565", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r565", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r565", "r567", "r568" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r566" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r569" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents incorporated by reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r560" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r580" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r577" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r568" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r565", "r567", "r568" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r567" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r561" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r559" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r558" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r564" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r579" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://nutralifebiosciences.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r111", "r242", "r246", "r251", "r395", "r396", "r400", "r401", "r447", "r551" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r111", "r242", "r246", "r251", "r395", "r396", "r400", "r401", "r447", "r551" ], "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r169", "r333", "r337", "r528" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r257", "r296", "r342", "r343", "r460", "r461", "r462", "r463", "r464", "r465", "r484", "r525", "r529", "r552", "r553" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ContingenciesDetailsNarrative", "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r257", "r296", "r342", "r343", "r460", "r461", "r462", "r463", "r464", "r465", "r484", "r525", "r529", "r552", "r553" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r169", "r333", "r337", "r528" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r166", "r333", "r335", "r487", "r524", "r526" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r166", "r333", "r335", "r487", "r524", "r526" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r257", "r296", "r339", "r342", "r343", "r460", "r461", "r462", "r463", "r464", "r465", "r484", "r525", "r529", "r552", "r553" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ContingenciesDetailsNarrative", "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r257", "r296", "r339", "r342", "r343", "r460", "r461", "r462", "r463", "r464", "r465", "r484", "r525", "r529", "r552", "r553" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ContingenciesDetailsNarrative", "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r167", "r168", "r333", "r336", "r527", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r167", "r168", "r333", "r336", "r527", "r536", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r170", "r445" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_VicePresidentMember": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "label": "Vice President [Member]" } } }, "localname": "VicePresidentMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r45" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCRUED EXPENSES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44", "r450" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r25", "r171", "r172" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net of allowance for doubtful accounts in the amount of $0 and $0" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r12", "r13", "r49" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Officer \u2013 Bonus" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses (related party $148,552 and $91,048)", "totalLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRentCurrent": { "auth_ref": [ "r12", "r13", "r49" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Rent" } } }, "localname": "AccruedRentCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r41", "r222" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r26", "r360", "r450" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r113", "r114", "r115", "r357", "r358", "r359", "r408" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r311", "r319", "r378" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Beneficial conversion feature", "terseLabel": "Additional paid in capital, beneficial conversion feature", "verboseLabel": "Beneficial conversion" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r253", "r311", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Warrants issued as compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r173", "r189", "r191", "r193" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "Accounts Receivable, Allowance for Credit Loss", "verboseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r31", "r173", "r189" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AlternativeInvestmentMeasurementInput": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure alternative investment.", "label": "Measurement input risk free interest rate" } } }, "localname": "AlternativeInvestmentMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r78", "r90", "r277", "r424" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of debt discount", "verboseLabel": "Amortization of Debt Discount (Premium)" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r90", "r208", "r214" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of intangible asset", "verboseLabel": "Amortization of Intangible Assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative", "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAnti-dilutiveExcludedFromComputationOfNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAnti-dilutiveExcludedFromComputationOfNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAnti-dilutiveExcludedFromComputationOfNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAnti-dilutiveExcludedFromComputationOfNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/LeasesDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r90", "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r106", "r155", "r158", "r164", "r185", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r395", "r400", "r415", "r448", "r450", "r504", "r515" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r8", "r10", "r62", "r106", "r185", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r395", "r400", "r415", "r448", "r450" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r346", "r356" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r37", "r92" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r16", "r93" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r85", "r92", "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "CASH AND CASH EQUIVALENTS AT END OF YEAR", "periodStartLabel": "CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r85", "r416" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET CHANGE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashUninsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.", "label": "Cash balances" } } }, "localname": "CashUninsuredAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r103", "r106", "r125", "r126", "r127", "r129", "r131", "r136", "r137", "r138", "r185", "r242", "r246", "r247", "r248", "r251", "r252", "r294", "r295", "r299", "r303", "r415", "r570" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical", "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrants exercise price", "verboseLabel": "Exercise price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Number of warrants issued" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Warrants outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r226", "r227", "r228", "r238", "r538" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r113", "r114", "r408" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative", "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, shares par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r311" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24", "r450" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock; $0.0001 par value, 499,990,000 authorized shares; 171,398,834 and 160,419,488 shares issued and outstanding" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r145", "r146", "r169", "r412", "r413", "r537" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r145", "r146", "r169", "r412", "r413", "r535", "r537" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r145", "r146", "r169", "r412", "r413", "r535", "r537" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.", "label": "CONCENTRATIONS OF CREDIT RISK" } } }, "localname": "ConcentrationRiskDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRisk" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r145", "r146", "r169", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r143", "r145", "r146", "r147", "r412", "r414", "r537" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r145", "r146", "r169", "r412", "r413", "r537" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r99", "r397" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r322", "r323", "r334" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Customer deposits" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r95", "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Shares converted" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r95", "r96", "r97" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of stock" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebtSecuritiesMember": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.", "label": "Convertible Debt Securities [Member]" } } }, "localname": "ConvertibleDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAnti-dilutiveExcludedFromComputationOfNetLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r294", "r295", "r299" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": { "auth_ref": [ "r22", "r23", "r306", "r312", "r315" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.", "label": "Convertible preferred stock shares issued" } } }, "localname": "ConvertiblePreferredStockSharesIssuedUponConversion", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r74", "r487" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r107", "r375", "r383", "r385" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r144", "r169" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r95", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt conversion, amount", "verboseLabel": "Debt conversion, total" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "auth_ref": [ "r95", "r97" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.", "label": "Debt Conversion, Converted Instrument, Shares Issued" } } }, "localname": "DebtConversionConvertedInstrumentSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r102", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r271", "r278", "r279", "r281", "r288" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r19", "r20", "r21", "r105", "r111", "r254", "r255", "r256", "r257", "r258", "r259", "r261", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r283", "r284", "r285", "r286", "r425", "r505", "r506", "r514" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r256", "r282" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "verboseLabel": "Debt instrument interest rate" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r105" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt forgiveness" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r19", "r21", "r312", "r505", "r506", "r513", "r514" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51", "r255" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r52", "r257", "r411" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt instrument maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r52" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt instrument, maturity date, description" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r53", "r105", "r111", "r254", "r255", "r256", "r257", "r258", "r259", "r261", "r267", "r268", "r269", "r270", "r272", "r273", "r274", "r275", "r276", "r277", "r283", "r284", "r285", "r286", "r425" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "auth_ref": [ "r267", "r424", "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt discount.", "label": "Original issue discounts" } } }, "localname": "DebtInstrumentUnamortizedDiscount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r424", "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Notes payable, unamortized discount" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": { "auth_ref": [ "r78" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses.", "label": "Debt Related Commitment Fees and Debt Issuance Costs", "negatedLabel": "Finance costs" } } }, "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r90", "r107", "r376", "r383", "r384", "r385" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfIncomeTaxProvisionDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfIncomeTaxProvisionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r33" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r369" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets, Net", "totalLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r369" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Total" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r373", "r374" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net operating loss carry forwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r373", "r374" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Accrued Wages" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r368" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less: valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r90", "r220" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/PropertyAndEquipmentNetDetailsNarrative", "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r90", "r220" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfLesseeLeasingArrangementsOperatingLeases": { "auth_ref": [ "r427", "r428" ], "lang": { "en-us": { "role": { "documentation": "A general description of the nature of the existing leasing arrangements of a lessee for all operating leases including, but not limited to: (1) rental escalation clauses; (2) renewal or purchase options; (3) guarantees or indemnities, if any, (4) restrictions imposed by lease arrangements; (5) unusual provisions or conditions; (6) contingent rentals, if any; and (7) lease expiration dates.", "label": "Description of operating lease" } } }, "localname": "DescriptionOfLesseeLeasingArrangementsOperatingLeases", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r130" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Net loss per weighted average common share - basic and diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r108", "r364", "r386" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "negatedLabel": "U.S. Federal statutory income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r364", "r386" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r364", "r386" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "negatedLabel": "State income tax, net of federal benefit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfReconciliationOfStatutoryFederalIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r67", "r68", "r69", "r113", "r114", "r115", "r117", "r122", "r124", "r135", "r188", "r311", "r319", "r357", "r358", "r359", "r379", "r380", "r408", "r417", "r418", "r419", "r420", "r421", "r422", "r530", "r531", "r532", "r581" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative", "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/ScheduleOfWarrantsActivityDetails", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMember": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "Trading in a derivative instrument whose primary underlying risk is tied to share prices.", "label": "Equity [Member]" } } }, "localname": "EquityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity method investment, ownership percentage", "verboseLabel": "Equity ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ExtinguishmentOfDebtAxis": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the debt extinguished including the amount of gain (loss), the income tax effect on the gain (loss), and the amount of gain (loss), net or the related income tax, by debt instrument.", "label": "Extinguishment of Debt [Axis]" } } }, "localname": "ExtinguishmentOfDebtAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ExtinguishmentOfDebtTypeDomain": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Type of debt extinguished." } } }, "localname": "ExtinguishmentOfDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r90", "r289" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value of Warrants", "verboseLabel": "Warrants issued as compensation" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r430" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Current portion of finance leases", "negatedLabel": "Less: current portion" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/ScheduleOfFinanceLeasesUndiscountedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "SCHEDULE OF FINANCE LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r430" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance leases, net of current portion", "totalLabel": "Present value of minimum lease payments, net of current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/ScheduleOfFinanceLeasesUndiscountedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r440" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfFinanceLeasesUndiscountedFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total undiscounted future minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfFinanceLeasesUndiscountedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r440" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfFinanceLeasesUndiscountedFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "verboseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfFinanceLeasesUndiscountedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r440" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfFinanceLeasesUndiscountedFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "verboseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfFinanceLeasesUndiscountedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r440" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: amount representing interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfFinanceLeasesUndiscountedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r433", "r437" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Payments on finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r177", "r178", "r180", "r181", "r182", "r190", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r280", "r309", "r407", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r570", "r571", "r572", "r573", "r574", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r213" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfIntangibleAssetDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedLabel": "Less: accumulated amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfIntangibleAssetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails": { "order": 6.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Thereafter" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "auth_ref": [ "r215" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r215" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails": { "order": 5.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2026" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r215" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails": { "order": 4.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2025" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r215" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails": { "order": 3.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r215" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r209", "r210", "r213", "r216", "r488", "r490" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r209", "r212" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r213", "r488" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://nutralifebiosciences.com/role/ScheduleOfIntangibleAssetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Intangible asset", "totalLabel": "Estimated amortization expenses" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/ScheduleOfEstimateAmortizationExpenseDetails", "http://nutralifebiosciences.com/role/ScheduleOfIntangibleAssetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedPatentsGross": { "auth_ref": [ "r213" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfIntangibleAssetDetails": { "order": 1.0, "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.", "label": "Patent", "verboseLabel": "Patent purchase price" } } }, "localname": "FiniteLivedPatentsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative", "http://nutralifebiosciences.com/role/ScheduleOfIntangibleAssetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r76" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r207", "r211" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Intangible Asset" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r73", "r106", "r155", "r157", "r160", "r163", "r165", "r185", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r415" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOfInvestments": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount by which the fair value of an investment is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.", "label": "Other than Temporary Impairment Losses, Investments" } } }, "localname": "ImpairmentOfInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "auth_ref": [ "r218", "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.", "label": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r70", "r155", "r157", "r160", "r163", "r165", "r503", "r509", "r511", "r522" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r108", "r365", "r366", "r371", "r381", "r387", "r389", "r390", "r391" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r109", "r123", "r124", "r154", "r363", "r382", "r388", "r523" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfIncomeTaxProvisionDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax expense", "totalLabel": "Total tax provision" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfIncomeTaxProvisionDetails", "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r66", "r361", "r362", "r366", "r367", "r370", "r377" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r89" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r89" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r89", "r485" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "verboseLabel": "Customer deposits" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r89" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "verboseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r89" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r89", "r437" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r89" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "verboseLabel": "Other current liability" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r89" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "INTANGIBLE ASSET" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAsset" ], "xbrltype": "textBlockItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r83", "r87", "r94" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "auth_ref": [ "r508", "r520" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables.", "label": "Accrued Interest" } } }, "localname": "InterestPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r58" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished Goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r60", "r450" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://nutralifebiosciences.com/role/ScheduleOfInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r15", "r61", "r100", "r134", "r202", "r203", "r204", "r486" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "verboseLabel": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r59" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw Materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTextBlock": { "auth_ref": [ "r179", "r183", "r186", "r187" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investment.", "label": "INVESTMENT" } } }, "localname": "InvestmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/Investment" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r519" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "verboseLabel": "Investment" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r221" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "verboseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SCHEDULE OF OPERATING LEASES UNDISCOUNTED FUTURE MINIMUM LEASE PAYMENTS" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r440" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfOperatingLeasesUndiscountedFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total undiscounted future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfOperatingLeasesUndiscountedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r440" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfOperatingLeasesUndiscountedFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfOperatingLeasesUndiscountedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r440" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfOperatingLeasesUndiscountedFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfOperatingLeasesUndiscountedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r440" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfOperatingLeasesUndiscountedFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfOperatingLeasesUndiscountedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r440" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: amount representing imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfOperatingLeasesUndiscountedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, operating lease, term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r48", "r106", "r159", "r185", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r396", "r400", "r401", "r415", "r448", "r449" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r106", "r185", "r415", "r450", "r507", "r517" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 (Deficit) Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders\u2019 (Deficit) Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50", "r106", "r185", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r396", "r400", "r401", "r415", "r448", "r449", "r450" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r335" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Notes payable - SBA, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermInvestments": { "auth_ref": [ "r38" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).", "label": "Investment" } } }, "localname": "LongTermInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r53", "r241" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r229", "r230", "r231", "r233", "r234", "r235", "r237", "r239", "r240" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDamagesPaidValue": { "auth_ref": [ "r229", "r232", "r236" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of damages paid to the plaintiff in the legal matter.", "label": "Contingency principal amount" } } }, "localname": "LossContingencyDamagesPaidValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r76" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Advertising and promotion" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputOptionVolatilityMember": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.", "label": "Measurement Input, Option Volatility [Member]" } } }, "localname": "MeasurementInputOptionVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r410" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability." } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r85" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r85", "r88", "r91" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "negatedLabel": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Used in Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LiquidityAndGoingConcernConsiderationsDetailsNarrative", "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r64", "r65", "r69", "r71", "r91", "r106", "r116", "r118", "r119", "r120", "r121", "r123", "r124", "r128", "r155", "r157", "r160", "r163", "r165", "r185", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r409", "r415", "r510", "r521" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r77" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r47" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Notes payable, net of unamortized discount of $200,524 and $206,542 (related party $1,000,000 and $1,000,000)" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r43", "r110", "r444" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes payable related parties current", "verboseLabel": "Notes payable to shareholders" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r155", "r157", "r160", "r163", "r165" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r430" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative", "http://nutralifebiosciences.com/role/ScheduleOfOperatingLeasesUndiscountedFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r430" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Current portion of operating lease liability", "verboseLabel": "Operating lease liability, current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r430" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r429" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use assets", "verboseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r90" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Amortization of right of use asset" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r439", "r441" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r438", "r441" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLossCarryforwards": { "auth_ref": [ "r372" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.", "label": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r3", "r404" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "NATURE OF OPERATIONS" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NatureOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r12", "r13", "r14", "r49" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Current Liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r11", "r12", "r49", "r450" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other current liability" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r392" ], "lang": { "en-us": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForParticipationLiabilities": { "auth_ref": [ "r489" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments related to participation costs.", "label": "Payments for participation liabilities" } } }, "localname": "PaymentsForParticipationLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r80" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23", "r294" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockRedemptionAmount": { "auth_ref": [ "r54", "r293" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The redemption (or callable) amount of currently redeemable preferred stock. Includes amounts representing dividends not currently declared or paid but which will be payable under the redemption features or for which ultimate payment is solely within the control of the issuer.", "label": "Preferred stock, redemption amount" } } }, "localname": "PreferredStockRedemptionAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "verboseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23", "r294" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23", "r450" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock value" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockVotingRights": { "auth_ref": [ "r23", "r312" ], "lang": { "en-us": { "role": { "documentation": "Description of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.", "label": "Preferred stock voting rights" } } }, "localname": "PreferredStockVotingRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r7", "r9", "r205", "r206" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid and other current assets" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r81" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Common shares issued for cash", "verboseLabel": "Proceeds from common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r82" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from debt issuances" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r81" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from warrants issued for cash" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.", "label": "Proceeds from issuance of stock" } } }, "localname": "ProceedsFromIssuanceOrSaleOfEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromNotesPayable": { "auth_ref": [ "r82" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.", "label": "Proceeds from SBA financing", "verboseLabel": "Proceeds from notes payable" } } }, "localname": "ProceedsFromNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StatementsOfCashFlows", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRentsReceived": { "auth_ref": [ "r86" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received for rents during the current period.", "label": "Proceeds from rent" } } }, "localname": "ProceedsFromRentsReceived", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Cash proceeds, exercise price" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r64", "r65", "r69", "r84", "r106", "r116", "r123", "r124", "r155", "r157", "r160", "r163", "r165", "r185", "r242", "r243", "r244", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r394", "r398", "r399", "r402", "r403", "r409", "r415", "r511" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LiquidityAndGoingConcernConsiderationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r222", "r431", "r436" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation and amortization from plant, property, and equipment and right-of-use asset from finance lease.", "label": "Finance lease equipment, accumulated depreciation" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "auth_ref": [ "r63", "r223", "r436" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.", "label": "Finance lease equipment" } } }, "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LeasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r41", "r223" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r225", "r539", "r540", "r541" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "PROPERTY AND EQUIPMENT, NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/PropertyAndEquipmentNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r40", "r221" ], "calculation": { "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, at cost" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r223", "r450", "r512", "r518" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net", "totalLabel": "Property and equipment,net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r39", "r223", "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r17", "r223" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "SCHEDULE OF PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/PropertyAndEquipmentNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r17", "r221" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r72", "r192" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Bad debt recoveries" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "auth_ref": [ "r32", "r174" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.", "label": "Allowance for Doubtful Accounts" } } }, "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r341", "r442", "r443" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r341", "r442", "r446", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r27", "r319", "r360", "r450", "r516", "r533", "r534" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/LiquidityAndGoingConcernConsiderationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r113", "r114", "r115", "r117", "r122", "r124", "r188", "r357", "r358", "r359", "r379", "r380", "r408", "r530", "r532" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r152", "r153", "r156", "r161", "r162", "r166", "r167", "r169", "r332", "r333", "r487" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r101", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r338" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RisksAndUncertaintiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "localname": "RisksAndUncertaintiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "License royalty fee" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Exercise, price per share" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r145", "r169" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ConcentrationsOfCreditRiskDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "SCHEDULE OF ACCRUED EXPENSES" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfAnti-dilutiveExcludedFromComputationOfNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF ANTI-DILUTIVE EXCLUDED FROM COMPUTATION OF NET LOSS PER SHARE" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "SCHEDULE OF INCOME TAX PROVISION" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r369" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "SCHEDULE OF RECONCILIATION OF STATUTORY FEDERAL INCOME TAX RATE" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r209", "r212", "r488" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "SCHEDULE OF INTANGIBLE ASSET" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r15", "r34", "r35", "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "SCHEDULE OF INVENTORIES" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r41", "r223" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r55", "r103", "r136", "r137", "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r299", "r303", "r309", "r312", "r313", "r314", "r316", "r317", "r318", "r319" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r320", "r344" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "SCHEDULE OF WARRANTS OUTSTANDING" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/EquityWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "SCHEDULE OF ESTIMATE AMORTIZATION EXPENSE" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r89" ], "calculation": { "http://nutralifebiosciences.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://nutralifebiosciences.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows", "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised", "negatedLabel": "Warrants Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Warrants Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Warrants Issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Warrants outstanding, ending balance", "periodStartLabel": "Warrants outstanding, beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r344", "r347" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r355" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/ScheduleOfWarrantsOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Stock price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Shares issued, price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r44" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r22", "r23", "r24", "r103", "r106", "r125", "r126", "r127", "r129", "r131", "r136", "r137", "r138", "r185", "r242", "r246", "r247", "r248", "r251", "r252", "r294", "r295", "r299", "r303", "r311", "r415", "r570" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical", "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r57", "r67", "r68", "r69", "r113", "r114", "r115", "r117", "r122", "r124", "r135", "r188", "r311", "r319", "r357", "r358", "r359", "r379", "r380", "r408", "r417", "r418", "r419", "r420", "r421", "r422", "r530", "r531", "r532", "r581" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative", "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/ScheduleOfWarrantsActivityDetails", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical", "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/LeasesDetailsNarrative", "http://nutralifebiosciences.com/role/ScheduleOfWarrantsActivityDetails", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r113", "r114", "r115", "r135", "r487" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/BalanceSheetsParenthetical", "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/LeasesDetailsNarrative", "http://nutralifebiosciences.com/role/ScheduleOfWarrantsActivityDetails", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssued1": { "auth_ref": [ "r95", "r96", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of stock issued in noncash financing activities.", "label": "Shares issued in connection with debt" } } }, "localname": "StockIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r56", "r272", "r311", "r312", "r319" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Conversion series B Preferred Stock to Common Stock, shares", "verboseLabel": "Stock issued during period, shares, conversion of convertible securities" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Shares issued for services, shares", "terseLabel": "Common stock, shares", "verboseLabel": "Consulting services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r23", "r24", "r311", "r319" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Shares issued for cash, shares", "terseLabel": "Stock issued during the period, shares", "verboseLabel": "Stock issued during period, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock issued during period, shares, purchase of assets" } } }, "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r23", "r24", "r311", "r319" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Stock issued during the period for stock based compensation, shares" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r57", "r311", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Conversion series B Preferred Stock to Common Stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Shares issued for services", "terseLabel": "Common stock, value", "verboseLabel": "Consulting services, value" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r23", "r24", "r311", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Shares issued for cash", "verboseLabel": "Stock issued during period, value" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination.", "label": "Stock issued during period, value, purchase of assets" } } }, "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IntangibleAssetDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r23", "r24", "r319", "r345", "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Stock issued during the period for stock based compensation, value" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r28", "r29", "r106", "r175", "r185", "r415", "r450" ], "calculation": { "http://nutralifebiosciences.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending Balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 (deficit) equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets", "http://nutralifebiosciences.com/role/StatementsOfChangesInStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 (Deficit) Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r104", "r295", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r310", "r319", "r321" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r423", "r452" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r423", "r452" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r423", "r452" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r423", "r452" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r451", "r453" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "LIQUIDITY AND GOING CONCERN CONSIDERATIONS" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/LiquidityAndGoingConcernConsiderations" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TradingActivityByTypeAxis": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Information by type of trading activity.", "label": "Trading Activity [Axis]" } } }, "localname": "TradingActivityByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_TradingActivityByTypeDomain": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit)." } } }, "localname": "TradingActivityByTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r177", "r178", "r180", "r181", "r182", "r280", "r309", "r407", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r570", "r571", "r572", "r573", "r574", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/InvestmentDetailsNarrative", "http://nutralifebiosciences.com/role/LeasesDetailsNarrative", "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/RevenueShareAgreementsDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r139", "r140", "r141", "r142", "r148", "r149", "r150" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "auth_ref": [ "r369" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.", "label": "Change in valuation allowance" } } }, "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/ScheduleOfAnti-dilutiveExcludedFromComputationOfNetLossPerShareDetails", "http://nutralifebiosciences.com/role/ScheduleOfWarrantsActivityDetails", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrant measurement inputs", "verboseLabel": "Warrants and rights outstanding, measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r411" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrant expected term", "terseLabel": "Warrant expiration term", "verboseLabel": "Warrants term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/NotesPayableDetailsNarrative", "http://nutralifebiosciences.com/role/StockholdersEquityDetailsNarrative", "http://nutralifebiosciences.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Number of weighted average shares outstanding - basic and diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://nutralifebiosciences.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r112": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714" }, "r183": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "321", "URI": "http://asc.fasb.org/topic&trid=75115024" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r186": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "325", "URI": "http://asc.fasb.org/topic&trid=2197064" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=51888271" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r204": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.CC)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r228": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=7516071&loc=d3e13374-112631" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21564-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r3": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r321": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e34017-109320" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r391": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r404": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(Note 1)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r453": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=6473203&loc=d3e55336-107963" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.27(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r554": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r555": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r556": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r557": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r558": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r559": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r561": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r562": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r563": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r564": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r565": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r566": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r567": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r568": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r569": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r571": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r572": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r573": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r574": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r575": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r576": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r577": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r578": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r579": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" } }, "version": "2.1" } ZIP 77 0001493152-22-009623-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-009623-xbrl.zip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�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

#Y#D_:==]O M/S3SMG#V\,';W5U_\'O#,]7'3F?8G:,;+;%C=EB40+U29+U*LO+@HB(['XYT MVXZ"K".8HE'^N6?.O5>BROGF1RE_D=V0^T+W9_8 ME>YZ*D]I%WE*_9?F*;V23"+XA3U9T@\S;V["#_\?4$L#!!0 ( ,6+BU01 MH7)\F#\ )9' 0 9F]R;3$P+6M?,# Q+FIP9[V["SR3?_\_?I5*9Q52 M*NND VF54))].@II$19B=P?)I'5RGEV5$-)*L2+VR9EA'S'*855 MM]Y1._#PQ;O%VX[G?E:W:11LU[]R]]&2I6LUUJW7U-ZQ<]=NG8,&AD:'#AN? M.'GJM-D9ON5YWN^%.N'??R]O'U\\_Z'%P2.B3L/"HEZ^B M8ZBOW\0F)B6GI*:E9V2^S\MG%A1^^%A45EY1657]Y6M-4W-+:QO[1WM'+Z_O M9__ K\&A8>'$Y)1H6BR9F9T;USQ :=Y_?/[+<:U&QC5_P0*E!TFH \@O)(;O OX7VSSC^ZD&>ST> M"],J-QE]KNTOG+4:P+1L"^2*8S_D'LI<9T%N*_EXY6S*.IF9E_D'?_8W1W$5 M8S7A+'RJYD>E_ M5 5R7MG[M]NUSB<7N9\:?\)&3( 6@@5>_$/%'.+XX;??& M-55E.]OO-U>27B3)"$+3"&.CZ2"\DP)0P^%+%< HO8NU2>;85.)%_$D/?&EC MUSF=PYU5$=,[/KE].$OZ>'6\5EII7=6O+1JK*K,ML55:O6S M8/8TO],]E_4C&N3 DV!^ZZ=RO^T'MK^(? 9YM<)C?G;(W0), BWL51 M[7#2R%51F^&]Q4=PDQFHQT.5)'WI(;AY-B8TRU'B4\FV(3@>;_L>5+W_%YTG<^%#,W&$FQ)S;VGAG=.<,XK@,(D64JFHX5C'G?I MKL0'_]W;H?HPK3WXQ;YDIV@%0,D O>:#3/GP#&@#Q<###K^B$^P]O_%=PH0< M%Z/N74ZKN$5YD1?" $FI*B:=;LYEC>[GGW\??TKNE\2VR.4F/#+WL@XM/Q.#5L-FU M=R#'M%IT^(YX/6V]P"6C"]6L?_O+IJWF_?MB:RI1?<)GC,-++6PB[?^]>ALZ MWJ0P2D?H65!@Z1!W26+= MZ\2)4?$RI*%B%4"WEW,*).R0_1#0'HO0ZWT?U5HV]7I$<#),4NP40 -7'BLW M%^!"-@M"'T\%:AJB5](\-F5"XH+?9^@-GV0VF,L]FNJ!3'_H*I4*=QM?;K!I MLF&GDUO^<\7\W]V,.F([E^I?XD_R- M&<+[K7/Y<.&LZ+1;3J:U24W4!OW6]0FI;X:?UKM$'THXZK#ZK&@$-9^E3U/J M7H&RI\+;FPMK=15 [2)8+(6Z&:@WPZ_J70969OTA"LS6_QYBG+J2P4PEQY3? M?GGR_V]7^/:^CIK@O>L/=]^SA=6>=36S]$LG1,0.O]'4NM7!+9:F5:J]PE\&1)7@I5<9(4WDBVD\U,__5V]2+YEZWP0L=9C1[LZ".#&V,&T(:* MA@IN:9!959NK DB%NA2 =TG8O2O:X[3'U]7WDYPH_>5FG91R>:NL263J):"4 MT];X3HA'.U92[V0<$-2OD47 D_)6AK\@=%27IW>BYF6%9F5,]%K3&]EV:0CH MN^+E2UGUC3),FJ\/-KSV7/ZCJN_:[1OMA:-VZOZ>Z:4:*#[NY.W;4K..?IG* MH_)JVGJT.[IH9QQ)1[*^%WH-/# 6RZV'^0*$ MG5I'.JHR5E)2.UTNF7[YW>J;: (=(3/#A#$YV1;>,\G$%Y@B6BT?%@" M9E;S,A1 \MMU16]?].\;\,_0;\D[:N/#J!DZ.1,>]6IL/9T MY#3(^T#M#P-[[$:[-\C?Y-?:F7O%?40C 4O8#P^C8227CS'2/[NN*\&5GC,= M>G7;2XA:CGV=VE5 4PD1!8BXGJG.G6GR_0^[6<,-,$H"'CL#?TYRY!0I !3U MHP+@I\[0 T9[34=OZ(ZD"UJ@_K$3#.G\"Y)A6H(8 4Z=O7R)&=.*)OJ%5@"K M+\'TI&%-G(SL4(]4I7-B.SX%XW94X![5P:DIOA9NB)^.*0;_V(8*>5=](?@J M)H0!6Y"=.UGUI<[4CAN/D]>/,0"8/^Y"U6&A3 MR"G!W(@JE.478GO?UU M9V9,\"L'VN^S3$()@?)ESO$:=K=,R],-N^K@VL V!!+I M;(>H,U4KS9ADG"]4IBE^Q,3^,6(<6!?,%E_'E\)]2)D3?8WZTIZQM%Y1K-@Y MIC70Q,@=Z0^('R.%!$NG,OIM4PRPH!6#'*W>J#:("9< M*'GIB(]N0\"BD4><3H;W0EZ@L$/RLAJ_RH#RI.-;$:O4GTU=(58=3[:4M^)[ M'7^95#\[$$__0^+4LU82W->E>BSB;G:+ H"\,-[:,V\@?C2A)\/>*Q^S[YO^ M6W 5+G()Z0"U>!WM)/D+9EY2R5K82+A@PSOD>6OH#E0I--$%3>.E(U+FM,[I M%*=E582$-RF.[H;V;=[/]ZSB5.2::=[.I(OM&7SGZ@$&(1KCJG5!_#1-]UWT MY6VA"$H20;^7C9:G'/C_B='_&[95;O)84.W^0,D)7G5E66YM\N#DK:X)J_NT M642F".WZKJ\/WEA 868I@)XWMAF:U@,O(H4TWM;A205PU7T,CE BBZBPHY$" M4'4QTV].]?>,?SN;_=/>N_$@>TU!I2VL([-4#\]X?<75$52CQ#)L['9^PX6T M!4@?/UHO!B2!([0EXKTP[][$WW M\:;?H5M 1\#E^%&DQ-5=7B6ISQI:/:]Z:D?"5\K2WH5\#BQ*]FX3.GSZX]B: MRC4K,I\4VQ%:]=3%0]JY8\@@S\X/W_7[@L28<.!GB4-//*K:\8)[1]UCHS9/ MV8$T)&KN3A)'UF[)F'3/,&JE557N[P=C4Q] !\,4 'IM+"GY:! =(,">$0^42) M1#O'CDH/1BZ\9>+<:XF74.7(79#3K16 U04YA8]&D+E83,:]!+G^ E<+VY3: M;3,C!VN$Z\]M&VY5 /)W"&4HAZ9;GU(K1RZ9*&-ER8-DQH6L76SF5PW8)(O' MC"QUM.]4 +.[0*[=1"RX*3!/NJB*WD-3K969IVX$)[F3EUA9K2Y=VN81V-V$/P5#C$-S S"7BHO<7Q MZP>A8;0;#%THP$Z36G/<["30._?&0NH>]JW2D^:%"N X8^?JV+_=YE8RUBD MSB.T%;M*7#T M9T;&!?+Y7V&1W],F8L9UA.78OWZ\=25Y8=U=+C696(A<,4_"N%Z!&H*KO4\$ M\G#"[&.\\,!'?/1ZL 6=)FW]A5I(6LG:+=3@W.)Q+U^=-$0PB]CK./N4E/&L M=59EA>M^JM0++_61?7^KOI+8_24J?!>CF7)S5V(X\*^;Q6[W7?/??OV5M$WG M/8WJ@?M5/V8N."@[(%PSHGD6+\02]G#LC)W,9=9@L9P+5T''%U?Y&$D-:F7' M!:8TX;+/LS%!Z6GC>Q/;(6+=!G 96IIM[1A+WX#:3?LIJ!.\#)65(.K(CQ;M M@J>>E8H*>?7+N;Y&%>PBK>2XO=D.+WW$R#3CISVTL%WL^F'* .'5K].W5"4A M2-(1+JQ%'FMJBKB'O?P(*+?%K.LKWL%U.GJG7-:P\ MB2_%I]+R%$ Y7V(/+;L?J$,*+*6.:8"B5B@45II@R.87"5[(?QV>=5MP>2=N MWVQU>QI*ODNDN2NQ-$@L^-_P]_^'FP5 (9JVM"=?9-\[D-/!" Q<&T>8["SX MTE:25-%]@';1+7S'#4\PV(:E\<0W;LGS"^+2X?>2JW#@BU+CNYG>CMP**XQE MEQIJZ"Y":]%E!-IJIB4DNB!_@RE>,Y;C[Y;Y\BAY$X7WC7. 6HJ+P=1NPO3$ M:WW?I^?B&W3^ W? ^0L'*N'0MP[T<_F&LSOF4BM,D^DF/#N0L3GVNM?,FP*[ MW0GQ^JT."<5#5=($3_-5Q?:_?Y[W$MY]$R< MADSW!:=MR.?OP5N;%,/C-!.TO:)ZB16'Z>-LP)IZZA M&(+B.%DFK-XQG6BJH<:4+SG^^/;4.PM$=&4\]MM68QJ^*^=]&0*)\_]M0R R MZH$):OJ1_.TH:^_%%%'8L_(*;WJ!;@AJ3ZT",*$I@'!&<(FG0.HL"4QG/BM, MN30T>6O&F?V3*J^69N/IRN.,KEG[6QG)#B-KZX@!'BODQ8&#;I$.H'!X(",D MDN@K63[R6-">C25:N'Q/@RVW3;@FQ6!9"D B=VPD83(D$381V*;1''1.LC37 MJ>)['3[54X#J_=DT0^F1HT"Y?XJ7YL['4Y25G!G-<]'N*97RVHMKT/)%'_H> M4CDO)EX=FI^?!C>ZF$!=9G7SYO4_\W0F>WCLG]2F@X%0"8*8 M*G"0Z*#9TZM+L!-R]QSEIE*=^WT6)KD8N]J)3D/K M6]:4W-8M)F4FW3,P'U@>_I.U>01_M;FMPW F3 HIVM/;?!Q> T87))0JG;M#LBYQ_7 M",&A1@4PM8L^-'%F\NH0^.37N[T$H6E\5G; )::@.S(@$Z^OG?+6RB2+7MSO MV)JSL\](%D59JP!^'$#4ZV^,+BSC,%9"J _E3LI]$#^8[9*40HB)[8XCIE_\ M7KB6NCHK]RS-*P;:!X:S'LI?DPW ,OV,G<',-PBXVMU'W&/S$3 ]&IJVI_Q?>-V>C<[3& MA[T*PS3;82FK-1/%I,JBUD,C$VAY+.N4!*< M-%E"F!:E8G(Q0Q;Y:%-=UBF MDC>_RPQ"FOHNQ9ZQ&7IS9;\9-*X I';MN#I, 5OVH&0_8BW&,5,+,Y0:2_2D MQWR-JKHWYS?F!Q2',7(B]MP0'$BK>MOP7@*>0M M[JB5!S]XK;ANOB4_!K_%99>8Q%D/35^X9"0S""VOGX&+%< G^W20@%U&Z$8+ MU*,3(M/J,BYE3U@T.N7PZ$S8?\8-5L-3H,&++1"__+QR*TW0AE+!_)KE*X!Y MCA2)ATHH#9%_?\8/OYT *G01$;/BLF 2!I&Y%*C3^Q>3E7V'>0>C,,L)*[.*HV4A:0J@+$(H MEB_3I,HEA,._26O+3+6;99Z_=XP8.^G_Z+PUT4[U(#$0F>":17F"5S?!"&I' MK1C8[;O]H)J)1*[8>TZRGN@QI02\(^DVWI94">!U9@[ IW5X!A,!&OKJ5-MOM33<72$]" M=S=$-N@C&DWXECN/%+BTV"@$#?:L)N;HVC0Q\BW3"EAY"66]Y"FCU<;&2&QV M]>^2GTADZLXWCCIY$A=^"6:;+BS\$'.@*+EXP_6?#[V-8 P.'/=ZED6U)V3R3*4 M/S<)E%-X=,:*2[7O.;;. I"-%"&/[2,71$];G9D#M(UN%'C'(&9Y4A[-)?:, M_9_%4OQGL01\-D4J,S QAYYLOKW-2O>DEEV'CYZOV5BN MB,70ZR*ZOAK\ZT M4830MH>@9F5SRS&_J[C_@\25XH6TR(/U\PC9]G%[,MWXO4'ORJV0*.#',5P&EV EP!#9.0\KZ% M=,;^@6EJCBY/H])J6>]3[[F4P=SD]OM9$Z5Q/N"@5P>[EHO4M9_D@EQ*D:?\ MMHG_]U)!]/EEX<7T M>I8J2;,97EV=D1(IJN/A_9S@QL+^=J3/$3G\\PJ @*_.FA?)L[)GR*QI!^Y&QH/K91E!)UD0&T)V$#" ;]9>6UN"FLQ@FKGPHV=9II!2!N'/9+B64 MCSZX^GUPE>G&@FAMYWLVG=!H2N#2B%P[PF]10X?QA MAG4&N@\)-*>7;" <]=5*N3<=E^$*B^OQ$;[4L%>W6_;E2FT&D&B!O=]E1ATO M;-PR\XX>GENME]@=BK-]_C4A\^S43$+FD3DNC+,Y<=T_2;^E^:BM#\/^+=8P M^4GJWY>Y[-Z,-*6IUF5L79_PYT*_;:H___'<\>O^4V![M]R3O+5F)X5'?E?JJ95$H=9 =Q_X5BUR*%=.G]/_3ODS>L=D[O0I@9KX[)!K1@!\Z M>KWY:W-A,*E4Z@E6TX(QW \*H,-.M.*O.VQ/JNC)8Z"?^3=HX\C0TQ@E(SWU M[1ZPY>DP>*P:#O>7?L_Y37T M5&F=+FO?MYPMLDNXJA> J^CC_@M*Z+839KM M0G,Y+/V-=+%)IMHCM[1R>CW0QM@B,#HGAX=@;3HYXBB.OQ%5:7451'#GR& MSGNUIX*E&M\4@)C;.6?4J_(YR^K7>,1,W]:]U-U]+E<']'LS,D7\[+(^Z#-9 MH_F@QTT_^]O;CT L;@4"43LRM\M^-GHYT5:,>,<&OV59M;X=V6,%-Y62GTF. M5+1U'Q"TO:%SKM:4/+S.D;?-9< #)LE<:N:K#*\"PW"LDP$'Y69R0PZ\4-P, M2Q%J>(;+)E=K82:S1.@E7>> "+DA F$S!-JL$OBIXVVX:6)BN XP0YG^H0"> M[PS!C/"06KV64S]]%E%>9BIR,E+X[W'KI3?!+ZKE*)'PSES33;H#_+HM%(:0 MQ[?KP%^TFD^IV0*(B9[7!S+=9"]*S6!6-B*<;S".RL/ %@D#1JAD.MM?8\P! M83\BHHP8=%"NJ5L/7L&+3'450"$HI]M-_S8;RW*1%T!]]64T?BU_/LE6I"*91/(X MAVB3E/4E*[MTPX"]8\3_8!@!?A213=K%Y321@#N[>V1J/G2$M5(2BA445EIM MLVMUDQK2%CQKLF+2B%\0%F7\ ?4FFR)TU_ %DBS#*(#5=IN/FH9/JDC<54(Q M4P?0\/QZ!5 QIQ>W"'[!(:<06$?F21+^'#FK3[9-J%_N8IK 6Z%TP6GH;W;N M%VKN=T "[9RRO[_ZM7#<-3^+*T2P>9Q)$OM*^_UGMYZ+GFQCJOP0;7AB.#KQ MA@K/,,I+SJ3M%!%H//G*FC62IP@S_&FK=OC+_%^=R=BZ>ZZM6VKS9J0U3?51 MSM\;DG :NZ]7O'0R8E,I)V-63 . M;KQA 8%C;8C?--#5M/%I^[@_W4/N9/2O'JF!1IY*1^6 M&PFXLHA9-[E_Y1R##!S_!Y)QR\$)]!#M3XS";:'M@5MH"\&\G%2A=Z@''':; M*]SW"$E71*U.LN5SKQ^@;L8ZB9M0];S$@Q<0:--86"Z^Y2DFO:R46>(3J3&W M"?;O.&,NRF )B-?JQO@PMW&9Y,\KR77?>T;@,Q!3IV&Y; MAZO1Y!%=NS/+6JQM&7NW-H^Y)O!.A70;7'_!'<]L>2CP&=/AL [Z/@&;+T)3 M-KA\71A>4JB>:Y"&L4@VQUL=7;61T2W .R+TQVN_R$^ M_M)*XN$5@)9!W?JG8%YB&AS,2G_)W87PT;/_/_F(>C_[BO14B66=Z43 $:8T MSZEF<$0!*#D.8GH)OK5P2* 3TD)< F_$9SI0,!W'8X0[VK_)=-03O_(*+"!@0B,0*2.U6W-!9UZJ5Z# OM].P,@N1]1%9=49F MK3*G#+^UAFSC[-%L\65<]$@WZ(Y]:$C68(96L#;E2PT>C85/M&'B:H@]H!BL M%^)>D79+*#Z"VLKIV92"(3V.&&XR37Y_#52]8FU#JLD2Z&R'Q-2!0$&GR1%QT9!0_W4/\J #RT/)) M%_%YZTG4OQLUQ#EL?_9WHW8M1_]_RH]V\N='4\-WI?_IY!!G3*B?V>9/D<_E MU&"C2X!TC0+($.+EB%,9'%-D7UDJM8=;#A'M(UZ+T"$*HC MF?X>E+TH1L_.(M@@B#J #!AT MG7LE.6J\:^!O;D,%8ZZ7/9:]SZO4W.:)F%:"U0G89!PS$M=:DY8.5L=7R^_Y M/\<ZVB+=$7 M[,4\UHB-_^983#@]L3WBZK%^3\0-*Q%$F?^QKKM[USQ:H$9>[ISOCH!3T MNEU,1;PL#7)IB1]Y*0GJG633L#Q**6JD MX4/M*X'?'!WNX6[SS,P1R7K/K;CQY9\.">% D?LX3EXX:OMF:!+Y-7>\9HYB2T>F[01YYEX9'I.I]MH3FXG3<;] M.16>92QOFBJ&5A':"M:^R"_$V619,,7HAR1MCQ[&TG;W?>K$'5L&,.(X22R+ ML[G,F%F:Q5H7_]%TP\@ZFL?T%2^O2A)B0Z*L>5SIHDO@H'H'VZBO;A%1W1?M MU*27?/$6<;2_T PLRJK%)Z-(Y)N,/WT59"4S4@!;823)77*1BR:(LOV4<)]Q M^,=_I$.@9S(GWLCR?<%U>]\M9^*(4EV[S0=UWPBY0?<1C'#1+&ID+D10)9[L M8-:-V(W@MB)'Q^<8 Y/ GL 3O>*P\7Q/BZ-1G[B(8UF0(5L9??7?#%)@FK"X M9ZRPTGF-06127NL8V-G MTB[K5N@C[INY*.5>]UY!5V&$[$C&D(;O/I>3#7D^+L-5,.9];%,);)%4 GY',5F)(#;BRW?(D9GW(M'MJ[9H1S>-RCI_3U4IX MA(UT:A5+PS> YTV;]KS>3,J 4X=143>@+L),>04W]]E'HKYA,+V=>ZQ8A^K$ M ^5O"&'&7(FGE4IMO6P;F^5MRD^(\_AJJDMN0JHRX/#]'YN=419$48'05$R5 MS^D>':+D&C)Q1PKD(6RY F!6.IN%@%\IR56.&O7JQX'#,='7C"Q0!Q<)M: M67I.@[D7G3N< L-2.F\YL *EF")H]+SR=\Q[MBPF4E7.HQ6-M] %^P*3.QJ+ZF$UWIR M*^TVFV"FRX63[4/^8+!>BGR,/6O773^.[L1+1^Z!G]:67)T&!2C93M2:@Y+M M$63:=2ZA2 %X@:'P HY]*B2O0 40=NY(SYGGT,SBH3\2# MFL0(O:29E_*E?*)\"K$Z[Q">P]NP]?MHRS_WX9<.QZI_75KXQP'$>WDAQ:L M>O0*'IANE"CW,23'R%N'Q =J\[!(UTXAVQTH I[/<8*5\.\,A/4(3H25D_YE M1EIF!4&#A$9(8(J&=2@2QX25 MR$CIIQ'2D$"2S!DJO*X:H3C-?Z$XTSF*:_L/BMNE-,3X]ZLZFT6ZGO;?=8LW M/!D?OP5\^]7ZPY10DS5:9^U%C5->7S<%L/[;FCFR^)S$3AN MS_R-!\[) ,=_R(".2>X/JAR+U,H88LH)[#P90;")6T&,9PL) M*]3W[!W38U4TC1LM5P"FT:!H:MOZ&$6-X>EQ3/ M%-+?&O82;[&I025, O:Z^%^ 09X1JE!*1G?2D9Z?NV]MW9\OLA,/DJH0]9O9P MQS]IS2N-$W=D@R^V^YF!Q?.]UJ?4YM8M !LM]QN_JZA+:#UF>6ZM64GRT0170.*[/Y%39 M^TB'J_OVB\DMX(RJ3BCE2*N9?Z'?\H*F$IN*+R/B%VUY _ZRV;>:G1/_\,^6 MC1PV*U5A%#)8@CJ#%]:,GZ=J4!'P= MN\[X0_O=ZEY=F;+D\,Z@L9!<>C6">T[!,U>(,W^C=2$55YI[1YS.J=)\M5R; M3 \IOU#6/&U;7UQ^.:/77:IS%2?1"B\:N<,H[K*I2_':^),[GOR@8YS%U@R1U.V5.\6[R M5D0LQ\1L34YOC+\H?TVUN93?ORVS013A&6!9".6#!Y:P29X%^6:.//)JC,QI M; /\$1QMY32&9NBT7+;'$[:F[27<>:YUHUZY*::$VF?VE'A?=Q/F=--,J\%A M4K*7M.8CHET##?GRI0E;\V_G]]NW#:R@K2TYW.L0V\$_;S[.YG,Z M8%'SW'+W"MT^]F,O\ZBUI1Y&Q"+QG5&L=#A9@"D[BOH\O=]$4)E!>%J<7/K! MF6LDQ70Y=K!+E-Y)$KO>M1PP2G+=GTW97=1Q&#/6VCLKEC. M%<0U=)EY:7[5:K_L*JWA9+)K"TIT/U$11;00, M#^QF>$F%[-.JJT7IK!L3-<9GNB.)'BB^JLVJW?9Y7A%A>E-Q[;U6DV:JQ@RI MDT?#VX_JWX/>"+&5^)62<[8AL)@T@S#P?+[KW-\%,..39/<$S[)O/U< -YA) MA5U2V[-/P![0^Z/* ^.]+[+<"XN8]=3T$:LC>_(N[?V%5P > XPS0E1YO'+E MJGS_D/AED*"&7H"4JA>]+,EI0_CC.VK]6KAIL"?!U?AU;.[TBWYC#[^F?O7H MZ&B6JRNL\[8-&R+#N/S%NSV85 )&/OJ5Q;UP!N$GI;4RF @@M4@G7:+BR3=7B=D/% (V+D<>677@]/E%M/ MOX#Y ZY/,G1L9Q(#+@[N=J>+S9KB73(:]K%I'K1U)>A>N6,?MI@5=>0'INWT M'T? 46:W_B_UWH1-S9X&&(K+KO#QQ>.K/7W&8K2),_TNAAA5>TI>)"KJ#9Q9? GHT(7#LUL-"2JQ4=CXW)-)_M[+LQ/R*5TKJ< MN97P&%$!E&U)1,T$7:1(KT R*ZQ';Y=Q%?8 &YM?2)4*CV>*K-,B?XE3M/ " M:')Q]>HZOL6.5CUM]9'XD-.Y&4XW_)TK19R;3&9DR@NHB&Y+0O/&C"IG?8N: M?CEAF4TF5DJ6/N^&C\1,ZT'# M;YP1-FJ?4PC?K^2M[Q7N#T47U_+]/*Y^9SR)7]H8VFZ:[)+BH71>&$*]S//0 M6Q00216'%:TK**P3SPFKUK3DX57#!>=='+_D'3.Q&$)BL(;]4L*!SRTK T7E MLUCG']\LWYU339E.055T,+%NZVI,S0J:FE8^BBF]D!7V8[F]=W:6PV !T2<= MNRE_B3@!U\&\=9H_^)&QH-GSFJ2WSX,3UXY(@,=N9ZDW5V_SG,3+9*W]5X1W MRR?*WOJEH!\/9#NUWRW#J#TK&YD.$KRR\;,TZ/H"RPP5 !H^ZHP.)6^_8;HO M%-;V?WJWMKN+?0T2U]H'4QY/16QP?<2Q8(9W@0^W65^**15@C[=Z.7D>;W0Z M4Q1N%QW[Q7,2(XE!LNG4>>)%_6 MI$XQ#L7UL8.V?/#EG(_S+VA3 ">0*7W".!8G/\%@^A(_!:I@6]\)U0J]GW>^ MQY.R]Q X'I555SRJF#H'#P>.$R.^]#!LD@FGXS'YW@C_F"(N\_?@:GC>G#RU M9P>3M6^8'HCBZ>T=&O#%M/$?-BN X]DHR8DIS*S2#Y4_<^=B7N-H?E?9]Z;N MQCB^WVJ=\>R,YJI)\H1UOP) [J9_1DHF^EL;[DH,%YU[']Q:8=C@][ZH.-YO6+?,7Q-#N"_0ZV0'@LVYEQ""SH/!<:"M:\S%@*.C4Q@'-QL)<6'VI>[VT4M-%<\?,=CUF5U:"SRQF/ I1K.X>178=#W#749P)>.Z;^EW&NZ78&5_S4VHXOS_^ MJ7ML&G_;6!]FHI+L^P[3[+D:$=<)F8:07.3BE$W^/M%+LX1P\*B192'B-1W% MQRQ=%NGN_-2G76=#*W'5V4^K(*4%"C"5WGW[W4<0=7GIE[4"R+,_25,F_:V. M>=\KN(B$6E,42PT$NOS9> S>9NV0O#UT8*C7A\M3N MCIJ0T;Z5#23=5,GU^M$.KV3#YZ"WFI3+!_T+"AKRC_!8CU9%'IKX)-JFKEZ[ M>BK?VG$YY4/.51Y&]L1TBP)@K%< 4XMR:'.[C)!=6_^Y:SE>H UKS*QKA=4H M* D^60+W?;:WN>%?&JU+>9=@D=2C(+[:GWM?'?(-*_4>)K'V^IFW*>@PG M%K,*O$)=Y?Q&"M6X=) >AOJ/P+L> ]4H8F*",&#E'[MQ,1H\G,,?Z M[[[Z8U:&<9,=53%;MI=PS0-QZ6QUX4O8/.J5?VW3/X/%-HA. M +=<5@!!\S'H\5@!?Q.8)",)2O(40#7C>7HQ5%J$E\>Y!KRXR?2C5F$76/%* MM9:-&=009J_.-'A*Z^!Z*5?OSL!]5WO*0?*W5ZR^/;:N.F1^^]'?]G',U'^R M5DAZ4PDQ7ST8M7)*YJF),U&R\#HY?QKL(G2UL?1]\<>9[BLS5O0AO5C+&"BV M;ZSN=<5V!)R9B-YHM]XL[C4/WK^O2/*NYTPVU#=X2=>4.^Z7@> UNV /B9+B MFU9>BLQ858(!M:JC4\5M#2,ZK>,CC.*#Q8@1T<<50,P[?SOD:"7VEFA$]USXE-!TP^=NP?236Q,T3K^4CL@^NV44-9*EA&0R=KV)X]R< MB"F)PK#H&D!,HEJ :]FE_S0D&PEW'2A#__=#2Y61#K=>1<[F8 M;KL?F=#L0O\T;T; 0L>42P;&T>3=6L^T;*(/U9S8?C96B%)_H3*VNO<7DDKG MVVK[Y[YN((\M+;TXQM@KJ>TIIJV^V#'L[W05UX2OBY!^@T81ZWKI3?SZ/K02.S*WG@ M>ZY4C^#!78]DN]20)CV]80@W_ID >Q3.V1@S5' TQGUL6XW'WP,]M7=M>!]K MDX1^07C]F=@_)EI.+<)V[N"7HL3TW.JOSBW#I[.VV>QH?.6J=>,I00A%*H") M([[*, 1-9]F-1KH8"2'8C @H +88;@TOR>+.R?]P3.RA.]#GN2_:Z'=0Q\,= M3TD38TJ9N8,O8F>^#U17:. WFIQ-V,1Z]%U:TUEW1^P]&B$/40#76>'M8OKG M^]PU[JSU$C$O+MMB7/>(3Q"A!.J6MY)@SW6U/^Y94KOEZ_O[#H,^=;(JOFP; MN!;QPLT@/QAQ+':MOCNQ0B]*!]2[ RJ .E6_2(TI5/XM>"%R\WB$E/!EX-0^ M=P4@GLYVAU:3#.C.>BG/\MP-FN4_HN'K]/(]>US7'X>,Y-#=H:JGKN,M"N#K ML_\=H(>^0P MG+ASXL>7\@_QH]]#E+W44Y6W@U,>[/IS&V>>7D7_!-]\UB;AY<6S;\V"F9;U M02P]Y&97[:-3&_@H;YHW=Z(6<3CA=-;^7]./!!3Y'?@E^W=?!?#9,,%8(&O3 MV&*#AQ;\&-B-*751ZHW(QL,:*B'WL_TP35-=#7[UXBX[;42X!/!QM"=/!:0/ MQ!F?.BW\^$CAC%;@C9I0/0W!I!E51LD<3(QA58B_857W))7//OH,?\Q.YL#3 M'9/X=N;OQ 5=?D=\]#A^-'$9.^?,L4NKRW$/.N7%/93(O3DVZ_>:Z*5CZOO! M6J2V>$@!:>%32 ,&11=C+Q8*JH14,7&:@^E5#P-O6E!JT34_#2QV"59 M^.,&DI]#,5N?DAM'6EY%B$\9%W]_E.?VQ?0#(Y:\SIVUOP3N)*X@Q!3LT_O% M7]-+G@2Y>GC+KV+S,9=Y K,J3:,0GG"!8TS:BL?ON42[:%A$ZG9;>J^B8?I] M/Z5T.KMA(M?Z*=UF@(JNN$\34$@7B3.OLT!^$RC,')>A/'(N#IGBGQ"W%)=V MX:?)KD2^ MGM\5F8Z0$83XA3(T3V\Z+D(ON[H&,SV7/!Z%DK"^".["8^Z!*RD[4BX7RW=< MC)/;-$]!$0EKV_3LSS#C+-T0Y8'S[#^@ +AVDY+7/;GJ,P3+F&1PC"NY]SU[ MXU''M^^I>UA]$4WPGA%X?>O85+WF4.W-O((OC+]):10!.S_L1/F'O1Z?3=&^ M<5@)94=T;^D\*J[4@V:0L]6Y\=2$\017@)9YE]:TFM;?RMW=:><]GK0W8[=M MAF5JTAJY A3NQR#E0O%^TQDDDI\/RG MI9&8_JTAZ[*O7.1%7HDTJ\DLMB-4JN%N=6B&%:0/QSKG9+OII?Q<=H>X>2:1 M'(D;TDSTB+N]V[W(JR#:33WEK2Z1N*HC-^T4O>7+T-1QDV+ 9M4^WY3$?*67 M[!+EWR6OU[;\ 7^E.S,0LD'7V>9S@[74&GXZ9.=[>$>31ZR*;"!QV_#8 MAO&FG9TY"T-2,-T?3L,A+F54(Z/=.NDN06K6ELX#[\ZXN^]2>M-6HIKH^P;D M74UQZK2DB+)H&+E(3#3]BDA3(@N_KY6!;"LSE-QO:,HS9)U@%N M5I=J;'8M5P7KG.#P\ MZYB6(MLM* C=:N6>=/PZOJ@IYA5#+BHJ/BW-#Q/K/KR<@17GK(;>4?](JZNK ML0 V+=KMOMNCI"7R0GAEJXE1F@?./J^KO?*>7ASQ83]>Y#FB )YEWV)8>)Y] MITE;O2:RVJ;QE/6U +*-;G0K>8/$Q[$T9IQO7A [C"W53?O6RK:UJ[>)-*YI MO7K7=7$][["*Q)8U%\5-2!0SIKBAIAN;T&L&JL\4%'[ %^OL_,9LLP'5[YDM M.4XK/X>YHU5%FXBP/*4^&/L*/;JY]>9 ?G'8CL)H0TM5>9OC+6IR^V#,:D>' M3P5MN8$_7HYGNR2FM5?37B^P=M!(V-A,-'ABL-MS2^!Q;G]X'_$[[9>7!U-O M39HF;55*3M]@8OB[,+M;V8DEA;X[(UW#0MK,<7>93HDO+=.U_#"?*)0R.&'TT8RL;XH>8S M]3^:GWY\99Z>N3A>*6<=#F545K_DV[>Z1$<^<=;5.;PIMBI5*YK(J_IY MMRRMXID^K(Y^# TN0PJ43,>>%%R/Z*V*L=*U*LCWPWGD6XKIWF];ZS8>U;E7 M^Y)C9">YT&ME81;EJ5B9A=HVTQZJ:[WBJ T))-R;[.#OX.Y,!]F9* ! MHOL!&MV-)OC^3P\;5[G#S"?4^W!V\>+\3,&>31WBK3Z<+:@YT_4SYTQ__ MX]\5^/?^/WL]942PZ[Q3AM3NZ=Z2_JI,T0:_4ZZQAQD**/M5N4%NR$OHB+B8 M*0.ZV;HXP% 1/^F=\OK%Q4ND]'HM^KW!GD/98JYG_:Z#8.N_Z_?O[^]?>/0. MW5/VU7]ATTV[#LT !:&?]7;^<)[\:]=\0GP[:_SVY\G6_^5A3CZOL/_O;Z;V^N\=?UW:>KM[=_W7S[;7>^#C_=G/]C0-59P"[5&WT< M/_*];Z_Q!BD AN=_../\)>S=OWQ!V:I_>7Y^T?\\&9L1W5E,^.[!)=[7.O*+ MMV_?]J/:E+1"^7#+W+3KEWU>?8M\G/4,M41 3SP_0)Y=H'>"K$&>^'4_KBR0 MDEK2GV-2DI(ZN$3G8_O%BM[UH0+H+R^^O4I)0[^W0FB;D2^1?QMUFU1$Y+WS MB][+B[2)SX(J.136D_:"W1;[M0WBJIIF3L!*S0J2A.H^K^8MSWG+RZSE='QE M9HV\,&#()4M\2ZAO$UB?.)KMT1,O+OGSL(LWV M&E&V&>(E"%UC[%O)&!#MG M2H#8"@=\^OI;9.,C>D[7 _(\"LL&UFY2PLNV6P+K @K^[3V?0.\8=;$%#"G\ M!RS8P\_AA/T!!05TIA#GPUG\D_<(_4=].GA)/!(].%FE%TJ/K\F0,PP_HR;O M^V7B7!>ACQW#^V/T>\NP#^TB3L90D#1,2!H:VX-ONAU#9)"E*)G2S# M*^3R]6BN,0[\6);%(K%,+T&07"WB3*B>3UWB0(FC)!TI<4^=J/-RG2$&/*YQ M0&#D-7(OUHM!>-D>!.6G0L=_^.%!R>3F&TMCR^T0>'*R$!KJQ&"\$H&Q[U&A M2V7?9P=#3M2#-?)6V-<],Z#VUS5U'3#^8'U64RX6_R_@%XS#.8Q=!19G^=T(,8PC=E"*]4 M4SNI/M('ZM12U,' 6$PM?7JMS(RQ M/M"U#O(Q 77O@,('F*XIH &*R<;,X_J).,55UY)6#./;,HQC_:\+?:A;7R+H MK@T.S\"8#K3YE/_?U(?=^DS FC$*"B^2/]^EMWS+F.(@1J>I4@C'Q7D9CMF< M*\0$#0V@F4U@;?V?,M6L'U[^.O#DK+A3+^Z(L;QT4U_1:OQIK MBFJ:G9!!R'?8#_CL3>6;_2T6[655M#>::?'I^\,+%79;%F)'>]ABST\WZW*A M6+POR^*%[72^T$!)?)YI4[/;2_M3&F!_AG8(=$%BI^9+Q.)]5;%0#4LSE9GZ M107=\,/+=H[OL!=B7%[\\FMD-^/#,_(<90IC!*96+!5OS.>(8JG]3Y7.WT S?8 MX">VT$,Z7_,%8ME6G$%].C FFF*IG[NIVP>_FL='H#2+KQ2+A,*]K+AVX$WS MX(;$_YJ)NJE>+/>*BQ=%,Z96$L7@4:G!7!OJ MEC+7S;_\\#B8X:V/OX7 FG:WM^DJI6*95WP_\'#/M M)%\,>.0%7B@1R[GBH\?!CTZZ]5&0O)1K:\32KGCMI8A()_::T$A1B9>+A0)_ M6?'D\V&23MJ9)VFOL1.ZV%CR,T,OH R,S"$.$'%3KU)$(<:@XM6;@X_:<#&. M/4,N:1:9GTU^&QE[8*=G_/(6X8D#NL/=ANZ&!GQ.B&OR43QIP;2S J MQ]3W9YA%1SD-R)W4EQCC:A0AAS%H-KTWU,<+2[_18 ,?C!=#V,E'A3/D&>*2R2C4+)A M=-.D7;)9_81X9%LQ])5 1/O$M0Y@X>Y0%V!H4/XB4C%\E4A$7K?71R4ZI7TH M3%2__-H2BP&K1"V$H:-N@0D6F.8'9(,"K&XH"\AOT:B3.$;#.FO10HQ>)?*1 M7VZ::>D3U=(4=6+,+?UO\::9Q$2Z55?KT!3"?HU.32V5&*E*[*3HV)0CA1TX M]4':>E5XB$@,34UZ1 , M2@R*,"Y3#;=WZJLF6;E^G0@IQ*!4 BF%9.9NL;1.<*Y'IB6M&*-***,I ;J# MJU52=#U4+>C$,%7"#LU)TQU0PDTH>5G86\4'BPO/ ;'R<"!V1B%_GW@"X]J$ MFZ@:]%Y^496WJI/Z$@,N#%0D+RM/K],3SL5TJ)M11)''HA?12\T3?:I/%I.8 MA"O=XC+NYL0>1S/<;N-KA)";OLK/[[UBFXB!.7;Y"_H6C6%NF R/ZT0\"ZKO M2N1F@;F8S<:1P5^!?T0\ M?L',$RB$$WH23P1A(&6D3]7I0.N4P0FSH; JRP<)]75BQ!J34;K=6; 4TPP4 M(PSX-7O\,L:&I2:@% -3":?DEU*6O&(L+--2827!)MNMDF:@5!NF\-Z>;4*I M3":$Z'4EQ%(+D3JP])N\P=OADP\")\E%,T;O"+]YM#%:W$0HQNA )DR:F<3/ M:VYTDQLC'4Q5F.;8IIY-7)(DK$07M :4[4:8GU"[&3IS,!X;$'Q4'V)PA2DP MYR? '-^Q--A7\5^B)>8,7 )T$-T+."K MGC,FZ!:0#)I3UEJV$N-;B?KD\1UJ(VT^YUX#H!<=,)C182L ?@6H6UUZ6T-R M9]-!0S.!&*5*T*>8\-D9DN)W9>OA$).( :D$90KOTG:('/5^;2,\;>G%6%5" M)\+W;SOL6KR3VQ#;/D0EQJD:V2B_L_O_&QO^'W[__!POE>C>^G?\8O0/9S[A M7PXX2\K6#"\_G'GNK=]++RC_.[#VXF'CIB2\:\&]]1&B96DD#TZ[0,RN]%*Y M5Q\ZB1*[0'WVT\&G'00DX,WS.;@*?PY8,?VG8-E%M\>R#$VP^XR\CGG_3\HD MS+YCF2Q-V&=B=;!_RI,R#$OG6(:+J^V9^!UF#\FSFWP"H+__!D#R=_D[ >^! M<QAC:D=="9KPOWIINQXOZEU<]EY>O'CPG?U(CQG$7@S' M#2)M]XA!-'[;HFX$?G,#_K,7_VS[:.%W,H2/KVW9QV[@IR6]?5^/&4[UJQHG MC"?J[!$#.OS!CJ9!'6H9_>T_:HI$QREL%W'8=Z";"76L: MQPM@?.%/B M+27[NLP[AVX0\?0 ;S@E2 *,4=#>(:>^9C3-RMR M451_A'K!#;%<9:] X%F:;&:,;XON4[7C&7Y+P5V3HR#8RL,G'E>1=%7FI MJY!AP-8]M=8T])'G6/=0L\MI43_*Q2SR<02]#.SQ8('-R%:P[,4D,C!1D7GM MD-N U:*A# P/\6U@XB"(R_>YIB5]?8A*!E9FC'@VV2)7W7!3L,A!4Z4, T_2 MXG4OP S[I8$W5]%?F/&H+UKA%MO04W8H M@X#V;Z(T:$01@0P,@%#! ;&_@J@#;//F\&O%T*:TN@Z2R< ,Z.C:Q/J*)A=3 M2<'*FC!GAEBPBV<0+1M!(@(9&(C M?O2\DJ\@))&!B=B%_RQR^,4D,C Q6!.\U!Y@ ^&G2,9R"2X:XZ<5Q.':U7.& MA(%J*L< CF\F [.@79TPTK,3Y,%.R,K&3E.U#(/7G!5BGQ!SBH.N%LLPV"2\ ME;-(#B^3%M0RL&:M0:/R&U/ ]T<5D[^Q5H:A#ZA-O3 8P!"_CES*B(/* M:%L0D,C Q6^]@4J]QV1BL%,LP6/#'HV3_YM!$0[4, M@X<-BMG$!VT"VY/AE;RFQEKIA@ZVM6#H^5KYAL[UH6CPA7KIAC^B(1.,OE M MW^#!-!,-/E\MW>!-\B 8>[Y6AJ'#&AR$X"YN*F'UVAI)AMPB]GR02@96&N*L MK8*Q4C&2A5L;HK!2#7:(M]0G@>'%[^]'6??%\[V]Z%M0'F0ISNP)TJI;Y/(\ M'V -WY(@Y3.NVU /!XCMGN1$,WZ38#>B+')&+'J%==\/L;,_UA21/)HO.TKT M?3[&J+?B1Y9\7?B#$)RM/6 -=;*R4G_O1_;%R9BG0T2R,EFN+WX(.@3"=;1'(_N3P"V,GZ/:" O\&V9B F/YCUK]KWA59U_A/%!I6]1 MU7&BW&GDSA#A#* M"9";OA%>SUCW)J5$!3R!F([KZ7LKD@'=@'"CT8#[)%P0[4BE M!;[%\(N[PC$-)(*Q>1N+YR&_>(*_REZRZ6NX?GQ/OX=)\$CN&N?(J?U][RDD MWM6+?-3OD0?;/'Y:/&\L!MP_QD^;ACC^O^ZU\OR/;R:K X'TA:>@UF\J<%. MEUPR1/8+X:0>I%475]C#2V(3GBR4SN,11OR&N91Q,8FTG,W):AT8RX4?7Y2> M6OI^A)+JVV]>768!KE:DTG):O#HT=X%+#:LM::7EE6O:/ M+MJ12\MQQ2SC/_B3^?T]>[?V,)FT'![ED_SNW;/]!17U>ZD*_3)D[X^ 6M.C MY%?*\Z,-KH#[>L]VNF#AA^#*S4%ZF.R$0[L@[>9)H8NO\6R&JEPO'31C##L= M+ETZ#9HR"P0FW\HM8_6(=M*!5_Q ;3.(3732@5DH2>U?AK#VY)/SE3AAW%L#AH\BK;.*O/;DD_.UO&4PO M,,]?:AYIB?W\BS]:7 7UM#ZDDT3Y!MM#7!^DEX3#O:D9QWJ&.$M[RLPV(4.>Q@5HA+!Y.#;9'M?C>(*N>%T;WDK/8\:17T05^7I#L M8IF:.4S77JL\W[96N9(;?J1ER68PQSYF=S@[:4.NWW#2^52=29I@'-E:'$9G M0#>J)S<'Z;^W3IZ&_&6+ MO?^J/=AKY*UP,;/@(-7WSA?(3GS_S.^#N8$ZL 2X8>IAYJ_)MG(RW$PGJ\$Z M8]3&V/%Y8GB]2;=_DZ8%I:QF;7[P>9 J[]NT(926R?@K<)G/#H[P'KWZ.EE9 M <-[ SYP$%#FX=)EE UU,KS75;F3S?!PJMT.W-Y61_FO9>E]/[[Z%7[^$U!+ M P04 " #%BXM47*I/ [,6 #K) $ %0 &YL8G,M,C R,3$R,S%?8V%L M+GAM;.U=ZW/C-I+_?E7W/W"=JJVDZC0>>V;RF&1NBY8HA[6RI".E2>:^I&@2 MLE%#$0X??MQ??P ?$E\ 4DDX%12NYF)C0:[^P>@&XU&XY=_/6]][1&$$43! MI[.+-V_/-!"XR(/!W:>SM3W2[;%IGFE1[ 2>XZ, ?#H+T-F__OL__T/#__SR MC]%(FT+@>Q^U"7)'9K!!/VMS9PL^:M<@ *$3H_!G[;/C)^0G: I]$&ICM'WP M00SP+[(/?]0^O+EXYVBC$4>_GT'@H7!MF;M^[^/X(?IX?O[T]/0F0(_.$PJ_ M1F]H/#N_/+MVXOSWV]FMGL/MLX(!D1O+C@KJ$@O;707/_WTTWGZVZ)IH^7S M;>@7WWAW7K"SZQG_%C+:ESB)X,_\C$9M0?YK5#0;D1^-+BY' M[R[>/$?>6:'\5(,A\H$%-AKY$Z.W^VJ0Q*'CPPVXA2AR(1Y]( 7OG#0\'R,\ M.#'7:1?W(=C@\>??1OA+EQ<7E]EWOJDTBE\>\""-(!EC9]KY"7BX M@#CJXJ6U<<\\+9T0!/$]B*'K^$(,ME*>GELRQ< 6?RE:;!8/9%G XZY3E6RJ M?KD^1Y>JB9@ UT8&W\F,'X1X9Z_MYZEA%3? M(#H]CW.\ H= 9&S0*?J8:Q'$>EB&(,(:2;^F!YZ=;+=.^++8V/ N@!A*)XAU MUT5)$&/CN40^!A=P+!?']WUZB6<0#TH/#TO,RS7"GQPCW" ,\!\1]'@Q$NOE M]%(L0X1'1_IY,LD>R'B>@[B+[0ZRT_-I8N"#.WCK SV*NOFC-.^#KT<0Q43\ M;I;J+4_/#1[_80(\X_D!!%'WQ*(T[V'M0C' =O3%N24]=JQ:+6U/SY$%'D&0 M8 N/C;M^%X)L(>_BC4W5AUW:FT)>BTJCZ&$%! ['(*NV.CT7F92_.6'H<"#8 MWKJ/=0'_%:R.19*VCMU?*]AO#!^O?%CN%N10Q-K_)7OS"8#\F41]V6 ^UMK:]FV/^3ACT?1JFWG''86@!ROCW@,O M\?&NG>P7@AB%> &9@-B!?K?%X:#MDV,=KWHC#_I)#!^!\>SZB0>\:8BV))B= M9(OF8H,7EQF*HB4(4S=:6+93?$4M"Y0S-R?#GPC5IRVB?4M6?$14]N-Z[7/T MMQE2X<'-T.,M=E+W:WJK;*6Y5F?3]1@1%-XC1U=],F_!5R\N8,^S/?T:1):C,*7*2 [/7_'G(67(6'1CNF] M3ZDG8 /"$"^KSG/J^T9X/S6#SBWF-#XD%B367Z_1-G&7NI.TYY,R48ZYB(<\ M23M ,&>^C]I$_90.>E9G+N.[R9^JH49_N\*!7B.0> !K^B','U(JF8,8T*8 M9])>:".2=IL03P+_-6\Y"%?M^9@5[BXQ2[N$MY2]($(^](@#J.7T6MY!SG+! MM(_<"J,^R:E%M835(C\YS9S=.-%MFCZ;1*,[QWDX)_"> S^.BI^D@(_>7N19 MM-_D/_XC6^'&21B6\FQ\YQ;XZ7?_R-O5FIU+Y)CXU7A%)G^0W=2CXY,AJ\=C M/%I?\%*29ES3)>$DKTM8&DAZZ&HHQ";OT]E%\1TG="O#IYG3G+P+P[CY.N9<)9!YKC[!? 3#SMSZ8@[A[ M)#*I^&"[E H;C]SJH56%IMU5$TL;^+40::&+:$ Q26R>DC-4'"W N%V?Q+'6,E: M&ZMA42BH,,0[(18MQVVS*_N/"7A $8P707;DD\:07&+2=H=8+:HFE#R$?&K_ M,+#:>;E7=3I,88"EGL%'X-6.TR.FA>FBXT/K>SF3A$]H]MIM/QX 2A&@76+W! ME:?;B(PQ!HELKU\$)K;8ZB%5')_EB3MT?!H-9;OXW*A01%0/"W*Z%CIN_!N, M[\=)%*,M" LI7SHG$!^U["T -VHBRNA_?[#[\A2%:8;8"ET!,XJ2_8%4;6/ MI)"](^A&H5.$P32?;PLGX)9U\I7RV]I4MC_/J6N&F.JM5.7D,?X5BDTEV[GG M7IEXA%H1A,Q_E1NZ3J(4/Q1[C"X]VD"D5GQ/RQUP!=ZPZ M![A.0H7",R*[G]< &KUT6!.GMK:2$\JR&&;*6$?.;&MCV5:54;BMD5%&$U6] M,35&VRT*>$!IMI1M4;D1H0FI'ARZYT$BN.,O'>B9P=AY@/&^J''+H1.-0+;Y MY :G0V3U,++(;94 >(83!MCX1[KK)MLDO6F;5T.FP\5#*]N"4. MV#O^.V#:MY7^OAOH(EM'-?R*-.]9TNP[TM!&*W4E<4VY#DE!LQ!M6!:@TDBN M&4O#<5EAMN9)=5:X#2_K)"$,_X]<3V;9M0,ZD[U.MN#5L' 'ZT@]DS=&4;S8 M7"/DI, MV!*EO>P%@1]( MJCH)VI&-+,,2"78CV^L3G5@':4G!)7]OOXJ $@P2K(-]]/(*;% (2E7UC&?L MZ6) 8."$+R96:GHSDX2BD.^GZHM!"")FA9P>/RI[B1Y HS07H\494=)[&EY% M0YK 4SEC(.;Q^&O-9(_^5JX;Y:;ZAU\Y.'?"Y /O"KL!S$,9*H'LVE*V>$'_C/"/-/:##0RA_YI_. HI^U;_./?:?53_&'TT'CB>J* MJ-\+B(I[TK*NY"ZJA)&T,#76SM7+.B(U/W86-"^XS X- MK^Q=4#DPS!<#5V#'>NQ$:1-:/;]IV(/ _LXHCH9KL!-" MR@)7O$F1E2HPR>-Y 7 )#R3]A,QU_)-'[+VTPT/Z$.M"=CF'XY;!0]2EWNPK M'Y&15R%NXTG^I,TR!%N8;.D3D8-4=A&)H^O5#WMG=I)-=P.+$4YNF&/4 W;VYA#WO"4INXTWB%X7N MZ'"RJ627NC@:3!ZEJ 4W>H"U12^O L_J:PXBD-8I.5%5,3+$+>,K K96/_:0I5BT M7H["X21N_;P20UNK.2N(;H.:$V"% U B6GH-&',7Z>4@Y417Q6 5OY"O!UIF MF5L1H#LZXH1=X0C6@;I[#8. 4@I)!'YJ%YS *QS"$M;7($>H-98.*4PHW LG MEBK&J@Z2]Q7-8)*]GA<#/- 5HW;!B;K"02UA?:D'.44'V6-5QZ7CM/8Q[.-6 MZP"/(3Y9^)Z-HG>H:-8.0WBQ![.Z5*E@O("BDJS2WW%CN[4/R8<.+@!>FL]; M+C?-/'"@4"@ZE!FX-0\;F,I0;QDN/UV0XR1?/E^!'E4HN"GAZ1FOR?>*^/C@_2H^RF=T0L)P;&9@-*UIS=.[$20BZJW/^H(TTDH#KHPBWQ_\QUU=KR] 64VVQ M-"Q]92[F]D"WZ*Z<"$:+S3($$0;5R4L.V63\A"^+C0WO KB!+G9!\V-RC,@2 M^= MXU&1[L>Z=%>Z;=I$N*5EV,9\EI/=;EG MYO^LS8FY^I+*>KT@\HP7\[%AS 1\/O2F-N#S-576Q,FQMJ7_1,?8#L=E^IM7.\('[^SK?]FHQ_O>OBQE>S^Q_?O/CY<4//Z<+Q.K+4,LV\3PH6FX8 MVYFA#S=L,STV@C@5#AL&,].=]IMN6?IP\)?*6+3SV3!PYGR\N#&TE?[[8/K, MJG#X@$ ]I;!G8F= LT_[W4 M" AC[C6RH TV M@(]Q99DN[67#")["I=6^+3XZU L"QRAH10PO13T-RWL:]62?'$HY%.>8)7?# M@#-\TQ9?'>L.YU]W1HWC-7A,5RP]QG#LG0C%8] M$Q;##;M?\T^&']H[1X7!]KN&'U!V5X;FV7;O@9?X@%S1W%T/FI!'H'P*^PV/ MP![_:DS6LS1,1/:*\]7"2M?)O)OO9!8L*J1Z*<43VO+>RJWD)O'EG%C.TXT3 M@Q Z>R 8C%>;RSY9:--Z(_N.(:AZ1XX[=J>D5#V>,^D+)!S U-K+/J800:95 M5%5CW/N%3,?^XYFX*7&W9@O;UK SE@=3 M]HND^JYVSNJH@?W4:MN+ M,&=.8R=2GCGMNQ(U_(9"TJ5/ID+[N41KWA"#2G(R5#MGZ9,1!TB4T\GV-'AP M:B8^<:A"/1>D\A3KOO0<_KL/\G6\7'2%*B8=[--]0;:;<\"P.+5ZE:W12PDH M\5FP1DR&&5I2P&0940SQB $M5:68EJL1P"E;+L->F3?ZRM#TFX6U,O\W)+3!/612S?#WOK%W MF99.3#+&.J*>5(+7OM-K$_]U+V(4+9D M U/6V>'#DON[%URRO&])%2KN8B@17*TEQ+%LX7MFWE S.TX%6]BLSYD7AV(> MH=!())\=$;:N4)!$_%+4F\NV?IUX-(]TZ%+W7X\O+2=6FR)TU1,2)H5LJ\2M M_4Y)A@(@_W[QN&G^WO32"4O,ZX%'GD)EPG) /[(C?D)@':PG]5S'0H;\1AXG MR+O,-PYBV=$[T4500"/JP5E>1D3,=[*B;*(A\>E /OYQE"S/)ZW14VLH. M@QWH<;3(JVI@JWQ_F6]3TLB&K=QGEK@O:;_CS"=4(VN5=N=9YKZK<0^:3[9& MUBG]7K02N\IJ(>UH'7CYHX# FR:DDLD-#. VV6:%KO+Z5LR])S,--2]M,K\N M+CRMYQ/33E.021[W.BV!Y(]KY\H*&@?+J/D"#L M1)\#NI*]X1]R%/"G^:AP8&LG#P]^Z@LZ/BGH-O71DQEL4)BI-8]VK%#F;3#] MB&:%F9(?8:^7RUGJ).HS;:S;OVK3V>(WS9Q/%]9-EB%L&3.=.!6KQ>YR]<#W MO_9J*5<+/86/Q4R8GIIS?3XV7JN'5=:5F&?53:E*(=WC/"GQGF1[4+R8,HKL MOFZ/J4L2GM1HO@YD>T@]02WD$7* M-$B-1("R0=K5"%FL5_9*Q_8([__E&>-"MKRF[ M+L ^-K(!6P?3QROQ<#NG( M*"F2%T39O1_.E*NCLDA1)(5<.?MLVL2?4L(YV$F9GW->@0!L(/.8B4(@M0A[ M%JX6%J:+3K:9[Q"HMN3S:4$]6UZ\-2H,7R>A;-LMAA^G'E0UU?NETP(N"ESL M<3A9N1([=N(D+LAHDQ-2R+;,RQD&F2H)W> M9\9ZN<+*62E3SJJA 69.=GMK%=:I'4?[B!.*HC'V@EXV*'QR0E9M):%.9-L? M%F*4Q4M .>I:HIT0^"_%S_+%V (1"!\!F;WI>;GC1R+OQ9_N"[)MVS%CXTBU M]I]\=Q3'1=(2)2'O1'W+CMGSX']"<5_-DO'9\9,,!=]'3R0&([ :M!'+SMD[ M9J+3E:'@4UX-[DM+CYBK4B<\Y=*4)M)<.1'P2$E /'V B5

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end